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Abstract 
Recent progress in synthetic chemistry has enabled the preparation of new highly-
defined polymers that exhibit changes in their structure in response to environmental 
changes. These responsive nanomaterials may be desirable as carriers of drugs to 
deliver at the cellular and sub-cellular level. However, the endocytic pathways used by 
these nanoparticles to access cells must be defined. 
Carboxylated polystyrene beads (C-PB) of 50 and 100 nm size were chosen as µmodel¶ 
nanomedicines and their route of uptake into cells characterised and compared to 
thermoresponsive PLGA-b-(PEGMA-co-PPGMA) and PLA-b-(DEGMA-co-OEGMA) 
block copolymers of 50-150 nm (µFDQGLGDWH¶drug delivery systems) uptake. A number 
of protocols were optimised for endocytosis inhibition studies. 
Results reported that the inhibition of clathrin mediated endocytosis (CME) with 
chlorpromazine (CPZ) was cell- and time-dependent. After the maximal effect of the 
inhibitor, the endocytosis of human transferrin (Htf), a marker of CME, recovered up to 
uninhibited levels in 3T3 and HCT116 cells. Furthermore, high passage number and 
ageing of cells showed a resistance towards the inhibition of the uptake of Htf with 
CPZ. 
Both PLGA-b-(PEGMA-co-PPGMA) and PLA-co-(DEGMA-co-OEGMA) 
thermoresponsive block copolymers presented colloidal instability and aggregation that 
impeded further endocytic pathway internalization experiments. However, the results 
reported in this thesis question some of the interpretation in the literature of the 
susceptibility of cells to CPZ in the internalization of nanomaterials. New experimental 
settings for CPZ inhibition studies should be considered and protocols optimised in 
order to avoid incorrect and potentially misleading outcomes.  
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1.1 Barriers to drug delivery 
Many powerful drugs fail to reach the market because of delivery-related issues. 
Problems such as lack of absorption, poor solubility, poor biodistribution, metabolic 
modification with either rapid loss of therapeutic effect or increased toxicity, and 
undesirable clearance kinetics are all reasons why drugs fail to progress through 
clinical trials1,2. 
Physiological barriers to drug delivery depend on the route of administration and on the 
compartmentalization of the target organ3. For example, in oral administration, the low 
pH in the stomach and consequent adsorption through the gut are important barriers to 
overcome. Other examples of barriers to drug delivery are the blood brain barrier for 
central nervous system delivery of drugs, skin penetration for topical and transdermal 
applications, and mucus penetration for aerosol, gastric, ocular or vaginal 
administration4.  
Drug delivery systems constitute a strategy for overcoming many of these barriers and 
are being actively studied in order to develop and optimise therapy with new drug 
compounds5-8. Amongst the classes of drug delivery systems are those classed as 
µQDQRPHGLFLQHV¶ Materials with at least one dimension ranging between 1 and 100 nm 
have been defined as nanomaterials by the National Technology Initiative, the Food 
and Drug Administration (FDA) and American Society for Testing and Materials9. The 
advantages and applications of FDUULHUV\VWHPVZLWKVL]H UDQJHV LQ WKH µQDQRPDWHULDO
UHJLRQ¶ are numerous. Firstly, they can be easily internalised in cells with an inverse 
relationship between size and absorption; secondly they have a high surface to volume 
ratio that makes the surface chemistry of these materials highly represented and hence 
important for cell/nanoparticle interactions. Finally, the use of nanocarriers of drugs 
could make possible the delivery of nucleic acids for gene therapy which are otherwise 
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challenged by ubiquitous nucleases10,11; they could be loaded with anticancer drugs 
and reduce their side effects and systemic exposure to the drug and toxicity. Moreover, 
they could be employed to increase the solubility of many drugs that are highly 
effective but their application is limited by their poor solubility by loading them in 
hydrophobic compartments of the carrier. Finally, not only therapy, but also diagnostics 
and probe technology, can benefit from these materials12-14. Examples are nanocarrier-
mediated delivery of aptamers (small RNA, single stranded sequences of DNA or 
peptides with high affinity for one molecule or protein due to their specific 3D 
rearrangement)210-212 for the diagnosis of cancer or gold nanoparticles for increased 
sensitivity in the detection of HIV-1 antigen15,16.  
1.2 Strategies for drug delivery 
1.2.1 Nanomaterials in drug and gene delivery 
A great variety of nanomaterials have been designed for use in drug delivery. Many of 
the investigated nanomaterials are based on polymers, usually with monomer 
components to confer surfactant or amphiphilic properties, i.e. with a hydrophobic 
region to interact with a hydrophobic drug compound and a hydrophilic component to 
enable dispersion in aqueous media or the bloodstream. To date, many combinations 
of different polymers have been investigated for drug and gene delivery17-19. 
1.2.1.1 Block copolymers 
When polymers are formed by two different monomers they are called copolymers; the 
two monomer constituents can be present randomly in the structure and in this case 
they are defined as statistical copolymers (Figure 1-1). When monomers of one type 
are grouped together and monomers of a second type are also attached to each other 
the resultant structure is defined as a block co-polymer. Depending on how many 
different monomer sequences and polymers are present, and consequently, how many 
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regions of the polymers can be distinguished, they are named diblock copolymers, 
triblock-copolymers and so on. Triblock copolymers can be classified as A+B+A or 
A+B+C depending on how many different polymers are included in the structure and 
how they are arranged with respect to each other20. Hence, monomers can be 
covalently linked to each other21 and can be formed by homopolymer or more polymers 
with different characteristics and different patterns of assembly. Polymers can be 
linear, branched, or hyperbranched (grafted copolymers, dendrimers) and examples of 
branched and hyperbranched polymers can be viewed in Figure 1-121.  
Polymers can also be bound through electrostatic interactions. Examples are polyion 
complexes (PIC) which are formed by the interaction of two polymers with opposite 
charges or nucleic acid and a cationic polymer for gene delivery22.  
 
Figure 1-1 Examples of block copolymers. In this picture are shown the rearrangement of a linear 
homopolymer, a diblock, an A+B+A and A+B+C triblock copolymers, a random or statistical copolymer 
and a dendrimer. Polymers blocks with different polarities are shown in different colours. 
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Block copolymers can self-assemble into superstructures under certain conditions. The 
assembly can be spontaneous and irreversible or it can be triggered by a reversible 
stimulus.  
1.2.1.2 Stimuli-responsive polymers 
Many approaches have been investigated in order to obtain µintelligent¶ or µsmart¶ 
materials that are able to release a loaded drug to a given target. Common examples 
are pH-sensitive, thermo-responsive, redox, light, ion, magnetic, ultrasound, enzymes-
sensitive polymers and so on22-28. 
Thermo-responsive polymers ZHUH WKH ILUVW µLQWHOOLJHQW V\VWHPV¶ LQYHVWLJDWHG and 
poly(N) isopropyl acrylamide was the first thermoresponsive polymer studied. 
Thermoresponsive polymers can be classified into two groups: polymers that present a 
Lower Critical Solution Temperature (LCST) and polymers that present an Upper 
Critical Solution Temperature (UCST). Thermoresponsive polymers below the LCST 
are soluble in appropriate solutions while above the LCST they lose their solubility 
(Figure 1-2). This effect is driven by the entropy of the system. Above a given 
temperature the most energetically convenient rearrangement of the polymer is out of 
solution. This is caused by the release of the water from the hydrophilic chains of the 
polymer that reduce the solubility of the polymer but also produces an increase of 
entropy which is energetically favourable. This effect is ruled by the Gibbs-Helmholtz 
equation29:  ?ܩ ൌ ܪ െ ܶ ?  ܵ
Where: 
ǻ* IUHHHQHUJ\ 
H= enthalpy 
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T= temperature in Kelvin 
ǻ6 HQWURS\ 
UCST polymers behave in an opposite way and are not solubilised below a given 
temperature while the solution results clear and homogeneous above an UCST. This 
effect is driven by the enthalpy of the system. Thermoresponsive carriers of drugs have 
been investigated for applications in inflammation sites where often a mild temperature 
gradient is present reaching a maximum temperature of 42°C or in conjunction with the 
external administration of mild hyperthermia by near infrared irradiation, ultrasound 
probes or microwave irradiation of the target body region. 
 
Figure 1-2 Schematic representation of the hydration state changes in thermoresponsive polymers 
above their LCST. Above the LCST the water molecules return to the solution and increase the entropy 
of the system and make this rearrangement energetically favourable. 
 
pH-responsive systems are among the most studied and well-characterised polymers. 
Their solubility, volume, configuration or conformation can be reversibly manipulated by 
pH changes30. Methacrylic acid and related co-polymers are examples of pH-
responsive polymers. They are hydrophobic at low pHs and are deprotonated and 
hydrophilic with the increase of pH. Their use has been suggested in the 
gastrointestinal (GI) tract where a pH gradient is present within the stomach (pH ranges 
between 1 and 3) and the jejunum and ileum (pH between 6 and 7) where the pH 
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gradient can trigger the release of the loaded drug. Other applications are in cancerous 
tissues as they are acidic (pH ranges from 6 to 7.2) and at the subcellular level where 
the pH for endolysosome compartments has been reported between 4.5 and 631. 
Other stimuli-responsive systems are sensitive to the naturally reducing environment 
inside the cell (redox polymers). Disulfide groups are often used in these systems as, 
when they reach the inner cellular environment, they are easily targeted by glutathione 
activity and cleaved (Kim et al., 2010 as reported by32). Ion-sensitive polymers have 
also been studied addressing the salting in and salting out properties of chaotrope 
(water structure breaker) and kosmotrope (water structure maker) ions25. Many other 
smart polymers have been reported in the literature but a detailed overview of such 
systems is beyond the scope of this thesis.  
Following stimulation, smart polymers produce a sharp conformational change that, in 
some cases, can be used to rapidly release the loaded drug. A recent new approach 
describes stimuli-responsive vesicles where only the permeability of such structures is 
increased instead of the arrangement being completely lost33. 
1.2.1.3  Micelles and vesicles 
Covalently bound block copolymers can self assemble and produce micelles, which are 
formed by a hydrophilic shell and a hydrophobic core, or vesicles (also called 
polymersomes) with the creation of a hollow compartment surrounded by three layers: 
hydrophilic, hydrophobic and hydrophilic again, as depicted in Figure 1-320. Also non 
covalently bound electro-statically associated polyion complexes can produce micelles 
and vesicles (PICsomes)34. 
Introduction ± Nanomaterials and Endocytosis 
30 
 
 
Figure 1-3 Schematic representation of micelles and vesicles with their typical loads. Hydrophobic 
regions are represented in orange, hydrophilic regions are represented in blue. 
Hydrophobic drugs are usually loaded in the hydrophobic core of micelles or in the 
hydrophobic layer of polymersomes while hydrophilic drugs are usually encapsulated 
into the hydrophilic hollow compartment of polymersomes. Drugs can also be 
covalently linked to polymers. If the drug retains its activity when bound to the polymer 
the structure can be termed a polymer-drug. Here the drug can be directly bound to the 
polymer or can also be bound through a spacer. More often the drug must be released 
by the polymer to be active; in this case, the polymer-drug conjugate is called a 
macromolecular pro-drug. In macromolecular pro-drugs the spacer must be cleaved by 
hydrolytic, oxidative or enzymatic activity and, ideally, becoming susceptible to 
cleavage only when it has reached the target.  
1.2.1.4 Formulation of copolymers into micelles, vesicles and nanoparticles 
Single block copolymers formed by a hydrophobic block and a hydrophilic block are 
surfactants. In other terms they are surface active materials and rearrange at the 
solvent-air surface to reduce the contact of the water insoluble block of the polymer 
with an aqueous solvent. In this way they also reduce the surface tension of the solvent 
at the interphase. Amphiphilic block copolymers can self-assemble in aqueous solution 
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and produce micelles. This process occurs above a critical micellar concentration 
(CMC) that is dependent upon the temperature of the solution and the length of the 
carbon chain of the polymer. Above the CMC the polymers produce aggregates by a 
process called micellarization36. These micelles can be spherical, rod-like (also called 
worms) or rearrange in flat membranes37. However, for all the above-mentioned 
rearrangements, the hydrophobic portion of polymers reorganize orienting their 
structures so that they do not come into contact with the aqueous solution38. The 
hydrophilic region of the polymer produces a corona around the hydrophobic region of 
the micelles minimising the contact area of the hydrophobic core with the incompatible 
solvent39. The micellarization process is reversible and single block copolymers can be 
freed in solution below the CMC of the polymer and this aspect is important in drug 
delivery where the dilution of the micelles in the blood stream below the CMC might 
cause the micelles to disassemble before reaching the target40. 
 
Vesicles are formed in a two step self-assembly process:  
1) The formation of a membrane; 
2) The closure of the membrane into a vesicle41. 
 
In the classical description, the shape of the vesicle is determined by equation 
123(Figure 1-4): 
ࡱ࢛ࢗࢇ࢚࢏࢕࢔૚ ൌ ࢖ ൌ ࢜ࢇ࢒ ൌ ૚ െࡴ࢒ ൅ࡷ࢒૛૜  
Where: 
S VXUIDFWDQWSDFNLQJSDUDPHWHU,VUDHOHDFKYLOL¶VSDUDPHWHU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v = volume of the hydrophobic portion; 
a = interfacial area; 
l = the chain length normal to the interface of the hydrophobic portion; 
H = mean curvature; 
K = Gaussian curvature. 
 
 
ࡼࢇࢉ࢑࢏࢔ࢍ࢖ࢇ࢘ࢇ࢓ࢋ࢚ࢋ࢘ ൌ  ࢜ࢇ࢒ Ǣ ࡹࢋࢇ࢔ࢉ࢛࢘࢜ࢇ࢚࢛࢘ࢋ ൌ ࡴ ൌ ૚૛൬ ૚ࡾ૚ ൅ ૚ࡾ૛൰ Ǣ ࡳࢇ࢛࢙࢙࢏ࢇ࢔ࢉ࢛࢘࢜ࢇ࢚࢛࢘ࢋ ൌ ࡷൌ ૚ࡾ૚ࡾ૛ 
Figure 1-4 Visual description of packing parameter, mean curvature and Gaussian curvature described 
in equation 1. 
 
When the interfacial area increases in proportion to the hydrophilic block length, a 
reduction of the hydrophobic/hydrophilic ratio produces the shift from spherical to 
cylindrical micelles, to membranes and finally to vesicles (Table 1-1). 
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Table 1-1 Correlation between rearrangement of polymers in aqueous solutions and v, a, l, H and K 
parameters. 
 
Other important parameters to consider are the entropy of the system or how stiff the 
block copolymer chain is, its degree of freedom and the level of interfacial energy. If the 
polymer is stiff, with low degree of freedom and entropy, membranes and vesicles are 
more probable. If the interfacial energy is high and the entropy loss is low, association 
thermodynamics are dominated by interfacial area energy minimization arrangements. 
Discher and Eisenberg suggested that a hydrophilic weight fraction of 35% ±10% is 
necessary in coil-coil block copolymers for vesicles formation23,42. Stiffness of a block 
copolymer can be enhanced by complementarities within the block copolymer such as 
VHFRQGDU\ LQWHUDFWLRQV +ERQGV9DQGHU:DDOV HOHFWURVWDWLFʌ LQWHUDFWLRQVDQGVR
on). 
Vesicles easily form when the elasticity of the membrane is low and the surface tension 
is high. The surface tension increases when the concentration of block copolymers is 
low. When the concentration is high instead, the membrane chooses different 
rearrangements such as sheet-like micelles (Figure 1-5)24,41. 
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Figure 1-5 Diagram for PEO-PBO block copolymers rearrangements in solution in relation to their 
concentration in water and their molecular weight. (Diagram from
24
).Reproduced by permission of the 
Royal Society of Chemistry.  
$OVRǻ$ ZKLFKLVWKHGLIIHUHQFHEHWZHHQLQWHUQDODQGH[WHUQDODUHDRIWKHSRO\PHUǻ$
= Ain ± Aext) is another key parameter. A is proportional to the volume to area ratio 
Y ʌ1/2VA-3/2 where V is the volume of the polymer. The following image describes the 
theoretical (a) and observed (b) changes in shape of poly-butadiene - polyethylene-
oxide (PB-PEO) vesicles (Figure 1-6)41. 
 
Figure 1-6 Diagram showing the theoretical (a) and observed (b) shapes of PB-PEO block copolymers in 
solution. (Diagram from
41
). Reproduced by permission of the Royal Society of Chemistry.  
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1.3 Routes of cellular uptake 
The knowledge of the pathway used by nanocarriers to access cells is an important 
starting point to design efficient transporters of drugs and it is being intensely 
investigated for this purpose. For this reason the current state of understanding in cell 
uptake pathways, essential protein machinery and compartmentalization are 
considered below. 
Eukaryotic cells use many different endocytotic mechanisms, some of which are still 
poorly understood. Endocytosis is an essential pathway for the uptake of nutrients and 
communication, and it is also used by toxins and viruses to enter cells43. It can be 
divided into two main subgroups: phagocytosis and pinocytosis. The classic definitions 
of phagocytosis and pinocytosis are now widely accepted. Phagocytosis is the 
internalization of solid materials and it is usually carried out by specialised phagocytic 
cells such as macrophages, neutrophils, monocytes and dendritic cells43. Pinocytosis is 
an ubiquitous process by which cells engulf liquids. Once internalised, cargoes 
undergo sorting towards different compartments and this often happens with the help of 
Ras-like small G proteins (Rabs). Rabs GTPases are the most prominent group of 
Rabs44, they are a group of about 63 membrane proteins and control many processes 
such as endocytosis, trafficking, endosomes-membrane fusion and exocytosis45,46. 
Examples of compartmentalization involving Rabs include endocytic vesicles and early 
endosomes (Rab5), late endosomes (Rab7), recycling endosomes (Rab4), the 
movement of vesicles from the trans-Golgi network to the plasma membrane (Rab11), 
endosomes directed to the Golgi (Rab9) and endoplasmic reticulum (Rab1 and 2)45,47.  
SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) are 
another important category of proteins. They are involved in membrane fusion of 
intracellular compartments and hence are a key class of proteins for endocytic 
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compartment maturation and in traffic48. They bind SNAP (synaptosome-associated 
protein) receptors on the target membrane and can be localised in vesicles, and they 
are defined as v-SNAREs, or on the target (t-SNAREs). Their hallmark is a SNARE 
motif which is constituted by a sequence of 60-70 amino acids that is formed by a 
series of 7 amino acid repeat units (heptad repeat). Monomeric SNAREs are not 
organised in a defined structure, but, upon assembly organise in helices of high 
stability and produce a hydrophobic core where strongly conserved hydrophilic amino 
acids reside. Each SNARE bears one of these amino acids so that three SNARE 
proteins consist of glutamines (Q) and one of arginine (R). The respective SNAREs 
proteins are named Qa,Qb, Qc and R-SNAREs46,49.  
1.3.1 Endocytic compartments 
Upon endocytosis, the endocytic vesicle is directed towards the first cellular 
compartment: the Early Endosome (EE). EE is composed of a thin tubular extension of 
about 60nm and vesicular regions of about 400nm that present a multivesicular 
structure of an immature multivesicular body (MVB). These two morphologies of 
different regions of the same EE are believed to be essential for the subsequent 
processing and compartmentalization of the endocytosed cargo where, for example, 
recycling cargoes cluster around tubular membranes with a local pH of 6.5, while 
cargoes undergoing a degradative pathway cluster around MVB structures of the same 
compartment in which the pH of the lumen is more acidic (ranging between 6.2 and 
5.5)50. The acidification process occurs through vacuolar type H+ ATPases (V-
ATPases) membrane proton pumps. EE are enriched in Rab5, in phosphatidylinositol 3 
phosphate (PI3P), early endosome antigen 1 (EEA-1) and they interact with actin and 
microtubules tracts that confer motility to the compartment 51,52.  
Another well-characterised subcellular compartment is the late endosome (LE). It is 
believed to be generated by maturation of EE where it becomes gradually enriched in 
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Rab7 and other proteins. This organelle is a pre-lysosomal compartment of about 100-
600nm that the endocytosed cargo access roughly after 4-30 min from endocytosis in 
mammalian cells. It is more spherical with respect to EE and is formed by MVBs that 
are the hallmark of this compartment. LEs can in fact also be referred to as MVBs or 
multivesicular endosomes. They have intraluminar vesicles with an average size of 
about 50 nm and are formed by the action of endosomal sorting complex required for 
transport (ESCRT). The ESCRTs are a relatively recently discovered class of proteins 
required for the inward invagination of the endosomal membrane to produce 
intraluminal vesicles53. LE are distinguished from the EE because they are more acidic 
(pH 5-5.5) and enriched in markers proteins such Rab7, and from the lysosomal 
compartments because they present mannose phosphate receptors (MPRs) that 
transport newly synthesised lysosomal protein from the Golgi complex. MVBs can 
mature to lysosomes or fuse to the plasma membrane and release intraluminar 
vesicles in the extracellular compartment in the form of exosomes49,54,55.  
Lysosomes are another compartment that endocytosed cargoes can be directed to. 
They are degradative compartments of less than 1µm in non specialised cells but can 
become larger in macrophages. They are enriched in hydrolases, and it is accepted 
that molecules smaller than 200Da can diffuse freely though their membrane. 
Lysosomes present about 20 different membrane transporters but to date only 3 have 
been fully characterised. They also present V-ATPases that acidify the pH of the lumen 
of the organelle to around 4.5. Lysosomes are defined as MPR negative and are 
positive for lysosomes associated membrane proteins 1 and 2 (LAMP1/2)56. 
Occasionally lysosomes can present multilamellar structures in their lumen. However, 
these compartments are unrelated to multivesicular bodies (MVB). Lysosomal 
degradation products can be directed to the trans-Golgi-network or exocytosed57. 
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Autophagosomes are other characteristic compartments that a cargo can be directed to 
by a process called autophagy that occurs during amino acid and nutrient starvation, 
oxidative stress and radical oxygen species production (ROS)58. Autophagy is 
dependent on lysosomes and is used by cells for the degradation and recycling of 
intracellular components. There are 4 different categories of autophagy in 
mammalians, classified as macroautophagy, microautophagy, chaperone-mediated 
autophagy and piecemeal microautophagy59. Macroautophagy relies on the use of 
specialised vesicles localised in the cytosol that engulf a cytoplasmic components and 
that ultimately fuse with a lysosomes. Microautophagy relies on the production of 
invaginations directly on the membrane of the lysosomes that envelops parts of the 
cytoplasm that are for degradation; chaperone-mediated autophagy uses chaperones 
that unfold proteins that are then translocated into the lysosomes59; piecemeal 
microautophagy has been observed in yeast and occurs by degradation of portions of 
the nucleus that are carried into a vacuole, where the vacuole is the yeast equivalent of 
lysosomes. The most common and best characterised process of autophagy is 
macroautophagy. It happens with a phagophore, also known as an isolation 
membrane, which has been suggested to originate from the point of contact of the 
endoplasmic reticulum and the mitochondria60. This membrane elongates and 
envelopes around the cytoplasmic components that are intended for degradation and 
produces a compartment called autophagosome with a double membrane. This 
structure is then fused with different compartments of the endocytic process. An 
autophagosome shares the same machinery that is used for endocytosis and fuses 
with an EE, subsequently with a LE and finally a lysosome and produces a 
autolysosome, this process is called maturation of the autophagosome61,62.  
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1.3.2 Membrane domains 
Eukaryotic membranes possess a high variability in lipid composition and are formed 
by hundreds of different lipids. The membrane bilayer has evolved the ability to 
segregate its constituents laterally by dynamics of liquid-liquid lipids immiscibility. 
Different regions have been recognised on the plasma membrane, and can be seen as 
a mosaic of organised microdomains enriched in a few lipids that associate and are 
supplemented with specific plasma membrane proteins63. This organization defines 
specialised subcompartments on the membrane that are used for endocytosis, 
signalling and trafficking. Lipid rafts are one of these domains. Lipid rafts are 
membrane microdomains of about 50 nm in diameter, with a membrane composition 
that differs from the adjacent areas and these are enriched in cholesterol, glycol-
sphingo-lipids, sphingo-myelin, long and unsaturated phospholipids, proteins bound to 
glycosyl-phosphatidyl-inositol as well as some membrane spanning proteins64,65,66. 
These structures are present as a metastable state that can be activated by specific 
lipid-lipid, lipid-protein and protein-protein interactions66.  
Another of the defined domains involved in endocytosis consists of clathrin-enriched 
large patches that have been described in both adherent and non adherent adipocytes. 
They present little lateral mobility and are also enriched with phosphatidylinositol 4,5 
bisphosphate (PI(4,5)P2), cholesterol and receptors that are endocytosed by this 
pathway67-70. This structure also defines a membrane ruffling region where ruffling can 
be triggered by an unconventional myosin 1c expression. Ruffles are regions on the 
plasma membrane that arise when exocytosis is activated and actin polymerization 
pushes outward the membrane71. Myosin 1c expression is also responsible for 
exocytosis of GLUT4 (glucose transporter 4) vesicles in adipocytes and for E-cadherin-
mediated cell-cell adhesion, both processes also rely on PI(4,5)P2 presence in the 
plasma membrane and also actin-enriched membrane projections72-75. 
Introduction ± Nanomaterials and Endocytosis 
40 
 
1.3.3 Phagocytosis 
Phagocytosis (Figure 1-7) is carried out primarily by specialised phagocytes such as 
macrophages, monocytes, neutrophils and dendritic cells and it is a highly efficient 
process. Fibroblasts, epithelial cells and endothelial cells are also known as non-
professional or paraprofessional phagocytes and can uptake particles via phagocytic 
mechanisms but to a lower extent with respect to phagocytic professional cells. Also 
many other cells have phagocytic capacities, for example thyroid and bladder cells 
phagocytose erythrocytes in vivo and other cells have been induced to phagocytose in 
vitro76. The major differences between professional and non professional phagocytes 
are in the numbers of phagocytic receptors on their membrane; these receptors both 
speed up the process and allow a wider range of particles to be recognised and 
phagocytosed76.  
Even if every specialised cell has different fine tuning events in the phagocytic process 
three general steps can be distinguished: 
a. Opsonisation of the particle. This usually occurs in the bloodstream 
and consists of tagging the target element with opsonins such as antibodies (especially 
IgG and IgM), complement elements C3, C4 and C5 (by complement activation via the 
classical, alternative or lectin pathway) and blood serum proteins such as laminin, 
fibronectin, C-reactive protein and type-I collagen and many others which opsonise 
foreign hydrophobic particles77-79. 
b. Recognition of the opsonised particle by the phagocytic cell. 
Opsonised particles are recognised by specific receptors on the phagocytic cell such 
as Fc receptor for antibodies and complement receptors. Mannose/fructose and 
scravenger receptors can also be involved in phagocytic mechanisms while many other 
receptors (i.e. CD44 receptors) are still being discovered.  
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c. Engulfment of the particle ± Phagosome formation. Opsonin±
phagocytic cell interaction activates a transduction cascade via the Ras homolog 
oncogene (Rho) ± family small GTPase that induces actin polymerization and activates 
the phagocytic process. The engulfment occurs via the formation of cytoplasmic 
protrusions or sinking for complement receptors-mediated endocytosis that finally 
enwrap the opsonised particle and translocate it into the cytoplasm (Figure 1-7)80. 
During phagosome formation the actin filaments depolymerise and make the 
phagosome accessible by early endosomes that finally mature to late endosome and 
lysosomes and produce a phagolysosome. The compartment is acidified by proton 
pump ATPases located on the membrane and enriched with digestive enzymes such 
as esterases and cathepsins as well as chemical factors such as superoxides and 
hydrogen peroxide to degrade the phagocytic load.  
 
Figure 1-7 Phagocytosis internalises different materials by different mechanisms of engulfment at the 
plasma membrane. 
 
Introduction ± Nanomaterials and Endocytosis 
42 
 
1.3.4 Clathrin-mediated endocytosis 
Clathrin-mediated endocytosis (CME, Figure 1-8) takes place for many essential 
events and well-studied examples are: low density lipoproteins (LDL) and transferrin 
receptor (TR) uptake. Other examples of receptor-mediated endocytosis though a 
clathrin-mediated mechanism are protease-activated receptor 1 (PAR1), the cation-
independent mannose 6-phosphate receptor (CI-MPR). Also amyloid precursor protein 
(APP) and epithelial growth factor (EGF) access cells thorough CME. CME also has a 
key role in intracellular signalling and regulation of the expression of cell membrane 
receptors and ion channels, the movement of receptors in other compartments of the 
cell, synaptic transmission as well as uptake of toxins and viruses. It is also clathrin-
mediated the µ]LSSHULQJ¶RIEDFWHULDZKHUHWKHODWWHUSURFHVV is used by pathogens that 
express proteins on their plasma membrane that interact with host receptors and 
trigger internalization81-90. 
CME is the best-characterized endocytic process. The unravelling of its mechanism of 
action has taken place over the past 30 years. Crystal structures of components of the 
CME such as clathrin, adaptor proteins and the combination of these proteins in the 
presence and the absence of their substrates has provided evidence at the molecular 
level of the mechanisms of CME. The best characterized process in CME is the 
formation of the clathrin lattice at the plasma membrane. This paragraph, although not 
exhaustive of all the evidence present in the literature, gives an overview of the CME 
and it reveals the complexity of this endocytic process. This complexity is most likely to 
be applied to other endocytic pathways that are far less characterized at the present. 
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Figure 1-8 Mechanisms of endocytosis. In the schematics are shown macropinocytosis, phagocytosis, 
clathrin- and caveolin-mediated endocytosis and clathrin-independent carrier 
glycosylphosphatidylinositol anchored protein enriched endocytic compartments (CLIC-GEEC) 
endocytosis. The dotted lines show pathways that are not fully confirmed in the literature. 
 
1.3.4.1 Clathrin, a brief introduction 
Clathrin is a protein formed by three heavy chains of about 192kDa, each of which is 
bound to one of the two 30-kDa isoforms of the light chains: LCa and LCb. The 3 heavy 
chains produce a structure that is called triskelion or trimer. The heavy chain has an 
DPLQR WHUPLQDO ȕ SURSHOOHU GRPDLQ and 7 WD40 ȕ-sheet repeats followed by 42 Į-
helical zig-zags of about 30 amino acids, a longer final Į-helix of 45 amino acids and a 
more flexible structure at the C-terminus of the protein91. The C-terminus contains a 
domain that is recognised by the heat shock protein family 70 (HSP70). This region is 
necessary for the disassembly of the clathrin cage after endocytosis and becomes 
accessible only upon assembly of the clathrin cage. The Į-helix domain produces a 
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FXUYHG VWUXFWXUH WKDW LV FDOOHG µOHJ¶ From the vertex where all the 3 legs of clathrin 
converge, a single Į-helix of clathrin light chain departs and connects on one heavy 
chain92,93. The presence of the clathrin light chain does not seem to be necessary for 
the CME, however it has been suggested that this Į-helical structure confers rigidity to 
the clathrin helping the CME process.  
1.3.4.2 Assembly Peptide (AP) proteins family 
Other essential components of the forming clathrin pit are the assembly polypeptides 
(APs). At the present 5 AP proteins are known, AP1, AP2, AP3, AP4 and AP5. Their 
schematic structure is shown in Figure 1-9. They are formed by 2 large L-shaped 
opposing regions that together form a squared µERZO¶VWUXFWXUH94. These two regions are 
FDOOHGȖ DQGȕ in AP1Į DQGȕ2 in AP2į DQGȕ3 in AP3, İDQGȕ3 in AP4, ȗ DQGȕ5 in 
AP5. On the same AP protein also two small domains are present. They are called ı
and µ and numbered from 1 to 5 depending on what AP protein they belong to; WKHı
regions interact with the two L shaped large regions at one point of contact while the µ 
GRPDLQ LVSRVLWLRQHGRYHUWKHDQJOHRIWKH/VKDSHGȕUHJLRQ (Figure 1-9)95-97. At the 
other point of contact of the large L shaped proteins two flexible domains called hinges 
are present, each one propelling from one of the L shaped regions, and each hinge 
connects to a small globular region forming a structure resembling antennae. In AP5 
the described antennae region is not present. AP proteins are present in two 
FRQIRUPDWLRQVµRSHQ¶DQGµFORVHG¶AP2 is responsible for the CME and it anchors the 
forming clathrin pit to the plasma membrane because clathrin itself does not contain 
any motifs for membrane binding (Figure 1-10). The other AP proteins are localised in 
different compartments of the cell and are responsible for clathrin-dependent cargo 
sorting to different intracellular compartments97. When AP2 is in the closed 
conformation the protein is localised in the cytoplasm and the cargo binding sites are 
not accessible. When the AP2 FKDQJHVFRQIRUPDWLRQWRDQµRSHQ¶IRUm (most probably 
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subsequently to phosphorylation by a AAK1, a kinase of the Prk/Ark serine/threonine 
kinase adaptor associated kinase family95) its cargo binding site present on the µ2 
subunit becomes accessible and FDQ UHFRJQLVH WKH <[[Ɏ PRWLI RQ the cytoplasmic 
region of trans-membrane proteins that can be endocytosis by CME83 (Figure 1-9 and 
1-10)7KH<[[ɎPRWLILVDOLQHDUVHTXHQFHRIamino acids that is widely used by cells 
in cargo sorting. It is a tyrosine-based sorting signal and the amino acid sequence is 
arranged as follows: Y is a tyrosine, x is any amino DFLGDQGɎLVDbulky hydrophobic 
amino acid (e.g. leucine, isoleucine, methionine, valine or phenylalanine)98. The µ2 
subunit is also responsible for the binding of PI(4,5)P2 on the C-terminal domain 
producing a bridge between the plasma membrane and the forming clathrin lattice95. 
2QWKHĮVXEXQLWanother common sorting motif recognition site becomes accessible in 
WKH µRSHQ¶FRQIRUPDWLRQupon phosphorylation and it is the dileucine-based sequence 
[DE]xxx[LI], were D represents an aspartic acid, E is a glutamic acid, L is a leucine and 
I is an isoleucine and x is any amino acid. The latter motif binds the nascent clathrin 
lattice interacting with EPS15 (epithelial growth factor receptor pathway substrate 15), 
amphiphysin and dynamin adaptor proteins. The hinge box of the ȕ2 subunit express a 
recognition site for clathrin called clathrin box that express an amino acid sequence as 
IROORZV/Ɏ[Ɏ'(ZKHUH[LVDQ\amino acid DQGɎLVDEXON\K\GURSKRELFamino acid 
and L is a leucine, D an aspartic acid and E a glutamic acid95,44,99-104. 
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Figure 1-9 Schematic representation of the AP adaptor proteins. A. Schematic representation of all the 
AP proteins known in their close configuration. B. AP2 protein in its close (left) and open (right) 
configuration.(Readapted from
97
). 
 
 
Figure 1-10 Schematic representation of the AP2 protein in its open state. dŚĞƌĞŐŝŽŶƐŽĨƚŚĞ ‘ĞĂƌ ? ?ĂůƐŽ
called appendage from some authors) known interactions are described in this Figure. (Readapted 
from
95
). 
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1.3.4.3 Clathrin nucleation at the plasma membrane and lattice assembly 
There are at least two distinct mechanisms of endocytosis called canonical and non-
canonical clathrin-mediated endocytosis. The canonical pathway is shared by LDL, 
EGF, transferrin and asialoorosomucoid and it is based on the evidence that all four 
clathrin-coated pits produced by the internalization of the above mentioned cargoes are 
identical. The non-canonical pathway is used by pathogens; requires clathrin and actin 
and follows a pathway and relies on accessory proteins that can differ from the 
canonical pathway88,93.  
1.3.4.4 The canonical clathrin pathway  
Upon receptor binding, one clathrin triskelion arrives at the clathrin pit. Only one 
clathrin triskelion arrives in 70% of the cases; less frequently, there are 2 or 3 
triskelions arriving at the same time. The clathrin triskelion arrives already bound to two 
AP2 proteins99. AP2 has been proposed to work as a hub where clathrin and other 
adaptor proteins that are specific for one internalising receptor are associated. These 
adaptor proteins have binding motifs for the receptor and also bending activity. This 
implies the formation of specific clathrin pits depending on the membrane protein 
endocytosed and the sorting of the specific cargo starts already at the assembly of the 
coated pit105. The F-BAR protein (Fer-CIP4 homology Bin/amphiphysin/Rvs protein) 
containing family FCHo1/2 (Fer/Cip4 homology domain-only (FCHo) protein 1 and 2) 
are not essential for the coated pit formation and have been suggested as part of a 
complex that stabilises the coated pit as 70% of the forming coated pits are not 
completing their process of endocytosis99,106. The FCHo1/2 proteins bind to the coated 
pit at low curvatures of the membrane and enhance the curvature by a bending 
activity105. Other members of this stabilising complex for the clathrin coated pit 
progression are epsin 1-2 and 3, EPS15, and intersectin99,107. In these conditions the 
clathrin triskelion starts assembling in a process that is called nucleation; the 
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progression of the assembly of the clathrin lattice then occurs at increasingly 
accelerated rates. A mean of 4 legs from different clathrin triskelions overlap and 
produce a cage-like structure that is formed mainly by hexagons but also by heptagons 
and pentagons108. Pentagons are essential to produce a curved cage where otherwise 
hexagons would produce a flat cage. The centre of the triskelion produces a tripod-like 
VWUXFWXUHWKDWLVIRUPHGE\WKHORQJWHUPLQDOĮ-helix of 45 amino acids followed by the 
C-terminal domain. This region stabilises the forming clathrin cage interacting with 
distal clathrins93. Actin involvement of CME has been questioned as the inhibition of 
actin polymerization does not reduce the levels of CME. However, microscopy has 
provided evidence of actin branched polymers at the endocytic site and around the 
neck of the forming endosomes109,110. Kirchhausen and co-workers showed that the 
inhibition of actin polymerization did not inhibit the growth and un-coating of a clathrin 
pit but it interfered with the formation of new clathrin pits and large clusters of clathrin 
and AP2 proteins were observed111. It has been proposed that actin is essential only 
when there is high membrane tension for example in adherent cells and when the 
cargo is unconventional and bulky (e.g. vesicular stomatitis virus, see also non-
canonical clathrin pathway)88. The last step of CME is the detachment of the clathrin 
vesicle from the plasma membrane. This process, also called membrane pinching, 
occurs through a large (100kDa) GTPase called dynamin112. This protein exists as a 
tetramer and upon contact with a lipid bilayer can produce rings, spirals and helical 
tubes structures. It is believed to constrict the neck of the forming clathrin vesicle and it 
has been recently demonstrated that the numbers of dynamins bound to the neck of 
the clathrin vesicles vary between 26 (20% of pits), 26-52 (55%) and 52-70 (20%). 
Once the clathrin pit has pinched off the endocytic vesicle the clathrin cage starts a 
process of destabilization and uncoating that is rapid and leaves promptly the emerging 
endocytic vesicle. Upon detachment of the clathrin vesicle from the plasma membrane, 
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auxilin is recruited and arrives at the clathrin lattice. Auxilin binds by J-domains at the 
C-terminal domain of the clathrin at the vertex of the tripod structure described above. 
One auxilin binds to each clathrin, bringing up to 3 J-domains at the tripod, enlarging 
the funnel-like structure of the tripod and making it accessible to Hsc70 (heat shock 
cognate protein 70)113. The latter protein belongs to the HSP70 family and bears a 
ATPase domain which, upon contact of the Hsc70 with the J-domain of auxilin, 
hydrolyses the ATP and changes the conformation of the Hsc70 to a closed state 
where interacts with a HSP70 binding motif on the clathrin tripod at the C-terminal. This 
interaction deforms the clathrin and it has been proposed that the more these deformed 
conformations are present at the clathrin tripods of the clathrin lattice, the more the 
clathrin lattice is destabilised and the quicker the disassembly of the clathrin pit108. 
Vesicles are then sorted towards two different kinds of endosomes, fast maturing and 
slow maturing endosomes. Fast maturing endosomes are targeted with Rab5 and 
acquire Rab7 within 30 seconds; slow maturing endosomes present only Rab5 on their 
membrane and do not acquire Rab7 after 100 seconds but acquire Rab11, which is a 
target for a recycling pathway. LDL, influenza virus and EGF are targeted towards fast 
maturing and high mobility early endosomes that are also Rab5 and 7 positive or 
become Rab7 positive within 30 seconds, while transferrin can be targeted towards 
both sorts of fast or slow maturing early endosomes101. 
1.3.4.5 The non-canonical clathrin pathway 
Some pathogens have refined their machinery for host invasion and use the clathrin 
endocytic proteins that are hijacked for their invasion purposes. An example is the 
enteropathogenic Escherichia coli, a bacterium that adheres to the membrane of host 
cells but is not internalised. It recruits clathrin which is used as a signalling molecule 
and triggers actin polymerization, does not require AP2 but uses an alternative 
endocytic protein disabled adaptor-2 (DAB2) that has a PI(4,5)P2 binding motif and it 
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has been suggested to require PI(4,5)P2 for endocytosis114. However, as for clathrin 
endocytosis it also requires epsin 1, dynamin and EPS15. In this way the bacterium 
produces a sort of pedestal that is used to bind on the membrane of host cells88. 
Another mechanism that is used by pathogens is the zippering which involves CME. 
Some pathogens, (e.g. Listeria monocytogenes, a bacterium that causes Listeria fever 
that can complicate to meningitis in immunodeficient subjects) express surface proteins 
that bind host cellular receptors and trigger clathrin-dependent internalization that only 
partially involves the machinery used in canonical clathrin endocytosis. As in the case 
of enteropathogenic Escherichia coli, Listeria monocytogenes needs clathrin, dynamin 
and DAB2 together with EPS15, cortactin and cortactin-interacting protein CD2AP 
(CD2 adaptor protein) and Huntingtin-binding protein 1 related (HIP1R). The latter 
protein is also involved in the binding of actin and clathrin at the endocytic clathrin pit. 
Neither pathogens require AP2 for exploiting their pathogenic action while 
phosphorylation of clathrin heavy chain also stabilises clathrin beneath the bacterium88.  
1.3.4.6  The endocytosis of transferrin 
Transferrin endocytosis occurs through a receptor-mediated endocytosis of the 
transferrin receptor 1 that is localised on clathrin coated pits. When the transferrin 
receptor binds holo-transferrin, which is a form of transferrin binding 2 ions of iron, the 
CME is triggered and the internalization of the transferrin-receptor complex occurs. The 
endocytic vesicle soon fuses with sorting or early endosomes. The pH of the endocytic 
vesicle is acidified and the iron load is released. However, the transferrin stays tightly 
bound to the transferrin receptor until the complex is recycled on the plasma 
membrane where the neutral pH of the extracellular compartment releases the 
transferrin from the receptor115. The transferrin receptor has been monitored with real 
time fluorescent Rab cell imaging. This method has allowed the recognition of two 
populations of endosomes, one fast maturing that is tagged with Rab5 and within 30 
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seconds also conjugates with Rab7, and a slow maturing population of endosomes that 
does not conjugates with Rab7 after 100 seconds from the internalization of the 
transferrin116. The transferrin receptor and transferrin complex can both undergo quick 
recycling on the plasma membrane (this process occurs in about 4 minutes from the 
internalization) or can be directed towards a late endosomes and recycling 
compartment delaying the recycling of the receptor on the plasma membrane to 24 
minutes47. This process occurs with the association of the transferrin-receptor complex 
with Rab5 and EEA1 for early endosome localization. Then the vesicles become 
enriched with Rabenosin and Rab22a and these proteins are believed to define the fate 
of the transferrin-receptor complex towards a recycling fate117-119. 
1.3.4.7 Involvement of clathrin with phagocytosis 
Clathrin has been recently found to be involved in phagocytosis. A recent paper using 
PLFUR 51$V VKRZV WKDW &+&Į LV LQYROYHG LQ SKDJRF\WRVLV processes in shrimp 
hemocytes and murine macrophages RAW264.7120. The same CHC has also been 
found involved in phagocytosis of apoptotic bodies by non-professional gliar cells 
during neuron differentiation and development. The paper showed a mechanism 
involving GULP, an adaptor protein involved in phagocytosis, associated with Jedi-1, a 
mammalian engulfment receptor also involved in phagocytosis. The phagocytic 
process was inhibited by the loss of interaction of a tyrosine phophorylated form of 
CHC and GULP121.  
1.3.5 Caveolae-dependent endocytosis 
Caveolae-dependent endocytosis (CDE) is one of the best known uptake pathways 
after CME (Figure 1-8). Caveolae are flask-shaped invaginations of the cytoplasmic 
membrane that range between 50 and 100 nm in size in the wider part of the flask 
(typical values are 50-80nm). These invaginations are present in lipid rafts rich in 
caveolins, a family of cholesterol binding proteins and a membrane integral protein of 
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21kDa122, as well as cholesterol and glycolipids123,124. They are highly stable and are 
produced spontaneously when caveolin-1 interacts with glycolipids of the membrane 
raft domains and disappear upon cholesterol depletion122,125. Their stability is given by 
the interaction with the underlying actin cytoskeleton and only upon specific signals 
they are internalised in endocytic vesicles.  
Endothelial cells are rich in caveolae that can constitute up to 10-20% of the 
cytoplasmic membrane. Abundance in caveolae has also been reported in smooth 
muscle cells, fibroblasts, skeletal muscle cells and adipocytes. The composition, 
function and appearance depend on the cell type. Caveolae in the endothelial cells are 
usually more narrowed at the neck of the flask shaped invagination and may have a 
diaphragm that reduces diffusion processes. Muscle cells present caveolae clusters of 
linear rows that produce the T-tubes while caveolae in epithelial tissues do not contain 
a diaphragm and are generally smaller122. Caveolae are formed by caveolin proteins, 
caveolin-1, caveolin-2, 3 and 4. Caveolin-1 and 2 are ubiquitous while caveolin-3 and 4 
are present in the striated muscle of cells43; caveolin-1 is essential for the formation of 
caveolae, together with cavin-1. Caveolin-1 is also present in bacteria where it triggers 
vesicles formation without cavin-1. However, in mammalian cells cavin-1 is essential 
for the formation of endocytic vesicles, while caveolin-1 is unstable and is quickly 
degraded in the absence of cavin-1126. Caveolae components can be isolated as a 
single 80S complex and the stoichiometry of the proteins components of this complex 
appear to be 12 caveolin-1, 3 cavin-1 and 1 caveolin-2 or 3 implying that cavin-1 can 
form trimers126. In the past two years two other proteins taking part in the caveolae-
dependent endocytosis have been discovered. They are Pacsin 2 (also known as 
Sindapin 2) that presents a BAR sensing/binding motif that induces membrane 
curvature and is involved in caveolae morphogenesis and partially colocalize with 
caveolae127-129. The other protein is EPS15 homology domain-containing protein 2 
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(EDH2). It is an ATPase present in caveolae and its action is involved in actin binding 
and caveolae stabilization. Immuno-electron microscopy studies show that the protein 
is also localised at the neck of the caveolae127,130,131. Caveolins have a specific 
orientation within the membrane as both the N and the C termini lie into the cytoplasm 
and are connected by a hydrophobic domain that is buried but does not span the 
membrane122. Furthermore, caveolins bind to palmitoyl acid on the C-terminus, to 
cholesterol and can be phosphorylated on tyrosine residues and aggregate and 
produce dimers or oligomers122. Cavins also are important coating proteins taking part 
in caveolae-mediated endocytosis. These proteins chaperone the formation of the 
membrane curvature but detailed mechanistic information on how these interact with 
caveolin and other caveolae components are not yet available132. Other components 
WKDWSOD\DUROHLQWKHFDYHRVRPH¶VVXEVHTXHQWIXVLRQZLWKWKHWDUJHWFRPSDUWPHQWDUH
vesicle associated membrane protein (VAMP2) and synaptosome associated protein 
(SNAP). Particles internalised by caveolae slide along the cell membrane until they 
reach a caveolae invagination78. The particles are anchored to the membrane during 
the caveolae-mediated uptake, which has been reported as a slower process than the 
clathrin-mediated uptake. This event could occur via receptor-ligand interactions. The 
closure of the vesicle occurs via the dynamin GTPase action. The resulting vesicle has 
typical values of 60-70nm and does not have any specific enzymatic content or low pH 
environment although some authors have reported that unassembled caveloin can be 
directed towards degratative lysosomal compartments by ubiquitination and the help of 
ESCRT proteins133.  
Caveolae appear to be formed into the Golgi complex where they are associated with 
cholesterol, undergo partial oligomerization of caveolin-1 and become detergent 
resistant. 
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Often caveolae cargoes overlap with clathrin-independent carriers and a study has 
shown that caveolin-1 specifically binds to a guanine nucleotide dissociation inhibitor 
attached to cdc42 (cell division control protein 42) protein which is implicated in 
clathrin-independent carriers (GPI) ± glycosylphosphatidylinositol anchored proteins 
enriched endocytic compartments (CLIC/GEEC) endocytosis134. Furthermore, depletion 
in caveolin-1 has been reported to increase cdc42 activation at the plasma membrane. 
The multi-functionality of caveolin-1 is also demonstrated by its interaction with 
endothelial nitric oxide synthase (eNOS). The binding of these two elements inhibits 
the enzymatic activity of eNOS while the disaggregation of the complex causes 
activation and production of nitric oxide and vessel dilation in vivo. 
Other evidence suggests that caveolae-dependent and non-caveolar raft endocytosis 
may be connected64. Nichols et al suggested that caveolin-mediated uptake may be 
effective in endothelial cells that express high rates of caveolins and caveolae while 
other mechanisms64 could be activated in cells with lower concentrations of both 
caveolins and caveolae64.  
Caveolin has also been implicated in the down-regulation of platelet derived growth 
factor (PDGF) and EGF via the inhibition of their receptors that are present on 
caveolae. Over-expression of caveolin-1 inhibits such receptors. Na+/K+ATPase are 
also present in caveolae and appear to exert a regulatory function135. 
Caveolae-mediated receptor endocytosis has been reported for folic acid, albumin and 
cholesterol internalization as well as for viruses (SV40, virus-Simian Virus 40, and 
polyoma virus) and the prion protein. Also this pathway is sensitive to cholesterol 
depletion78,136 and, upon cholesterol depletion or oxidation, caveolae relocate to 
endosomes, Golgi complex or endoplasmic reticulum122.  
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1.3.6 Non-clathrin, non-caveolae-mediated endocytosis 
Non-clathrin and non-caveolae-mediated endocytosis have not been extensively 
studied because of the lack of known specific cargoes that are endocytosed by one of 
these pathways. However, recently some markers of clathrin- and caveolin-
independent endocytosis have been recognised. They are the major histocompatibility 
complex 1 (MHC1), interleleukin 2 receptor ɴ (IL2Rɴ) and glycosylphosphatidylinositol-
anchored proteins (GPI-APs) and some more information have started to emerge137. 
However, data on these pathways are still fragmentary. For example, MHC I dependent 
endocytosis was found to necessitate of dynamin, tyrosine kinase and ubiquitin for 
correct endocytosis. IL2Rɴ relies on actin though the regulation of PAK 1 and 2 (p21-
activated kinase 1 and 2), Ras-related C3 botulinum toxin substrate 1 (Rac1), dynamin 
and phosphatidyl inositol 3 kinase, (PI3K) that are also essential in macropinocytosis 
but a clear understanding of the mechanism is still not known138-140. 
1.3.6.1 CLIC-GEEC endocytic pathway 
The Clathrin-independent carrier/GPI-AP-enriched early endosomal compartments 
(CLIC-GEEC) pathway is an important uptake route of bulk fluid uptake in fibroblasts137. 
The endocytic cargoes internalised by this pathway have a peculiar ring or tubular 
morphology141. The CD44 membrane glycoprotein receptor is internalised by this route 
and it has been used as marker of the pathway. The CD44 receptor is responsible for 
the uptake of hyaluronic acid and it is involved in cell-cell interaction, adhesion and 
migration. It localises with lipid rafts but upon stimulation and binding of its ligand ezrin, 
CD44 translocates to a different membrane region and partially colocalises with the 
transferrin receptor142. CLIC-GEEC endocytosis is regulated by the protein GTPase 
regulator associated with focal adhesion kinase-1 (GRAF-1) that possesses GAP 
activity and inhibits the activity of small GTPases by accelerating the hydrolysis of GTP 
to GDP143. It has been shown to display such activity on the small GTPases RhoA, that 
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also displays actin cytoskeleton activity, and cdc42 through the interaction of FAK 
(focal adhesion kinase) DQG3.1ȕNLQDVHV (protein kinase 1FRQVWUXFWȕ144,145. GRAF-
1 also presents a BAR domain for the membrane deformation activity necessary to 
form endocytic vesicles, a PH domain (Pleckstrin Homology domain, involved in cell 
signalling and trafficking) and a SH3 domain (SRC- sarcoma oncogene homology 3 
domain) and a prolin rich region that is a SH3 binding domain as well146. GRAF-1 BAR 
and PH appear to be important for the formation of tubular endocytic structures and the 
protein showed affinity for PI(4,5)P2 suggesting a PI(4,5)P2 mechanism for the 
anchoring of the protein to the plasma membrane. GRAF-1 needs dynamin for 
endocytosis, appears to colocalize with caveolin-rich domain of the plasma membrane 
but does not colocalize with clathrin143. 
1.3.6.2 Macropinocytosis 
Macropinocytosis was the first endocytic process indentified by Lewis in 1931 as for147. 
However, the lack of specific ligands that are internalized selectively by this mechanism 
makes the distinction of the macropinocytic pathway challenging with respect to other 
pathways. Macropinocytosis is a quiescent process that is constitutively activated only 
in some cell lines such as immature dendritic cells, macrophages and transformed 
cells147. When not constitutively activated, it can be transiently triggered (5-10 min) by 
growth factors and tumour inducing factors such as Sonic hedgehog in neurons and 
epidermal growth factor in ephythelial cells148,149. Many studies have associated 
macropinocytosis with the formation of actin rich extensions of the plasma membrane 
referred as planar and circular membrane ruffles but the formation of such structures 
does not appear necessary for macropinocytosis, as inhibition of ruffles does not inhibit 
macropinocytosis uptake150. Macropinocytosis occurs at lipid rafts membrane 
subdomains, involves an actin-mediated membrane protrusions formation which than 
collapse and fuse back into the membrane or on themselves and generate large 
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pinocytic vesicles (~0.5-1µm) although vesicles of diameter up to 5 µm have been 
reported with the involvement of dynamin-2151. Once in the cytoplasm the vesicles 
usually acidify and shrink but the destiny of these compartments depends upon the cell 
type: examples of different fate for macropinocytosis include fusion with a lysosome or 
recycling of their load on the cellular surface. No specific coatings have been 
associated with this uptake pathway but it is often involved in nanocarrier uptake, the 
clearance of apoptotic bodies as well as some viruses (i.e. adenoviruses)78,136,152. 
Cholesterol, actin and PAK1 are essential for macropinocytosis. The latter kinase binds 
to Rho family GTP-binding protein rac1 and activates it. Also, PI3K, ras (another small 
GTPase family member), src protein tyrosine kinase, histone deacetylase 6 (HDAC6), 
heat shock protein 90 (hsp90) are involved in this uptake pathway but the extent and 
mechanisms are poorly understood. Macropinocytosis is involved in the internalization 
of viruses and bacteria as well as in the clearance of apoptotic bodies. This pathway 
has been reported as cholesterol-dependent. Virtually all cells can undergo 
macropinocytosis but some authors report that macrophages and micro-vessel 
endothelial cells do not adopt this pathway while others state that macrophages can 
also perform macropinocytosis. Macropinocytosis is considered a dynamin 
independent process although some specific types of macropinocytosis appear to be 
dynamin dependent. This specific way of internalization is called non-canonical 
macropinocytosis and it has been demonstrated to be involved with the uptake of the 
Ebola virus and quantum dots (QD)153-155.  
1.3.6.3 Flotillin-mediated endocytosis 
Flotillins are membrane bound proteins that are found almost ubiquitously in 
mammalian tissues. Flotillin microdomains are present in lipid rafts and are 
characterised by puncta on the plasma membrane. They are rich in flotillin which is 
formed by the oligomerization of flotillin 1 and 2156 and possess membrane lateral 
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mobility that make them float and from this characteristic they derive their name. 
Although they do not share any homology with caveolin-1 they present some topology 
similarity such as the presence of both the N and C terminus in the cytoplasm and 
membrane domains that do not span the membrane157. Flotillins are involved with 
endocytosis, membrane trafficking and signalling but it is not clear at the present if they 
constitute a separate endocytic pathway or if they induce endocytosis when the 
clathrin- and caveolin-dependent endocytosis is inhibited. Also, their endocytic 
machinery has not been defined at the present. 
1.4 The biological environment and nanomaterials 
Formulating new polymers for drug delivery is challenging as many different 
parameters such as particle charge, shape and size can affect the biodistribution and 
uptake of the delivery system. As bacteria, viruses and protozoa have hydrophobic 
surfaces, the human body has strategies to opsonise hydrophobic particulates, 
including synthetic hydrophobic nanoparticles77,79. This occurs via interactions with 
serum proteins such as antibodies, complement factors (common examples are C3, C4 
and C5) and blood serum proteins such as laminin, fibronectin, C-reactive protein, type 
I collagen and many others77. These serum components facilitate the binding of 
nanoparticles with phagocytic cells such as macrophages, neutrophils, monocytes and 
dendritic cells that have a scavenger role79. For this reason, hydrophobic polymers 
alone are not effective in drug delivery by intravenous routes. A well-known method to 
overcome such problems is the addition of a hydrophilic, protein-repelling polymer such 
as polyethylene glycol (PEG) to the drug delivery system. (please see below for a more 
extensive description of the process). On the other hand, positively charged polymers 
have shown higher toxicity profiles in vitro. 
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1.4.1 Nanoparticles in the bloodstream 
Nanocarriers do not pass the intestinal epithelium158 and only a slow absorption has 
EHHQVKRZQ WKURXJK3H\HU¶VSDFKHV LQ WKHJXW12; hence, they are often administered 
intravenously or subcutaneously, by inhalation through the lungs159 or by intranasal 
adsorption160. 
Interaction of nanoparticles with blood components is an important aspect to take into 
account as it can change the biodistribution of the injected materials. Nanoparticles are 
known to bind serum proteins and molecules constituents. They can form a shield 
around the nanoparticles called corona within 30s161. The 'DZVRQ¶V JURXS KDV
introduced the concept of hard and soft corona162,163. According to their description, the 
hard corona strongly interacts with the nanoparticles by electrostatic, Van Der Waals 
and hydrogen weak bonds and constitutes a hardly modifiable shield. A second layer 
that is bound less tightly to the hard corona is constituted by proteins and serum 
molecules that restore the original polarity of the nanoparticles, this compartment is 
more dynamic and interchanges more frequently with components of blood and 
constitutes the soft corona. The combination of soft and hard corona increases the 
overall size of the material. This idea of corona formation around the nanoparticles is 
not fully accepted and some authors question the existence of such distinct 
compartments around the nanoparticles and more generally refer to a unique corona of 
blood components that interchanges dynamically with blood constituents over time164. 
Interactions of the nanocarriers with blood molecules can lead to formation of 
aggregates, might produce adducts with sizes bigger than capillaries and cause 
ischemia and blood clotting, which is potentially life-threatening. McGuinness and co-
workers pointed out that amine and carboxyl derivatization of polystyrene and silica 
nanoparticles could produce aggregation of nanoparticles with platelets in vitro164,165. 
Furthermore, the surface of blood vessels is negatively charged and it has been 
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reported that an ideal nanoparticle should have a neutral or slightly negative charge to 
avoid interaction with the vessel walls166. However, it has also been proposed that 
negative charges reduce the extent of interactions of nanoparticles with cells 
membrane phospholipids that are negatively charged and, consequently, their access 
to intracellular compartments. 
1.4.1.1  Opsonisation 
One important aspect to evaluate in nanocarrier drug-delivery systems is the level of 
opsonisation of the particle in the bloodstream. Opsonisation reduces the concentration 
of particles in minutes with loss of their therapeutic effects. It occurs in vivo and it is 
carried out by the mononuclear phagocytic system, also known as reticulo-endothelial 
system77. This process (described in §1.3.3) is the way the body scavenges foreign 
particles that are bigger than the renal threshold (typically around a molecular weight of 
5,000 for linear polymers but up to 100,000 for branched or compacted polymers77). 
Phagocytosed particles are readily accumulated into the spleen and liver, the main 
scavenger organs and, depending on the nature of the particle, can be either digested 
(biodegradable particles) or accumulated (non biodegradable particles) with high risk of 
toxicity77.  
The polarity of the surface of nanocarriers is an important aspect to evaluate when 
designing new drug delivery devices. As mentioned before, since bacteria, viruses and 
protozoa have hydrophobic surfaces, the human body has strategies to efficiently 
opsonise hydrophobic particulates77,79. Hydrophobic particles are targets for serum 
proteins that adhere to the particles and tag them for rapid phagocytes recognition77,78. 
On the other hand, nanoparticles with dense surface charge have also shown a high 
rate of opsonisation and scavenge rate including opsonisation by complement 
elements77,78. 
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The process of adhesion of serum proteins to nanoparticles that produces a corona 
can give important information about both opsonisation and immunogenic reactions167. 
Gold nanoparticle coronas coated with poly(acrylic acid) (PAA), for example, activate a 
cascade signal that leads to production of cytokines in human acute monocytic cell line 
THP1168.  
One strategy to reduce or block opsonisation consists of shielding the carrier with long 
hydrophilic but uncharged compounds that reduce non-specific protein binding such as 
polyethylene glycol78. However, various shielding devices have been used for such a 
purpose: dextrans, alginates, cyclodextrins, hyaluronic acid, trehalose, polyacrylamide, 
poly-vinylalcohol, poly N vinyl pyrrolidone, poloxamines, and polysorbates 77,169-171.  
1.4.1.2 Polyethylene glycol coating of nanocarriers 
Among the above-listed shielding strategies, one of the most efficient is PEGylation. It 
can be carried out by surface adsorption but a clear drawback is represented by the 
easy desorption of the PEG which can lead to gaps in the shield and consequent 
opsonisation. Harper, Bazile and co-workers have shown that PEG covalent binding is 
more efficient with respect to surface adsorption172,173. A classic view suggests that 
PEG chains of 2000Da or longer have reduced binging protein ability and hence are 
suggested for cargo shielding of drugs174-176. However, more recently it was shown that 
PEG chains of 400Da had reduced unfolding properties when incubated with bovine 
serum albumin (BSA) and lysozyme as measured by fluorescence spectroscopy 
emission of tryptophan. In the same study, longer chains were more disruptive on 
these proteins inducing a partial unfolding of the 3D structure177. Also the unfolding 
ability towards proteins of a nanocarrier is an important parameter to take into 
consideration when evaluating its biocompatibility as this process can cause the 
exposure of antigenic domains to the immune system that can be buried in the 3D 
structure of a protein. Other important parameters for PEG coating are the surface 
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conformation of PEG and density. It has been reported that optimal PEG coating is 
obtaiQHGZKHQ3(*DVVXPHVDµPXVKURRP¶FRQIRUPDWLRQZKHUH3(*FKDLQVDUHERWK
more flexible and generally closer to the carrier surface. However, a minimum 
concentration of PEG must be assured as low PEG concentration is not sufficient for 
an efficient coverage of the carrier. Also a too high concentration of the polymer is not 
desirable as it produces a PEG conformation denoted as semi-OLQHDU RU µEUXVK¶
configuration which leads to a loss in flexibility and hindrance volume of the PEG chain 
and increased opsonisation. PEGylated particles are known to accumulate in the 
spleen upon opsonisation. Even if PEGylation is a key tool in reducing opsonisation, it 
has been often reported that PEG coated carriers show a reduced cell uptake, a 
phenomenon known as the PEG dilemma178. 
1.4.2 Extravasation of nanoparticles 
Nanoparticles in the bloodstream must overcome the endothelial barrier in order to 
reach tissues and organs. The endothelium is typically formed by endothelial cells 
adhering to the each other through tight junctions and lying on a basement membrane. 
Tight junction gaps between cells have typical diameters of about 2nm; they are even 
smaller in the blood-brain barrier while the underlying basal membrane does not allow 
passage of materials bigger than 13-15nm79. Some organs and tissues, depending on 
their physiological functions, allow the passage of larger particulates. For example, the 
liver has a fenestrated endothelium which increases the upper size limit to 100 nm 
while the discontinuous endothelium present in the spleen is even more accessible. 
However, in pathologic conditions such as inflammation and some kinds of cancers, 
the endothelium becomes leaky and allows the passage of particles of larger size. It 
has been reported that inflammation and tumors can cause an increase of fenestrae 
size up to 700nm in some capillaries179. Inflammation is common in many pathologic 
events and, in cancer inflammation, is often associated with the loss of lymphatic 
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vessels that increases the retention of particulates in such tissues79. The increased 
permeability of  tumor sites is often referred as enhanced permeability and retention 
(EPR) effect180. It is nevertheless true that the oncotic pressure is increased in 
extracellular compartments of cancerous tissues and the efficiency of drug delivery by 
this means is still a matter of debate.  
1.4.3 Nanocarriers passage into body tissues and organs 
Nanoparticles that overcome the endothelial barrier reach the extracellular matrix. The 
latter is composed by an aqueous solution of proteins (i.e. collagen), polysaccharides 
(i.e. hyaluronic acid) and glycoproteins (i.e. chondroitin sulphate). This environment 
impedes nanoparticle diffusion but the presence of aqueous channels makes this 
compartment still accessible12,181. 
1.4.4  Nanoparticles uptake into cells 
Many efforts are being made to characterize the way that nanocarriers enter cells and 
draw some generalizations in order to understand further the process of uptake. 
However, at present, just a few concepts are clear182,183. 
1.4.4.1  Size, shape and charge of nanocarriers and endocytosis 
1.4.4.1.1  Phagocytosis of nanomaterials 
The size of nanocarriers, in the absence of any other changes in chemistry or surface 
properties, influences phagocytosis. Moghimi179 reported that particles with size greater 
than 200nm were more promptly cleared from the bloodstream. Champion et al on the 
other hand, showed that the shape of the particle at the point of contact with 
macrophages determines the kinetics of uptake. In this study, polystyrene spheres 
were internalised promptly when in contact with alveolar macrophages while flat sides 
of rod-like polystyrene particles were internalised more slowly. A critical angle of 45º 
between the particle and the phagocytic membrane surface was calculated as the limit 
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for efficient phagocytosis where efficient uptake was obtained with lower angle values. 
This effect could be ascribed to the more complex actin structure to be realised in order 
to achieve phagocytosis. Surface charged nanoparticles are more readily taken up by 
macrophages. 
1.4.4.1.2 Pinocytosis of nanomaterials and biodistribution 
The characteristics of specific nanoparticles influence uptake by mechanisms other 
than phagocytosis in a more complicated and less evident way and it is thought that the 
degree of influence for such characteristics is dependent on to the cell type tested. 
Size, for instance, can limit internalization in some cells (i.e. Hepa 1-6 hepatoma, 
HepG2 and KLN 205) while it is reported not to influence uptake in HUVEC endothelial 
cells, ECV 304 bladder carcinoma cells and squamous carcinoma cell lines. Size can 
also influence the specific pathway of endocytosis78. In melanoma B16 cells for 
instance small particles (<200nm) were taken up by a clathrin-mediated endocytic 
pathway while bigger particles showed a caveolae-mediated endocytic pathway. Other 
studies on HeLa cells reported that polystyrene particles of 40nm were internalised by 
clathrin-mediated endocytosis but particles smaller than 25nm were internalised by a 
non-clathrin-, non-caveolae-mediated endocytosis. Macropinocytosis, on the other 
hand, does not show size dependency and it has been reported to often occur together 
with other uptake pathways. Minchin studied the uptake of AuNP encapsulated in 
dendrimers of different charges and sizes and reported that distribution in some organs 
was dependent upon these properties. Studies of biodistribution in mice showed that 
small (5 nm) positive dendrimers were accumulated into the kidneys for days and 
mainly excreted through the urine; 5 nm neutral and negative particles were 
accumulated in spleen and liver. When the size of positive nanoparticles was increased 
to 22 nm they were not excreted by the kidneys but accumulated in lungs, liver and 
spleen184. 
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Charged carriers can also influence cellular uptake. It has been reported that positively 
charged nanocarriers are promptly internalised by cells. This could be due, as reported 
before, to electrostatic interactions with the negatively-charged cell surface. Positively-
charged nanoparticles have also been reported to produce defects on cell membrane 
in cell membrane models. Experiments on dendrimers and other amine containing 
polymers have been reported to strongly interact with lipid bilayers of membrane 
models9,185. Such carriers produce membrane thinning at low concentrations and holes 
at higher concentrations9. Charged carriers have been classified in three categories:  
a. Charged particles that adhere closely to already present membrane defects but 
that cannot enhance these defects; 
b. Charged particles that cannot induce membrane defects but can increase them; 
c. Charged particles that can both start or increase membrane defects. 
However, the membranes used to carry out these studies are not natural membranes. 
They are usually formed by a mixture of natural lipids that are often present in 
membranes but lack superficial and intercalating proteins and glycoproteins that can 
represent up to 50% of natural mammalian membranes and this should be taken into 
account when extrapolating to in vivo studies186.  
In the attempt to increase the efficiency of nanomedicines, and to enhance their 
uptake, nanoparticles have been conjugated with cell penetrating peptides (CPP). 
These peptides are short sequences that often resemble peptides that have been used 
by pathogens to access cells. They are rich in arginine and lysin that makes them 
positively charged or amphiphilic. Examples of CPP are TAT (HIV tat protein 
transduction domain) and penetratin (Drosophila antennapedia homeodomain)187. 
Some of these materials have reached the market for topic applications.  
Introduction ± Nanomaterials and Endocytosis 
66 
 
Shape of nanoparticles in endocytosis has not been thoroughly investigated but it is 
known that some viruses (i.e. some strains of Ebola and H5N1) have filamentous 
shapes. When producing rod-like nanoparticles for drug delivery also the stability of the 
shape must be taken into consideration as it has been reported that rod-like micelles 
formed with PEG-p-PLA block copolymers were unstable and eventually shortened and 
produced spherical micelles188. Other observations focusing on the increased 
penetration of worm-like micelles in gels suggested that rod-like micelles could have an 
enhanced penetration in tissues and organs which could be interesting to investigate to 
enhance oral adsorption of nanoparticles166. However, depending on the length of 
nanoparticles, a rod-like shape might induce toxicity and inflammation and ROS 
production caused by phagocytic cells frustrated internalization as shown by asbestos 
and more recently by carbon nanotubes research189. 
 
From this brief overview it is possible to understand the complexity of the field. It is not 
trivial designing a new nanoparticle for drug or gene delivery and one approach can be 
a success or failure depending on the target.  
However, some generalizations are possible. For example, the size and surface 
properties of nanoparticles size must be carefully controlled to avoid aggregation in the 
bloodstream, opsonization and reduced access in target cells. The ideal size range of 
drug delivery systems is likely to be similar of that of viruses, i.e. between 10 and 100 
nm. The nanoparticle should not be strongly negatively or positively charged in order to 
prevent opsonisation, and respectively: low uptake or disruption of the plasma 
membrane of cells with consequent toxicity. Hence, the nanoparticle should ideally 
have a surface which is hydrophilic but not charged. The coating of drug delivery 
nanoparticles is intensely debated desSLWHPRUHWKDQ\HDUV¶ literature on the subject. 
PEGylation of nanoparticles appears to delay the opsonisation but reduce the access 
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of the nanoparticle into cells and other coating materials are being investigated. Finally, 
rod like shape would be preferred as it increases the penetration of the nanoparticle 
into tissues and organs. However, possible side effects such as inflammation caused 
by a frustrated phagocytosis can also be triggered with detrimental effects for patients.  
1.5 Nanoparticles in the literature 
Nanoparticles such as polystyrene beads (PB), QD superparamagnetic iron oxide 
nanoparticles (SPION) and gold nanoparticles (AuNP) can be synthesised with a 
narrow size distribution and a controlled surface chemistry. For this reasons they are a 
useful tool in research, in diagnostics and in endocytosis studies and they have also 
been extensively used to understand the safety of nanomaterials190-193.  
1.5.1 Colloidal Gold Nanoparticles 
Nanoparticles derived from colloidal gold were the first colloidal nanoparticles 
synthesised. They present physiochemical characteristics that differ from metallic gold 
and are ruled by the Laws of Quantum Physics194. The resulting nanoparticles in the 
range of 1-10nm present characteristics that are strictly dependent upon their size and 
do not resemble bulk metal or molecular characteristics of gold. They have a plasmon 
resonance band at around 530nm. The precise wavelength of that band depends on 
nanoparticle size and shape, and medium properties, and has found application in 
diagnostics195. AuNP can be used in conjugation to polymers or proteins for drug 
delivery purposes196. The gold core of such conjugates stabilises the geometry of the 
shell-like region around the nanoparticles and can be tailored to suit the most disparate 
applications. Sulphur-polymers anchored to AuNP for an easy release of the drug 
conjugate is an example, or polyethyleneimine (PEI) with a cyclodextrin-derivatised 
terminal co-polymers to enhance the hydrophobicity of the polymer terminal part for an 
enhanced DNA delivery197. Furthermore, also their physical characteristics can be 
Introduction ± Nanomaterials and Endocytosis 
68 
 
exploited for therapeutic purposes. When the nanoparticles are hit by a light radiation in 
the range of 800-1200 nm they produce heating of the region and could be used in 
hyperthermia applications or, if conjugated with a thermoresponsive polymer could 
release the drug-load specifically at the intended target. From a recent review by Oh et 
al. it emerges that unconjugated AuNP of 50 nm were the most easily internalised 
nanoparticles while PEG coating reduced drastically internalization. Endocytosis of 
AuNP conjugated with cell penetrating peptide TAT and NLS (nuclear localization 
sequence) were enhanced. Unexpectedly, rod-like AuNP were more actively 
phagocytosed by macrophages than spherical nanoparticles183,198. 
1.5.2 Quantum dots (QDs) 
QDs can be produced from many materials. Graphene, silica and hybrid CdSe or Zs-S 
are the most common examples of such structures. They are semiconductors 
nanocrystals formed by a colloidal core and one or more layers to increase their water 
solubility199. They are exceptionally bright with an intense and extremely stable 
fluorescence that finds many applications, from research in cell penetration studies, to 
cell imaging and cancer targeting. Uncoated CdSe core and CdS or ZnS coated QDs 
have been shown to access HEK (primary neonatal human epidermal keratinocytes). 
QD of 20 nm coated with COOH groups promptly accessed HEK cells with a caveolae-
mediated internalization mechanism199. It has been shown that the more the QDs are 
charged (both positive and negative charges) the more they are internalised by cells. 
Also 100 nm negatively charged nanoparticles are taken up more promptly than QDs of 
28nm with the same charge according to Kelf et al200. The same group also points out 
that the literature suggests a higher level of internalization with a clathrin-mediated 
mechanism of endocytosis for QDs of 50 nm. 
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1.5.3 Iron oxide nanoparticles 
In the last decade iron oxide nanoparticles (especially maghemite, Fe2O3, and 
magnetite, Fe3O4) have been studied for many applications. They are particularly 
interesting because of their biocompatibility and they have been approved by the 
FDA192,201. As for AuNP, nanosized iron oxide nanoparticles present unique 
superparamagnetic and magnetic properties that do not resemble the atomic or the 
bulk material. They can produce hyperthermia in an alternating magnetic field and can 
be directed towards a specific tissue with a magnetic field202. Unmodified SPIONs can 
precipitate in solution as they do not show water solubility and they must be coated to 
enhance their water compatibility for biological applications. Their most studied 
applications include cell labelling for cell separation, magnetic resonance imaging 
(MRI) and hyperthermia therapy. Recently, EGF-conjugated SPIONS have been tested 
in C6 glioma cells for the detection of early stage of cancer and so substitute 
gadolinium contrast agents203. Although SPION nanoparticles are not normally 
produced for internalization and many studies have shown that the nanoparticles are 
safe at concentrations up to 100 µg/ml, local accumulation of SPIONs can lead to 
toxicity202. Colloidal iron can easily oxidise leading to the Fenton reaction that is 
extremely toxic for cells and it destabilises membranes, proteins and DNA. Their 
application is oriented towards the recognition of a specific tissue for diagnosis and 
therapy in conjunction with other therapeutics (e.i. thermoresponsive drug-carriers 
conjugates). 
1.5.4 Polystyrene nanoparticles 
There are many protocols to synthesise polystyrene beads (PB). One of the most 
common is with a dispersion polymerization method but other protocols are available in 
the literature (i.e. macro-raft agents and other techniques)204-207. The advantage in 
using polystyrene beads is that these materials can be easily synthesised in a relatively 
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economical way and produce materials with narrow distribution of sizes conveniently 
customized from the range of microns to about 20-25 nm. Furthermore, PB can easily 
be labelled with fluorescent or luminescent dyes for a detection with an array of 
techniques; they are visible in TEM without any labelling and can be readily modified to 
change the polarity of their surface or for derivatization with receptor proteins or 
vitamins208. For all these reasons they are a useful tool in research, in endocytosis 
studies and they have also been extensively used to understand the safety of 
nanomaterials190. Many studies have been carried out on PB of the range of 50-100 
nm. It has been shown that there is usually a good correlation between PB uptake and 
other nanomaterials despite differences in surface chemistry and composition209. 
However it appears that the pathway of internalization is strongly influenced by the cell 
lines used for the study and the same material can be susceptible to different inhibitors 
of endocytosis depending on the cell lines adopted for the study182. 
 
In an attempt to enhance internalization of nanoparticles and specificity towards a 
target organ, many strategies have been adopted. For example, nanoparticles have 
been associated with cell targeting ligands such as proteins specific for cells 
membrane receptors, with antibodies and aptamers. Nanoparticles have been tagged 
with specific proteins to enhance their ability to accumulate in specific tissues. An 
example is prostate-specific membrane antigen (PSMA) that target prostate cancer 
cells and virtually all solid tumour neo-vasculature213. Recently, nanoparticles 
composed of polylactic acid or polylactic-co-polyglycolic acid-PEG and tagged with 
PSMA were used to chemically entrap tamoxifen. This anticancer drug, has been 
approved for the treatment of many cancers including prostate, gastric, breast, lung, 
and head and neck, and has entered Phase I clinical trials with the identity name of 
BIND 014210,214 (Table 1-2). Transferrin protein is also commonly conjugated to 
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nanoparticles (Table 1-2). Transferrin binds to the transferrin receptor that is 
ubiquitously expressed in functional cells but it is modestly expressed in quiescent cells 
such as some endothelial, endocrine pancreas, breast, kidneys and liver cells116. The 
expression of transferrin receptor is dependent on the level of proliferation the cell is 
undergoing. For example, transferrin receptor is expressed in foetal cells and the 
extent of its expression can be modulated by the presence of iron in the diet. 
Transferrin receptor has also been found over-expressed in many cancers such as 
colon, pancreas, bladder and lung and for this reason has been used conjugated to 
nanoparticles in order to enhance specificity of the delivery of anticancer drugs. 
Another common strategy applies folate targeting to nanocarriers to enhance specificity 
towards a pathologic region. The concept behind this approach is that often folate 
receptors are over-expressed in ovarian, cervical, breast, brain, and lung cancer. 
Again, as for transferrin receptor, it is also expressed in healthy tissues such as lungs, 
kidneys and placenta. Folate is needed for DNA replication and many other cell 
functions and it acts binding to the folate receptor that is internalised by caveolae. This 
localization has made the functionalization of nanoparticles with this receptor highly 
appealing as there is little evidence in the literature that has observed caveolae-
internalized materials being directed towards lysosomes and acidic degradation. The 
possibility of bypassing the lysosome compartment is a highly attractive feature in drug 
delivery. However, folate tagged nanomedicines have failed clinical trials so far and the 
latest example is Vintafolide, a vinblastine-folic acid conjugate that reached Phase III 
clinical trials for the treatment of platinum resistant ovarian cancers (the same 
compound is in Phase II trial for non-small cell lung cancer). Although there is 
increasing evidence of the efficacy of receptor protein conjugation approaches in vitro 
and in animal models, drugs that use these means to enhance specificity have failed in 
clinical trials to demonstrate the efficacy of such ligands. Furthermore, in vitro studies 
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show that the ligand internalization pathway is influenced by the presence of the 
conjugated nanoparticles. For example, CPP can be endocytosed by different 
machineries depending on the specific sequence and in the presence and absence of 
the intended cargo215. Also, transferrin-conjugated nanoparticles studies suggest that 
transferrin-conjugated QDs are not internalised by the same route as transferrin 
alone154. The same has also been confirmed for ricin and Shiga toxin-conjugated QDs 
and vitamin B12-conjugated polystyrene nanoparticles208. Also, it has been shown that 
using the same ligand protein (herceptin) specific for a membrane receptor (ErbB2) 
herceptin-conjugated AuNPs of 40 and 50 nm had the ability to change the 
internalization outcome, to modulate the expression of the receptor as well as inducing 
caspases and induce apoptosis with respect to the same nanoparticles of smaller or 
bigger sizes (size range 2-100 nm)216. Finally it is known in the literature that 
nanocarriers in the blood stream can lose their specificity towards the target when in 
serum due to the formation of a corona of proteins enveloping the nanocarrier and 
shielding its functional molecules on their surface217. There is a clear need for a better 
understanding of the nanoparticle characteristics that make cells activate a specific 
pathway. A recent publication has found a correlation between the specific serum 
proteins that bind the nanoparticles and the pathway of internalization which may 
provide a route forward for understanding this complex area218. 
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Table 1-2 Summary of nanomedicines that have reached clinical trials or the market(
219,210
).  
 
1.6 Aims and thesis outline 
Despite numerous attempts to trigger the desired endocytic machinery for the uptake of 
nanomaterials, literature suggests that nanoparticles conjugated to a ligand specific for 
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a membrane receptor are internalised according to their physical characteristics rather 
than the conjugation ligand. Information on how these characteristics guide the 
internalization of nanoparticles through one pathway or the other is still limited, 
fragmentary and sometime contradictory. Also, results in the literature are challenged 
by the numerous variables that constitute the experimental environment of the in vitro 
studies and complicate the recognition of similarities and patterns of behaviour. 
However, this information is essential in order to develop nanocarriers of drugs with a 
desired internalization and hence, a more sophisticated control of nanomaterial 
interaction with cells. 
The aim of this study was to investigate the pathway of internalization employed by 
carboxylated polystyrene nanoparticles of 50 and 100 nm as model particles to access 
a panel of both epithelial and fibroblastic cells. Firstly, the focus of the study revolved 
around understanding if there were any differences in the pathway involved in the 
uptake of carboxylated polystyrene nanoparticles based on differences in size. 
Secondly, an investigation was carried out on how different cell lines, such as 
fibroblasts and epithelial cancer cells could employ different mechanisms of 
internalization for the same material. The aim was to compare and contrast these 
findings with the uptake of thermoresponsive negatively charged PLGA-b-(PEGMA-co-
PPGMA) and PLA-b-(DEGMA-co-OEGMA) polymeric micelles. These concepts are 
schematically summarised in Fig. 1-11. To pursue these objectives, inhibitors of 
endocytosis were employed to investigate the possible route of uptake of these 
materials. An assessment of the toxicity of both polystyrene nanoparticles, and 
inhibitors of endocytosis was carried out as well as optimization of the experimental 
settings for the endocytosis inhibition studies. These results are summarised in 
Chapter 3. Flow cytometry was used to investigate the inhibition of uptake of 
carboxylated polystyrene nanoparticles in the presence of inhibitors of endocytosis 
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while their internalization was detected by confocal live studies (Chapter 4). Finally, the 
results on the biocompatibility and internalization ability of thermoresponsive polymers 
are summarised in the last chapter of results (Chapter 5). Results are further 
commented on in a discussion chapter and some conclusions drawn (Chapter 6). 
1.7 Experimental Approach 
Two types of nanomaterials were used to study cellular uptake of nanoparticles. 
Carboxylated polystyrene nanoparticles, with sizes of 50 and 100nm, and a 
hydrophobic core and a hydrophilic coat were considered a valid model resembling 
research grade thermoresponsive polymers with the same size range and polarity 
distribution and were included in these studies. In addition, thermoresponsive PLGA-b-
(PEGMA-co-PPGMA) and PLA-b-(DEGMA-co-OEGMA) block copolymers were used. 
The investigation of different routes of uptake in different cell lines was carried out with 
human transferrin (Htf) and lactosylceramide (LacCer).These two molecules are 
routinely used and widely accepted markers of clathrin-dependent and -independent 
endocytosis. Chlorpromazine (CPZ) and methyl beta cyclodextrin (MBCD) have been 
extensively used as pharmacological inhibitors of clathrin-dependent and -independent 
endocytosis in the past 20 years. However, the lack of specificity of both CPZ and 
MBCD towards only one specific endocytic pathway is well documented in the literature 
and these experimental limitations were taken into account when drawing conclusions 
from results.  
The choice of the cell lines for the study was based on evidence that many pathologies 
affect epithelial cells and for this reason are relevant for pharmaceutical investigations. 
Furthermore, increasingly significant data in the literature report of a role of 
mesenchymal cells in the instigation and progression of pathologies such as cancer 
and for this reason fibroblasts were included in the study. Immortalized cells were 
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preferred over primary cells because of the inherent genetic differences within primary 
cells from different patients. However, the limitations of this choice such as known 
differences between immortalized and normal cells, genetic instability are important 
and experimental limitations that should be devalued before drawing more general 
conclusions from the experimental results. 
Further limitations in the above-mentioned experimental approach was due to the 
choice of in vitro settings over 3D or in vivo experiments that are known to resemble 
more closely the body environment and hence are physiologically more relevant. 
However, it is important to stress that much of the research field of endocytosis in 
mammalian cells at the moment is limited to more or less sophisticated 2D in vitro 
studies. The reason for such limitations is that 3D culture approaches are challenged 
by the level of perfusion of the more internal compartments of the 3D scaffolds. 
Another important limitation is provided by the level of detection of optical fluorescence 
techniques currently available and the level of penetration in thick specimens for the 
detection of fluorophores. 
 
Figure 1-11 Flow chart showing the aims and experimental plans of this thesis. 
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2.1 General Materials 
2.1.1 Cell lines 
HCT116 human colon cancer cells1, MGLVA-1 ascites gastric cancer cells2 - ascites 
of a variant of MKN45 human gastric adenocarcinoma cells3, gastrin producing 
(MKN45G) generated in our laboratories -, 3T3-Swiss albino mouse embryo 
fibroblasts4 and MRC-5 human foetal lung fibroblasts5 were purchased from the 
American Type Culture Collection (ATCC) and LGC Standards, Teddington, UK and 
from the Health Science Research Resource Bank, (Osaka, Japan). Cells were 
harvested in Roswell Park Memorial Institute (RPMI) medium or Dulbecco Modified 
Eagle Medium (DMEM) supplemented with 10% v/v heath inactivated Foetal Bovine 
Serum (FBS), 2 mM L-glutamine (Sigma-Aldrich, Dorset, UK) and in minimum 
essential medium Eagle (MEM) 10% v/v FBS, 2 mM L-glutamine, 1% v/v non 
essential amino acids (NEAA) according to ATCC and Cell Bank specifications. 
HCT116 cells were grown from passage 4 to 50, MGLVA-1 for passage 5 to 50, 3T3 
from passage 21 to 60, MRC-5 from passage 34 to passage 50. All the cell lines used 
were adherent. A summary of the characteristics of the cells can be viewed in Table 
2-1.  
2.1.2 Cell culture materials 
Trypan blue (0.4% w/v), porcine trypsin (0.5 g/l)/Ethylenediaminetetracetic acid 
(EDTA, 0.2 g/l) and dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich, 
Dorset, UK. Phosphate buffered saline (PBS) was purchased from Oxoid (Thermo 
Scientific, Basingstoke, UK), 96 wells clear bottom and clear or black wall plates, 
clear 24 and 6 well plates, 75 and 25cm2 tissue culture vented flasks, 2 ml cryovials, 
0.6-1.7 ml Eppendorf tubes were obtained from Corning Life Sciences (Amsterdam, 
The Netherlands; Tultidan, Mexico). 10 and 1000 µl pipettes tips from Starlab, Milton 
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Keynes, UK; 200 µl tips from Sarstedt, Leicester, UK; Minisart filters for tissue culture 
0.1 and 0.2 µm pore size were purchased from Sartorius, Stonehouse, UK. Needles 
0.8x40 mm were purchased from BD Microlance, siringes from BD Plastipactm, 
Oxford, UK.  
 
Table 2-1 A summary of the cells lines used in this study with their most important characteristics 
such as tissue of origin, species, genetic modifications and immortalization procedure as well as the 
growth media employed. All the cell lines employed in these studies were adherent. 
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2.1.3 Polymers studied 
 
Figure 2-1 Poly(lactide-co-glycolide)-block-poly(poly(ethylene glycol methyl ether methacrylate)-co-
poly(propylene glycol methacrylate)) (PLGA-b-(PPGMA-co-PEGMA)) thermoresponsive polymers. 
 
Figure 2-2 Polylactide- block- poly(poly(diethylene glycol methacrylate)-co-poly(oligoethylene glycol 
methacrylate)) (PLA-b-(DEGMA-co-OEGMA)) thermoresponsive polymers. 
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Thermoresponsive polymers used in these studies were based on previous work form 
Abulateefeh et al and they were synthesised by Lee Moir (School of Pharmacy, 
University of Nottingham, UK)6. Their chemical names are poly(lactide-co-glycolide)-
block-poly(poly(ethylene glycol methyl ether methacrylate)-co-poly(propylene glycol 
methacrylate)) and its abbreviation is PLGA-b-(PPGMA-co-PEGMA) (Figure 2-1) and 
polylactide- block- poly(poly(diethylene glycol methacrylate)-co-poly(oligoethylene 
glycol methacrylate)) and its abbreviation is PLA-b-(DEGMA-co-OEGMA). (Figure 2-
2). In these polymers the PLGA/PLA region formed the hydrophobic solid core of the 
micelle while the PPGMA/PEGMA or DEGMA/OEGMA formed the hydrophilic region 
of the polymer. 
2.1.3.1 Polystyrene nanoparticles   
Polystyrene Fluoresbrite Yellow-Orange carboxylated polystyrene beads (C-PB) of 50 
nm (catalogue number 19775) and 100 nm (catalogue number 18791), Omax ex 529nm 
± Omax em 546nm, were purchased from Polysciences, Heppelheim, Germany. 
2.1.4 Materials for inhibition studies 
LacCer complexed with Bovine Serum Albumin (BSA), transferrin from human serum, 
conjugated with Alexafluor 633 (Htf), and 2-[4-(2-hydroxyethyl)piperazin-1-yl] 
ethanesulfonic acid (HEPES) buffer were purchased from Fisher Scientific, 
Loughborough, UK. Chlorpromazine (CPZ), methyl-ȕ-cyclodextrin (MBCD) and any 
other material not specified in this list was purchased from Sigma (Sigma-Aldrich, 
Dorset, UK). Methanol free paraformalehyde (PFA) was purchased from Electron 
Microscopy Science, Sunnyvale, CA, Alexafluor 488 and 594 secondary antibodies 
were purchased from Molecular Probes, Paisley, UK, anti-clathrin heavy chain 
monoclonal antibody (mAb) (clone X22) was purchased from Merk Biosciences, 
Feltham, UK and anti-caveolin-1 mAb (clone 2297) from BD Transduction 
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Laboratories, Lexington, KY, defatted albumin (dBSA) was purchased from Sigma-
Aldrich, Dorset, UK. 
2.2 General methods 
2.2.1 General cell maintenance procedures 
2.2.1.1 Routine tissue culture procedures 
Cells were routinely grown in 75cm2 vented cap flasks in tissue culture incubators at 
controlled CO2 atmosphere (5% v/v), 37°C and 95% v/v humidity. Routine cell 
maintenance was carried out 3 times per week. Cells were checked under a reverse 
microscope to verify health, lack of contamination and confluence. For cell splitting 
procedures, cells were grown to reach 80% confluence. EDTA and trypsin/EDTA 
were pre-warmed to 37°C in a tissue culture water bath before use. After checking 
cells at the microscope they were treated as follows: MGLVA-1, and MRC-5 were 
washed with 5 ml EDTA before applying trypsin/EDTA 8ml (MGLVA-1) and 4ml 
respectively (MRC-5). HCT116 and 3T3 cells were treated with 4ml trypsin/EDTA 
only. Upon detachment of cells, cell suspensions were collected in a sterile vial and 
the culture flask rinsed with 6 or 12ml of the appropriate cell culture media. Cell 
suspensions were centrifuged at 200g for 5 minutes, the supernatant was removed 
by aspiration and cells were re-suspended in 10 ml appropriate media. Cells were 
seeded depending on the desired numbers for setting up purposes or 1/10 of cell 
suspension re-cultured in a 75cm2 sterile flask for cell line routine maintenance 
according to ATCC and Japanese Cell Bank protocols. For MRC-5 only the splitting 
ratio was kept to 1/3.  
2.2.1.2 General procedures for cell counting and experiments setup 
Cells detached as described above and re-suspended in their own media were mixed 
with the aid of a vortex (3T3, MRC-5) or passed through a 0.8 mm needle to get rid of 
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clamps of cells and to ease the counting process (HCT116 and MGLVA-1). 
Subsequently, four aliquots of 50 µl of cells were added to 50 µl trypan blue and cells 
counted on a Neubauer haemocytometer counting chamber (Hawksley, Cambridge, 
UK) with a manual counter (ENM, Chicago, USA). The count averaged according to 
the following formula: 
൤ሺ ?ሻ ൅ሺ ?ሻ ൅ሺ ?ሻ ൅ ሺ ?ሻ ? ൨ ݔ ?ݔ ? ?ସ ൌ ݊ݑܾ݉݁ݎݏ݋݂݈݈ܿ݁ݏȀ݈݉ 
The number of dead cells was also annotated on a lab-book and experiments were 
not set up if the number of dead/trypan blue positive cells was more than 5% for each 
count. MGLVA-1 and HCT116 cells prepared for experiments were passed through a 
needle as described above before an aliquot of the appropriate volume of cells was 
diluted to the appropriate number of cells/ml for experiments setup. 
2.2.1.3 Preparation of frozen stocks of cells 
Confluent cells were detached from cell culture flasks with trypsin/EDTA as described 
above and centrifuged at 200 g for 5 minutes. Supernatant was aspirated off and the 
pellet re-suspended with the aid of a vortex. Fresh culture media supplemented with 
10% v/v dimethyl sulfoxide (DMSO, Sigma-Aldrich, Dorset, UK) suitable for cell 
culture was applied to re-suspended cells and the mixture quickly transferred to a 
sterile labelled cryovial where the cell line, passage number, date and name of the 
owner was annotated for future reference. The cryovial was placed in a Mr Frosty 
(Thermo Scientific, Loughborough, UK) at -80°C for 24 h and to a storage box in a -
80°C freezer for up to 6 months or to a -150°C freezer for long storage and 
maintenance of cells stocks.   
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2.2.1.4 Cell revival from -150°C freezer 
Prior to defrosting the desired cell line, a 75 cm2 flask containing 15 ml of the 
appropriate media was prepared and left to equilibrate in a tissue culture incubator at 
37°C and 5% CO2 95% humidity for 30 minutes. Cryovials of the desired cell lines 
were removed from the freezer, moved quickly to 37°C water-bath and swirled until 
defrosted. Subsequently, the cryovial content was moved with the aid of sterile 5 ml 
pipette into the pre-warmed flask and cells left to recover for 24 h or until completely 
adherent to the bottom of the flask. Finally, the media was replaced with fresh warm 
media to remove the DMSO present in the freezing media. A buffer period of 7-10 
days was applied before using the defrosted cells for experiments.  
2.2.2 Dynamic Light Scattering (DLS)  
DLS is a technique used to measure the hydrodynamic radius of particles in solution. 
During the measurement, the solution is irradiated by coherent laser light, and a 
detector measures the scattered light from the particles. Fluctuations in scattering 
intensities are fitted to a correlation function to determine the diffusion of particles in 
solution. From the estimated diffusion coefficient, the hydrodynamic radius of the 
nanoparticles is derived by the Stoke- Einstein equation:  
ܴு ൌ ݇ܶ ?ߨߟܦ 
where RH is the hydrodynamic radius, k is the Boltzmann constant, T the absolute 
temperature and Ș LV WKHYLVFRVLW\RI WKHVROYHQW and D is the translational diffusion 
(also known as Brownian motion) coefficient. The particles are assumed spherical 
and non-interacting. A Malvern Instruments Viscotek802 DLS (Malvern, UK) was 
used for all the measurements. The light source for the instrument is a diode laser, 
830nm wavelength, 50 mW internal laser, 90° angle of detection. All measurements 
were carried out at 20°C. 
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50 nm C-PB were diluted in PBS buffer at a concentration of 200 µg/ml and 100 nm 
C-PB were prepared at a concentration of 50 µg/ml according to Malvern support 
suggestions. The solution was diluted to the desired concentration in PBS filtered 
with a 0.2 µm filter and vortexed for 1 minute to remove any C-PB aggregates before 
each measurement. Each reading was the result of averages of 10 readings carried 
out for 10 s each. 3 readings for each polystyrene bead were made and the 3 
readings were averaged and data plotted in GraphPad Prism. 
2.2.3 Transmission Electron Microscopy (TEM) of C-PB 
TEM images were obtained with a Tecnai G12 Bio Twin Digital Transmission Electron 
Microscope System. 
Stock solutions of 50 and 100 nm C-PB were diluted to 25 and 26.5 µg/ml in filtered 
PBS as described above, the prepared solution was mixed with a vortex for one 
minute to get rid of any aggregates and applied on a Formvar/Carbon support film 
300 mesh copper grids and allowed to dry overnight. A minimum of 12 images for 
each size of polystyrene nanoparticles were taken for a minimum count of 250 
particles for each size of C-PB. Images were analysed with ImageJ software and the 
Feret diameter (the larger diameter of a particle not assumed to be spherical) plotted 
in GraphPad Prism. 
2.2.4 Zeta potential of C-PB 
Electrokinetic potential or zeta potential is the description of the charge of particles in 
suspension. Particle suspensions are loaded onto a special chamber that is provided 
with two electrodes. The electrophoretic mobility of the particles is measured and the 
measurement converted to zeta potential through the following equation: 
ߞ ൌ  ?Ǥ ? ? ?ݔ ൤ ߟǤ ߤாߝ௥Ǥ ݂ሺܭ௔ሻ൨ 
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ZKHUHȘLVWKHYLVFRVLW\RIWKHVROXWLRQE is the measured electrophoretic mobility, ܭr 
is the solution dielectric constant and f(Ka) is a constant calculated on the basis of 
experiments conditions such as ionic strength and temperature.  
Zetasizer measurements were acquired with a Malvern Zetasizer Nano, Malvern, UK. 
The particles suspensions were prepared in HEPES buffer 1 mM, Ph 7.4 at a 
concentration of 200 µg/ml. The values obtained were the result of 12 measurement 
replicates. All measurements were carried out at 20°C. 
2.2.5  Toxicity Tests 
2.2.5.1 MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazomium 
bromide) assay 
The MTT assay is a colorimetric assay used to determine metabolic activity of cells. 
Upon application of the yellow MTT solution, the MTT is converted by the functional 
mitochondrial and cytoplasmic succinate dehydrogenase activity of viable cells to a 
purple, water insoluble formazan. The absorbance of the solubilised purple formazan 
can be quantified at a wavelength of 550 nm by a spectrophotometer.  
The optimal concentration of cells for toxicity tests was verified by a titration curve 
prior the test of drugs/nanoparticles. The titration curve was obtained by serial 1 to 2 
dilutions of cells from a maximum of 312000 to the limit of the detection of cells for 
the assay. 100 µl of cells dilutions were seeded in triplicates in the middle wells of a 
clear 96 well plate and extra triplicate wells for media only were left for the blank. The 
edges of the wells used for the titration curve were filled with 200 µl media to avoid 
excessive evaporation of media from assay wells.  
For toxicity assays, 100 µl of cells were seeded into the middle 60 wells of a clear 96 
well plate at a density of 31200 cells/cm2, allowed to attach to the well overnight and 
successively treated for 4.5 h with chemical inhibitors of endocytic pathways or for 4-
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24 and 48 h with nanoparticles. Each inhibitor was applied in triplicates and both 
inhibitors, C-PB and polymers were prepared in HBSS supplemented with HEPES 
buffer 20 mM. Serial dilutions were prepared at a 1/2 ratio for CPZ, MBCD and 
thermoresponsive polymers or 1/10 for C-PB. CPZ and MBCD toxicity were tested 
every time a new stock solution was prepared to avoid weighing errors. Both CPZ, 
MBCD and nanoparticle toxicity tests were carried out with a reference positive and 
negative control consisting of PEI 0.5 mg/ml and HBSS/HEPES 20 mM respectively. 
A blank consisting of the same C-PB serial dilutions triplicates used in toxicity tests 
applied to wells without cells was also analysed in C-PB toxicity studies and the 
absorbance values of the blank subtracted accordingly. Upon completion of the 
incubation time at 37°C and 5% CO2, MTT (50 µl of 1 mg/ml solution) was applied 
and cells supplemented with MTT incubated for further 4 h. Upon completion of the 
MTT incubation time the solution was aspirated and 75 µl of DMSO applied to 
solubilise the purple water-insoluble crystals formed by the functional mitochondrial 
and cytoplasmic succinate dehydrogenase activity of viable cells. Blanks plates of C-
PB were processed as the other tested samples (same time of incubation, same 
volume of MTT added, same incubation time of MTT, MTT aspirated off and DMSO 
applied). Absorbance readings were recorded at 550 nm on a MRX revelation 
microplate reader, Thermo Lab Systems, Altrincham, UK. The results were plotted in 
GraphPad Prism and normalised against the untreated controls. 
2.2.5.2 Apo I (caspase 3/7) apoptosis assay 
Caspase 3 and 7 are members of cysteine aspartic acid-specific protease (caspase) 
family and they are synthesized during apoptosis. Apo I caspase 3/7 detection kit 
(Promega, Southampton, UK) consists of profluorescent substrate formed by a 
peptidic region conjugated to a fluorescent dye (Rhodamine 110). In the presence of 
caspase 3/7 the peptidic region of the substrate is specifically cleaved by caspases 3 
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and 7 and releases the fluorescent dye that is detected at 535nm. The fluorescence 
detected is therefore proportional to the number of apoptotic cells. 
25 µl of HCT116, MGLVA-1 and 3T3 cell suspensions were seeded into the middle 
240 wells of a 384 clear bottom black well plate at a density of 31200 cells/cm2 in full 
growth media and left to attach to the bottom of the wells overnight. Two rows of 
wells at the edges of the 384 wells plate were filled with 50 µl of growth media to 
provide moisture and help to avoid excessive evaporation of media from the wells 
overnight. The day after, the medium was carefully aspirated off with a pipette tip and 
replaced with 25 µl of HBSS/HEPES 20 mM for negative control, PEI 0.5 mg/ml and 
CPZ dilutions of 320-240-160-80 and 40 µM obtained in HBSS/HEPES 20 mM. 
Quintuplicate wells devoid of cells were replaced with HBSS/HEPES 20 mM for a 
blank reading. CPZ and control wells were applied in quintuplicate and 3 independent 
experiments repeated for each cell line. CPZ was incubated for 4.5 h. When the 
incubation time was over 25 µl of Apo I reagents mix was prepared according to 
manufacturer specifications and added to each well. Briefly, Apo I reagents were 
thawed and equilibrated to room temperature and Apo I substrate diluted 1/100 with 
Apo I buffer and added to assay wells to lysate the cells and start the conversion of 
the substrate to the fluorescent product by caspase 3 and 7 enzymatic activity of 
apoptotic cells. The plate was placed on an orbital plate shaker for 30 minutes and 
plate read on a spectrofluorometer (Flex Station II 384 microplate reader, Molecular 
Devices, Wokingham, UK). The excitation was set at 485nm, emission at 535 nm, 
495 nm cutoff. 
2.2.5.3 Cell Titer Glo viability assay 
Cell Titer Glo viability assay is based on the activity of ultra glo recombinant 
luciferase, a mono-oxygenase enzyme that converts luciferin substrates to 
oxyluciferin. Oxyluciferin emits a luminescence signal and the quantity of oxyluciferin 
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produced is dependent on ATP that is provided by the cells in the tested sample. 
Hence, the amount of conversion and luminescence signal is directly proportional to 
the ATP content in the tested sample and the ATP levels are directly proportional to 
the metabolic activity and numbers of cells.
 
 The luciferase reaction is shown below:  
 
The luminescence signal can be quantified by a luminometer.  
The optimal concentration of cells for toxicity tests was verified by a titration curve 
prior to the testing of drugs and nanoparticles. The titration curve was obtained in 
HBSS/HEPES 20 mM by 10 serial 1 to 2 dilutions of cells from a maximum of 312000 
to a minimum of 635 cells/cm2. 100 µl of cells dilutions were seeded in triplicates in 
the middle 36 wells of a 96 well plates and extra triplicate wells for media only were 
left for the blank. The edges of the wells used for the titration curve were filled with 
200 µl media to avoid excessive evaporation of assay media.  
For the Cell Titer Glo assay, cells at a density 31200 cells/cm2 were seeded in the 
middle 60 wells of a clear bottom, black well plate and allowed to attach to the bottom 
of the wells overnight. The day after, the media of cells was aspirated off and 100 µl 
of the material of interest was applied in HBSS/HEPES 20 mM in triplicates. Two or 
three independent experiments were carried out. C-PB of 50 and 100 nm were tested 
at concentrations ranging between 1000 µg/ml and 1 and dilutions of 1/10. CPZ 
tested concentrations ranged between 320 and 10 µM with dilutions 1/2. For each 
experiment a positive and negative control were also used consisting of PEI 0.5 
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mg/ml and HBSS/HEPES 20 mM respectively and a blank consisting of 
HBSS/HEPES 20 mM without cells. C-PB were incubated at 37°C and 5% CO2 for 4 
h. Endocytosis inhibitors were incubated 4.5 h. 15 minutes before the incubation time 
was over, the cells were removed from the incubator and left to equilibrate to room 
temperature according to manufacturer specification. Subsequently, Cell Titer Glo 
mix 100 µl was applied and plates loaded on an orbital mixer for 2 minutes to allow 
cell lysis. The plate was further incubated at room temperature for 10 minutes to 
allow the luminiescence signal to stabilize. For C-PB toxicity studies only, prior to the 
application of the Cell Titer Glo mix, the wells content was removed with a pipette tip 
and 100 µl of HBSS/HEPES 20 mM applied. This procedure was carried out to 
prevent or reduce the interaction of the nanoparticles with the Cell Titer Glo 
recombinant proteic enzyme and potentially reduce its activity. The luminescence 
signal was read for 1 second per well according to manufacturer specifications and 
recorded with a FluoStar Optima microplate reader (BMG LABTECH GmbH, 
Ortenberg, Germany). 
2.2.5.4 Statistical Analysis 
For all toxicity tests the Z factor and Signal Window were calculated according to the 
formulas below: 
ܼܨܽܿݐ݋ݎ ൌ  ? െ ቆሺ ?ݔܵܦ݌Ǥ ܿǤ ൅ ?ݔܵܦ݊Ǥ ܿǤ ሻŇܯ݌Ǥ ܿǤ െܯ݊Ǥ ܿǤŇ ቇ 
(7) 
݈ܵ݅݃݊ܽܹ݅݊݀݋ݓ ൌ ൬ሾܯ݊Ǥ ܿǤ െܯ݌Ǥ ܿǤ െ ?ݔሺܵ ܦ݌Ǥ ܿǤ ൅ܵܦ݊Ǥ ܿǤ ሻሿܵܦ݊Ǥ ܿǤ ൰ 
(8) 
Where: 
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SDp.c = Standard Deviation of the positive control 
SDn.c = Standard Deviation of the negative control 
Mp.c = Mean of the positive control 
Mn.c. = Mean of the negative control 
These two parameters were calculated to confirm that there was sufficient separation 
of the signals obtained from the negative and positive control at the chosen 
concentration of cells for cell activity studies and hence the studies carried out were 
producing good quality and reliable cell activity data.  
2.2.6  Htf and LacCer Wash Efficiency Studies 
Detection methods such as flow cytometry or plate reading of the signal of 
fluorescent markers of endocytosis cannot distinguish between the fluorescence 
signal from the membrane or internalised markers of endocytosis. For this reason, 
both Htf and LacCer washes are routine procedures for efficient removal of the 
endocytic marker from the plasma membrane in endocytosis inhibition studies. The 
following procedures were carried out to verify the efficiency of the wash of Htf and 
LacCer from the membrane of cells. In these experiments the buffers of the washes 
suggested from the literature were not altered. However, two different procedures 
were attempted:  
x Cells treated with markers of endocytosis were washed in flasks with standard 
buffers before being removed with trypsin and fixed for flow cytometry. 
x Cells treated with markers of endocytosis were removed from flasks with 
trypsin, collected in Eppendorf tubes and cells washed with standard buffers 
on cells suspensions. Each wash step was followed by a centrifugation step at 
2000 g for 5 minutes at 4°C. 
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2.2.6.1 Htf and LacCer removal from the cell membrane with washes on 
cells suspensions 
Cells were seeded at a density of 31200 cells/cm2 in 25 cm2 flasks and allowed to 
attach to the bottom of the flask overnight. Subsequently, cells were detached from 
flasks with trypsin, collected in Eppendorf tubes and centrifuged at 2000 g for 5 min 
at 4°C. The supernatant was aspirated off with a pipette tip and Eppendorf tubes 
placed on ice and left to equilibrate for one minute. Subsequently, cells were re-
suspended in ice cold HBSS /HEPES 20 mM (negative control) or ice cold Htf 6.7 
µg/ml in HBSS/HEPES 20 mM in or LacCer 0.81 µM in HBSS/HEPES 20 mM in 
duplicate Eppendorf tubes. The 2 Eppendorf tubes treated with Htf 6.7 µg/ml or 
LacCer 0.81 µM in HBSS/HEPES 20 mM consisted of one positive control not treated 
with consequent washing steps and used as a reference control of the membrane 
bound marker of endocytosis, and one positive control treated with washes on cells 
suspensions. The Eppendorf tubes were incubated for 5 minutes on ice to allow the 
binding of the marker of endocytosis on the cell membrane without internalization. 
Hence, cells were washed with the buffers and procedures described below.  
The buffers used to remove membrane bound Htf consisted of 2 rinses with ice cold 
HMEM-G+I, on ice +DQN¶V 0LQLPXP (VVHQWLDO0HGLXP HMEM) without glucose - 
Gibco, Paisley, UK - supplemented with 10 mM HEPES and 5 mM sodium azide, 
NaN3, to inhibit metabolic activity) followed by 1 minute ice cold wash with 0.2 mM 
acetic acid 0.2 mM NaCl buffer pH 4.69. The acidic wash was then rinsed on ice with 
2 cold washes of HMEM-G+I.  
The buffers used to remove membrane bound LacCer consisted of two ice cold 
washes with HMEM-G+I followed by 6 rinses (10 minutes each, on ice) of HMEM-G+I 
supplemented with 5% w/v dBSA (back exchange method)10.  
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The washes described above were carried out on cell suspensions and each wash 
was followed by 5 minutes centrifugation at 2000 g at 4°C. The last wash step was 
then followed by centrifugation at 2000 g for 5 minutes at 4°C and cells re-suspended 
in PFA 4% v/v PBS and fluorescence of cells analysed by flow cytometry with a 
Becton-Dickinson (BD) LSR II flow cytometer, Oxford, UK and detected with optical 
filters (FITC 530/30 bandpass filter for LacCer detection or an APC channel, 660/20 
optical bandpass filter for the detection of Htf). Data were analysed with Weasel 
software, normalised against the positive and negative controls assumed being 100% 
and 0% uptake of the markers of endocytosis and plotted in GraphPad Prism. 
2.2.6.2 Htf and LacCer removal from the cell membrane with washes on 
adherent cells 
Cells were seeded at a density of 31200 cells/cm2 in 25 cm2 flasks and allowed to 
attach to the bottom of the flask overnight. The day after, cells were placed on ice 
and left to equilibrate for 10 minutes. Subsequently, full growth media was aspirated 
off and cells treated with ice cold HBSS/HEPES 20 mM for the negative control or ice 
cold Htf 6.7 µg/ml or LacCer 0.81 µM in HBSS/HEPES 20 mM in duplicate flasks. 
The 2 additional flasks for each marker of endocytosis consisted of one positive 
control not treated with consequent washing steps and used as a reference control of 
the membrane bound marker of endocytosis, and a positive control subsequently 
treated with flask washes. The flasks were incubated for 5 minutes on ice to allow the 
binding of the Htf or LacCer on the cell membrane without internalization. Hence, 
cells were washed on ice with the buffers and procedures described below.  
The buffers used to remove membrane bound Htf consisted of 2 rinses with ice cold 
HMEM-G+I, on ice followed by 1 minute ice cold wash with 0.2 mM acetic acid 0.2 
mM NaCl buffer pH 4.69. The acidic wash was then followed by 2 cold washes of 
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HMEM-G+I on ice, cells were trypsinised, centrifuged at 2000 g for 5 minutes at 4°C 
and fixed in PFA 4% v/v PBS.  
The buffers used to remove membrane bound LacCer consisted of two ice cold 
washes with HMEM-G+I followed by 6 rinses (10 minutes each, on ice) of HMEM-G+I 
supplemented with 5% w/v dBSA (back exchange method)10. Cells were then 
trypsinised, centrifuged at 2000 g for 5 minutes at 4°C and fixed in PFA 4% v/v PBS 
and analysed by flow cytometry with a Becton-Dickinson (BD) LSR II flow cytometer, 
Oxford, UK and detected with optical filters (FITC 530/30 bandpass filter for LacCer 
detection or an APC channel, 660/20 optical bandpass filter for the detection of Htf). 
Data were analysed with Weasel software, normalised against the positive and 
negative controls that were assumed being 100% and 0% uptake of the endocytosis 
markers and plotted in GraphPad Prism. 
 
Table 2-2 Summary of the inhibitors of endocytosis used in this study 
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2.2.7  Inhibition of Htf uptake with CPZ  
Cells were seeded in 25 cm2 vented caps flasks at a density of 31200 cells/cm2 and 
allowed to attach to the bottom of the flasks overnight. Subsequently, full media was 
replaced with HBSS supplemented with 20 mM HEPES with or without chemical 
inhibitors of endocytic pathways for 30 minutes and then replaced with HBSS/HEPES 
20 mM with or without LacCer 0.81 µM or Htf 6.7 µg/ml and chemical inhibitors. 
Chemical inhibitors working concentrations were selected as 1.25 mM MBCD and 40, 
60 and 80 µM CPZ (Table 2-2). Upon completion of the incubation time, cells were 
washed as described above, detached from flasks with trypsin-EDTA or EDTA alone, 
centrifuged at 2000 g for 5 minutes and re-suspended in a fixation buffer consisting of 
PFA 4% v/v in PBS. Cells were then analysed with a BD LSR II flow cytometer (APC 
660/20 bandpass filter). Briefly, Htf acidic wash consisted of two cold washes with 
HMEM-G+I followed by 1 minute ice cold wash with 0.2 mM acetic acid 0.2 mM NaCl 
buffer9. The acidic wash was then rinsed out with 2 cold washes of HMEM-G+I. The 
Htf washes were carried out in 25 cm2 flasks. A variant of this protocol included the 
used of HBSS devoid of Ca2+ and Mg2+ supplemented with 20 mM HEPES instead of 
standard HBSS. This protocol was aiming at depleting cells of Ca2+ and consequently 
of ATP and overall energy. 
2.2.8  Inhibition of Htf uptake with Pitstop 2 
Cells were seeded at a density of 31200 cells/cm2 in 25 cm2 vented cap flasks and 
allowed to attach to the bottom of the flask overnight. Subsequently, full media was 
replaced with HBSS supplemented with HEPES 20 mM with or without Pitstop 2 
(abCam, Cambridge, UK, Table 2-2) for 15 minutes and then replaced with 
HBSS/HEPES 20 mM with or without Htf 6.7 µg/ml and chemical inhibitor. Working 
concentrations of Pitstop 2 were selected as 12.5, 18.75 and 25 µM and incubation 
times set at 1 or 2 h. Upon completion of the incubation time, cells were washed as 
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described above, detached from flasks with trypsin-EDTA or EDTA alone, centrifuged 
at 2000 g for 5 minutes and re-suspended in a fixation buffer consisting of PFA 4% in 
PBS. Cells were then analysed with a BD LSR II flow cytometer (APC 660/20 
bandpass filter). Briefly, Htf acidic wash consisted of two cold washes with HMEM-
G+I followed by 1 minute ice cold wash with 0.2 mM acetic acid 0.2 mM NaCl buffer9. 
The acidic wash was then rinsed with 2 cold washes of HMEM-G+I. The acidic 
washes were carried out in flasks. 
2.2.9  Inhibition of LacCer uptake with MBCD  
Cells were seeded at a density of 31200 cells/cm2 and allowed to attach to the 25 cm2 
flasks overnight. Subsequently, full media was replaced with HBSS supplemented 
with 20 mM HEPES with or without chemical inhibitors of endocytosis for 30 minutes 
and subsequently replaced with HBSS/HEPES 20 mM alone (negative control), 
LacCer 0.81 µM (positive controls) or with LacCer 0.81 µM in the presence of 80 µM 
CPZ or 1.25 mM MBCD (Table 2-2). The incubation times were 1-2-3 and 4 h for all 
cell lines. Chemical inhibitors working concentrations were selected as the lowest 
affective inhibiting concentration of the chemical inhibitors. Upon completion of the 
incubation time cells were washed as described above and subsequently detached 
from flasks with trypsin-EDTA. Detached cells were centrifuged at 2000 g for 5 
minutes and re-suspended in a fixation buffer consisting of PFA 4% v/v in PBS. Cells 
were then analysed with a BD LSR II flow cytometer and detected with optical filters 
(FITC 530/30 bandpass filter).  
Briefly, LacCer wash consisted of two ice cold washes with HMEM-G+I followed by 6 
rinses (10 minutes each) of HMEM-G+I supplemented with 5% w/v dBSA (back 
exchange method)10.  
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2.2.10  Endocytosis inhibition in the presence of C-PB 
Cells were seeded at a density of 31200 cells/cm2 and allowed to attach to the 25 cm2 
flasks overnight. Subsequently, full media was replaced with HBSS supplemented 
with 20 mM HEPES with or without chemical inhibitors of endocytosis for 30 minutes. 
The buffer was subsequently replaced with HBSS/HEPES 20 mM alone (negative 
control), 50 nm C-PB 100 µg/ml or 100 nm C-PB 100 µg/ml (positive controls), or with 
50 or 100 nm C-PB 100 µg/ml in the presence of 80 µM CPZ or 1.25 mM MBCD. C-
PB and inhibitors were further incubated for 1-2 or 4 h. Subsequently, cells were 
washed twice with HBSS/HEPES 20 mM and EDTA, detached from flasks with 
trypsin/EDTA, centrifuged at 2000 g for 5 minutes and re-suspended in PFA 4% v/v 
PBS. Cells were then analysed with a BD LSR II flow cytometer and detected with 
optical filters (FITC 530/30 bandpass filter).  
2.2.11  Procedures for sterilization of coverslips for microscopy 
Round 22x1.5 mm glass coverslips (SLS, Nottingham, UK) were handled in a Class II 
cabinet. They were picked up with autoclaved tweezers and immerged in absolute 
ethanol (Sigma, Dorset, UK) for 5 minute. The coverslips were then removed from 
ethanol and left to dry to the air of the class II cabinet in a sterile six well plate before 
use. 
2.2.12  Confocal microscopy live imaging methods 
Cells were seeded in full media to a final density of 31200 cells/cm2 in 6 well plates in 
the presence of sterile rounded 22x1.5 mm glass coverslips (SLS, Nottingham, UK). 
Cells were left to attach to the glass coverslips overnight. On the next day the cells 
were stained with Hoechst 33342 (Thermo Scientific, Rockford, USA) 1 µg/ml and 
Cell Mask deep red cell membrane stain 1 µg/ml for 30 minutes (Molecular Probes, 
Paisley, UK). The media was then replaced with HBSS/HEPES 20 mM for live 
imaging. Confocal equipment consisted of a Zeiss Laser Scanning Microscope (LSM) 
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710, Jena, Germany. This was supplied with a heated chamber at 37°C that was 
switched on and equilibrated to temperature overnight. Glass rounded coverslips 
were mounted on a coverslip holder that had been previously sterilised and 
equilibrated at 37°C overnight. Images of stained cells in buffer were taken prior to 
the exposure of cells to C-PB. The C-PB solution was then added to the buffer 
solution at a ratio 1:1 to obtain a final concentration of C-PB of 50 µg/ml. Images of 
the 4 regions of interests were acquired at 4-10-20-30-40-50 and 60 minutes on a 
40x water objective.  
2.2.13  Immunofluorescence of clathrin and caveolin-1 
Cells were seeded at a density of 31200 cells/cm2 and allowed to attach to squared 
22x22x1.5 mm glass coverslips (SLS, Nottingham, UK) or 25 cm2 flasks overnight. 
The day after cells were washed and fixed for 30 minutes at room temperature with 
PFA 4% v/v for immunofluorescence or trypsinized and pelleted at 2000 g for 5 
minutes before fixation for flow cytometry. Cells on coverslips were washed 3 times 
for 5 minutes in PBS while trypsinized cells suspensions for flow cytometry were 
washed in PBS once for 5 minutes on a rocker. Subsequently, PBS, 0.3% v/v Triton 
X-100, 5% v/v goat serum blocking buffer was applied for 1.5 h. When the incubation 
time was over, the blocking buffer was gently removed with a pipette tip and the 
chosen antibody applied according to manufacturer specifications. Anti-clathrin heavy 
chain mouse IgG1mAb (clone X22) prepared in PBS, 1% w/v BSA, 0.3% v/v Triton X-
100 was used at a concentrations of 0.12 µg/ml and anti-caveolin-1 mouse IgG1mAb 
(clone 2297), prepared in PBS, 1% w/v BSA, 0.3% v/v Triton X-100, was applied at a 
concentration of 0.83 µg/ml for all cell lines. Mouse IgG1 was utilised as a negative 
control at concentrations of 0.12 µg/ml for clathrin IgG1 negative control and 0.83 
µg/ml for caveolin-1 IgG1 negative control. An additional negative control consisting 
in cells treated with secondary antibody were incubated with PBS, 1% w/v BSA, 0.3% 
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v/v Triton X-100. All cells were incubated for 1.5h; subsequently, cells on coverslips 
were washed 3 times for 5 minutes in PBS while cell suspensions were washed once 
on a rocker for 5 minutes, and goat anti-mouse (H+L) IgG1 AlexaFluor 488 nm or 594 
nm secondary antibody (Molecular Probes, Paisley, UK) in PBS, 1% w/v BSA and 
0.3% v/v Triton X-100 was applied overnight at 4°C. The secondary antibody was 
diluted to 5 µg/ml for both clathrin and caveolin staining. The following day, the 
secondary antibody was aspirated off and cells washed 3 times for 5 minutes with 
PBS. Cells prepared for microscopy were removed from the wells with the aid of a 
needle and tweezers, further stained with Prolong Gold Antifade DAPI mounting 
media (Invitrogen, Paisley, UK) applied on glass slides and left to dry at room 
temperature in the dark overnight. The following day, coverslips edges were sealed 
with nail polish to the glass slides and stored at 4°C until used on a Zeiss LSM700 
confocal microscope, Jena, Germany. Cells prepared for flow cytometry were 
resuspended in PBS. Flow cytometry data were acquired with a BD LSR II flow 
cytometer (FITC 530/30 bandpass filter for AlexaFluor488 secondary antibody) and 
analysed with Weasel software. 
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3.1 Introduction 
Synthetic and natural polymers are being extensively studied as carriers of drugs1,2. 
The ability of some polymers to self-assemble, creating protected compartments for 
the transport of drugs, together with the possibility to respond to external stimuli by 
conformational rearrangement and release of the drug load, are appealing 
characteristics for biomedical use. However, chemical and physical characteristics of 
these polymers such as size and superficial charge can modulate the extent of their 
internalization in cells as well as influencing their pathway of uptake3-6. A better 
understanding of how these characteristics can change cellular processing of these 
materials in different cell lines will help the design of more reliable carriers of drugs. 
For this reason, commercially available Polysciences Carboxylated Yellow-Orange 
Polystyrene Beads (C-PB) of well defined size charge and shape were used as a 
model for polymeric nanomaterials with a hydrophobic bulk and slightly negative 
surface charge. The C-PBs were characterized in the intended buffer for the 
endocytosis experiments by ȗ potential measurements and their sizes determined by 
both DLS and TEM. The effects of these materials on cell viability were also 
characterized by MTT and Cell Titer Glo ATPase assays. 
The choice of the cell lines for the study was made on the basis of evidence that 
many pathologies affect epithelial cells7-9. However, literature reports an increasing 
role of mesenchymal cells in the instigation and progression of pathologies such as 
cancer. Here, myofibroblasts are heavily involved in the production and preservation 
RIWKHWXPRUPLFURHQYLURQPHQWWKHVRFDOOHGµQLFKH¶RUVWURPDZKHUHP\RILEUREODVWV
and epithelial cell signalling and cross-talk promotes changes in epithelial cells 
towards more aggressive cancers10,11. Moreover, fibroblasts are also involved in other 
pathologies such as fibrosis, inflammation and arthritis which make their activity also 
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a potential target for new therapeutics. For all these reasons, two epithelial cancer 
cells, HCT116 and MGLVA-1 and one fibroblastic cell line, Swiss Albino 3T3 
fibroblasts, were chosen for the study and characterized for the presence of clathrin 
and caveolin that are involved in the two best characterized endocytic pathways.  
In this chapter a series of experiments were carried out to define the experimental 
settings for the studies of endocytosis inhibition. The investigation of different routes 
of uptake in different cell lines was carried out with human transferrin (Htf) and 
lactosylceramide (LacCer).These two molecules are widely accepted markers of 
clathrin-dependent and -independent endocytosis12. Chlorpromazine (CPZ) and 
methyl beta cyclodextrin (MBCD) have been widely used as pharmacological 
inhibitors of clathrin-dependent and -independent endocytosis13,14. As the specificity 
of both CPZ and MBCD have been questioned in the past, the inhibition experiments 
with each marker of endocytosis were carried out in the presence of both 
pharmacological inhibitors to spot any non-specific inhibition of endocytosis13-15. The 
extent of inhibition was measured by flow cytometry as this technique gives a better 
snapshot of the rate of internalization of markers of endocytosis at the single cell level 
and can detect also small shifts in inhibition of endocytosis in a statistically robust 
way. Finally, as both CPZ and MBCD have been reported as cytotoxic, a thorough 
characterization of their cell activity was carried out16-24. The effects of MBCD on cell 
activity was tested with both MTT and Cell Titer Glo while CPZ was investigated with 
MTT, Cell Titer Glo and Apo I assays. 
3.2 Methods  
3.2.1 C-PB size and charge characterization  
Detailed information on the DLS and TEM methods used to characterize 50 and 100 
nm C-PB can be found in the materials and methods §§ 2.2.2 and 2.2.3. Briefly, for 
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DLS studies, 50 and 100 nm C-PB were diluted to 200 µg/ml and 50 µg/ml in filtered 
PBS buffer, vortexed for 1 minute to remove aggregates of nanoparticles and 10 µl of 
the nanoparticles suspension loaded into a quartz micro-cuvette in a DLS reader 
previously equilibrated to 20°C. The DLS equation settings were updated for the PBS 
buffer, and the mean size of nanoparticles was given by 10 replicates measurements. 
These measurements were repeated 3 times, averaged and plotted in GraphPad 
Prism.  
For TEM, the nanoparticles were diluted to 25 or 26.5 µg/ml in PBS, loaded on a 
copper grid and allowed to dry overnight. The day after, a minimum of 12 TEM 
images were collected for a minimum of 250 nanoparticles counts. Nanoparticle sizes 
were measured from images with ImageJ software and data plotted in GraphPad 
Prism. The coefficient of variance for the TEM and DLS measured size was 
calculated as follows: 
ܥܸ ? ൌ ቀߪܯቁ  ? ? ? ? 
Were CV% = coefficient of variance % 
ı 67'(9 
M = mean size of the nanoparticles 
ȗ potential measurements were carried out in HEPES buffer 1 mM, Ph 7.4 at 20°C at 
concentrations of C-PB of 200 µg/ml. The results are reported as the mean of 12 
measurement replicates. 
3.2.2 Cell viability studies of C-PB, MBCD and CPZ 
3.2.2.1 Cell viability assays titration curves and statistical analysis 
The seeding density of cells to obtain a linear relationship between numbers of cells 
and viability signal was investigated by a titration curve for MTT and Cell Titer Glo 
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prior to toxicity tests. Different titration curves were run for different time of 
incubations. For a more detailed description of the procedures used to obtain the 
titration curves please refer to §§ 2.2.5.1 and 2.2.5.3. Briefly, cells were counted and 
seeded at densities ranging from 312000 to 1985 cells/cm2 and incubated overnight. 
The day after, the media was aspirated off and HBSS/HEPES 20 mM added to cells 
for the desired time-length. Upon completion of the incubation time, the cells were 
treated according to the standard assay protocol and colorimetric or luminescence 
signals recorded.  
For all toxicity tests the Z factor and Signal Window were calculated according to the 
formulae below: 
ܼܨܽܿݐ݋ݎ ൌ  ? െ ቆሺ ?ݔܵܦ݌Ǥ ܿǤ ൅ ?ݔܵܦ݊Ǥ ܿǤ ሻŇܯ݌Ǥ ܿǤ െܯ݊Ǥ ܿǤŇ ቇ 
(25) 
݈ܵ݅݃݊ܽܹ݅݊݀݋ݓ ൌ ൬ሾܯ݊Ǥ ܿǤ െܯ݌Ǥ ܿǤ െ ?ݔሺܵ ܦ݌Ǥ ܿǤ ൅ܵܦ݊Ǥ ܿǤ ሻሿܵܦ݊Ǥ ܿǤ ൰ 
(26) 
Where: 
SDp.c = Standard Deviation of the positive control 
SDn.c = Standard Deviation of the negative control 
Mp.c = Mean of the positive control 
Mn.c. = Mean of the negative control 
These two parameters were calculated to confirm that there was sufficient separation 
from the signal between negative and positive control at the chosen concentration of 
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cells for cell viability studies and hence the studies carried out were producing good 
quality and reliable cell viability data.  
3.2.2.2 Metabolic activity (viability) of cells in the presence of C-PB 
Studies at 4 h of C-PB of 50 and 100 nm in cells were carried out in triplicate wells in 
3 independent experiments. Effects of C-PB were investigated by MTT and Cell Titer 
Glo assays. Only one replicate for MTT viability tests at 24 and 48 h were carried out 
with 50 nm C-PB in triplicate wells. For a thorough description of the methods used 
please refer to §§ 2.2.5.1 and 2.2.5.3. Briefly cells at a density of 31200 cells/cm2 
were seeded in a 96 well plate and allowed to attach to the wells overnight. The day 
after the media was replaced with serial dilutions of C-PB in HBSS/HEPES 20 mM, 
for C-PB concentrations ranging from 1 to 1000 µg/ml and a negative control 
consisting of assay media (HBSS/HEPES 20 mM) or PEI 0.5 mg/ml positive control, 
in triplicate wells. The same serial dilutions were placed on 96 well plates without 
cells for a blank reading for both the MTT and the Cell Titer Glo assays and blank 
values subtracted from the absorbance/luminescence readings on the C-PB with 
cells. C-PB of 50 and 100 nm were incubated for 4 h, 50 nm C-PB were also tested 
with an MTT at 24 and 48 h. Upon completion of the incubation time MTT or Cell Titer 
Glo were applied according to standard protocols. Acquired absorbance and 
luminescence measurements were normalised against the negative control that was 
assumed being the 100% viability of cells. 
3.2.2.3 Studies on the effects of MBCD on cell viability 
The effects of MBCD on cells were carried out in triplicate wells for a minimum 3 
independent experiments using the MTT and Cell Titer Glo assays. For a more 
complete description of the methods used refer to §§ 2.2.5.1 and 2.2.5.3. Briefly, cells 
at a density of 31200 cells/cm2 were seeded in a 96 well plate and allowed to attach 
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to the wells overnight. The day after the media was replaced with serial dilutions of 
MBCD in HBSS/HEPES 20 mM, for concentrations ranging from 0.33 to 10 mM. 
Each assay presented also a positive control consisting of PEI 0.5 mg/ml, a negative 
control of cells in HBSS/HEPES 20 mM only and a blank reading in HBSS/HEPES 20 
mM assay media devoid of cells. MBCD was incubated for 4.5 h and upon completion 
of the incubation time MTT or Cell Titer Glo were applied according to manufacturer 
protocols. Acquired colorimetric and luminescence measurements were normalised 
against the negative control that was assumed being the 100% viability of cells. 
3.2.2.4 Effects of CPZ on cell viability 
A thorough investigation of the effects of CPZ was carried out using MTT, Cell Titer 
Glo and Apo I caspase 3/7 viability assays. Studies using CPZ were carried out in 
triplicate wells in 3 independent experiments. Cells were seeded in 96 well plates for 
MTT and Cell Titer Glo and on 384 well plate for Apo I caspase 3/7 assay. For a 
thorough description of the methods used please refer to § 2.2.5.1 for the MTT, § 
2.2.5.3 for Cell Titer Glo and § 2.2.5.2 for Apo I. Briefly cells at a density of 31200 
cells/cm2 were allowed to attach to the wells overnight. The day after the media was 
replaced with serial dilutions of CPZ in HBSS/HEPES 20 mM, for concentrations 
ranging from 10 to 457 µM and incubated for 4.5 h. Upon completion of the 
incubation time, MTT, Cell Titer Glo and Apo I caspase 3/7 were applied according to 
standard protocols.  
3.2.3 Immunofluorescence of clathrin heavy chain isoform Į 
(CHCĮ) and caveolin-1 (cav-1) in 3T3, HCT116 and MGLVA-1 
A more extensive description of these methods can be found at § 2.2.13. Here, 3T3 
mouse fibroblasts, MRC-5 human fibroblasts, HCT116 human colon cancer and 
MGLVA-1 human gastric cancer cells were seeded at a density of 31200 cells/cm2 
and allowed to attach to glass coverslips or 25 cm2 flasks overnight. The day after, 
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cells were washed and fixed for 30 min at room temperature with PFA 4% v/v for 
confocal microscopy or trypsinized and pelleted at 2000 g for 5 min before fixation for 
flow cytometry. Rinsed cells were treated with PBS, 0.3% v/v Triton, 5% v/v goat 
serum blocking buffer for 1.5h. Subsequently, the blocking buffer was gently removed 
with a pipette tip, and anti-&+&ĮPRXVH,J*P$E,PPXQRJOREXOLQ*PRQRFORQDO
antibody, clone X22) 0.12 µg/ml and anti-caveolin- LVRIRUP Į PRXVH ,J*P$E
(clone 2297) 0.83 µg/ml incubated for further 1.5 h. Mouse IgG1 was utilised as a 
negative control at concentrations of 0.12 µg/ml for clathrin IgG1 negative control and 
0.83 µg/ml for cav-1 IgG1 negative control. An additional negative control consisting 
of cells treated only with secondary antibody were incubated with PBS, 1% w/v BSA, 
0.3% v/v Triton. Upon completion of the incubation time, cells were rinsed and treated 
with goat anti-mouse (H+L) IgG1 AlexaFluor 488 nm or 594 secondary antibody 
overnight at 4°C. The following day, the secondary antibody was removed and cells 
washed with PBS. Cells prepared for microscopy were removed from the wells with 
the aid of a needle and tweezers, further stained with Prolong Gold Antifade DAPI 
mounting media, applied on glass slides and left to dry at room temperature in the 
dark overnight. The following day, coverslips edges were sealed to the glass slides 
with nail polish and stored at 4°C until use on a Zeiss LSM 700 confocal microscope. 
Cells prepared for flow cytometry were resuspended in PBS. Flow cytometry data 
were acquired with a BD LSR II flow cytometer with a FITC 530/30 bandpass optical 
filter and analysed with Weasel software and plotted in GraphPad Prism.  
To verify that the binding affinity of the mAb was comparable between human and 
murine proteins, &+&ĮDQGcav-1 protein 3D rearrangement were compared to the 
human sequences with ICOS protein 3D simulator software, where a score ranging 
between 0 and 4 was given for the amino acids (aa) more or less exposed to the 
surface of the protein and external environment. 
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3.2.4 Wash efficiency studies for the removal of markers of 
endocytosis 
A detailed description of the methods carried out in these experiments can be found 
in the general materials and methods section at § 2.2.6.  
Briefly, two wash procedures were attempted to verify the removal of membrane 
bound endocytic markers: one with adherent cells in 25 cm2 flasks and another in 
Eppendorf tubes and cell suspensions. The wash solutions used for both Htf and 
LacCer removal were the traditional buffers reported in the literature27,28. The buffer 
wash procedures used to remove membrane bound Htf consisted of 2 rinses with ice 
cold HMEM-G+I, on ice (HMEM without glucose supplemented with 10 mM HEPES 
and 5 mM sodium azide to inhibit metabolic activity) followed by 1 minute ice cold 
wash with 0.2 mM acetic acid 0.2 mM NaCl buffer pH 4.627. The acidic wash was 
then followed by 2 cold washes of HMEM-G/HEPES/NaN3 on ice. 
The buffer wash methods for removal of membrane bound LacCer consisted of two 
ice cold washes with HMEM-G+I followed by 6 rinses (10 minutes each, on ice) of 
HMEM-G+I supplemented with 5% w/v BSA (back exchange method)28.  
3.3 Results 
3.3.1 Size and Charge Characterization of 50 nm C-PB 
Polysciences described C-PB as in the size range of 50 nm ±15% coefficient of 
variance. DLS studies of the 50 nm C-PB showed that the measured sizes of the 
materials were in general agreement with the sizes stated by the manufacturer 
(Figure 3-1A). DLS intensity, mass and number distribution ranges of the diameter of 
the nanoparticles reported a mean size of 57 nm. However, the coefficient of variance 
for intensity, mass and number distributions were higher than those stated and equal 
to ±39.7%. TEM measurements (Figure 3-2A) indicated a mean diameter of 30 nm 
Results - Characterization of Materials and Cell lines 
121 
 
and a coefficient of variance of ±29%. Figure 3-4A shows a TEM picture of 50 nm C-
PB. From TEM data the diameters of C-PB ranging between 20 and 40nm accounts 
for 286 events while the edges of the Gaussian distribution (from 5 -19 to 41 ± 70 nm) 
account for 51 events.  
ǽpotential measurements revealed a charge of -37.7 mV.  
  
 
 
Figure 3-1 DLS characterization of 50 and 100 nm C-PB shown as intensity, mass and number plots (A and B). 100 nm CPB intensity peak is broad and the data fit 
a double Gaussian distribution. 50 and 100 nm C-PB were diluted to 200 µg/ml and 50 µg/ml in filtered PBS buffer, vortexed for 1 minute and loaded into a quartz 
micro-couvette in a Malvern Instruments Viscotek 802 DLS reader previously equilibrated to 20°C. The DLS equation settings were updated for the PBS buffer, and 
the mean size of nanoparticles was given by 10 replicates measurements. This procedure was repeated 3 times and data plotted in GrapPad Prism. Intensity, mass 
and number distributions of the 50 nm C-PB report a peak diameter of 57nm. Intensity measurements for 100 nm C-PB shows a broader peak that corresponds to 
a double population of nanoparticles. Peak diameter is at 108 nm for intensity, 71 nm for mass and 67 nm for number distributions. 
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Figure 3-2 dD ?Ɛ ƉůŽƚ ŽĨ &ĞƌĞƚ ?Ɛ ĚŝĂŵĞƚĞƌ ŵĞĂƐƵƌĞŵĞŶƚƐ confirming the presence of a second 
population of smaller nanoparticles for 100 nm C-PB. The measurements were obtained from 12 
images and a minimum of 250 nanoparticles for 50 and 100 nm C-PB. C-PB were diluted to 25 µg/ml 
and 26.5 µg/ml in PBS, loaded on a copper grid and allowed to dry overnight. The day after, a 
minimum of 12 TEM images were collected for a minimum of 250 nanoparticles counts. Nanoparticle 
sizes were measured with ImageJ software and data plotted in GraphPad Prism. TEM data confirm the 
DLS findings: 50 nm C-PB present a single but slightly broad size distribution with a maximal peak at 30 
nm while 100 nm C-PB showed two main populations at 20 and 100 nm. 
 
3.3.2 Size and Charge Characterization of 100 nm C-PB 
 
Figure 3-3 Intensity DLS data for 100 nm C-PB fit a double Gaussian distribution. The double 
Gaussian distribution was calculated by GraphPad Prism. Here, two sizes of nanoparticles are 
measured with peak diameters at 75 nm and 123 nm (red arrows). 
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Figure 3-4 TEM images of 50 nm (A) and 100 nm (B) C-PB. The arrows on picture B point to the 
smaller particles sizes detected also by DLS. TEM measurements report a size of around 20 nm for the 
second population of nanoparticles (about 5% of the total population of cells). Scale bar for 50 nm C-
PB: 200nm; Scale bar for 100 nm C-PB: 500 nm. 
Polysciences described the C-PB as 100 nm ±10% coefficient of variance. DLS data 
(Figure 3-1B) reported a mean of 108 nm and coefficient of variance of 45% for the 
intensity values, a mean of 71 nm and ±93% variance for the mass and a mean of 67 
nm and ±80% variance for the number distributions. Furthermore, the analysis of the 
DLS intensity values revealed a double Gaussian distribution with mean diameter 
values at 75 and 123 nm (Figure 3-3). TEM data (Figure 3-2B) reported a mean value 
of 83 nm and a coefficient of variance of ±39% for the main peak of nanoparticles. 
The size range 90-110 nm accounts for 195 events with 11 off peak events in total for 
nanoparticles size of 80-89 nm and 111-140 nm. However, a second peak of 
materials was detected around 20 nm. The size distribution of this peak ranged 
between 10 and 40 nm for a total of 51 events (5% of the total) and was also 
confirmed in TEM data where two size populations were visible at 20 and 100 nm 
diameters. Picture 3-4B shows the smaller population of nanoparticles (arrows). ǽ 
potential measurements revealed a charge of -34.2 mV. 
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3.3.3 Cell viability studies of C-PB, CPZ and MBCD  
3.3.3.1 Cell viability assays titration curves and statistical analysis 
Titration curves obtained with MTT and Cell Titer Glo at 4.5h are shown in Figure 3-5, 
titration curves with MTT at 24 and 48 h are shown in Figure 3-6. The titration curves 
show that the density used in toxicity assays of 31200 cells/cm2 is within the linear 
correlation range between number of cells and detection signal. To further confirm 
these results, statistical measurements of the Z factor and Signal Window measured 
for negative and positive controls were also calculated for MTT, Apo I and Cell Titer 
Glo assays and are shown in Table 3-1. The statistical analysis confirms that the 
concentration of cells used for all endocytosis experiments was also suitable for 
toxicity studies. The Z factor and Signal Window calculated for the MTT tests at 24 
and 48 h are reported in Table 3-2. The ǽ factor values range between 0.9 and 0.6, 
which correspond to excellent assays according to Zhang¶V classification while Signal 
Window values range between 1.4 and 34 corresponding to ideal and acceptable 
assays according to Iversen¶V classification (Table 3-1,3-2 and 3-3)25,26 
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Figure 3-5 MTT and Cell Titer Glo titration curves for 3T3, HCT116 and MGLVA-1 cells showing a 
linear correlation between numbers of cells and signal from viable cells at the concentration used 
for toxicity tests and inhibition studies (red dotted lines). The readings were obtained at 4.5 h in 
HBSS/HEPES 20 mM for both MTT (left) and Cell Titer Glo (right). The upper density of cells for both 
assays was set to 312000 cells/cm
2
 and was diluted 2-fold to achieve the minimum detection limit for 
the assay. Cell viability assays should be set within this linear detection region in order to obtain a 
linear correlation between signal and number of cells. Error bars represent the standard deviation of 
the mean (n=3). 
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Figure 3-6 MTT titration curves for 3T3, HCT116 and MGLVA-1 cells at 24 and 48 h showing a linear 
correlation between number of cells and signal from viable cells at the concentrations of cells used 
for toxicity and inhibition studies (dotted lines). Error bars represent the standard deviation of the 
mean (n=3). 
 
 
Table 3-1 Statistical analysis to confirm that the cell density of 31200cells/cm
2
 was suitable for cell 
viability studies. For MTT, Cell Titer Glo and Apo I toxicity assays, the Z factor and Signal Window in 
the 3 cell lines used was calculated against the positive and negative control signal values for each test 
according to equations described in the material and methods. (*
25
; **
26
). 
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Table 3-2 Statistical analysis to confirm that the cell density used for MTT assays at 24 and 48 h was 
giving a good separation between negative and positive control according to 
25
(*) and (**)
26
. 
 
Table 3-3 Reference values for Z factor and Signal Window provided according to 
25
 (*) and 
26 
(**). 
 
3.3.4 C-PB cell viability studies  
Cell viability studies at 4 h incubation were mainly in agreement for the effects of 100 
nm C-PB and generally showed very little toxicity of the nanoparticles with broad IC50 
values due to low toxicity.  
In contrast, 50 nm C-PB were found to be more detrimental for cell viability in both 
tests, with the largest effects shown in the MTT assay. The IC50 values of 50 nm C-
PB were cell dependent and the IC50 and 95% confidence interval at 4 h for 50 nm C-
PB with an MTT and Cell Titer Glo tests are summarised in Table 3-4. No signs of 
cell toxicity were detected by the visual examination of cells treated with both 50 and 
100 nm C-PB under a reverse microscope for concentrations up to 100 µg/ml. 
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Figure 3-7 Biocompatibility studies of 50 and 100 nm C-PB at 4 h in 3T3, HCT116 and MGLVA-1 cells. 
Metabolic activity as a proxy for toxicity was detected with MTT (black lines and squares in the graphs) 
and Cell Titer Glo assays (red lines and circles in the graphs). Error bars represent the standard 
deviation of the mean (n=3). 
As a consequence, a preliminary screening with an MTT of 50 nm C-PB was also run 
at 24 and 48 h (Figure 3-8 and Table 3-4). Results are based on one experiment only 
and show that the MTT assay does not report the same low viability for 50 nm C-PB. 
The IC50 and 95% confidence intervals at 24 and 48 h incubation of 50 nm C-PB are 
summarised in Table 3-4. Z factor and Signal Windows for 3T3 cells at 24 h were 
equal to 0.8 and 12.2 respectively and 0.9 and 34 at 48 h corresponding to an 
excellent assay for the Z factor values and a recommended value for the Signal 
Window according to Zhang¶V and ,YHUVHQ¶V classification. Z factor for HCT116 at 24 
h was equal to 0.6 and a Signal Window of 5, Z factor of 0.8 and Signal Window of 11 
at 48 h. In MGLVA-1 cells the Z factor at 24 h was equal to 0.7 and Signal Window of 
8 and 0.9 and 28 for the Z factor and Signal Window at 48 h. the reported Z factor 
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values correspond to an excellent assay, Signal Windows values correspond to a 
recommended assay. The IC50 results reported above refer to one single experiment 
replicate for 50 nm C-PB incubated at 24 and 48 h1. 
 
Table 3-4 Summary of the IC50 and 95% confidence intervals obtained with MTT and Cell Titer Glo 
triplicate experiments at 4 h incubation of 50 nm C-PB and preliminary results from one experiments 
only with an MTT assays at 24 and 48 h incubation. The values are expressed in µg/ml of C-PB. 
 
Figure 3-8 MTT toxicity assay of 50 nm C-PB at 24 and 48 h incubation in HBSS/HEPES 20 mM in 3T3 
(black triangles and connecting line), HCT116 (white squares and black connecting line) and MGLVA-
1 cells (grey circles and connecting lines). The results report the mean and standard deviation of a 
pilot study experiment obtained from triplicate wells. The experiments were not repeated due to lack 
of time. Error bars represent the standard deviation of the mean of triplicate wells (n=1). 
 
3.3.5 Characterization of the viability of cells treated with MBCD 
MBCD reduction of viability of cells was tested with both MTT and Cell Titer Glo 
toxicity studies of MBCD reported no toxicity for MBCD at concentrations up to 10 
mM (Figure 3-9A, B and C). Although the toxicity of this drug was low, from the MTT 
inhibition curves it was possible to measure IC50 values. MBCD in 3T3 cells had an 
                                               
1
 The experiments were not repeated because of lack of time. 
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IC50 value of 140.8 mM; in HCT116 the IC50 was 15.5 mM while MGLVA-1 presented 
an IC50 of 10.6 mM. However, the IC50 95% confidence intervals (IC5095%) were very 
broad limiting the reliability of such values. As both toxicity tests were in agreement 
no further tests on the effects of MBCD on cells were carried out. 
 
Figure 3-9 MBCD (left) and CPZ (right) toxicity studies at 4.5 h with MTT (black lines and squares), 
Cell Titer Glo (red lines and circles) and Apo I caspase 3/7 (green lines and diamonds) in 3T3, HCT116 
and MGLVA-1 cells. From graphs A, B and C it is possible to appreciate the low toxicity of MBCD at the 
concentration used in endocytosis inhibition studies of 1.25 mM (red dotted line in the graph) and the 
marked difference in cell viability of cells treated with CPZ reported in 3 different assays at 80 µM (red 
dotted line in the graph). 80 µM was the highest concentration used for endocytosis inhibition studies. 
Cells were seeded in triplicate wells and treated with different concentrations of inhibitors of 
endocytosis for 4.5 h. After the incubation time cells were processed as from standard protocol for 
each test and data recorded and normalised against the positive control assumed to be 100% viability 
or 0% caspase 3/7 expression. Error bars represent the standard deviation of the mean (n=3). 
 
3.3.6 Characterization of the effects on cells of CPZ 
The effects of CPZ (Figure 3-9, D, E and F, Table 3-5) was analysed by the 3 
different viability tests: MTT Cell Titer Glo, and Apo I caspase 3/7, which quantifies 
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the presence of apoptotic caspase 3/7 enzyme activity. MTT, Cell Titer Glo and 
Caspase 3/7 IC50 ± CI95% of CPZ are reported in Table 3-5. No visible signs of cell 
toxicity were detected after examination under a reverse microscope for 
concentrations of CPZ up to 80 µM.  
 
Table 3-5 IC50 and 95% confidence intervals calculated with 3 different cell viability tests: MTT, Cell 
Titer Glo and Apo I caspase 3/7 activity at 4.5 h. Results are expressed in µM. 
 
3.3.7 Clathrin and caveolin immunocytochemistry studies 
The qualitative and quantitative characterizDWLRQRI&+&ĮDQGFDY-1 proteins in the 
cell lines intended for endocytosis inhibition studies was carried out by both confocal 
microscopy and flow cytometry. Flow cytometry (Figure 3-10) and fluorescence 
microscopy data (Figures 3-11 and 3-12) show that HCT116 cells expressed high 
OHYHOVRI&+&ĮZKLOH0*/9$-1 cells expressed high levels of cav-1. Furthermore, 
7PXULQHILEUREODVWLFFHOOVSUHVHQWHGD ORZIOXRUHVFHQFHIRU&+&ĮDQGFDY-1 and 
these results were reproducible over triplicate experiments. To confirm that the levels 
of immunostaining were comparable to the levels in human mesenchymal cells, 
expression of caveolin-1 was characterised by flow cytometry and confocal 
microscopy experiments using MRC-5 human fibroblasts (Figures 3-10, 3-12). The 
data report consistently similar levels of the immunostaining of the protein in the 
human and mouse cell lines.  
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Figure 3-10 ,ɲĂŶĚĐĂǀ-1 flow cytometry immunofluorescence quantification. The plot shows a 
merge of 3 independent replicates of immunocytochemistry experiments. Here, the expression of 
,ɲĂŶĚĐĂǀ-1 were investigated in the 3 cell lines used for endocytosis studies (3T3, HCT116 and 
MGLVA-1). An additional human mesenchymal cell line was characterised and used to compare the 
expression of the 2 endocytic proteins in human and mouse fibroblasts. Error bars represent the 
standard deviation of the mean (n=3). 
 
The same approach was undertaken to confirm the reliability of immunofluorescence 
H[SHULPHQWV ZLWK &+&Į LQ PRXVH 7 FHOOV However, immunocytochemistry 
H[SHULPHQWV VKRZHG WKDW KXPDQ &+&Į OHYHOV LQ 05&-5 were high and this 
FRQWUDVWHGZLWKWKHOHYHORI&+&ĮIRXQGLQ7FHOOs. To further probe that there were 
unlikely to be any differences in binding of anti-human antibody to human and murine 
cav-1, murine cav-1 was compared to the human sequence with ICOS protein 3D 
simulator software where a score ranging between 0 and 4 was given for the amino 
acids (aa) more or less interacting in the 3D structure of the protein and/or exposed 
to the external environment. The simulation reported a different score for murine and 
human antibody epitope regions of cav-1 both when analysing only the exposure to 
the solvent of the epitope region and when analysing the total 2D and 3D 
rearrangements of the protein. This suggested that the murine protein rearranged in a 
3D structure that did not resemble the human cav-1 in the epitope region and 
subsequently the mAb could potentially bind to the two regions with different strength 
and affinity (Appendices I and II)29-31. 
Results - Characterization of Materials and Cell lines 
134 
 
To verify that the binding affinity of the mAb was comparable between human and 
murine proteins, mouse &+&Į protein 3D rearrangement was compared with the 
human sequences with ICOS protein 3D simulator software. The prediction 
suggested that the 2 point mutations were sufficient to modify the 3D structure and 
the exposure to the solvent of the epitope region recognised by the mAb. In other 
terms, the aa in the epitope region did not present the same 3D architecture and 
H[SRVXUH WR WKH VROYHQW LQ KXPDQ &+&Į DQG PXULQH &+&Į DFFRUGLQJ WR WKH
simulation (Appendices III and IV). From these data it is possible to suggest that the 
ORZ H[SUHVVLRQ RI &+&Į LQ 7 FHOOV PLJKW not be genuinely due to the level 
expression of cav-1 and &+&Į.  
Finally, cav-1 levels in the epithelial cells tested were represented by a broad peak or 
dot plot suggesting that within the same cell line some cells might have expressed 
more cav-1 than others (Figure 3-13).  
 
Figure 3-11 Qualitative immunocytochemistry confocal microscopy experiments for the detection of 
,ɲ ŝŶ 3T3, MRC-5, HCT116 and MGLVA-1. Here two negative controls were used: IgG1 and the 
secondary antibody. Blue fluorescence: nuclei (Dapi), Red fluorescence: ,ɲ ? /Ő' ?or Secondary 
antibody (Sec. Ab.). Scale bars represent 10 µm. 
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Figure 3-12 Immunocytochemistry confocal microscopy images of the staining of cav-1 in 3T3, MRC-
5, HCT116 and MGLVA-1 cells. The above pictures show the blue fluorescence of the nuclei (Dapi) and 
the red fluorescence of cav-1 (first row of pictures), IgG1 and secondary antibody (Sec ab.) negative 
controls (second and third row of pictures). Scale bars represent 10 µm. 
 
Figure 3-13 Histograms of the fluorescence intensity for Clathin mAb X22 / Caveolin-1 mAb clone 
2297 immunolabelling (Green), IgG1 (Black) and AlexaFluor 488 secondary antibody (Grey) negative 
controls in 3T3 murine fibroblasts, MRC-5 human lung fibroblasts, HCT116 human colon carcinoma 
and MGLVA-1 human gastric cancer cells. 
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3.3.8 Wash efficiency studies of endocytosis markers  
Experiments were designed to verify that the surface-bound ligands used as markers 
of endocytosis were efficiently removed to ensure that only the fluorescence of 
internalised markers was detected. Results of the wash efficiency studies are shown 
in Figure 3-14. These set of experiments show wash efficiency differences between 
Htf and LacCer. Here two different experimental setups were investigated: the 
washes were carried out both on cell suspensions in Eppendorf tubes on ice and 
were compared to the same buffer combination on 25 cm2 flasks on ice and adherent 
cells. Results show that a more efficient removal of Htf was obtained when the 
washes occurred in Eppendorf tubes, on trypsinized cell suspensions. The opposite 
was true for LacCer where the most efficient removal of the surface-bound marker of 
endocytosis occurred in 25 cm2 flasks on ice. 
 
Figure 3-14 Flow cytometry results of 3 replicates experiments on the different efficiency of the 
removal of Htf and LacCer endocytic markers from the plasma membrane of cells. The washes were 
carried out on adherent cells (in 25 cm
2
 flasks (T25)) or in cell suspensions (Eppendorf tubes washes 
(Epp wash)). The dotted line represents the fluorescence of the unwashed plasma membrane of cells 
calculated for positive controls and normalised to 100%. Error bars represent the standard deviation 
of the mean (n=3). 
 
3.4 Discussion 
C-PB of 50 and 100 nm diameter were characterized for effects on cell viability, size 
and charge; the concentration-dependent effects of endocytosis inhibitors were also 
HYDOXDWHGDQGWKHSUHVHQFHRI&+&LVRIRUPĮDQGFDY-1 in the cell lines designated 
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for endocytosis studies was determined by immunofluorescence. Finally, surface 
bound markers of endocytosis washing efficiency was also investigated with two 
different experimental procedures.  
Size and charge characterization showed that C-PB of 50 nm displayed a broad size 
distribution with particle diameters ranging between 10 and 65 nm from TEM images 
and 28 and 97 nm from DLS measurements. The mean diameter was 30 nm from 
TEM and 57 nm from DLS studies. The fact that TEM results reported a smaller size 
than the one stated from the manufacturer is expected as TEM is a technique that 
measures the size of materials in dry conditions. Accordingly, the hydration diameter 
due to the solvent is not taken into consideration in TEM, although this is likely to be 
low for surface-carboxylated PS particles in aqueous media. However, DLS 
measurements reported a size of 57 nm which is closer to 50 nm of the 
PDQXIDFWXUHU¶V UHSRUW 7KH EURDGGLVWULEXWLRQ RI VL]HV FRQILUPHG E\ ERWK 7(0 DQG
DLS, was an unexpected result and it is essential information to take into 
consideration when studying endocytosis as it has been extensively reported in 
literature that the size of the nanomaterials endocytosed can heavily affect the route 
of uptake32-34.  
Characterization of 100 nm C-PB reported a double Gaussian distribution of sizes by 
both TEM and DLS studies. TEM data showed particles in two size ranges of 20 and 
100 nm in diameter. The double Gaussian distribution in the DLS data did not allow 
distinction between the two populations of sizes, and the intensity measurements 
reported sizes ranging from 43 to 249 nm. DLS intensity data fitted a double 
Gaussian correlation as derived using GraphPad Prism with two major peaks 
apparent at 75 and 123 nm. The diameter of these materials as denoted in DLS was 
bigger than the TEM diameter for the two populations. This again might be due to the 
hydration diameter measured by DLS that is not measured in dry TEM conditions. 
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Another explanation might be that the two overlapping Gaussian distribution of sizes 
are too close for a precise discrimination of the size of the two populations of particles 
by DLS. TEM images of 50 and 100 nm C-PB show nanoparticles that are mainly 
separated and not aggregated on the grid which means that the sample preparation 
technique was appropriate for size characterization studies. The same images show 
that some nanoparticles are also less electron-dense with a lower extent of staining. 
This may have been due to heterogeneous composition of the material (for example 
as a result of uneven cross-linking during the polymer synthesis process) and 
suggests that these materials might not behave as one component during 
subsequent cell trafficking assays. 
Zeta potential measurements of C-PB of 50 and 100 nm showed a negative charge 
that is slightly above the 30 mV threshold that is considered an approximate limit for 
colloidal stability35. This meant that the nanoparticles used in this study were 
expected to be relatively stable to aggregation.  
Preliminary studies using viability tests, statistical analysis and titration curves 
showed that it was possible to test for cell viability at the same cell numbers and 
concentrations consistent with endocytic pathway inhibition studies. Indeed, it has 
previously been reported that increasing the concentration of cells in toxicity tests 
changes the susceptibility of cells to toxic materials36. The aim in these preliminary 
studies was to obtain accurate measures of any toxicity of materials under conditions 
analogous to those used in inhibition experiments. 
C-PB viability studies were carried out with Cell Titer Glo and MTT assays. Both 
assays are routinely used to study the effects of nanoparticles on cell metabolic 
activity37-40. Both MTT and Cell Titer Glo are in agreement and report a low 
interference of such nanoparticles with the dehydrogenase activity of the MTT test 
and high levels of ATP in cells treated with 100 nm C-PB. These results suggest low 
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interference of these nanoparticles with the physiological functions of the tested cells. 
However, a big discrepancy between the results of the two tests was observed in 
regards to IC50 of 50 nm C-PB in MTT and Cell Titer Glo experiments. For this 
reason, a preliminary screening of cell viability for cells treated with 50 nm C-PB at 24 
and 48 h was attempted with an MTT assay in order to confirm the toxicity of the 
materials. Cell viability profiles of the same 50 nm C-PB incubated for longer times 
with the cells showed IC50 values markedly higher that the ones reported for 4 h 
incubation. This result was not expected as toxicity is believed to be proportional to 
the extent of time that the toxic material is in contact to the cell line. Another group of 
researchers showed that MTT tests overestimate the toxicity of amine modified 
mesoporous silica nanoparticles (MSN). This effect is due to an increase of the 
exocytosis of the formazan crystals forming by the dehydrogenases of living cells, 
and that this is affected by the presence of MSN41. It is likely that this effect might not 
be only limited to positively charged MSN but also to other synthetic materials. Cell 
activity interference of 50 nm C-PB at 4, 24 and 48 h with an MTT test also accredit 
the hypothesis that MTT test should not be used with materials that interfere with 
endocytic processes as it is more extensively discussed below. 
CPZ and MBCD were chosen as pharmacological inhibitors of endocytosis. As these 
materials have been repeatedly reported as toxic, the effects of CPZ and MBCD were 
characterised by two assays: MTT and Cell Titer Glo. An additional toxicity test was 
also used for CPZ and consisted of an Apo I caspase 3/7 assay13,42-44.  
MBCD toxicity was found to be low at the concentrations tested (up to 10 mM) in 3T3, 
HCT116 and MGLVA-1 cells. The Cell Titer Glo assay reported an increase of ATP 
content in 3T3 cells treated with increasingly high concentrations of MBCD when 
compared to ATP content of negative control cells. A possible explanation of this 
phenomenon might be that an increase in MBCD concentration might cause a 
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progressive increase in inhibition of endocytosis. It has been shown that endocytosis, 
which is a constant and energy demanding process, necessitates actin 
rearrangements, with energy required for cytoskeleton movements as well as for 
small GTPase intervention in the endocytic process (dynamin, Rab GTPases). As a 
consequence, inhibition of endocytic pathways might lead to a general increase of 
ATP and energy levels as ATP normally produced by cells for endocytic processes is 
not being used at the typical physiological rate 45-48. The above mentioned hypothesis 
might also explain why Cell Titer Glo usually underestimated toxicity profiles in CPZ 
studies (please see below).  
CPZ has also been extensively reported as toxic in prior literature. The drug affects 
mitochondria at concentrations lower than 10 µM causing rounding, swallowing and 
migration to the periphery of the nucleus of these organelles21,49. At concentrations of 
20-30 µM it interferes with the cytoskeleton and blocks cell cycle in G2-M phase20 
while at concentrations of 50-100 µM it binds to calmodulin. Calmodulin regulates the 
recruitment of myristoylated alanine rich C kinase substrates (MARCKS) that 
sequester phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2). Consequently, CPZ 
inhibits CME by stopping the interaction of the AP-2 adaptor complex with membrane 
bound PI(4,5)P219,50. For all these reasons, a full evaluation of its effects in the used 
cell lines was necessary.  
It has been suggested that, since the MTT assay relies on endocytosis for the test 
compound to access healthy cells, and thus convert MTT to purple formazan, 
conducting an MTT assay in the presence of endocytosis inhibitors is inherently 
flawed51-53. For all these reasons it was necessary to run further tests. Because of the 
high ATP levels in tested cells reported by Cell Titer Glo assay, it was hypothesized 
that if CPZ were to be toxic, the overall effect would lead to apoptosis. As a 
consequence, the presence of apoptotic cells was investigated through an Apo I 
Results - Characterization of Materials and Cell lines 
141 
 
Caspase 3/7 kit. For 3T3 cells, IC50 and confidence intervals of the three tests 
suggested that the real IC50 values of CPZ ranged between 68 and 151 µM for 3T3 
and 64 and 209 µM for MGLVA-1 cells. For HCT116 cells the three toxicity assays 
gave broader IC50 values ranging from 54 to 223 µM. The Cell Titer Glo assay 
reported the highest IC50 values in the range, suggesting the effects of CPZ on ATP 
levels in all cell lines were lower than its effects on other metabolic pathways. MTT 
and Apo I assays were in partial agreement, suggesting that there was toxicity 
associated with the use of the drug at 4.5 h. However, the MTT test reported the 
highest effects on cell viability compared to Apo I and Cell Titer Glo. This might have 
been due to the effect of CPZ on mitochondria, where dehydrogenases that are 
partially involved in the conversion of the MTT to formazan reside. More specifically, 
CPZ has been reported to inhibit mitochondrial complex I activity that has been also 
reported to be involved in the reduction of the MTT to purple formazan in in vitro 
isolated mitochondria49,51. If this hypothesis were to be true the MTT assay might be 
the most sensitive and reliable toxicity assay of the three reported in this chapter. 
However, even though reduction of activity of mitochondrial complex I is an excellent 
indication of cell viability given that the complex is involved in the oxidative 
phosphorylation and ATP production, CPZ is inhibiting a rather energy demanding 
process and for this reason ATP levels stay high. Hence, in these conditions, it is not 
clear if cells are really less viable or if there is a fine balance between the reduction of 
ATP production and ATP usage that enables cells to carry on with their physiological 
activities at low CPZ concentrations. Another point must be stressed: if the MTT 
assay relies also on an energy-dependent pathway for the MTT dye to enter cells 
rather than passive diffusion, a lack of purple formazan dye detected in the assay 
may have been due to lack of MTT uptake rather than loss of cell viability. These 
considerations might explain another anomaly: i.e. why did the Apo I caspase 3/7 
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assay do not indicate toxicity until CPZ concentrations reached higher levels than 
those in the MTT assay where viability decreased. Another possible way to explain 
such an anomaly might be that caspase 3/7 enzymes are produced at a rather late 
stage of the cell death process and thus would not have been activated at time points 
by which cell viability (as shown by MTT) had already decreased. However, evidence 
in the literature suggests that apoptosis is a rather rapid process that occurs within 5-
15 minutes. In these papers, evidence of apoptosis activation was detected as a 
sharp increase of caspase 3 activity54,55.  
Immunofluorescence confocal and flow cytometry studies with anti human CHC 
LVRIRUP Į FORQH; DQG FDY-1 clone 2297 revealed that HCT116 cells expressed 
KLJK OHYHOVRI&+&Į0*/9$-1, on the other hand, presented high levels of cav-1 
expression and this was an interesting result per se because the literature reports 
that in vitro cell lines often lack caveolae56. Finally, cav-DQG&+&ĮH[SUHVVLRQZDV
relatively low in 3T3 fibroblasts compared to the other cell lines. However, given that 
3T3 fibroblasts were the only non human cell lines tested, a legitimate doubt was that 
WKHDQWLERG\XVHGIRULPPXQRIOXRUHVFHQFHZDVOHVVDFWLYHDJDLQVWPXULQH&+&ĮDQG
cav-1. Cav-1 is a protein with 178aa and the mAb clone 2297 anti cav-1 recognises a 
region between aa 61 and 7157. This region is conserved in both human and mouse 
according to FASTA database but murine and human cav-1 are not identical. They 
present 9 point mutations, two before the mAb target region (aa 36-37) and 7 after 
and corresponding to aa 106-107, 154, 163, 170 and 173-174. &+&Į DDRI
mouse and human are better conserved with respect of cav-1, DQG PRXVH &+&Į
presents 2 point mutations only at aa 1146 and 1406 respectively. These mutations 
are after the mAb clone X22 epitope region 1109-112858. To investigate whether the 
immunocytochemistry results in murine 3T3 cells could be correlated to those in 
human cells, an additional human fibroblastic cell line, MRC-5 lung derived, was also 
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used. Concentrations of cav-1 expression in MRC-5 was also found to be low. For 
&+&ĮOHYHOVRQWKHRWher hand, 3T3 immunofluorescence data was at variance with 
MRC-5 clathrin expression levels. These differences brought to the decision to 
investigate further the reliability of the immunofluorescence data with ICOS 3D 
prediction software. Results from the analysis of the 3D rearrangement of the 
proteins and their exposure to the solvent showed that both cav- DQG &+&Į 3D 
architecture of the epitopes recognised by the two mAb were different. For these 
reasons it is not SRVVLEOHWRFRQFOXGHWKDW&+&Įand cav-1 quantification in 3T3 cells 
with immunofluorescence experiments can be compared to human expression of the 
same proteins as the mAb used are likely to have different levels of activity against 
human and mouse proteins.  
The last experiments in this series were for the determination of the most efficient 
procedures for the removal of endocytic markers from the plasma membrane. Here 
two techniques were investigated:  
x flask wash procedures using traditional buffers for the removal of endocytic 
markers from the plasma membrane of cells were applied on adherent cells 
before trypsinization, or  
x cells were trypsinized and wash steps carried out on suspensions of cells.  
When comparing washes in cell suspensions to washes on adherent cells of Htf it 
was evident that the best way to remove the Htf marker was with washes of 
suspensions of cells in Eppendorf tubes. The contrasting settings (in flasks) were 
better for the removal of LacCer from the plasma membrane. Three possible 
explanations can be hypothesised here for the more efficient removal of Htf in 
Eppendorf tubes. It is known in the literature that trypsin cleaves the membrane 
localised Htf receptor 59. This is only a partial pool of the overall transferrin receptors 
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that are also present in the cytoplasm of cells, but the cleavage nevertheless 
neutralizes part of this pool and continuing these washes on ice might slow down and 
stop any further recycling on the plasma membrane. Trypsinization might have 
removed both the free receptor and the receptor bound to Htf. By doing so the 
application of trypsin might have aided the effects of the wash by contributing to the 
removal of membrane- and receptor-bound Htf. Trypsin cleavage of Htf receptor free 
from Htf might also have limited any unwanted interaction of the Htf that was being 
removed from the membrane and freed into solution with the Htf receptor. The 
detachment of the Htf from the receptor occurs during the last 2 steps of washes and 
DIWHU WKHDFLGZDVK7KHDFLGZDVK S+ UHGXFHVDQG UHPRYHV WKH LURQIURP WKH
holo-Htf producing an apo-Htf59,60. Apo-Htf remains tightly bound to its receptor at 
acid pH (apparent dissociation constant, Kd=13x10-9M,61). When the complex is then 
exposed again to neutral pH the apo-Htf is released. Apo-Htf has a binding affinity to 
the receptor at neutral pH that is 3 orders of magnitude lower than holo-Htf but still 
can bind the receptor, especially when the concentration of holo-Htf (Kd=7x10-9M) is 
low in solution and it is not competing for its binding. Also, the media used for washes 
has 0.1µg/ml of ferric nitrate Fe(NO3)3ǜ9H2O which means that potentially the apo-Htf 
can bind to the iron in the media and produce a new holo-Htf for high affinity receptor 
binding. Finally, another practical consideration might contribute towards the 
efficiency of the washes in Eppendorf tubes. When Eppendorf tubes are on ice it is 
easier to control the temperature compared to the analogous experiments with larger 
25cm2 flasks on ice, as uneven distribution of the ice might create local gradients of 
temperatures making possible the internalization of Htf, which is a high speed 
process with recycling of the receptor back to the plasma membrane in as little as 4 
minutes62,63. 
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Removal of LacCer from the plasma membrane was more efficient in flasks than in 
Eppendorf tubes. A possible explanation is that the diffusion of the buffer components 
used for the washes was less efficient in Eppendorf tubes with respect to flask 
washes. Here, interaction of defatted albumin with the plasma membrane is essential 
for the displacement of LacCer from the membrane of cells and it is possible that a 
PDMRUH[SRVXUHRIWKHFHOOV¶VXUIDFHWRWKHEXIIHULQDGKHUHQWFHOOVRn flasks might aid 
the process. Also, defatted albumin buffers are usually applied for 10 minutes and it 
might happen that the natural sedimentation of suspensions of cells might interfere 
with the process. Finally, another hypothesis might explain why the surface of 
trypsinized cells is less accessible to the wash buffer and albumin. Cells presenting 
hydrophobic LacCer on their membrane might more promptly aggregate and 
consequently make the access of defatted albumin to the adherent portions of the 
two plasma membranes virtually impossible and by doing so reduce the overall 
efficiency of the wash processes. 
3.5 Conclusions 
In this set of experiments the conditions for the inhibition studies of endocytic 
pathways with pharmacological inhibitors were delineated. It was established that the 
C-PB chosen for the experiments were negatively charged as expected and that they 
were more colloidally stable than assumed. However, they also presented a broader 
range of size variation than expected, which was an unwanted characteristic for these 
materials in the intended experiments. Also, the bi-modal size distributions of 100 nm 
C-PB, although affecting only 5% of the population of such materials, was also an 
undesirable characteristic to take into consideration in inhibition studies. The effects 
of 50 nm C-PB on cell viability were shown to be low for Cell Titer Glo while a high 
toxicity profile was obtained for MTT in HCT116 and MGLVA-1 cells. These findings 
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suggested setting the concentration of nanoparticles for endocytosis inhibition to 100 
µg/ml and microscopy studies to 50 µg/ml. The intended concentration of MBCD of 
1.25 mM for inhibition studies was found to be appropriate as MBCD was virtually 
non toxic at this concentration in all cell lines. However, the intended concentration of 
CPZ for inhibition studies (80 µM) was accompanied by some toxicity. Although a 
final IC50 for the drug was not measured univocally by three separate tests, Apo I and 
MTT assays suggested that the dose of CPZ suitable for inhibition studies (80 µM) 
might be close to a toxic level. For this reason, it was decided to carry out inhibition 
studies also with 40 and 60 µM CPZ. Immunocytochemistry experiments delineated 
the experimental conditions in terms of quantity of endocytic proteins such as clathrin 
and caveolin in the cell lines used. The final experiments of this set on the efficiency 
of the removal of Htf and LacCer from the plasma membrane gave evidence that the 
best procedure for the washes utilized small scale Eppendorf tube washes and cells 
suspensions for Htf stripping from the membrane and on adherent cells and flasks for 
LacCer removal. 
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4.1 Introduction 
Endocytosis is a highly regulated and efficient process that takes place in all cells. 
This process is used to introduce nutrients and growth factors by receptor-mediated 
pathways and the same route is also used for signalling1,2. Furthermore, some 
pathogens such as viruses have evolved mechanisms to enter cells by endocytosis3-
9
. An increasingly high proportion of the literature reports that synthetic nanomaterials 
can access cells through endocytosis8,10-13.  
In this chapter are reported and discussed the results on the optimization of inhibition 
studies with both LacCer and Htf, markers of clathrin-dependent endocytosis (CME) 
and clathrin-independent endocytosis (CIE), and CPZ and MBCD, inhibitors of CME-
phagocytosis/macropinocytosis and CIE. MBCD was tested at 1.25 mM and CPZ at 
80 µM; these quantities were chosen from a preliminary screening as the lowest 
concentrations of inhibitors that efficiently inhibited CME and CIE. From viability 
results shown in chapter 3, MBCD did not produce any toxic effects at 1.25 mM, and 
for this reason this concentration only was tested in inhibition studies. However, as 
viability and a toxicity assay reported IC50 values close to 80 µM for CPZ, 
experiments with 40 and 60 µM CPZ were also carried out. The results of the cell 
entry inhibition assays with low concentrations of CPZ were compared to the results 
obtained with 80 µM CPZ to detect any effects on endocytosis that the higher and 
supposedly toxic concentration was having on the uptake of Htf. To further probe that 
the effects obtained with 80 µM CPZ were not due to general toxicity of the drug on 
cells, experiments in the absence of Ca2+ and Mg2+ were also performed. Finally, from 
the data obtained, the effect of the passage number of cells on inhibition studies was 
also investigated. CME inhibition was also studied with Pitstop 2, a relatively new 
molecule that binds the amino-terminal domain of CHC that is involved in the 
Results - Inhibition of Endocytosis and Microscopy Studies 
152 
 
interaction of clathrin with the adaptor proteins that help the formation of the clathrin 
lattice14. Finally, C-PB of 50 and 100 nm were chosen as a model of negatively 
charged nanocarriers of drugs and their route of uptake inhibited with CPZ 80 µM and 
MBCD 1.25 mM in 3T3, HCT116 and MGLVA-1 cells. Confocal microscopy was 
carried out on live cells treated with C-PB of 50 and 100 nm that were shown from 
inhibition studies to access cells through specific pathways. The aim of these 
experiments was to verify that the C-PB accessed cells and to characterize the 
specific route of uptake by any differences in compartmentalization.  
4.2  Methods 
4.2.1  Optimization of the inhibition of Htf uptake 
4.2.1.1 Inhibition of Htf uptake with CPZ 
For a more complete description of the methods used in these experiments please 
refer to §2.2.7 of the materials and methods. Here, cells were seeded at a density of 
31200 cells/cm2 and allowed to attach to the bottom of the 25 cm2 flasks overnight. 
Subsequently, full media was replaced with HBSS supplemented with 20 mM HEPES 
with or without 40-60 or 80 µM CPZ and 1.25 mM MBCD for 30 minutes and then 
replaced with HBSS/HEPES 20 mM with or without Htf 0.81 µM and 40-60 and 80 µM 
CPZ or 1.25 mM MBCD. Upon completion of the incubation time, cells were washed, 
detached from flasks and then analysed with a BD LSR II flow cytometer. The acid 
wash was carried out on 25 cm2 flasks on ice. 
4.2.1.2  Inhibition of Htf uptake with Pitstop 2 
HCT116 cells were seeded at a density of 31200 cells/cm2 and allowed to attach to 
the bottom of 25 cm2 flasks overnight (§2.2.8). Subsequently, full media was replaced 
with HBSS supplemented with 20 mM HEPES with or without Pitstop 2 for 15 minutes 
and then replaced with HBSS/HEPES 20 mM with or without Htf 6.7 µg/ml and 
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chemical inhibitor for 1 or 2 h. Pitstop working concentrations were selected as 12.5, 
18.75 and 25 µM. Upon completion of the incubation time, cells were washed, 
detached from flasks and then analysed with a BD LSR II flow cytometer. The results 
are shown as the mean of 2 independent experiments. Htf was removed by an acid 
wash as reported in the literature16 and in methods described above and §2.2.6. 
4.2.2  Optimization of the inhibition of LacCer uptake with MBCD  
Cells were seeded at a density of 31200 cells/cm2 and allowed to attach to 25 cm2 
flasks overnight. Subsequently, full media was replaced with HBSS supplemented 
with 20 mM HEPES with or without chemical inhibitors of endocytosis for 30 minutes 
and subsequently replaced with HBSS/HEPES 20 mM alone (negative control), 
LacCer 0.81 µM (positive controls) or with LacCer 0.81 µM in the presence of 80 µM 
CPZ or 1.25 mM MBCD. The incubation times were 1-2-3 and 4 h for all cell lines. 
Upon completion of the incubation time, cells were washed with the back exchange 
method and subsequently detached from flasks and then analysed with a BD LSR II 
flow cytometer and detected on a FITC channel, 530/30 optical bandpass filter17. The 
results were normalised against the positive and negative controls15. The LacCer 
washes were carried out in 25 cm2 flasks on ice to inhibit endocytosis. 
4.2.3  Inhibition of endocytosis of C-PB with CPZ and MBCD 
Inhibition of endocytosis in the presence of 50 and 100 nm C-PB was carried out 
according to the protocols described in the materials and methods section §2.2.10. 
Cells were seeded at a density of 31200 cells/cm2 and allowed to attach to 25cm2 
flasks overnight. Subsequently, full media was replaced with HBSS supplemented 
with 20 mM HEPES with or without 80 µM CPZ and 1.25 mM MBCD for 30 minutes. 
The buffer was then replaced with HBSS/HEPES 20 mM alone (negative control), 50 
nm or 100 nm C-PB 100 µg/ml, (positive controls) or with 50 or 100 nm C-PB 100 
µg/ml in the presence of 80 µM CPZ or 1.25 mM MBCD. C-PB and inhibitors were 
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further incubated for 1 and 2 h with 3T3 and HCT116 cells and for 2 and 4 h with 
MGLVA-1 cells. Subsequently, cells were washed twice with HBSS/HEPES 20 mM 
and EDTA, detached from flasks with trypsin/EDTA, centrifuged at 2000 g for 5 
minutes and re-suspended in PFA 4% v/v in PBS. 10000 gated cells were then 
analysed with a BD LSR II flow cytometer and detected on a FITC channel, 530/30 
optical bandpass filter. The results were normalised against the positive and negative 
controls15. 
4.2.4  Confocal microscopy live imaging  
Cells that showed sensitivity to CPZ and MBCD for the internalization of 50 and 100 
nm C-PB were also investigated by live cell confocal microscopy studies. Endocytosis 
of 100 nm C-PB was investigated in 3T3 cells, endocytosis of 50 nm C-PB was 
studied in HCT116 cells and endocytosis of 50 and 100 nm C-PB were examined in 
MGLVA-1 cells. The confocal microscopy experiments were run on live cells for a 
period of 1 h. For a more detailed description of the materials and methods of this 
section please refer to §2.2.12. Briefly, cells were seeded in full media to a final 
density of 31200 cells/cm2 in 6 well plates on sterile rounded 22x1.5 mm glass 
coverslips. Cells were left to attach to the glass coverslips overnight. The day after, 
cells were stained with Hoechst 33342 (1 µg/ml) and CellMask deep red cell 
membrane dye (1 µg/ml) for 30 minutes at 37°C. The cells were then rinsed with 
HBSS/HEPES and the media replaced with HBSS/HEPES 20 mM for live imaging. 
Live images of 4 regions of interest were acquired at 4-10-20-30-40-50 and 60 
minutes on a 40x water objective.  
The measurements of the integrated fluorescence density of the C-PB for each cell 
and time point were processed with ImageJ software and subtracted from the 
integrated background from a region adjacent to each cell taken into the analysis as 
for the equation below: 
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(ݕFluor)Corr = ݕFluor - (Acell X MFluor bkd) 
Where: 
(ݕFluor)Corr = Correct integrated fluorescence density 
ݕFluor = Integrated fluorescence density of the cell of interest (IntDen in ImageJ) 
Acell = area of the cell (Area in ImageJ) 
MFluor bkd = mean fluorescence of the background (Mean in ImageJ) 
Analysis of the integrated fluorescence density was derived from measuring a 
minimum of 30 cells for each time-point and plots showing the mean and the 
standard deviation.  
Co-localization of the C-PB with Hoechst and CellMask was determined by 
FDOFXODWLRQRI WKH 3HDUVRQ¶V FRUUHODWLRQ FRHIILFLHQW ZLWKD -$&R3SOXJLQ RI ,PDJHJ. 
7KH3HDUVRQ¶VFRHIILFLHQWREWDLQHGIRUHDFKSLFWXUHDQGWKHWLPH-point was averaged 
and the mean and the standard deviation are shown in the results. For each 
experiment, one z stack was also obtained to acquire a 3D image of the distribution 
of C-PB in cells. 
4.3  Results 
4.3.1 Optimization of the inhibition of Htf uptake 
4.3.1.1 Optimization of the inhibition of Htf uptake with CPZ 
In these experiments, CPZ at a concentration of 80 µM was used to inhibit the uptake 
of Htf in 3T3, HCT116 and MGLVA-1 cells. Endocytosis was also inhibited with 40 µM 
CPZ in 3T3 fibroblasts while additional inhibition studies in HCT116 cells were carried 
out with 40 and 60 µM CPZ. For each experiment and time-point 1.25 mM MBCD 
was used as a control to evaluate if any interference on CME by MBCD occurred. All 
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these experiments were run for 1, 2, 3 or 4 h and results at each time-point 
compared. The experimental results shown below are the combination of 2 
independent experiments for concentrations of CPZ of 40 and 60 µM and up to 6 
independent experiments for 80 µM CPZ.  
Inhibition of Htf uptake with CPZ was temporary and occurred over an incubation time 
that was cell-dependent (Figure 4-1 and 4-2, Table 4-1). The maximum inhibition of 
Htf uptake was obtained at 2 h for 3T3 fibroblasts, 1 h for HCT116 cells and 4 h for 
MGLVA-1. After that maximal inhibition, the uptake of Htf recovered to normal non-
inhibited levels in 3T3 and HCT116 cells at 4 h. The extent of inhibition was affected 
by the concentration of CPZ used, with low inhibition of the uptake of Htf at lower 
concentrations of CPZ (Figure 4-3). However, the pattern of inhibition at different time 
points also remained unchanged at lower concentrations of CPZ and was time-
dependent, with an optimal incubation time at 2 h for 3T3 and 1 h for HCT116. After 
maximal inhibition at that time-point, the uptake of Htf was restored in 3T3 and 
HCT116 cells. The extent of the recovery was dependent on the concentration of 
CPZ used with longer recovery times for higher concentrations of CPZ.  
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Figure 4-1 Flow cytometry results showing the time and cell dependence of the inhibition of the 
uptake of Htf with 80 µM CPZ in 3T3, HCT116 and MGLVA-1 cells. Cells were preincubated with one 
inhibitor of endocytosis or HBSS/HEPES 20 mM for negative and positive control for 30 minutes. After 
that period of incubation the buffer was aspirated and replaced with HBSS/HEPES 20 mM for the 
negative control or Htf 0.81 µM in HBSS/HEPES with or without inhibitors of endocytosis and further 
incubated for 1, 2, 3 or 4 h. The results are the combination of up to 6 independent experiments. They 
are shown as the mean and standard deviation of the fluorescence of 10000-20000 gated cells for 
each experiment and are normalised against the Htf treated positive control that was considered as 
100% uptake. The dotted lines refer to 50 and 100% uptake of Htf. 
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Figure 4-2 Flow cytometry histograms on the inhibition of Htf uptake with 80 µM CPZ at different 
time points and cell lines. The X axes show the fluorescence intensity of Htf, the Y axes show the 
number of cells. The dark shadows show Htf uptake at basal, uninhibited levels while the light 
shadows show Htf uptake in the presence of 80 µM CPZ.  
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Inhibition of CME was also obtained with 1.25 mM MBCD and the extent of inhibition 
was time-dependent, affecting up to 15% of Htf uptake in 3T3 cell lines at 1 h 
incubation, 10% of Htf uptake in HCT116 cells at 4 h, and 13% at 2 h with MGLVA-1 
(Figure 4-1). However a two-way ANOVA statistical analysis showed that the 
inhibition of internalization of Htf by the action of MBCD was not statistically 
significant (Table 4-1). 
Table 4-1 Two-Way ANOVA and Bonferroni post-analysis test of the inhibition of Htf uptake in the 
presence of CPZ and MBCD. Htf uptake of untreated cells was compared with the uptake of Htf in the 
presence of CPZ and MBCD. The results above show that there is a significant inhibition in the uptake of 
Htf in the presence of CPZ and the significance is time dependent and depend on the cell line. MBCD 
inhibition of endocytosis of the uptake of Htf on the other hand, does not show statistical significance. 
(ns: non significant, P>0.05; *: P<0.05; **: P<0.01; ***: P<0.001). 
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Figure 4-3 Lower concentrations of CPZ reduce the extent of inhibition of Htf uptake in 3T3 and 
HCT116 cells. The flow cytometry results are normalised against the fluorescence of Htf positive 
control and expressed at the mean and standard deviation of a minimum of 10000 gated cells for each 
experiment (n=2). Cells were preincubated with HBSS/HEPES 20 mM with or without inhibitor for 30 
minutes. Subsequently the pretreatment buffer was aspirated and 3T3 cells were treated with 40 and 
80 µM CPZ for up to 4 h and HCT116 with 40, 60 and 80 µM of CPZ for up to 4 h. The dotted lines refer 
to 50 and 100% uptake of Htf. 
In addition, to assess the consequences on cell viability induced by energy depletion 
resulting from endocytosis, CPZ stock solutions of 40 and 80 µM were prepared with 
HBSS without Ca2+ and Mg2+ (instead of the standard HBSS with supplements of the 
two ions), complemented with HEPES 20 mM and applied on 3T3 and HCT116 cells 
as for standard protocol for a period of up to 4 h. The results are given by the 
combination of 2 independent experiments for 3T3 fibroblasts while only one 
experiment was attempted for HCT116 cells2.  
 
                                               
2
 The experiment was not repeated due to lack of time. 
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Inhibition studies with HBSS without Ca2+ and Mg2+ (Figure 4-4) in 3T3 cells showed 
that the effects on cell viability and induction of apoptosis by media depletion of 
essential ions was not sufficient to produce a recovery of the internalization of Htf. 
This suggested that the recovery of uptake of Htf is an energy dependent process 
that happens in viable cells but not in energy-depleted and stressed cells. 
 
Figure 4-4 Effects of the absence of Ca
2+
 and Mg
2+
 from the assay media on the inhibition and 
recovery of the uptake of Htf with CPZ. The results shown are represented as the mean and standard 
deviation of 2 independent experiments in 3T3 cells and only one pilot study experiment in HCT116 
cells. The results are normalised against the Htf positive control and show the mean and the standard 
deviation of 10000 gated cells. Cells were preincubated with HBSS/HEPES 20 mM devoid of Ca
2+
 and 
Mg
2+
 with or without inhibitor for 30 minutes. Subsequently the pretreatment buffer was aspirated 
and replaced with fresh solutions of HBSS/HEPES 20 mM devoid of Ca
2+
 and Mg
2+
 with or without Htf 
6.7 µg/ml, different concentrations of CPZ ranging from 40 to 80 µM and MBCD 1.25 mM. The cells 
were further incubated for 1, 2, 3 or 4 h for 3T3 cells and 1, 2 and 3 h for HCT116 cells. The dotted 
lines refer to 50% and 100% uptake of Htf. Error bars represent the standard deviation of the mean of 
duplicate experiments, n=2 (3T3 cells). 
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Finally, the effect of passage number on the extent of the inhibition of endocytosis 
was investigated in 3T3 and HCT116 cells. Endocytosis was inhibited on 3T3 
fibroblasts at passage number ranging between 28 and 53 and HCT116 at passage 
number 18-44. The experiments were run as from standard protocol for 1 h and 2 h. 
Each set of experiments was run in duplicates independent experiments and the 
results merged and averaged.  
The inhibition of endocytosis with CPZ was affected by the passage number of the 
cells used for inhibition studies, with higher passage numbers being more resistant to 
the inhibition of Htf uptake (Figure 4-5 graph B for 3T3 cells and E for HCT116 cells). 
The maximal incubation time did not change at low passage numbers but was 
gradually lost in aged cells. When 3T3 fibroblasts at passage number 53 and 55 were 
inhibited with 80 µM CPZ at 1 and 2 h, the inhibition was reduced and also the 
pattern of inhibition of endocytosis of Htf changed, as shown in graph C in Figure 4-5 
with a comparable extent of inhibition at 1 and 2 h.  
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Figure 4-5 Passage number and ageing of cells affects the extent of inhibition of Htf uptake with 
CPZ. Cells at different passage numbers were incubated with Htf 6.7 µg/ml and 80 µM CPZ at 1 and 2 
h in 3T3 and HCT116 cells. Graph A shows the inhibition obtained with 80 µM CPZ in 3T3 cells at 
passage number 28 and 30, graphs B and C show the inhibition obtained by the same inhibitor and cell 
line at passage number 39-41 and 53-55 respectively. Graphs D and E show the extent of the 
inhibition obtained with 80 µM CPZ in HCT116 cells at passage number 18-20 (graph D) and passage 
number 42-44 (graph E). Cells were treated as in previous experiments with 30 min preincubation of 
CPZ or HBSS/HEPES that was replaced by HBSS/HEPES 20 mM buffer supplemented of Htf for the 
positive control or 80 µM CPZ and Htf, and further incubated for 1 or 2 h. The dotted lines refer to 50 
and 100% uptake of Htf. The results show the mean and standard deviation of a minimum of 10000 
gated cells for each experiment (n=2). 
 
4.3.1.2 Optimization of the inhibition of Htf uptake with Pitstop 2 
HCT116 cells incubated with Pitstop 2 12.25 µM did not show any significant 
inhibition of endocytosis for a period of up to 2 h (Figure 4-6). When the concentration 
was raised to 18.75 and 25 µM, Pitstop 2 reduced endocytosis to a consistent level 
and the extent of such inhibition was dependent on the concentration of the inhibitor. 
The recovery of the Htf uptake was not observed here at the incubation times and 
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concentrations used. Finally, indications of toxicity were detected at concentrations of 
Pitstop 2 of 18.75 and 25 µM, with cells appearing rounded and unhealthy. 
 
Figure 4-6 Effects of the inhibition of Htf endocytosis with Pitstop 2 at 12.5, 18.75 and 25 µM in 
HCT116 cells. The results represent the combination of 2 independent experiments and show the 
mean fluorescence of Htf uptake of 20000 gated cells per experiment and the standard deviation of 
the mean of replicate experiments (n=2). The dotted lines refer to 50 and 100% uptake of Htf. 
 
4.3.1.3 Optimization of the inhibition of LacCer uptake with MBCD 
In these experiments, MBCD 1.25 mM was used as an inhibitor of CIE. The effect of 
the inhibitor on the uptake of LacCer, a marker of CIE, was studied at 1,2,3 and 4 h 
on 3T3, HCT116 and MGLVA-1 cells. As a further control, the specificity of CPZ on 
the inhibition of CME at each time point was also investigated with LacCer incubated 
in the presence of 80 µM CPZ.  
LacCer uptake inhibition with MBCD was easier to obtain, compared to the Htf 
inhibition with CPZ, as the inhibition was strong and steady for a period of up to 4 h 
(Figure 4-7). The effect of MBCD inhibition on LacCer uptake was less cell-
dependent and a concentration 1.25 mM of MBCD produced a potent inhibition of 
endocytosis for all cell lines tested. A 1 h incubation period of the drug was sufficient 
to obtain maximal inhibition of endocytosis in 3T3 and HCT116, whereas 2 h were 
necessary for MGLVA-1 cells. Also, when CPZ was used as a control for specific 
clathrin-mediated endocytosis (CME), CPZ showed no ability to inhibit clathrin-
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independent endocytosis (CIE). Instead, treatment with CPZ resulted in substantial 
increase of endocytosis of LacCer in all cells tested, enhancing the uptake of LacCer 
to 3 times higher levels than those observed in the positive control. 
 
Figure 4-7 Effect of the inhibition of LacCer uptake with 1.25 mM MBCD. Cells were treated as 
described before. A preincubation step of 30 min was carried out in the presence and in the absence 
of endocytosis inhibitors. Upon completion of the preincubation time the media was aspirated and 
replaced with LacCer 0.81 µM in the presence of in the absence of inhibitors of endocytosis. Cells 
were incubated for a maximum of 4 h and the results are the combination of 2 independent 
experiments (n=2), the error bars represent the standard deviation of the mean of a minimum of 
20000 gated cells per experiment. The dotted lines refer to 50 and 100% uptake of LacCer. 
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4.3.2  Inhibition of the endocytosis of C-PB with CPZ and MBCD 
The optimized protocol for the inhibition of Htf and LacCer uptake with CPZ and 
MBCD was applied for the inhibition of the endocytosis of 50 and 100 nm C-PB.  
Results (Figure 4-8) show that the inhibition of 50 nm C-PB uptake was obtained with 
80 µM CPZ in both epithelial cells investigated, HCT116 and MGLVA-1. The 
reduction of the uptake of 50 nm C-PB in HCT116 cells was strong already at 1 h 
incubation of the inhibitor and the inhibition obtained was steady and uptake did not 
recover by 2 h. Reduction in the uptake of 50 nm C-PB with CPZ in MGLVA-1 cells 
was already evident at 2 h with approximately 35% reduction of endocytosis. 
However, the maximum effect of CPZ was obtained at 4 h with 60% inhibition of 50 
nm C-PB uptake with respect to the positive control. The incubation of 50 nm C-PB 
with CPZ and MBCD in 3T3 fibroblasts produced an activation of the endocytosis of 
C-PB as for CPZ in LacCer inhibition studies. The same effect was observed in 
HCT116 and MGLVA-1 cells for 50 nm C-PB incubated with MBCD where an 
activation of endocytosis at 1-2 h in HCT116 and 2-4 h in MGLVA-1 cells were 
obtained. The activation was stronger in MGLVA-1 cells than HCT116 cells. No 
inhibition of endocytosis of 50 nm C-PB was obtained with CPZ and MBCD incubated 
for 1 and 2 h in 3T3 cells but the endocytosis was up-regulated by both inhibitors.  
Endocytosis of 100 nm C-PB was sensitive to CPZ in 3T3 cells and sensitive to 
MBCD in MGLVA-1 cells. 100 nm C-PB nanoparticles were endocytosed by a non-
CPZ non-MBCD sensitive pathway in HCT116 cells. Here, both CPZ and MBCD up-
regulated the endocytosis of 100 nm C-PB.  
Inhibition of 100 nm C-PB with CPZ in 3T3 cells was obtained at 1 h incubation and 
the endocytosis recovered almost completely at 2 h. The endocytosis of the same 
nanoparticles was only partially inhibited with MBCD at 2 h incubation in MGLVA-1 
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cells, and subsequently completely recovered, showing a modest up-regulation after 
4 h.  
 
Figure 4-8 Inhibition of the uptake of 50 nm and 100 nm C-PB with 80 µM CPZ and 1.25 mM MBCD. 
3T3 and HCT116 inhibition of the uptake of C-PB was monitored for 1 and 2 h while MGLVA-1 
inhibition of the uptake was examined at 2 and 4 h. The results are shown as the mean and standard 
deviation of 2 independent flow cytometry experiments obtained on 10000 gated cells (n=2). The 
dotted lines refer to 50 and 100% uptake of C-PB. 
4.3.3  Confocal microscopy live imaging studies 
Cell lines that showed sensitivity to endocytic inhibitors in the presence of 50 or 100 
nm C-PB were further investigated with confocal microscopy live imaging with the aim 
of confirming endocytosis and localization of the nanoparticles within the cell 
membrane boundaries. The internalization was not verified in flow cytometry 
experiments as the technique does not distinguish between membrane-bound and 
internalized signal from cells. As some cell lines incubated with C-PB showed 
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different susceptibility to inhibitors of endocytosis, live images of cells in the presence 
of C-PB were also carried out to study any pattern in compartmentalization of C-PB 
sensitive to different inhibitors of endocytosis.  
Cells incubated with 50 and 100 nm C-PB showed a rapid uptake of nanoparticles. 
Endocytosis could already be detected at 4 minutes incubation in all cell lines studied 
(Figures 4-9, 4-14, 4-19 and 4- 7KH 3HDUVRQ¶V FRHIILFLHQW RI FR-localization for 
each time-point did not show any significant increase of co-localization of C-PB and 
Hoechst with time suggesting that the nanoparticles did not access nuclei under the 
experimental conditions used and time-points investigated (Figures 4-13, 4-18B, 4-23 
and 4-28). Only a minor, non-statistically significant increase of colocalization of 
green fluorescence from the nanoparticles and blue fluorescence from the nuclei was 
detected in HCT116 that might be attributed to a possible effect of proximity with the 
nuclei of the nanoparticles localized to a perinuclear region resembling the 
endoplasmic reticulum (ER).  
  
 
 
Figure 4-9 Confocal live imaging studies of 3T3 cells treated with 50 µg/ml 100 nm C-PB for a period of 60 min. Red fluorescence: CellMask deep membrane 
staining, Green: C-PB, Blue: Hoechst nuclei staining. Time 0 refers to cells before application of the C-PB. Pictures were then acquired at 4 and at 10, 20, 30, 40, 50 
and 60 minutes from the application of the C-PB. The red intracellular structures stained by CellMask are believed to be the ER. Scale bars represent 50 µm.  
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Figure 4-10 Orthogonal projection of a 3D image of 3T3 cells treated with 50 µg/ml 100 nm C-PB 
showing internalised green nanoparticles (arrows) that can be seen inside the red membrane limit 
of the cells. Green: C-PB, Red: CellMask deep red membrane dye, Blue: Hoechst nuclei staining. The 
Cell Mask deep red membrane dye is staining a perinuclear intracellular compartment believed to be 
the ER. Scale bar represents 50 µm. 
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Figure 4-11 This picture shows the differences in the redistribution of CellMask red plasma 
membrane staining at 4 and 60 minutes in 3T3 fibroblasts treated with 100 nm C-PB. Less confluent 
cells appear to redistribute the dye more quickly to the plasma membrane of cells, while more 
confluent cells show the dye in the cytoplasmic region of cells also after 60 minutes incubation of cells 
in the presence of C-PB. The redistribution of C-PB from a perinuclear region to a cytoplasmic region is 
not evident from these pictures. Scale bar represents 50 µm. Green: 100 nm C-PB; Red: CellMask deep 
red membrane staining. 
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Figure 4-12 Zoom images of live experiments shown in Figure 4-9  ? 4-11 of 3T3 cells treated with 
100 nm C-PB 50 µg/ml for a period of 60 minutes. The arrows show aggregates of nanoparticles that 
detach from the membrane (details pictures). The arrow heads point to the membrane ruffling on the 
plasma membrane of 3T3 cells. Scale bars represent 10 µm. Green: C-PB; Red: CellMask membrane 
staining; Blue: Nuclei. 
 
Figure 4-13 Analysis of the fluorescence of 3T3 cells treated with 50 µg/ml 100 nm C-PB for a period 
of 60 min. G: Green fluorescence of 100 nm C-PB; R: Red fluorescence of the CellMask deep red 
membrane staining; B: Hoechst nuclei staining. Here the green fluorescence normalised per area of 
cells and subtracted of the background of a region adjacent to the cells taken into the analysis is 
measured at different time points. From the graph it is possible to visualize an increase of the green 
fluorescence up to 20 minutes with a subsequent relative non statistically significant drop in the 
fluorescence of the C-W ?dŚĞWĞĂƌƐŽŶ ?ƐĐŽĞĨĨŝĐŝĞŶƚĂŶĂůǇƐŝƐ ?ŽďƚĂŝŶĞĚǁŝƚŚĂ:ŽWƉůƵŐŝŶŐŽĨImageJ, 
shows there is little co-localization of the nanoparticles with the nuclei and a partial co-localization of 
the CellMask deep red membrane staining and the C-PB. Error bars represent the standard deviation 
of the mean (n>20). 
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All cell lines showed some extent of internalization of the CellMask with a different 
degree of internalization depending on the cell line (Figures 4-11, 4-16, 4-21 and 4-
26). The extent of internalization was higher in 3T3 and HCT116 cells with respect to 
MGLVA-1 cells.  
CellMask stained the intracellular compartments of 3T3 cells more promptly than the 
plasma membrane where only weak staining was obtained (Figure 4-11), while a 
strong and stable staining of the cell membrane for up to 60 minutes was obtained 
with the dye in HCT116 cells (Figure 4-16). The same dye predominantly labeled the 
plasma membrane of MGLVA-1 cells, with moderate staining of intracellular 
compartments (Figure 4-21 and 4-26).  
Furthermore, CellMask appeared to redistribute after application of the C-PB on cells 
with a stronger staining of the plasma membrane after application of 50 nm C-PB on 
HCT116 cells (Figures 4-14 and 4-16). A similar pattern was observed in 3T3 cells 
(Figures 4-9 and 4-11). However, here different confluence of cells also showed a 
different pattern of redistribution of CellMask where more confluent cells redistributed 
CellMask more slowly from the cytoplasm to the plasma membrane, while cells in 
less confluent regions looked more rounded and lost their elongated features (typical 
for this cell line) and presented a lower level of CellMask staining into the cytoplasm. 
The redistribution of CellMask in MGLVA-1 cells was less obvious after application of 
50 and 100 nm C-PB (Figures 4-19, 4-21, 4-24 and 4-26). Uptake of C-PB was 
already evident at 4 minutes from their application in all cell lines.  
Green fluorescence from C-PB in 3T3 cells (normalized per area of cells) increased 
immediately after application of 100 nm C-PB for up to 20 minutes, with a slight 
reduction of fluorescence at 10 minutes. However, after 20 minutes the green 
fluorescence due to the C-PB began to decrease with time. Here, the difference in 
the green fluorescence at different time points was not statistically significant with a t 
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test (Figure 4-13). Figure 4-12 at 20 and 30 minutes gives evidence of the presence 
of aggregates of nanoparticles adjacent to the plasma membrane at 20 minutes from 
the application of the 100 nm C-PB. These structures were also detected at other 
time-points (arrows) suggesting a rather active process taking place. Zoom images at 
20 and 30 minutes in Figure 4-12 suggest that the process occurring might be 
exocytosis. Here, it is possible to see that 2 out of 3 C-PB aggregates present on the 
plasma membrane at 20 minutes (arrows) are detached and in the extracellular 
compartment at 30 minutes. The measured size of these aggregates was between 
500-700 nm and lower than 1µm as measured by ImageJ. Also, at 30 minutes 
incubation (see expanded image) vesicle-like structures loaded with nanoparticles 
were detected in the extracellular compartment, with ImageJ measured size of about 
1µm. The white arrowheads in the same set of pictures show ruffling of the plasma 
membrane that is symptomatic of exocytic, macropinocytic or phagocytic processes 
taking place. Co-localization studies of CellMask and C-PB show that 100 nm C-PB 
presented a partial degree of co-localization that was steady over time (Figure 4-13). 
Finally, the green fluorescence of the 100 nm C-PB in 3T3 cells did not appear to 
redistribute towards different regions of the cells over a 1 h period (Figure 4-11).  
HCT116 cells incubated with 50 nm C-PB showed a rapid uptake of the nanoparticles 
at 4 minutes and localization of the nanoparticles in the cytoplasm of cells and 
adjacent to the peripheral region of nuclei (Figures 4-14, 4-16). The presence of the 
nanoparticles in this region was also suggested by a slight, albeit statistically non 
significant according to a t test, increase of the colocalization obtained by the green 
and blue channels of the C-PB and the nuclei at 4 and 10 minutes that was reduced 
upon translocation of the nanoparticles towards more peripheral regions of the cell 
(Figure 4-18B); this result is likely to be due to an effect of proximity of the 
nanoparticles with the nuclei. The analysis of fluorescence in cells showed that the 
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emission from 50 nm C-PB was steady and not increasing for up to 20 minutes 
(Figure 4-18B). Over time, the fluorescence of the cells increased slightly but in a 
non-statistically significant way. From 30 minutes, it was possible to appreciate the 
presence of C-PB on the cell membrane of HCT116 cells (Figure 4-14, 4-16 and 4-
17). Nanoparticles appeared to redistribute from the perinuclear region towards the 
periphery of the cells and the membrane (Figure 4-16) where the cytoplasmic 
membrane, stained in red at 4 minutes, turned orange at 60 minutes incubation 
suggesting co-localization of green nanoparticles and red membrane staining. This 
effect was also suggested by a small increase of co-localization at 40, 50 and 60 
minutes of incubation (Figure 4-18B). From the higher magnification images in Figure 
4-17 the redistribution of the CellMask membrane dye from time 0 can be seen. Cells 
appeared more rounded and the membrane more clearly defined after application of 
the C-PB. Cells internalized quickly the C-PB in the cytoplasm of cells. However, cells 
gradually moved the C-PB towards the membrane (white arrows), where they 
became increasingly more concentrated on the edges of cells, immediately above the 
CellMask membrane staining towards the extracellular compartment at 50 and 60 
minutes (yellow arrows and zoom at 60 minutes of the same Figure). Furthermore, 
aggregates of nanoparticles of about 500 nm in diameter were present in proximity of 
the plasma membrane from 30 minutes (zoom at 30 minutes on the same Figure). 
The intense activity of the membrane of cells was also demonstrated by the spindle-
like structures (Figure 4-18A) that were already visible at 4 minutes incubation of the 
nanoparticles with cells and from membrane ruffling in Figure 4-17 as indicated by 
the arrowheads.  
  
 
 
 
Figure 4-14 Merge of fluorescence live images for HCT116 cells incubated with 50 µg/ml of 50 nm C-PB for 60 minutes. Red: CellMask deep membrane staining, 
Green: C-PB, Blue: Hoechst nuclei staining. Scale bars represent 50 µm This set of pictures was obtained at time 0, before applying the solution of C-PB and at 4, 
10, 20, 30 ,40 ,50 and 60 minutes after the application of the solution of C-PB. From the images it is possible to observe a quick uptake of the nanoparticles that 
were already internalised and localizing in a perinuclear region 4 minutes after their application on cells.  
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Figure 4-15 Orthogonal projection of a 3D image obtained with HCT116 incubated with 50 nm C-PB. 
This picture shows that the nanoparticles are localized inside cells (arrows). Scale bar represents 50 
µm. Green: C-PB; Red: Membrane staining; Blue: Nuclei. 
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Figure 4-16 Images of the redistribution of the red CellMask membrane staining at 4 and 60 minutes 
in HCT116 cells. Also the 50 nm C-PB redistribute from a perinuclear region towards the membrane of 
HCT116 cells at 60 minutes incubation. Scale bar represents 50 µm. Red: Membrane staining; Green: 
C-PB. 
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Figure 4-17 Details of the live imaging pictures shown in Figure 4-14  ? 4-16 with HCT116 cells 
incubated with 50 nm C-PB 50 µg/ml for a period of 60 minutes. The white arrows point to aggregates 
of nanoparticles on the cell surface of HCT116 cells, the yellow arrows point to the layer of C-PB in the 
cell membrane at 60 minutes (the same aspect is also reproduced in detail in the adjacent 
magnification image). The arrowheads point to membrane ruffling. Scale bars represent 10 µm. 
Green: C-PB; Red: Membrane staining; Blue: Nuclei. 
 
Figure 4-18 A. Spindle-like structures of HCT116 membrane of cells incubated for 4 minutes with 50 
nm C-PB, demonstrating an intense activity of the membrane. Blue: Nuclei; Green: C-PB; Red: 
Membrane staining. Scale bars represent 10 µm. B. Analysis of the green fluorescence of HCT116 cells 
incubated with 50 nm C-PB (white squares and black connecting ůŝŶĞ ?ĂŶĚŽĨƚŚĞWĞĂƌƐŽŶ ?ƐĐŽĞĨĨŝĐŝĞŶƚ
measuring the co-localization of the green fluorescence of the C-PB and the red membrane staining 
(light grey triangle and connecting line) and the green and the blue staining of the nuclei (dark grey 
diamonds and black connecting line). Error bars represent the standard deviation of the mean (n>20). 
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From confocal live cell imaging studies (Figures 4-19, 4-21, 4-24 and 4-26) on 
MGLVA-1 cells incubated with 50 µg/ml of 50 and 100 nm C-PB it was not possible to 
detect any distinct difference in the compartmentalization of the 2 nanoparticles 
(according to inhibition studies, the two nanoparticles were endocytosed by two 
discrete CPZ and MBCD sensitive pathways). The 50 and 100 nm C-PB 
nanoparticles showed little co-localization with CellMask, which mainly stained the 
plasma membrane of these cells (Figures 4-21 and 4-26). The normalized 
fluorescence per cell area was constant over the 60 minutes time-lapse of the 
experiment suggesting that the cells were balancing the ingress of nanoparticles with 
membrane localization or particle exocytosis. Evidence of accumulation of 
aggregates of nanoparticles on the plasma membrane is provided by images shown 
in Figure 4-22 for 50 nm C-PB and in Figure 4-27 for 100 nm C-PB (zoom at 10 and 
20 minutes incubation for 50 nm C-PB and 20 and 30 minutes incubation for 100 nm 
C-PB). From zoom images at 10 and 20 minutes obtained for MGLVA-1 cells 
incubated with 50 nm C-PB (Figure 4-22) it is not possible to define any likely 
direction of the movement of the aggregates of nanoparticles and for this reason it is 
not possible to suggest any specific exocytic or endocytic process. For MGLVA-1 
cells treated with 100 nm nanoparticles (Figure 4-27), zoom images at 20 and 30 
minutes show a movement towards the plasma membrane of aggregates of 
nanoparticles of 700 nm according to ImageJ measurements suggesting an exocytic 
process taking place (arrows). Finally, evidence of membrane ruffling is shown by the 
arrow heads in both MGLVA-1 cells incubated with 50 nm (Figure 4-22) and 100 nm 
C-PB (Figure 4-27). 
  
 
 
 
Figure 4-19 Confocal live studies of MGLVA-1 cells treated with 50 µg/ml 50 nm C-PB for a period of 60 minutes. Pictures were taken before applying the C-PB 
(time 0) and after 4, 10, 20, 30, 40, 50 and 60 minutes from the application of the C-PB. Green fluorescence: C-PB, Red: CellMask deep membrane staining and 
blue: Hoechst nuclei dye. Scale bars represent 50 µm.  
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Figure 4-20 Orthogonal projection of a 3D image taken from MGLVA-1 cells treated with 50 µg/ml 
50 nm C-PB. The arrows show that the nanoparticles (green) are internalized by cells and are localized 
inside the membrane (red) periphery of cells. Blue: nuclei. Scale bar represents 50 µm. 
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Figure 4-21 MGLVA-1 cells treated with 50 µg/ml 50 nm C-PB for 60 minutes. The images show the 
green channel of the C-PB at 4 and 60 minutes incubation with cells, the red channel for the CellMask 
deep membrane staining and a merge of the two. There is only little evidence of redistribution of the 
C-PB over time in different compartments of the cells as well as only little internalization of the 
CellMask over time. Scale bars represent 50 µm. 
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Figure 4-22 Details of the live images studies shown in Figures 4-19  ? 4-21 of MGLVA-1 cells treated 
with 50 µg/ml 50 nm C-PB for a period of 60 minutes. The zoom at 10 and 20 minutes and the arrows 
give evidence for aggregates of nanoparticles trafficking the cytoplasmic membrane. The white arrow 
heads point to the membrane ruffles. Green: C-PB fluorescence, red: CellMask deep membrane 
staining and Blue: Hoechst dye are shown in these images. Scale bars represent 10 µm. 
 
Figure 4-23 Analysis of the fluorescence of MGLVA-1 cells treated with 50 nm C-PB for 60 minutes. 
Quantification of the green fluorescence of the C-PB normalised by cell area and background (white 
squares and black connecting line). Co-ůŽĐĂůŝǌĂƚŝŽŶ ƋƵĂŶƚŝĨŝĐĂƚŝŽŶŐŝǀĞŶ ďǇ ƚŚĞ WĞĂƌƐŽŶ ?Ɛ ĐŽĞĨĨŝĐŝĞŶƚ
measured at different time-points with a JACoP plugin from ImageJ. Co-localization for the green 
fluorescence of C-PB and the red CellMask membrane dye (dark grey diamonds and black connecting 
line); C-PB and the Hoechst blue fluorescence colocalization is shown by the light grey triangles and 
connecting line. Error bars represent the standard deviation of the mean (n>20). 
  
 
 
 
Figure 4-24 MGLVA-1 gastric cancer cells treated with 100 nm C-PB for a period of 60 minutes. Time 0 refers to cells before the treatment with nanoparticles. 
Pictures were subsequently taken at 4, 10, 20, 30, 40, 50 and 60 minutes from the application of the C-PB. Green fluorescence from the 100 nm C-PB is present in 
the cytoplasm of MGLVA-1 at 4 minutes from the application of the C-PB. Red fluorescence: CellMask membrane staining, Blue fluorescence: Hoechst nuclei dye. 
Scale bars represent 50 µm. 
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Figure 4-25 Orthogonal projection of a 3D image obtained from MGLVA-1 cells treated with 100 nm 
C-PB. Blue: Hoechst, Green: C-PB, Red: CellMask membrane staining. The arrows point to the regions 
that show that the nanoparticles are internalized and localize in a region between the nuclei and the 
membrane. Scale bar represents 50 µm. 
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Figure 4-26 Redistribution of the C-PB (Green) and CellMask membrane staining (red) over time for 
MGLVA-1 cells treated with 50 µg/ml of 50 nm C-PB (green). The Figures show 4 and 60 minutes 
images with single channels for C-PB and cell Mask and a merge of both. Scale bars represent 50 µm. 
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Figure 4-27. A. Details of live images shown in Figure 4-24 - 4-26 of the endocytosis and trafficking of 
100 nm C-PB in MGLVA-1 cells for a period of 60 minutes. B. Magnification of the regions enclosed 
in the squares of Figure 28A. From the enlarged images it is possible to verify some degree of 
rearrangement of the CellMask membrane dye on the plasma membrane from time 0 and 4 minutes 
were the dye concentrates in a more compact fashion of the plasma membrane of the cells after the 
application of C-PB. Also C-PB appear to redistribute, and from 30 minutes it is possible to see a more 
diffuse and less discrete cytoplasmic fluorescence. From the magnification detail in Figure 28B at 20 
and 30 minutes incubation it is possible to detect a movement of aggregates of nanoparticles towards 
the plasma membrane of cells and the extracytoplasmic compartment. (arrows). The arrow heads 
point to the membrane ruffling present on the membrane of MGLVA-1 cells. Scale bars represent 10 
µm. 
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Figure 4-28 Analysis of the fluorescence of MGLVA-1 cells treated with 100 nm C-PB for 60 minutes. 
Quantification of the green fluorescence of 100 nm C-PB normalized by cells area and subtracted of 
the background fluorescence from regions adjacent the cells subtracted from the analysis (white 
ƐƋƵĂƌĞƐĂŶĚďůĂĐŬĐŽŶŶĞĐƚŝŶŐůŝŶĞ ? ?WĞĂƌƐŽŶ ?ƐĐŽĞĨĨŝĐŝĞŶƚƋƵĂŶƚŝĨŝĐĂƚŝŽŶŽďƚĂŝŶĞĚǁŝƚŚĂ:ŽWplug-in 
of ImageJ of the co-localization of the C-PB with the red CellMask membrane staining (dark grey 
diamonds and black connecting line) and C-PB and Hoechst nuclei staining (light grey triangles and 
connecting line). Error bars represent the standard deviation of the mean (n>20). 
4.4  Discussion  
Initial experiments on the inhibition of clathrin-mediated endocytosis focused on the 
use of the dopamine antagonist CPZ (Table 4-2). 
 
Table 4-2 CPZ chemical structure, chemical nomenclature and molecular weight. 
 
CPZ is an amphiphilic molecule that intercalates in the inner leaflet of the membrane 
of cells18. Its cationic portion interacts with the negative charge of phospholipids and, 
in particular, phosphoinositides19. This binding alters the properties of the membrane, 
causing redistribution of phospholipids between the inner and outer leaflet and 
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clustering of membrane proteins19,20. As a consequence it has been widely used as a 
CME inhibitor. However, its specificity has been often questioned in the literature. Its 
interference with other endocytic processes such as phagocytosis in neutrophils and 
macrophages has been repeatedly shown and it has been hypothesised that CPZ 
could interfere also with macropinocytosis in non specialised cells21. This conclusion 
has been justified by the similarity of the machinery of macropinocytosis and 
phagocytosis. However, recent findings suggest that clathrin might be also involved in 
phagocytosis processes partially restoring the credibility of the CPZ as a specific 
CME inhibitor22,23.  
Experiments described above showed that the inhibition of CME with CPZ was time- 
and cell-dependent and the duration of the incubation period of cells with specific 
pathway inhibitors was an important factor to take into consideration in these studies 
as effects were time-dependent.  
As described in chapter 3, at the working concentrations used in the experiments 
reported in this chapter, CPZ inhibits endocytosis by binding to calmodulin, which 
regulates the recruitment of the myristoylated alanine-rich C-kinase substrate protein 
(MARCKS) that sequesters the phospholipid phosphatidylinositol 4,5-bisphosphate 
(PI(4,5)P2). This phospholipid is essential for the interaction of AP-2 adaptor protein 
with the plasma membrane in CME24,25. These data from the literature suggested a 
first hypothesis in order to explain the unusual pattern of Htf inhibition of uptake with 
CPZ: that with increased CME activity in the cell and consequent expression of 
clathrin, the longer is the time taken by CPZ to inhibit CME. However, conversely to 
the expectations, +&7FHOOVIRUZKLFKWKHKLJKHVWH[SUHVVLRQRI&+&ĮZDVIRXQG
by immunocytochemistry experiments (please see chapter 3), were more quickly 
inhibited by the drug, while for MGLVA-1 cells, which expressed relatively low levels 
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of clathrin and higher levels of caveolin-1 compared to HCT116 and 3T3 cells, Htf 
uptake was less easily inhibited by CPZ.  
Two other hypotheses were then formulated:  
x A disparity of expression of MARCKS in different cell lines might be the cause 
for the difference in CPZ action where, an increase in MARCKS would be 
expected to decrease the time needed to inhibit the Htf uptake pathway, or  
x Calmodulin expression might be different in different cell lines and thus the 
higher the level of cells with increased calmodulin, the longer the time taken 
for CPZ to inhibit Htf uptake.  
There are prior reports of differences in expression of MARCKS in different cell 
lines26,27 but there is very little literature on the different levels of expression of 
calmodulin depending on the cell line. Furthermore, Bickeboller et al specifically 
characterized HCT116 cells for the expression of MARCKS by immunoblotting 
showing that the expression of the protein is low with respect to other colon cancer 
cell lines27. This experimental observation alone is not sufficient to rule out the above-
mentioned hypothesis as the expression of MARCKS should be evaluated in 
conjunction with time of inhibition of endocytosis. At the moment it is not possible to 
draw definitive conclusions from the data available. Further studies are necessary to 
better characterise any connections between the expression of calmodulin/MARCKS 
and the length of time needed to inhibit endocytosis with CPZ. 
The finding that CPZ was inactive in the inhibition of Htf uptake after the maximal 
inhibition time-point of the endocytosis of Htf has not been reported in the literature 
previously. It was hypothesized that the recovery of the endocytosis of Htf was due to 
membrane toxicity of CPZ and the theory that increased Htf internalization after a 
maximal inhibition of CME was a consequence of such toxicity was evaluated.  
Results ± Inhibition of Endocytosis and Microscopy Studies 
192 
 
The possibility of effects on cell activity by CPZ, additional to endocytic uptake 
inhibition, was investigated. CPZ has been also reported as a pore-forming 
molecule28 and it is regularly used as a promoter of membrane fusion in experiments 
studying the dynamics of membrane reorganization in cells. However, this 
membrane-fusion property of CPZ is exerted only at concentrations that are near its 
critical micelle concentration (4 mM), i.e. well above the concentrations used in the 
pathway inhibition experiments of 80 µM29. Nevertheless, concentrations of CPZ 
above 50 µM have been reported to produce leakage of low molecular weight 
cytoplasmic materials in platelets (< 2000 Da) suggesting that CPZ is indeed able to 
produce small pores in the membrane of cells20. On the other hand, Htf is a large 
protein with a molecular weight of 80kDa and dimensions of 5 x 5 x 1.6 nm30, 
suggesting that Htf is unlikely to enter cells as a consequence of CPZ-induced 
membrane pore formation. In addition, from the experiments using CPZ at 40 and 60 
µM, it was observed that the extent of the recovery of Htf uptake after inhibition was 
more significant at lower concentrations of CPZ, where any toxicity and pore-forming 
ability would be reduced. Further evidence that the recovery of the levels of Htf 
uptake was due to active transport of the protein inside cells was obtained from 
experiments in which media were used containing no Ca2+ and Mg2+. By depleting the 
levels of these two ions, the cells became energy-depleted too, and recovery of Htf 
uptake stopped with a steady reduction of the Htf internalization over a period of 4 h 
in 3T3 cells31. These data together suggest that inhibition of Htf uptake by CPZ and 
subsequent recovery of Htf endocytosis was not likely have occurred via a general 
toxicity effect of CPZ on cells, but instead was due to temporary interruption by CPZ 
of an active and energy-dependent transport of Htf into cells. Although this 
mechanism might be attributed to off target effects of a non-specific and complex 
Results ± Inhibition of Endocytosis and Microscopy Studies 
193 
 
inhibitor of endocytosis such as CPZ, some speculations in other directions might 
also be worth some consideration. 
The internalization of Htf by a non-transferrin receptor-mediated mechanism in 
KHSDWRF\WHVZDVILUVWUHSRUWHGLQWKH¶V32 with transferrin receptor 2 (TR2) being 
cloned some years later33. The presence of TR2 in tissues other than the liver and 
erythroid precursor cells has been debated. However, some authors report the 
presence of TR2 in colon cancer and glioma cells and, more importantly, in HCT116 
cells, which are part of the panel of cell lines used in these studies34-37.  
TR2 is a type II transmembrane glycoprotein with at least two alternative splicing 
LVRIRUPV75ĮDQGȕ3875ĮKDVDWUDQVPHPEUDQHDQGVKRUWF\WRSODVPLFGRPDLQ
ZKLOH 75ȕ KDV RQO\ WKH H[WUDFHOOXODU SRUWLRQ RI WKH SURWHLQ DQG ODFNV WKH
transmembrane and cytoplasmic domains. TR2 also binds iron, although at a lower 
affinity (Kd= 30x10-9M) with respect to transferrin receptor 1 (TR1, Kd=7x10-9M) also 
known as p90, CD71 and transferrin receptor39. The endocytic process by which the 
transferrin is endocytosed together with TR2 is identical to the endocytosis of TR1. 
The complex is internalized, it is transported to an acidic compartment and then 
recycled back to the plasma membrane where the apo-transferrin is released32. TR2 
SUHVHQWVD<[[ɎPRWLI WKDWFDQELQGDQ$3DGDSWRUSURWHLQZKLFKVXJJHVWVWKDW LW
can be internalized by a clathrin receptor pathway. Chen and coworkers also showed 
that TR1 and TR2 can internalize through an AP2 pathway and compete for the 
pathway in the presence of holo-transferrin confirming support for a clathrin-mediated 
uptake pathway36,39. Chen et al showed that the internalization of TR2 in the 
presence of holo-transferrin is directed towards a multivesicular body degradative 
pathway and this might explain the short half life of TR2 in the presence of holo-
transferrin when TR1 is active. The presence in the media of transferrin and binding 
of the transferrin to the TR2 can extend the half life of the receptor and direct it 
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towards a recycling pathway instead. The binding to the TR2 in physiological 
conditions has been reported to occur only when the TR1 was down-regulated in the 
liver which suggests that the receptor has a physiological role in the maintenance of 
the homeostasis of iron such as a sensor for transferrin levels in serum36,38,40. From 
the data reported in this chapter and the literature it is possible to suggest that TR2 
might be responsible for the uptake of Htf when TR1 is inhibited. There is prior 
evidence of the presence of the receptor at least for one cell line used in the 
experiments reported in this chapter (HCT116), and the mechanism by which the 
TR2 is activated and directed to a recycling pathway fits well with the results shown in 
this thesis34,35. The mechanism hypothesized from these data is the following: when 
the TR1 is inhibited by CPZ, the TR2 starts binding Htf. This event triggers the switch 
from a degradative to a recycling pathway, which increases TR2 expression. The 
proposed increase in concentration of the receptor can be hypothesized in the 
experiments reported at 3 and 4 h in 3T3 cells and 2, 3 and 4 h in HCT116 cells. At 4 
h the levels of endocytosis in these cell lines is comparable to the positive control, 
where the internalization of Htf occurs by a TR1-mediated route, which suggests that 
the TR2 can replace the activity of TR1 in the absence of functional TR1. However, 
there are a few points that still remain unclear. 
Chen et al showed that both TR1 and 2 were active by clathrin-mediated endocytosis, 
but it is not clear why a TR2-mediated pathway would not be inhibited by the action of 
CPZ since the activity of CPZ is not due to specific TR1 or TR2 binding. A key 
question is whether the TR2 triggers a different endocytosis mechanism when it 
switches from a degradative to recycling pathway. It may be possible that TR2 
induces clathrin-mediated endocytosis but employs a different connector protein 
(other than AP2) which does not rely on PI(4,5)P2 for anchoring the forming clathrin 
lattice to the plasma membrane. If this were to be the case, it must be a new and 
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uncharacterised protein given that all the known clathrin adaptor proteins rely on 
PI(4,5)P241 at the moment42 (the presence of new and uncharacterised adaptor 
proteins has been already suggested in the literature)43. Chen et al also reported that, 
in the absence of holo-transferrin, TR2 can internalize through a different pathway 
and Calzolari and coworkers also came to this conclusion34. The latter group of 
researchers showed that TR2 is associated with the detergent resistant insoluble 
fraction of cells in lipid rafts (colocalising to some extent with caveolae and caveolin-1 
and in a different region with respect to TR1) and they also suggested a more 
signalling relevant role of the receptor in these conditions given that there was high 
colocalization with a CD81 membrane protein involved in exosome formation and 
signalling39,44,45. However, these studies were not carried out on the panel of cell lines 
used in the experiments presented in this thesis. A caveolin-dependent endocytosis 
mechanism for internalization of Htf after the TR1 is inhibited is unlikely as Htf uptake 
is universally recognized as a CME marker46. Clathrin has been recently found to be 
involved in phagocytosis as described more in detail in §1.3.4.7 of this thesis. 
However also phagocytosis is known to necessitate PI(4,5)P2 for its function 
(although through a slightly different process) and seems an improbable alternative 
internalization process candidate at the present47. However, there may still be 
uncharacterized mechanisms by which proteins such as transferrin can enter cells 
when highly potent amphiphiles such as CPZ are present, and/or cells are stressed 
by being in the artificial cell culture environment rather than in a tissue.  
Another feature of the inhibition of CME by CPZ might be explained by the data from 
different passage numbers of the cell lines used in inhibition studies. It was found that 
the higher the passage number or ageing of cells, the lower the levels of endocytosis 
inhibition by CPZ. This finding was partly expected, since dynamin expression, which 
is implicated in both clathrin and caveolin endocytosis, has been reported to be 
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susceptible to passage number and confluence of cells48. Calmodulin expression has 
also been shown to change in relation to cell ageing and this might contribute to 
these results49. As the density of cells in these experiments was deliberately kept 
constant to sub-confluent levels to control the expression of endocytic proteins, it 
seems likely that an important determinant factor in the variability of the inhibition of 
Htf uptake was the passage number and ageing of cells.  
In order to investigate further the endocytic pathways involved in Htf uptake and 
therefore of relevance to nanoparticle and drug delivery system uptake, assays were 
carried out with the inhibitor Pitstop 2 (Table 4-3). Pitstop 2 is a small molecule that 
was originally selected from screening assays based on structure-activity relationship 
(SAR)14,50.  
 
Table 4-3 Pitstop 2 chemical structure, nomenclature and molecular weight. 
 
Pitstop 2 is believed to bind specifically to the amino-terminal domain of clathrin 
which is essential for the interaction of the CHC with the endocytic machinery, which 
in turn assembles the clathrin lattice leading to vesicle formation. Pitstop 2 has been 
described as the first chemical inhibitor specific for CME, and is claimed to be non 
toxic in HeLa cells for up to 24 h. However, a number of papers have shown toxic 
effects of Pitstop 2, including reports of interactions with spindle formation in dividing 
HeLa cells, leading to cell death51. Also the specificity of Pitstop 2 has been 
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questioned, as it has effects on processes specific to other pathways of 
endocytosis52,53. However, the differences in structure of Pitstop 2 and CPZ were 
sufficient that investigation of the effects of Pitstop 2 on Htf uptake were considered 
of interest in comparison to those of CPZ. Strong inhibition of Htf uptake was 
obtained at 1 and 2 h incubation with Pitstop 2 in HCT116 cells, in contrast to 
experiments involving CPZ, where a partials recovery of Htf uptake was observed at 
2 h. However, toxicity of Pitstop 2 was observed during inhibition experiments and 
thus the incubation time of Pitstop 2 with cells was reduced to 2 h instead of 4 h 
incubation as used in experiments with CPZ. Toxicity, as suggested by the 
experiments using HBSS depleted of Ca2+ and Mg2+, can generate a failure in the 
recovery of the Htf uptake after inhibition.  
CPZ was also used in LacCer inhibiton studies as a further control of CPZ specificity 
towards CME. Here, CPZ did not show any inhibition of endocytosis of LacCer as 
expected and already reported in the literature15,21. However, an increase of LacCer 
endocytosis was observed in the presence of the inhibitor and confirms results 
obtained by Vercauteren and coworkers15.  
LacCer inhibition of endocytosis by MBCD was not complicated by the recovery of 
inhibition and cell passage number. Incubation times and cell line characteristics did 
not affect the ability of the inhibitor to function. The inhibition obtained was steady 
and maximal for a period of 4 h incubation and, as shown by viability studies in 
chapter 3 as well as experimental observations, it was not due to toxicity of the 
inhibitor on cells. Only a minimal dependence on cell lines was observed in MGLVA-1 
cells. Here, although a good inhibition of LacCer uptake was obtained already at 1 h 
incubation of the inhibitor with cells, a maximal inhibition was obtained at 2 h. No 
dependence on passage number of cells was observed in these experiments and this 
gives evidence of the inherent non specificity of the drug towards a caveolin and 
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dynamin-mediated endocytosis where passage number of cells indeed affects the 
results of the inhibition. Furthermore, when MBCD was used as a control of its 
specificity towards CIE in Htf inhibition studies, the drug had a small but detectable 
inhibition of CME that was more evident at specific incubation times of the drug with 
cells. The latter result might be interpreted differently if the hypothesis that a caveolin-
dependent pathway is involved in Htf uptake proves to be true.  
Inhibition of C-PB uptake in the presence of CPZ and MBCD shows that the same 
material can be directed towards different endocytic machineries depending on the 
cell line tested and, significantly, without modification of the nanoparticles with 
specific targeting molecules. This result is not entirely unexpected as some other 
authors already showed different sensitivity to inhibitors of endocytosis depending on 
the cell line54. 50 nm C-PB showed specificity towards CME, macropinocytosis or 
phagocytosis as demonstrated by the inhibition of their endocytosis in the presence 
of CPZ. Even if phagocytosis is considered not to be a highly represented process in 
non-specialized cells, it cannot be completely ruled out from these data. After 
inhibition of the uptake of 50 nm C-PB in HCT116 and MGLVA-1 cells with CPZ, no 
recovery of the uptake of 50 nm C-PB was observed. The nanoparticles that had not 
been targeted with any specific receptor binding molecules appeared to be selectively 
internalized by a CPZ-sensitive pathway. This might be due to the specificity of the 
uptake of these nanoparticles towards a CPZ-sensitive pathway. However, another 
possibility for these results might be due to a combination of CPZ and C-PB of 50 nm 
resulting in toxicity. 
The same nanoparticles were endocytosed by 3T3 fibroblasts quite efficiently but the 
mechanism of internalization remains unknown. Both inhibitors used were ineffective 
in the inhibition of their endocytosis and suggests that 3T3 fibroblasts use non-CPZ 
non-MBCD sensitive machinery for the endocytosis of 50 nm C-PB. When cells 
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actively engaged in endocytosis were exposed to endocytic inhibitors that were not 
active on the pathway involved in the endocytosis of materials, the uptake of these 
materials was boosted and this mechanism has already been shown in the 
literature15. These results suggest a more dynamic way of thinking of endocytosis 
ZKHUHSDWKZD\VFRPPXQLFDWHZLWKHDFKRWKHUDQGµVHQVH¶WKHOHYHOof activity of one 
pathway and compensate for its failure. This compensation can be quite substantial 
with up-regulation of the pathway up to 3 times the positive control in which the level 
of endocytosis is not perturbed by inhibitors of endocytosis. 100 nm C-PB on the 
other hand, internalized through a less specific mechanism of endocytosis and its 
endocytosis was only marginally inhibited before other pathways of internalization 
intervened and endocytosis recovered quickly to positive control levels.  
Microscopy live studies gave evidence that the nanoparticles studied accessed 3T3, 
HCT116 and MGLVA-1 cells and they were endocytosed in less than 4 minutes. This 
data is in line with the literature that suggests a time of internalization as quick as 1 
minute for some synthetic materials56. Microscopy data did not rule out the possibility 
that the process taking place for the internalization of 50 nm C-PB in MGLVA-1 and 
HCT116 cells is due to phagocytosis or macropinocytosis. Microscopy pictures in fact 
show intense membrane activity and ruffling compatible with exocytosis, 
macropinocytosis and phagocytosis. 50 nm C-PB endocytosis was proven to be 
sensitive to CPZ in HCT116 and MGLVA-1 cells by inhibition studies and these data 
alone were also compatible with macropinocytic or phagocytic processes together 
with a CME uptake. CPZ inhibition of endocytosis, in fact, is not limited to CME only 
but also to phagocytosis and macropinocytosis. Although recent evidence suggests a 
clathrin involvement in phagocytosis which partially restores CPZ credibility as a CME 
inhibitor, from the data obtained it is not possible to assert with certainty what is the 
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endocytic process taking place for the uptake of 50 nm C-PB in HCT116 and 
MGLVA-1 cells. 
As shown from analysis of C-PB treated cells over time, the level of fluorescence 
reaches a plateau which suggests that cells are able to counterbalance the presence 
of extracellular C-PB. From experimental evidence, it is possible to suggest, from 2 
out of the 4 experiments described, that one of the ways used by cells to 
counterbalance the endocytosis of C-PB might be through active exocytosis of 
nanoparticles. The most evident drop of C-PB fluorescence after 20 minutes was 
observed in 3T3 cells with respect to the other cell lines tested as shown by analysis 
of the total cell fluorescence normalized by area of cell (Figure 4-13, 4-18B, 4-23 and 
4-28). 3T3 cells showed an extracellular vesicle of about 1µm (zoom image at 30 
minutes of Figure 4-12), loaded with C-PB as it is possible to extrapolate from the 
green fluorescence of the core of the vesicle, and it was enveloped by a membrane. 
However, even if the literature reports sizes of 0.1-1 µm for exocytic vesicles, the size 
of the vesicles detected in the extracellular compartment of 3T3 cells is close to those 
of apoptotic bodies. It has been shown that the size of apoptotic bodies is in the 
range of 1-5 µm, a factor which should be taken into account when suggesting 
exocytosis57. In support of the hypothesis of exocytosis is the size of the aggregates 
of nanoparticles on the membrane of cells: these ranged between 0.5 and 0.8 µm 
and thus were of sizes that fit well with those of exocytic vesicles reported in the 
literature. Furthermore, from the magnification pictures shown of the 3T3 and 
MGLVA-1 cells, it is possible to suggest directionality towards the extracellular 
compartment of the cells for these aggregates of nanoparticles, again supporting the 
hypothesis. Aggregates of 50 nm C-PB were also observed on the plasma membrane 
of HCT116 and MGLVA-1 cells. However, a clear direction was not detected for the 
nanoparticles in these latter experiments. At least for HCT116 cells, a possibility is 
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that cells were not able to release the C-PB into the extracellular compartment 
because of the strong interactions of the nanoparticles with plasma membrane 
proteins. This process can be observed in the higher magnification image at 60 
minutes in Figure 4-17 where a layer of green nanoparticles can be clearly 
distinguished over the CellMask membrane staining dye at 60 minutes. As C-PB are 
predominantly hydrophobic nanoparticles with a surface shell of negatively charged 
carboxyl groups, in serum-free media they may interact avidly with hydrophobic 
and/or positively charged proteins54,58. It is possible to suggest that the event reported 
might be due to the interaction of C-PB negative charge and positive membrane 
proteins or positive domain of membrane proteins that are present on the plasma 
membrane of HCT116 cells. Exocytosis is known to be affected by the experimental 
use of buffers instead of full media. However, the effects described change 
depending on the material and cell line taken into consideration and some authors 
suggest that the presence of serum-free media boosts exocytosis while some others 
report an opposite effect54,56.  
4.5  Conclusions 
From the experiments reported in this chapter some novel data have emerged in 
regard to the inhibition of endocytosis with CPZ. The time and cell specificity of the 
inhibitor of endocytosis and the subsequent recovery of the endocytosis of Htf have 
not been reported before and explains the difficulty reported by scientists working on 
inhibition of endocytosis in the use of CPZ as an inhibitor of this process. The effect 
on the passage number and ageing of cells on the endocytosis process also is a 
significant piece of information that has not been reported in the literature before and 
that has been important in establishing appropriate conditions for effective use of the 
inhibitor in C-PB inhibition studies in the reported experiments. The effect of the 
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inhibitor on LacCer uptake was also another interesting result that has been reported 
only once in the literature. Both LacCer and C-PB endocytosis were boosted in the 
presence of inhibitors of endocytic pathways that were not actively involved in the 
pathway of internalization of the material investigated. This suggests that the 
inhibition of one pathway activates other pathways of internalization giving a more 
organic and interconnected picture of endocytosis. Finally, 50 nm C-PB appear to be 
endocytosed by a CPZ-sensitive pathway and their uptake does not recover over 
time. Although this effect could be due to the combined toxicity of C-PB and CPZ, 
another hypothesis might be that C-PB show some specificity towards a CPZ-
sensitive pathway and further investigations are required in order to understand the 
mechanisms underlying such specificity. Microscopy studies confirm that the 
nanoparticles are internalized by cells and that the endocytic process is rapid and 
efficient with nanoparticles internalized by cells already after 4 minutes. A suggestion 
of exocytosis of 100 nm C-PB in 3T3 and MGLVA-1 is also provided by these studies 
together with evidence of a membrane specific binding ability of 50 nm C-PB in 
HCT116 cells but not on MGLVA-1 cells. This observation supports the idea that the 
same nanoparticles can interact with different cells in different ways.  
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5.1 Introduction 
One of the major problems in the development of new drugs is producing molecules 
that are not only effective, with specificity at the target cell, but which also have the 
required physico-chemical properties to ensure they accumulate, after administration, 
at the intended tissue. In many cases it is not possible to combine these features in 
one molecule and thus carriers or delivery systems are needed in order to take a 
drug with sub-optimal solubility or stability to a target in the body. Delivery systems 
can facilitate administration and biodistribution and can reduce unwanted off target 
toxicity of the drug. A large variety of materials have been developed which can 
encapsulate delicate, potent and/or poorly soluble drugs during transit in the body 
and then release the drug at a distal site. The specificity of delivery at the target cell, 
tissue or organ can be affected by a variety of methods, many of which take 
advantage of the specific characteristics of the inflammation site that often develops 
as a consequence of the medical condition and/or of the cell biology in the 
pathological tissues. The changed physiology at a disease site can lead to 
hyperthermia, a modified oxidative or reductive environment, and/or a changed pH. 
As a consequence, drug delivery systems which change their properties with 
temperature, redox state and pH are potential means of delivering drugs specifically 
at disease sites. Polymeric micelle-like nanoparticles are an example of such delivery 
systems, as their self-assembly into supramolecular structures is reversible and can 
be triggered in the forward or reverse direction by a variety of stimuli. Polymer 
micelle-like nanoparticles for biomedical applications are easily formed by preparing a 
hydrophobic core polymer block, which can accommodate hydrophobic compounds 
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(e.g. anticancer drugs) and coupling this block to a hydrophilic shield polymer that 
bestows water solubility to the carrier system.  
In this chapter the results on biocompatibility and cell penetration of 
thermoresponsive micelle-like nanoparticles are studied and reported. The 
thermoresponsiveness of the system was designed in the long term to target 
specifically inflamed tissue, as found in a variety of diseases. Pathological conditions 
can produce an inflammation that has been reported to raise the local temperature up 
to 42°C in some cases (hyperthermia). Hyperthermia can also be administered by 
ultrasound probes and near infrared irradiation in conjunction with the treatment with 
thermoresponsive materials1-4. 
5.2 Materials used for the studies 
The thermoresponsive materials studied were based on polymers synthesized 
previously in our group by Abulateefeh et al and subsequently synthesized by Lee 
Moir. They can be described by the following general formulas in Figure 5-1 and 5-25: 
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Figure 5-1 Poly(lactide-co-glycolide)-block-poly(poly(ethylene glycol methyl ether methacrylate)-co-
poly(propylene glycol methacrylate)) (PLGA-b-(PPGMA-co-PEGMA)) thermoresponsive polymers. The 
different regions (or blocks) that constitute the polymer are labelled for easy detection. Some of the 
characteristics of these structures are summarised in the description in the text. X, y, m and n 
numbers are different in each polymer. 
 
Figure 5-2 Polylactide- block- poly(poly(diethylene glycol methacrylate)-co-poly(oligoethylene glycol 
methacrylate)) (PLA-b-(DEGMA-co-OEGMA)) thermoresponsive polymers. The blocks that form the 
polymer are labelled for an easy detection. Both the hydrophobic and hydrophilic regions of these 
polymers have been modified in these second set of polymers with respect to polymers in Figure 5-1 
and 
5
. Some of the characteristics of these structures are summarised in the description in the text. X, 
y, m and n numbers are different for each polymer. 
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The structures of poly(lactide-co-glycolide)-block-poly(poly(ethylene glycol methyl 
ether methacrylate)-co-poly(propylene glycol methacrylate)), (PLGA-b-(PPGMA-co-
PEGMA)) is given in Figure 5-1. The polymer shown in Figure 5-2, which is slightly 
different to those prepared by Abulateefeh et al5 is polylactide- block- 
poly(poly(diethylene glycol methacrylate)-co-poly(oligoethylene glycol methacrylate)) 
(PLA-b-(DEGMA-co-OEGMA)). The PLGA/PLA region forms the hydrophobic, inner 
core of the micelle when these co-polymers are added to water. PLGA is a polyester 
block copolymer formed by poly-lactic acid (PLA) and poly-glycolic acid (PGA) 
(Figure 5-1). The PLA contains an asymmetric Į carbon producing 2 enantiomeric 
structures referred as D and L or, R and S. The PLGA acronym refers to R and S 
poly lactic acids represented in equal ratio in the polymer6. PLGA is a biocompatible 
and biodegradable material that has been approved by the Food and Drug 
Administration (FDA)7. The susceptibility to degradation is affected by the molecular 
weight of the PLGA and by the ratio between PLA and PGA, where increasing the 
ratio of PLA reduces the rate of hydrolysis and acid-catalysed degradation8. The 
thermoresponsive properties of the polymer are given by PEGMA, PPGMA, DEGMA 
and OEGMA. These regions have the ability to change their structure from coil to 
globule with increasing temperature, changing their conformation from stretched and 
highly hydrated to collapsed and only partially hydrated9. This phenomenon occurs 
above a designed lower critical solution temperature (LCST) that in these polymers 
has been determined indirectly as the increase of turbidity of the polymer solution 
(cloud point) and it is referred to as the thermal transition temperature (TTT)10. The 
ratios between the PEGMA and PPGMA monomers in the chain can change the 
LCST of the polymer with higher quantities of PPGMA lowering the LCST of the 
individual polymer chains and the TTT of micelle-like nanoparticles and nanoparticles 
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formed from the co-polymers5,11. Different ratios of PLA and PGA were used in these 
polymers to modify the size of the polymer and hence the size of the hydrophobic 
core of the micelle as well as different ratios of PEGMA (LCST §90°C), PPGMA, 
DEGMA (LCST § 26°C) and OEGMA (LCST § 90°C) to study how these 
modifications affected the LCST and TTT12-15. Micelle-like nanoparticles were formed 
by nanoprecipitation16, adding an acetone solution, containing the solubilised 
polymer, to water either dropwise or with the aid of a syringe pump. These 
nanoparticles were of the size range (50-150 nm) similar to that of common virus 
particles, and thus were considered of interest as drug delivery systems. 
The specific aim of this part of study was to produce polymers and micelle-like 
structures that were stable in suspension at normal physiological temperatures and 
resistant to cell uptake, but which were able to internalise into cells when above their 
TTT. Prior data from Abulateefeh et al, as well as numerous studies from the Chilkoti 
group, had shown that thermoresponsive polymers, polypeptides and nanoparticles 
were selectively internalised into some specific cell lines only when above their 
TTT16,17. This study aimed to investigate if this phenomenon was cell-dependent, and 
if the polymer thermal response could be used for target specificity against cancer 
cells, as a first step towards organ or diseased issue specificity. Furthermore, it was 
intended to study the routes of internalization used by the polymer micelle-like 
nanoparticles to access cells as well as to compare and contrast the intracellular 
trafficking pathways of thermoresponsive polymers with those of C-PB reported 
earlier. 
In this chapter are shown the results of tests of cell activity of micelle-like 
nanoparticles following incubation with the thermoresponsive polymers (formulated 
as kinetically trapped micelle-like nanoparticles), and microscopy studies to assess 
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the ability of the micelle-like nanoparticles polymers to access cells. The 
characteristics of the original polymers and the micelle-like nanoparticles formed by 
the assembly of these polymers are summarised in Table 5-1 and 5-2. The ȗ potential 
for the nanoparticles tested was negative and close to neutrality (values ranging 
between -0.5 and -4 mV). ȗ potential measurements were run in HEPES buffer 1 mM, 
pH 7.4 at 20°C.  
 
 
 
 
 
 
 
 
Table 5-1 Summary of the characteristics of the PLGA-b-(PPGMA-co-PEGMA) thermoresponsive 
polymers and micelle-like nanoparticles used for the study. Molecular weights have been determined by 
Gel Permeation Chromatography (GPC). The diameter of the nanoparticles was measured by DLS and 
carried out at 20°C in HEPES 20 mM. 
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Table 5-2 Summary of the characteristics of PLA-b-(DEGMA-co-OEGMA) thermoresponsive micelle-
like nanoparticles used in the study. Molecular weights have been determined by Gel Permeation 
Chromatography (GPC); the diameter of the micelles was measured by DLS at 20°C and HEPES 20 mM 
buffer. A double system of detection was used here consisting of Rhodamine and Fluorescein 
methacrylate covalently bound to the backbone of the polymer
*
. 
                                               
*
 Rodamine B and Fluorescein methachrylate were inserted randomly in the backbone of the hydrophilic region of the polymer 
and constituted 5% w/w of the reagents of the polymerization. 
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Table 5-3 Summary of experiments carried out for each polymer formulation. 
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5.3 Methods  
For a schematics of all the experiments carried out with polymers formulations 1-9, 
cell lines used, and aggregation state please refer to Table 5-3. 
5.3.1 Cell viability studies 
Cell viability of thermoresponsive nanoparticles 1, 2, 3, 4 and 6 was assessed with an 
MTT test at 4 h incubation. The incubation time of the nanoparticles with cells for cell 
viability studies was decided on the basis of the inhibition studies timescale. The aim 
was to evaluate the effects of the polymers on metabolic activity when used with cells 
for the time-length needed for the inhibition studies. These tests were intended to 
verify that the synthesis and formulation process (in which potentially cytotoxic 
solvents and catalysts were used) did not lead to contamination of the final polymer 
formulations with toxic components. It was also intended to verify that the polymer 
structure was cell compatible. Cell viability of micelle-like nanoparticles from polymer 
5, 7, 8 and 9 were not assessed because of lack of time.  
Cells were counted and seeded in full media at a density of 31200 cells/cm2 in a clear 
96 well plate and allowed to attach to the bottom of the wells overnight. The day after, 
the medium was aspirated off and replaced with HBSS/HEPES 20 mM for the 
negative control, with PEI 500 µg/ml (positive control) and concentrations of polymer 
nanoparticles ranging from 31.25 to 1000 µg/ml in triplicate wells. Subsequently MTT 
(50 µl of 1 mg/ml solution) was applied. Upon completion of the MTT incubation time 
the absorbance readings were recorded at 550 nm and results were plotted in 
GraphPad Prism, subtracted of the reading of the blank measurements without cells 
and normalised against the untreated negative controls. As a further control of the 
reliability of the data obtained with MTT tests, statistical measurements of the Z factor 
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and Signal Window were measured according to equations in §2.2.5.4 of the general 
materials and methods section. 
5.3.2 Cell uptake studies 
Uptake of thermoresponsive polymers was assessed with two techniques: widefield 
and confocal microscopy. Widefield microscopy was used for a screening on the 
behavior of the polymer nanoparticles in the presence and in the absence of cells. 
However, for a thorough assessment of the uptake of the nanoparticles in cells, 
confocal microscopy was used as the latter technique is the most suitable for uptake 
studies given that the resolution allows for the distinction of the regions outside and 
inside cells18. 
The micelle-like nanoparticles chosen for uptake studies were 5, 6, 7, 8 and 9. The 
reasons why polymer formulations 1-4 were excluded from uptake studies were 
many: they presented a Rhodamine dye that was only adsorbed to the micelle and 
was susceptible to leakage, the polymerization of polymer 3 and 4 was only partially 
successful producing rather small polymers that were not ideal for the formation of 
micelle-like nanoparticles. Also all these polymers, when formulated via the 
nanoprecipitation technique, presented a double distribution of sizes which was 
problematic for interpreting endocytosis inhibition studies. Finally, their transition 
temperature was rather high and ranging between 40 and 64°C and mostly not 
compatible with cell studies. As the polymer nanoparticles were predicted not to 
internalize when in a hydrated (and less protein interacting form) when below their 
TTT, the microscopy study of polymers 1-4 in cells was not taken further5,16.  
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Figure 5-3 Manual method for the formation of micelle-like nanoparticles from amphiphilic 
polymers. This simple method consisted in dropwise addition of the acetone polymer-containing 
solution to an aqueous solution under constant stirring. The acetone/water solution obtained was left 
to evaporate overnight to remove the acetone from the solution. This method was used for the 
production of the polymer formulations 1-7. 
 
Figure 5-4 Schematic representation of the mixing apparatus used for the production of polymer 
formulation 8 and 9. The apparatus consisted of two chambers, one for the polymer dissolved in 
acetone and another for the water. The mixing was occurring gradually, controlling the flux of the two 
solutions that were coming to contact at a T junction of the apparatus.  
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5.3.3 Assessment of the uptake of polymer micelle-like 
nanoparticles 5  
3T3 and HCT116 cells were counted and seeded at a density of 31200 cells/cm2 in 6 
well plates in duplicate and in full media and incubated at 37°C and 5% v/v CO2 to 
allow cells to attach to the bottom of the plate overnight. The following day micelle 5 
suspensions were thawed, vortexed and sonicated for 1 minute. Full media from cells 
was aspirated and replaced with 500 µl solution of 500 µg/ml of the micelle or 
HBSS/HEPES 20 mM for the negative control. Cells were incubated for further 8 h. 
Cells treated with the nanoparticles were incubated at 42°C. Two negative controls 
were used, one untreated control was incubated at 37°C and another incubated at 
42°C. Standard tissue culture incubators were used for these experiments with a 
controlled atmosphere of 95%v/v humidity and 5% v/v CO2. Upon completion of the 
incubation time cells were viewed on a Nikon Eclipse Ti widefield microscope, 
Kingston Upon Thames, UK, to detect any signs of toxicity due to the micelle or the 
treatment at 42°C as well as internalization of the nanoparticles in cells. 
5.3.4 Assessment of the kinetics of endocytosis of formulation 6  
3T3 cells were counted and seeded at a density of 31200 cells/cm2 on round glass 
coverslips in 6 well plates and full media and incubated overnight to allow cells to 
attach to the glass coverslips. The following day, CellMask deep red plasma 
membrane staining 1µg/ml was applied and incubated for 30 minutes. The media was 
subsequently aspirated, the coverslip applied on a mounting chamber and cells 
treated with HBSS/HEPES 20 mM. Micelle formulation 6 was previously thawed, 
equilibrated to room temperature, vortexed and sonicated for 1 minute and 
subsequently added to the buffer at final working concentration of 500 µg/ml. Live 
images were acquired on untreated cells in HBSS/HEPES 20 mM before the 
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application of the polymer nanoparticles and at 10, 20, 40, 50 and 60 minutes from 
their application on cells. Micelle-like nanoparticles 6 were labeled with a fluorescein 
methacrylate dye for confocal microscopy.  
5.3.5  Uptake studies for nanoparticle formulations 6 and 7  
3T3 cells were counted and seeded on glass coverslips as described above and 
allowed to attach to coverslips overnight. The following day, micelle 6 and 7 
suspensions were thawed to room temperature, vortexed, sonicated for 1 minute and 
incubated at 37°C for 30 minutes before diluting an aliquot of the stock in 
HBSS/HEPES 20 mM to 500 µg/ml and applying them to cells. Cells were further 
incubated with nanoparticles 6 and 7 for 2 h while a further incubation time set at 17 h 
was attempted for micelle 6. Negative control cells and micelle-treated cells were 
imaged on a Zeiss 710 confocal microscope.  
5.3.6 Uptake studies of the internalization of micelle 8 
3T3 and HCT116 and MGLVA-1 cells were counted and seeded at a density of 
31200 cells/cm2 in clear 96 well plates in full media and allowed to attach to the 
bottom of the plate overnight. The following day, the micelle suspensions were 
thawed and left to equilibrate to room temperature, vortexed and sonicated for 1 
minute. The media from cells was aspirated and different concentrations of the 
nanoparticles were applied to the wells in triplicates for concentrations ranging 
between 31.25 and 1000 µg/ml in HBSS/HEPES 20 mM. The negative control 
consisted of cells treated with HBSS/HEPES 20 mM. Treated cells were incubated for 
further 24 h. Upon completion of the incubation time cells were viewed on a Nikon 
Eclipse Ti widefield microscope to detect and signs of toxicity and internalization of 
the nanoparticles in cells.  
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HCT116 cells were counted and seeded in full media at a density of 31200 cells/cm2 
in a 25 cm2 flasks and allowed to adhere to the bottom of the flask overnight. The day 
after, the media was aspirated and cells treated with 250 µg/ml of the nanoparticles in 
HBSS/HEPES 20 mM in which micelles had been previously thawed, vortexed and 
sonicated for 1 minute. Cells were incubated at room temperature for 1 h, viewed on 
a Nikon Eclipse Ti widefield microscope and subsequently incubated overnight at 
37°C. A 25 cm2 flask without cells was rinsed with full media and used as a control, 
incubated with the same solution of the micelle that was applied on cells, at room 
temperature for 1 h and subsequently incubated overnight at 37°C. Images were 
taken after 1 h incubation at room temperature in both cells treated with nanoparticles 
and flasks with nanoparticles but devoid of cells. Another set of images was taken 
after overnight incubation at 37°C before and after rinsing the nanoparticles 
suspension.  
5.3.7 Uptake studies of the internalization of micelle-like 
nanoparticles 9 
HCT116 and 3T3 cells were seeded at a density of 31200 cells/cm2 on rounded glass 
coverslips in 6 well plates and allowed to attach to the glass coverslip overnight. 
Subsequently, cells were incubated with 250 µg/ml of polymer formulation 9 overnight 
with and without an additional incubation step carried out for 1 h at room temperature. 
Alternatively, cells were treated for 1 h at room temperature with 500 µg/ml of 
micelles formulation 9 before confocal microscopy. Cells were stained with Hoechst 
33342 1 µg/ml and/or CellMask deep red plasma membrane staining 1 µg/ml for 30 
minutes and the staining solution removed prior to confocal microscopy on a Zeiss 
Confocal microscope 710.  
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5.4 Results 
5.4.1 Acute cell viability studies 
MTT studies on polymer nanoparticle formulations 1, 2, 3, 4, are shown in Figure 5-5, 
and MTT assays of polymer 6 are shown in Figure 5-6. The graphs in Figure 5-5 
represent the mean and standard deviation of triplicate experiments. Graph in Figure 
5-6 represent the mean and standard deviation of duplicate experiments. Graphs 
illustrate that the nanoparticles were generally well tolerated in the cell lines tested 
and at the chosen experimental settings.  
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Figure 5-5 Assessment of cell activity interference of micelle-like formulation 1 (A), 2 (B), 3 (C) 4 (D) 
following incubation in 3T3, HCT116 and MGLVA-1 cells with an MTT acute test at 4 h. Cells were 
seeded in a clear 96 well plate and different dilutions of micelle applied in triplicate wells. Absorbance 
readings were recorded at 550 nm. PEI 500 µg/ml was used as a positive control. Results are 
normalised against the negative control and represent the mean and standard deviation of triplicate 
experiments (n=3). 
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For all the polymers tested there was little effect on cell metabolic activity and for this 
reason broad IC50 values and 95% confidence intervals were calculated. The Signal 
Window between the negative and positive control was calculated to investigate that 
there was enough separation between the positive and negative control absorbance 
for the MTT test, as this is an indication of the reliability of the assay19. In 3T3 
fibroblasts the Signal Window was 5 which corresponds to a recommended value, in 
HCT116 it was 1.6 that corresponds to an acceptable value and in MGLVA-1 cells it 
was 7 and a recommended value according to Iversen et al19. Z factor values were 
equal to 0.5 for 3T3 cells (excellent separation between positive and negative control 
according to Zhang et al20), for HCT116 it was equal to 0.2 which corresponds to a 
small separation between the positive and negative control, and Z factor for MGLVA-
1 cells was equal to 0.7 corresponding to an excellent separation between positive 
and negative control. 
 
Figure 5-6 Assessment of cell activity of polymer micelles 6 on 3T3, HCT116 and MGLVA-1 cells with 
an MTT test. The data plotted here are the result of MTT readings at 550 nm of the viability of cells 
and are reported as the mean and standard deviation of duplicate experiments. Cells were seeded at a 
density of 31200 cells/cm
2
 and allowed to attach to the bottom of a clear 96 well plate overnight. The 
following day cells were treated for 4 h with the formulated polymers (n=2). 
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Cell activity tests for micelle-like nanoparticles 6 are shown in Figure 5-6. The graph 
represents the mean and standard deviation of duplicate experiments and suggests 
that the polymers were well tolerated in the chosen cell lines and experimental 
settings. IC50 values for polymer formulation 6 in 3T3 cells were equal to 5 mg/ml at a 
95% confidence interval of 3.4-8 mg/ml; the obtained IC50 value and confidence 
interval were not reliable in HCT116 cells (low toxicity) while in MGLVA-1 cells the 
polymers were essentially inactive. The Z factor and Signal Window for 3T3 cells 
were 0.2 and 1.7 respectively corresponding to a low separation between positive 
and negative control calculated by Z factor and an acceptable Signal Window; 
HCT116 cells presented a Z factor and Signal Window of -0.46 and -1.5 that are 
unacceptable while Z factor and Signal Window for MGLVA-1 cells were equal to 0.2 
and 1.3 that correspond to poor separation between positive and negative control 
according to Z factor statistics but an acceptable Signal Window. The rather poor Z 
factor and Signal Window results obtained for polymer 6 were likely due to the 
unexpectedly low toxicity of the PEI positive control used in these studies. 
5.4.2 Internalization studies of micelle-like structures from 
polymer 5 
Polymer 5, formulated into nanoparticles with a single population of micellar 
diameters, and containing a Fluorescein dye covalently bound to the polymer 
backbone, were the first to be analyzed for internalization. The aim was to test the 
internalization of micelle-like nanoparticles of the polymer in 3T3, HCT116 and 
MGLVA-1 cells. As the TTT for the polymer was 41°C, the experiments were 
conducted at 37°C and 42°C (respectively below and above the TTT of the polymer). 
As the high transition temperature was a limiting step for confocal microscopy (which 
required special arrangements with the confocal microscopy unit), an initial screening 
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of the uptake of the micelle-like nanoparticles was carried out with a more accessible 
widefield microscope. As apparent from Figure 5-7, the micelle-like structures 
obtained from polymer 5 were not sufficiently fluorescent for further confocal 
microscopy. However, it was noted that the polymers appeared to have an 
unexpected protective action on cells undergoing treatment at 42°C for 8 h. As it can 
be seen from the images in Figure 5-7, 3T3 control cells treated at 42°C were 
rounded and unhealthy compared to the control cells treated at 37°C. The same cells 
incubated at 42°C in the presence of formulation 5 looked slightly more flattened and 
less rounded which suggested a higher resistance to the increase of temperature 
(arrows).  
The density of HCT116 control cells treated at 42°C was reduced with cells detaching 
from wells and floating in the media as a consequence of the heat. The same cells 
treated at the same temperature in the presence of suspensions of nanoparticle 
formulation 5 presented a cell density that was similar to the untreated control at 
37°C suggesting an acquired resistance to the increase of temperature. Although the 
HCT116 cell morphology is mainly rounded, some of the cells looked slightly 
elongated when in good health (see arrows in Figure 5-7 at 37°C). This morphology 
is not detected in cells treated with the micelle at 42°C and can be interpreted as an 
indicator of cell stress. 
 
  
 
 
Figure 5-7 Micelle-like structures 5 incubated at 42°C (above TTT) for 8 h. The pictures shown above were taken on 3T3 and HCT116 cells incubated for 8 h in 
the presence and in the absence of the nanoparticles at 42°C. Another set of cells from the same experiments were incubated at 37°C and are inserted in the 
above picture as a further control. Pictures show a merge of the green channel and the brightfield. Arrows point at some of the features of the cells that suggest 
good health (see text for further information). Exposure time for the Green Fluorescent Protein (GFP) filter was set at 1 s. Scale bars represent 100 µm.  
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5.4.3 Micelle 6 and 7 live imaging studies 
Micelle-like nanoparticle formulations 6 and 7 (produced from the same polymer in 
two different circumstances with the manual method illustrated in Figure 5-3), were 
the first polymers to be screened for internalization with confocal microscopy. The 
fluorescence of these materials in suspension was assessed by quickly exposing the 
Eppendorf tube containing the polymer to a GFP filter in a widefield microscope. As 
the suspension was strongly fluorescent, it was apparent that dye-labeling of the 
polymer had been successful. The polymer forming the micelle-like nanoparticles 
presented a TTT of 24°C, suggesting that, for internalization studies at 37°C, the 
polymers would present a hydrophobic surface. Prior DLS studies (Table 5-1), 
indicated that formulations 6 and 7, although made with the same technique (Figure 
5-3) and from the same polymer, were not identical. Formulation 6 showed a low 
tendency towards aggregation, while micelle-like nanoparticles from the same 
polymer, but as formulation 7, were already aggregated before application on cells. 
Also the size distributions of the two micelle-like nanoparticles were different. 
Nanoparticles in formulation 6 were of 118 nm diameter while those in formulation 7 
displayed two populations with diameters of the nanoparticles of 49 and 312 nm as 
measured by DLS (Table 5-1).  
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Figure 5-8 Confocal live studies of the kinetics of uptake of micelle-like formulation 6 on 3T3 cells. 
Images were acquired before applying the polymers (time 0) and after and at 10, 20, 40, 50 and 60 
minutes from the application of the nanoparticles. The pictures above represent the merge of the 
green (micelles) and red (CellMask membrane staining) channels. Scale bars represent 50 µm. 
 
A first set of experiments (Figures 5-8 and 5-9) was carried out using formulation 6 to 
investigate the uptake and to verify the time length of the uptake in 3T3 cells. The 
presence of the membrane dye was also introduced to investigate that, if uptake was 
occurring, as expected, the polymer formulation was localizing inside the membrane 
boundaries and not on the membrane or outside cells. 
A timepoint experiment was carried out to understand the kinetics of internalization of 
micelle-like nanoparticles 6 and pictures of the cells treated with the nanoparticles 
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were acquired at 10, 20, 40, 50 and 60 minutes. The pictures showed in Figures 5-8 
and 5-9 illustrate that nanoparticles were not internalized by 60 minutes from their 
application on cells.  
 
Figure 5-9 Comparison of the fluorescence intensity of 3T3 cells before and after 1 h treatment with 
micelle-like formulation 6. The pictures shown represent the single channels of emission for 
formulation 6 (Green channel) and CellMask deep red membrane staining (Red channel). Scale bars 
represent 50 µm. 
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To further investigate the reasons underlying this lack of internalization of formulation 
6, another set of experiments was carried out, which consisted of preincubation of the 
micelle-like nanoparticles at 37°C before application on cells for increased times of 
incubation. These conditions were chosen taking into consideration the 
thermoresponsive properties of the polymer. For these polymers, formulated by 
nanoprecipitation into micelle-like nanoparticles, the surface in the hydrated state 
below the TTT (24°C) was considered less likely to promote internalization. By 
contrast, the change in conformation at the exterior around the thermal transition 
temperature (TTT) would produce a less hydrophilic surface to the particles, 
predicted to enhance uptake across lipid cell membranes. The extended incubation 
time with polymers pre-transitioned across their TTT was thus expected to lead to 
greater particle internalization. However, increases in the incubation time from 1 to 2 
h did not result in 3T3 cells with fluorescent interiors, despite evidence (Figure 5-10) 
that the nanoparticles were strongly fluorescent when external to the cells. The 
formulation of micelle-like nanoparticles from formulation 6 also appeared to be well 
dispersed and non-aggregating, suggesting no changes in size over the temperature 
ranges compared to similar polymers which had been internalized by MCF-7 cells in 
previous studies5,16. A second batch of the same polymer, nanoparticle formulation 7 
(Table 5-1) was used and experiments carried out as explained above and in the 
materials and methods section. These micelle-like nanoparticles were applied to 3T3 
cells after pre-incubation for 30 minutes at 37°C and were further incubated for 2 h on 
the cells. A higher tendency for aggregation was observed with this formulation, and 
large, self-associated structures were present as can be seen from Figures 5-11 and 
5-12. The size of the aggregates ranged from a few microns to tens of microns 
making the internalization of such structures very unlikely. These data suggested 
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significant differences in the two formulations derived from the same precursor 
polymer. As polymer formulation 6 showed less tendency to aggregate, these 
nanoparticles were incubated with 3T3 cells for up to 17 h at 37°C, with a pre-
incubation stage for the polymers of 30 minutes at 37°C before application to cells 
and imaging. Results, shown in Figure 5-13, illustrate that the nanoparticles 
formulation 6 were internalized (arrows) in 3T3 cells at 17 h. Absolute comparison of 
internalization was problematic as the negative control cells were accidentally 
contaminated by a sterilization product and exhibited toxicity-induced 
autofluorescence21,22. Quantification and analysis with a Mann-Whitney t test of the 
fluorescence of each cell (subtracted from the background value of a region adjacent 
to the cell) reported a significantly increased fluorescence of cells treated with 
micelle-like nanoparticles 6 for a P value = 0.0038 (Figure 5-14). Fluorescence in 
cells treated with the micelle-like nanoparticles was not attributable to poor health of 
cells as the brightfield images showed no evidence of cell damage. However, further 
studies of the uptake of these polymer formulations were interrupted as the longer-
term stability of nanoparticles 6 against aggregation was insufficient after one month 
incubation of the nanoparticles at -20°C. The study was suspended and the chemistry 
of the polymers as well as the method used for the constitution of the suspension of 
micelle-like nanoparticles rethought for further experiments. 
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Figure 5-10 3T3 cells treated with micelle-like formulation 6 for 2 h. Nanoparticles were thawed and 
pre-incubated at 37°C for 30 minutes before being diluted, applied to cells and further incubated at 
37°C for 2 h. Images show the green channel, the brightfield channel and a merge of the two. Scale 
bars for the top row of pictures represent 50 µm; Scale bars for the bottom row of pictures represent 
20 µm. 
 
 
Figure 5-11 3T3 cells treated with micelle-like nanoparticles 7 preincubated for 30 minutes at 37°C 
before application on cells for 2 h. Scale bars for the top row represent 50 µm; Scale bars for the 
bottom row of Figures represent 20 µm. 
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Figure 5-12 Micelle-like nanoparticles 7 preincubated at 37°C for 30 minutes prior to the application 
on 3T3 cells for 2 h. This set of images show the green channel, brightfiled and a merge of both. Scale 
bars for the top row of pictures represent 50 µm; bottom row scale bars represent 20 µm. 
 
Figure 5-13 Micelle-like formulation 6 preincubated at 37°C for 30 minutes and subsequently 
applied to 3T3 cells for 17 h. This set of pictures shows the green channel, the brightfield and a merge 
of the two in 3T3 negative control (top row of pictures) and positive control of cells treated with 
nanoparticles 6 (bottom row of pictures). The negative control cells shown in this set of pictures look 
stressed, retracting their elongated features and rounding up. The reason for this behaviour is 
believed to be due to the accidental contamination of cells with the sterilising solution of the 
mounting chamber of the coverslips used for confocal microscopy. Arrows point to the green 
fluorescence of nanoparticles 6 internalised into 3T3 fibroblasts. Scale bars represent 50 µm. 
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Figure 5-14 Mann-Whitney t test of the fluorescence for the negative untreated cells and positive 
control cells treated with formulation 6. The fluorescence was measured with ImageJ for each cell for 
both the negative and the positive controls, subtracted of the background measured from a region 
adjacent to the cell before analysing the measurements with a t test. Statistical analysis show a 
significance of the increase of fluorescence in cells treated with the nanoparticles for a P value of 
0.0038. Error bars represent the standard deviation of the mean (n>15). 
5.4.4 Live cell imaging of nanoparticles 8 
Nanoparticles derived from polymer 8 (TTT = 29 °C) were based on very similar 
chemistries with respect to polymers 1-7, but formulation was carried out in a slightly 
different way. The polymer used for formulation 8 contained a hydrophobic PLA core 
and a thermoresponsive polyDEGMA/OEGMA outer block. The nanoparticles were 
prepared using nanoprecipitation, as before, but with a syringe-injection pump system 
for a more reproducible mixing of the acetone-polymer solution with water. The 
controlled fluid flow from the pumps allowed for a constant and reproducible flux of 
the two solvents when contacted at the T junction of the apparatus (Figure 5-4). 
Although good quality nanoparticles from polymer 8 were produced with the above 
mentioned technique (radius < 60 nm, narrow population distribution), after storage at 
-20°C and thawing, aggregated structures were present that required intense 
vortexing and sonication for dispersal. Experiments using widefield microscopy to 
assess uptake in 3T3, HCT116 and MGLVA-1 cells were carried out using 
nanoparticles 8 at a range of concentrations. The set of pictures in Figure 5-15, 5-16, 
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5-17, 5-18, 5-19 and 5-20 was also acquired to investigate that the two dyes used 
during the synthesis of the polymers and nanoparticles (Fluorescein methacrylate 
and Rhodamine B) were both visible. As apparent from Figures 5-15, 5-16, at the 
highest concentration of nanoparticles, (1000 µg/ml) large aggregates formed which 
produced a thick layer of material on cells. Furthermore, although this concentration 
was the highest of the ones tested and the exposure of the green channel was tested 
up to 3 times higher than the one used for the red channel in 3T3, and 10 times 
higher with respect to the exposure time used with HCT116 and MGLVA-1 cells, no 
fluorescence was detectable for the Fluorescein dye that was inserted in the 
backbone of the hydrophilic portion of the nanoparticles. Reducing the concentration 
from 1000 to 500 µg/ml did not reduce sufficiently the thick layer of the aggregated 
polymer on cells, thus it was not possible to determine if any particles were 
internalized. Concentration of 500 µg/ml of formulation 8 appeared to produce two 
different sorts of aggregations depending on the cell line tested (Figure 5-µ:RUP-
OLNH¶ DVVHPEOLHV RI QDQRSDUWLFOHV  ZHUH IRXQG WR EH DVVRFLDWHG ZLWK 7 DQG
HCT116 cells while MGLVA-FHOOVZHUHVXUURXQGHGE\VKRUWHUDQGWKLFNHUµWXEHV¶RI
associated particles together with sheet-layers of the polymer. At lower 
concentrations of nanoparticles (250 µg/ml) cells were more clearly discerned. 
HCT116 cell density was low enough to suggest that the polymer aggregates were 
preferentially interacting with cell surfaces rather than the underlying cellBIND coating 
of the 96 well plates substrate (Figure 5-18). The same association between 
nanoparticles and cell surfaces was also apparent, although less definitively, for 3T3 
cells. The larger size of 3T3 cells makes them more confluent than HCT116 and thus 
the interactions between polymers and cells were less defined. Polymers incubated 
with MGLVA-1 cells did not appear to show a similar strong affinity for these cell 
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surfaces and aggregates of the polymers were distributed both on cells and on the 
bottom of the well. At polymer concentration of 31.25 µg/ml the association of the 
nanoparticles with 3T3 and HCT116 cells was evident (Figure 5-20). Polymer 
nanoparticles were preferentially found on the cells with respect to the cellBIND-
treated plastic of the well. For all experiments, polymers were detected not only as 
associated nanoparticles but also as layers and sheets of agglomerated material. It 
was also notable that the polymers were associated with the 3 cell lines in different 
ways (Figure 5-19). For polymers attached to 3T3 cells, the nanoparticles were 
present in longer, thinner regions compared to those at HCT116 and MGLVA-1 cell 
surfaces. This suggested that the polymer nanoparticles were associated at the cell 
surface structures, which are known to differ for the 3 cell lines chosen, rather than 
being present in the cytosol in each case. It is known that 3T3 cells produce 
extracellular matrix components and it is possible that the nanoparticles were 
attached to these regions as well as to the rest of the 3T3 cell surface, accounting for 
the difference in the appearance of the nanoparticles aggregates on 3T3 cells 
compared to HCT116 and MGLVA-1 cells23,24. Internalization of the polymer 
nanoparticles in the 3 cell lines was not clearly evident from the pictures at this 
magnification, suggesting either that no internalization had taken place or that any 
internalized nanoparticles were masked by the aggregated particles at the cell 
surfaces.
  
 
Figure 5-15 3T3, HCT116 and MGLVA-1 cells treated with different concentrations of formulation 8 for 24 h at 37°C. The Figure shows the Green and Red 
channels, brightfield and a merge of all. Cells were seeded at 31200cells/cm
2
 in a 96 well plate and treated with formulation 8 previously thawed, vortexed and 
sonicated before application on cells. Images were acquired with a Nikon Eclipse Ti widefield microscope. The exposure time for the ds red tomato filter is 300 ms 
for 3T3 cells and 100 ms for HCT116 and MGLVA-1 cells. The exposure time for the GFP filter is 1s for all cell lines. The nanoparticles were expected to fluoresce in 
both the Green and the Red channels. Scale bars represent 50 µm. 
  
 
 
 
 
 
Figure 5-16 3T3, HCT116 and MGLVA-1 cells treated with 1000 µg/ml of formulation 8 for 24 h at 37°C. The Figure shows the Green and Red channels (bottom 
Figures), brightfield and a merge of all (top Figures). The nanoparticles were expected to fluoresce in both the Green and the Red channels. Scale bars represent 50 
µm. 
 
  
 
 
 
 
Figure 5-17 3T3, HCT116 and MGLVA-1 cells treated with 500 µg/ml of formulation 8 for 24 h at 37°C. The Figure shows the Green and Red channels (bottom 
Figures), brightfield and a merge of all (top Figures). The nanoparticles were expected to fluoresce in both the Green and the Red channels. Scale bars represent 
50 µm. 
 
 
  
 
 
 
 
Figure 5-18 3T3, HCT116 and MGLVA-1 cells treated with 250 µg/ml of formulation 8 for 24 h at 37°C. The Figure shows the Green and Red channels, brightfield 
and a merge of all. The nanoparticles were expected to fluoresce in both the Green and the Red channels. Scale bars represent 50 µm. 
 
  
 
 
Figure 5-19 3T3, HCT116 and MGLVA-1 cells treated with 62.5 µg/ml of formulation 8 for 24 h at 37°C. The Figure shows the Green and Red channels, brightfield 
and a merge of all. The nanoparticles were expected to fluoresce in both the Green and the Red channels. Magnification images are provided at the bottom of the 
Figure and show some features of the aggregates. Scale bars represent 50 µm. 
  
 
 
 
 
Figure 5-20 3T3, HCT116 and MGLVA-1 cells treated with 31.25 µg/ml of formulation 8 for 24 h at 37°C. The Figure shows the Green and Red channels (bottom 
Figures), brightfield and a merge of all (top Figures). The nanoparticles were expected to fluoresce in both the Green and the Red channels. Scale bars represent 
50 µm. 
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As this polymer formulation was found to aggregate rapidly under the tested 
experimental conditions and did not appear to internalize, the polymers from this 
batch were not brought further to confocal microscopy studies.  
However, from these initial results two hypotheses were formulated: 
1. The aggregation was a consequence of the incubation of the micelle with 
cells; i.e. that components in the cell culture media were interacting with the 
nanoparticles causing aggregation and precipitation. 
2. The aggregation was a consequence of the change of conformation of the 
thermoresponsive part of the micelle at 29°C and inherent instability of the 
resultant hydrophobic micelle surfaces in the aqueous suspension.  
Following these hypotheses a second set of widefiled microscopy experiments was 
run to enquire of the nature of the aggregates. 
HCT116 cells were treated with the micelles at room temperature for 1 h (<21°C and 
below the TTT of the micelle = 29°C). In this conformation the micelles were 
predicted to stay in a more hydrated and less interacting and expectedly less 
aggregated conformation. This anticipated conformation was left to stabilize for 1 h 
before imaging. Cells treated at room temperature were then incubated at 37°C 
overnight and imaged again before and after rinsing the micelles from the flasks. 
Furthermore, to investigate that the aggregation of the micelle was not due to the 
presence of cells, a control without cells was also introduced in the experimental 
design.  
After the thawing, the micelles looked more aggregated than previously noticed 
(Figure 5-21A). However, after vortexing and sonicating the nanoparticles, the 
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aggregates disappeared and the experiment was carried out as scheduled. Results 
showed that the treatment at room temperature did not reduce the formation of the 
aggregates that were still present and forming sheets of micelles in the range of a few 
micrometers. The following incubation at 37°C did not change the aggregation state 
of the micelles and pictures taken after the rinse of the micelles showed that some of 
the nanoparticles bound quite readily with the cellBIND treated polystyrene plastic of 
the flask. The presence of cells did not appear to change the aggregation state of the 
micelles. However, when comparing the conformation of the micelles from the images 
of the previous experiment where the micelles were incubated at 37°C without 
additional incubation steps (Figures from 5-15 to 5-20), some differences could be 
noticed. The presence of aggregated micelles in pseudo-filamentous filamentous and 
fibrous structures in the previous experiments was not apparent in the second set of 
experiments (Figure 5-22). In contrast, in the second experiment, micelles of 
formulation 8 were observed in wide sheet-like layers. After removing the polymer 
solution from cells and rinsing once with PBS, the aggregates appeared to be 
retained more in the presence of cells (Figure 5-22). The micelles were thawed a 
second time to repeat the experiment reported above on 3T3 and MGLVA-1 cells. 
However, this time the nanoparticles appeared heavily aggregated (Figure 5-21B and 
C) and vortexing and intense sonication did not disperse the aggregates. The 
experiment was interrupted. 
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Figure 5-21 Evidence of aggregation over time of formulation 8 upon storage at -20°C. Figure A 
shows the aggregates of the micelles upon thawing after 2 weeks of storage of the micelle in a -20°C 
freezer. The aggregates, in that occasion were eliminated by the routine procedures of vortexing and 
sonication before the use of the micelles on cells. Figure B and C show two different Eppendorf tubes 
of the same micelles thawed after 4 weeks of storage of the nanoparticles in a -20°C freezer. The 
aggregates pictured in Figure B and C were only reduced upon vortexing and sonication and structures 
were prone to re-aggregation after a few minutes of settling of the polymer at the bottom of the 
Eppendorf tubes. 
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Figure 5-22 Flasks with or without HCT116 cells treated with formulation 8 at room temperature for 
1 h, at 37°C overnight and before and after rinse. This set of pictures show the behaviour of 
formulation 8 (red channel) in the presence and in the absence of cells. Different settings were 
applied in these experiments. Flasks with or without cells were treated with micelle 8 for 1 h at room 
temperature

. Flasks were then moved to an incubator overnight at 37°C. The following day images 
were acquired prior and after rinsing the micelle from the flasks. Pictures shown in this Figure are the 
merge of the ds Red channel and the brightfield. Scale bars represent 50 µm.  
                                               
 The flask without cells was rinsed with full media before the experiment to better resemble the conditions of 
the flask with cells. 
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5.4.5 Micelles 9 live imaging 
The last polymer studied for cell internalization was polymer formulation 9. The 
chemistry of the polymer was very similar to formulation 8. The molar mass of the 
polymer, the diameter of the nanoparticles formed and the TTT closely resembled 
polymer 8 (Table 5-2). Because of the complications caused by the aggregation of 
the nanoparticle formulations upon freezing, the polymer was synthesized two days 
before the confocal microscopy experiment and the micelles produced by the syringe 
pump method described in Figure 5-4. The polymer was tested fresh without any 
freezing steps in between the synthesis and the application on cells. The 
internalization in HCT116 cells, assessed by confocal microscopy, was tested at 
room temperature and also below the TTT of the polymer (27°C). The polymer was 
also tested at a lower concentration of 250 µg/ml and incubated overnight at 37°C in 
HCT116 and 3T3 cells. As a further control of the aggregation stability, the polymer 
was also preincubated at room temperature for 1 h before the overnight incubation at 
37°C in HCT116 cells. 
The pictures of cells incubated with and without the polymer are shown in Figure 5-
23, 5-24 and 5-25. Upon incubation at room temperature for 1 h and 500 µg/ml, some 
aggregation of the polymer in solution was visible. However, the aggregation was 
reduced when the polymer was used at 250 µg/ml and after overnight incubation. All 
cells treated with the polymer showed some extent of internalization, although the 
fluorescence was low. Internalization was apparent also when the polymer was 
incubated at room temperature and below the TTT. This suggests that the 
rearrangement of the polymer corona upon hydrophilic chain collapse above the TTT 
observed in buffer solutions either did not take place in the same way in the presence 
of cells, or that a change from a hydrophilic corona to a hydrophobic outer surface did 
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not significantly alter the internalization into cells. The distribution of the fluorescence 
resulting from polymer nanoparticles internalization was also different from that 
observed in C-PB. The fluorescence was more uniformly distributed in the cytoplasm 
and nuclei of cells and did not show the usual punctate structures that were detected 
for both C-PB nanoparticles and formulation of polymer 6. It should also be noted that 
z stack images (Figure 5-25) showed a tendency for the dye to undergo photo-
bleaching and the internal fluorescence of the micelle was reduced upon repeated 
exposure to the laser beam. 
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Figure 5-23 Formulation 9 incubated with HCT116 cells in different conditions. HCT116 cells were 
incubated with polymer formulation 9 for 1 h at room temperature, or overnight at 37°C, with or 
without a preincubation step of 1 h at room temperature. The concentration of formulation 9 is 500 
µg/ml in room temperature experiments and 250 µg/ml in overnight experiments. Green: micelles; 
Blue: Hoechst staining of the nuclei; Red: CellMask deep red membrane staining. Polymers were 
labelled with Rhodamine B which is detected in a red channel. For an easy distinction of the micelles 
from the Deep Red CellMask dye, the micelles are shown in Green. The last row of images is given by a 
magnification of the most significant features of the internalization of formulation 9 in HCT116 cells. 
Scale bars for the first 4 rows represent 50 µm. Scale bars for the bottom row represent 20 µm. 
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Figure 5-24 Internalization of 250 µg/ml of micelle suspension 9 after overnight incubation at 37°C. 
Images were acquired on a Zeiss 710 confocal microscope after staining the cells with Hoechst 33342 
1 µg/ml (Blue). Green: Formulation 9 stained with a red Rhodamine B dye. The magnification picture 
in this Figure has been modified enhancing the fluorescence signal from the micelles to help the 
reader to detect the key features of the internalization of formulation 9 in 3T3 cells. Scale bars 
represent 50 µm for the full images and 10 µm for the zoomed image.  
 
Figure 5-25 Orthogonal projection of a 3D image acquired on 3T3 (left) HCT116 cells (right) treated 
with 250 µg/ml of micelle suspension 9 overnight at 37°C. The arrows point at the internalization of 
the nanoparticles (Green) where its fluorescence can be localised within the boundaries of the red 
membrane. Nuclei: Blue. Scale bars represent 50 µm. 
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5.5 Discussion 
Cell activity studies on micelles 1, 2, 3 and 4 showed that the materials were 
generally well tolerated in the tested cell lines. HCT116 cells were the most sensitive 
to polymer micelle-like nanoparticles 1-4 with a minimum cell activity observed at 250 
µg/ml polymer. The drop in viability reached a minimum of about 70% viable cells in 
HCT116 with micelle 1-4 which implied a good overall biocompatibility of the micelles. 
The U shaped viability profile might have been due to different aggregation states of 
the polymers with the higher concentrations producing aggregates that reduced 
association and internalization of the polymers with/in the cells and hence interfering 
less with the cells activity.  
Cell activity was also not affected adversely by polymer formulation 6. 3T3 fibroblasts 
were the most sensitive cell line of the panel of cells used. However, the PEI positive 
control in these experiments did not sufficiently reduce the viability of cells. This 
unexpected result must be taken into consideration when extrapolating from this set 
of data that micelle formulation 6 was well tolerated from cells.  
Widefield microscopy studies at 37°C and 42°C for micelles 5 produced some 
inconclusive results on the ability of the micelle-like structures to access cells, given 
that the polymer did not present any detectable fluorescence. The reason for this 
absence of fluorescence was due to the insufficient concentration of the Fluorescein 
methacrylate dye used for the labelling of the polymer. However, the pictures 
obtained at 42°C showed that cells incubated with the micelles acquired some 
resistance to the increase of the temperature with respect to the negative control. 
This unexpected event has not been reported in the literature before and it should be 
further investigated in order to confirm that this phenomenon is consistently and 
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reproducibly happening as the data shown are based on one experiment only. One 
hypothesis can be attempted to justify this observation. Micelles 5 were brought from 
37°C to 42°C upon initiation of the experiment. The solution that contained the 
polymer gradually increased its temperature from 37°C up to 42°C. While the 
temperature of the plates was increasing, at temperatures near 41°C that is the TTT 
of the polymer, the change in conformation of the nanoparticles started occurring, 
subtracting energy from the system, which in other terms means that, for some 
reasons the transition in conformation started happening in a endoergonic way while 
WKHǻ*RIWKHWUDQVLWLRQZDVVWLOOSRVLWLYHVXEWUDFWLQJHQHUJ\IURPWKHVROXWLRQ7KLV
process might have slowed down the escalation of the temperature of the solution in 
contact with the cells delaying the increase of the temperature to up to 42°C for a 
time sufficient to produce this apparent protective effect of the nanoparticles on cells. 
Confocal live imaging of polymer formulation 6 thawed and applied to 3T3 cells for 1 
h at 37°C did not show any internalization of the micelles. Nanoparticles from 
formulation 6, with a transition temperature of 24°C, were anticipated to display a 
hydrophobic, more amphiphilic and more cell-interacting conformation upon 
incubation at 37°C. Based on prior data with similar nanoparticles, the collapsed 
structure of the PLGA-b-(PEGMA-co-PPGMA) above its TTT was expected to have 
interacted more promptly with the phospholipids bilayer and membrane proteins at 
the cell surfaces and promote an internalization process for the material. The 
internalization process is believed to occur in two steps: 
1.  The polymer chains at the nanoparticle surface interact with the cell and bind 
to its membrane/membrane bound proteins; 
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2. The nanoparticles are subsequently internalised via the triggering of a 
receptor-mediated process or through fluid phase endocytosis. 
As no evidence of internalization was provided by confocal microscopy studies for 
micelle-like structures 6, it is possible to hypothesise that one of the two processes 
described above must have failed to occur. In other terms, the polymer might have 
failed the binding on the cell surface or the polymer was binding on the cell surface 
but was not internalised. However, if it was the internalization process to be failing, 
the membrane of cells might have been fluorescent because of the polymer-
aggregates binding to the cell membrane; experimental evidence does not support 
this hypothesis. As a consequence, it is possible to suggest that a low interaction with 
the membrane of cells of the micelles was reducing its internalization. The pre-
incubation step at 37°C and the extension of the incubation time to 2 hours did not 
produce any detectable internalization. This time-length of internalization was proven 
sufficient for the similar nanoparticles in other studies16. Nevertheless preincubation 
at 37°C and extension of the incubation time to 2 h showed that the micelles were not 
prone to aggregation and stable in their conformation and size. The internalization of 
the micelle-like nanoparticles occurred only when the micelles were incubated with 
cells for 17 h and this timescale of internalization was not compatible with the 
intended endocytosis pathway studies. This brings into question as to why the 
internalization of this formulation of polymer 6 was so slow. It might be possible that 
polymer 6 formulation had high affinity towards only a few proteins on the plasma 
membrane and this reduced its interaction with the membrane and consequently its 
internalization. Another hypothesis is that the polymer did not have any affinity for the 
plasma membrane of 3T3 cells but the prolonged incubation with 3T3 cells allowed 
for the cells to secrete enough proteins to condition the media. It has been reported in 
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the literature that such processes can enhance binding of the secreted protein to the 
SRO\PHUDQGKHQFHLWVDIILQLW\IRUWKHFHOOV¶PHPEUDQHDQGLQWHUQDOL]DWLRQ25. It is also 
important to stress that the lack of fluorescence inside cells upon incubation of the 
micelle-like polymer 6 might be due to a lack of detection of the polymer inside cells. 
It is known in the literature that Fluorescein methacrylate is a pH sensitive dye. It 
bears a carboxylic group that is protonated and hence switches the chemistry of the 
dye towards a less fluorescent form upon acidification of the solution in which 
resides. As many intracellular compartments to which the micelles can be directed 
upon internalization are acidic and with pH ranging between 6.5 and 4.5, it might be 
possible that the micelles were not poorly internalised but were not detectable as a 
result to traffic to acidic compartments. A reasonable question at this point might be 
on why the micelles were detected upon incubation at 17 h. One possible explanation 
might be that the polymer had moved to a less acidic compartment during the 
extended incubation. However, if the lack of cellular fluorescence was due to a failed 
internalization instead of a lack of fluorescence another consideration might be due. 
Previous work on polymers of very similar constituents and formation parameters 
showed internalization on MCF-7 epithelial cancer cell lines. Hence, it is possible to 
consider factors which might account for differences in the present study compared to 
the prior work: the 3T3 cells used for the studies were fibroblastic cell lines from 
mouse embryos and were not originating from a cancer line, thus suggesting some 
specificity of the PLGA-b-(PEGMA-co-PPGMA) micelles towards epithelial cancer cell 
lines. 
Confocal microscopy on micelle formulation 7 showed that the formulation of the 
micelles with a manual nanoprecipitation method was not giving reproducible sizes of 
the micelles and it was confirmed by DLS studies (Table 5-1). The polymer used for 
Results ± In vitro Studies of Thermoresponsive Polymers 
255 
 
 
the formulation of these nanoparticles was the same as for formulation 6. However, 
upon incubation with cells, it produced large aggregates of tens of microns in size. 
The evidence that formulation 7 was more aggregated than micelle-like structures 6, 
that were originated from the same polymer, was already provided by DLS studies 
carried out straight after the formulation of the micelles where DLS was showing a 
double peak at 49 and 312 nm. It might be possible that the presence of bigger 
aggregates already in the original formulation of the polymer might have speeded up 
the process of nucleation that is essential for the formation of larger aggregates. 
Although formulation 6 showed a much slower tendency to aggregation, upon 
prolonged storage at -20°C (about one month) the polymer presented large 
aggregates that were not dissolving with intense vortexing or sonication. These 
results suggest a more general instability upon storage of PLGA-b-(PEGMA-co-
PPGMA) nanoparticles produced by the manual nanoprecipitation route. 
From the above evidence of colloidal instability of PLGA-b-(PEGMA-co-PPGMA) 
formulation 6 and 7, nanoparticles 8 and 9 were synthesised. They were constituted 
from subtly different co-monomers and were formulated into nanoparticles by an 
automated system in order to increase the reproducibility of the size and surface 
characteristics of the nanoparticles. Also, in the attempt to produce a more reliable 
probe to detect the polymer in any cell compartment, the materials were synthesised 
in the presence of 2 dyes: Rhodamine B for a clear detection of the polymer at acidic 
pH26, and Fluorescein metachrylate for a convenient detection in non acidic 
compartments27,28. However, when nanoparticles from formulation 8 were tested at 
different concentrations for 24 h at 37°C, aggregates nevertheless formed. While self-
association and colloidal instability at 37°C might be expected for polymer 
nanoparticles with a TTT of 24°C, it was not expected when initial incubations were 
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carried out at room temperature (< 21°C). Indeed, DLS measurements of the 
formulation 8 nanoparticles reported a size of 56.4 nm at 20°C, clearly indicating an 
initial non-aggregated formulation of the nanoparticles in HEPES 20 mM. The 
micelles aggregated at 37°C, which although not entirely unexpected owing to 
predicted loss of colloidal stability above the TTT, was problematic for cell assays as 
the self-association occurred rapidly. Literature reports of phase transitions of 
polymers have shown that aggregation depends on many variables: temperature, 
ionic strength of the solution, concentration of the polymer in solution, as well as 
geometry of the hydrophilic to hydrophobic block of the micelles. However, these 
considerations have been made on relatively small aggregates that are usually 
detected with TEM techniques. The aggregates reported in the experiments in this 
thesis were of several microns in size and this suggests that the rod-like structures 
and worms so easily detectable might be given by complex interactions of the 
micelles with each other producing layers and layers of particles tick enough to 
become detectable in a widefield microscope with a low power objective. The 
presence of such bulky aggregates suggests that the materials were exceptionally 
more stable when aggregating with respect to the single micelles in solution. Also, 
reducing the concentration to 31.25 µg/ml did not prevent aggregation suggesting 
that the polymer nanoparticles were not stable in solution above their TTT and that 
aggregation was not intrinsically a consequence of a too high concentration of 
micelles in solution. Polymer formulation 8 appeared to show affinity for 3T3 and 
HCT116 cell surfaces. It is not clear if the presence of aggregates associated with 
3T3 and HCT116 cells was due to an entrapment in the extracellular matrix proteins 
produced by 3T3 cells or to a more general affinity to the membrane composition of 
the cells as suggested by HCT116-aggregates interactions.  
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Furthermore, given that the fluorescence of aggregates was quite strong and the 
magnification used for the experiments was quite low, it is not possible to rule out 
some extent of internalization in cells of the modest portion of the nanoparticles that 
were non-aggregating. If some internalization occurred, it is possible that the lack of 
Fluorescein signal might have been due to internalization in acidic compartments as 
Fluorescein is well known for its pH dependent loss of fluorescence. However, most 
of the polymer was present outside cells and Fluorescein remained undetected in the 
GFP channel. The loss of fluorescence emission of Fluorescein methacrylate was 
most likely due to poor incorporation of the Fluorescein-based monomer during 
synthesis, as Fluorescein was used in low monomer feed ratios. 
This double system of detection based on two dyes consisting in Fluorescein 
metacrylate and Rhodamine B is not new in literature and is has been already 
reported29. This probe-system was chosen to give extra information on the pH of the 
compartment that the material was accessing upon endocytosis and also probing that 
the lack of florescence obtained with previous fluorescein labelled polymers was not 
due to the acidic compartmentalization of the materials upon internalization. It was 
disappointing not to be able to observe the dual signal in these experiments.  
A hypothesis to explain the reasons for the strong tendency to aggregation of 
polymer nanoparticles 8 is that it might have been due to the chemistry of the PLA-b-
(DEGMA-co-OEGMA). The portion of the DEGMA block, in fact, is highly represented 
in these polymers and constitutes 95% of the hydrophilic portion of the block 
copolymer. Although this ratio of the DEGMA portion is justified to lower the TTT of 
the polymer from about 90°C of the OEGMA to more physiologically relevant 
transition temperatures, literature reports that the more the thermoresponsive chains 
are short (and DEGMA is formed by only 2 repetitions of ethyl ether), the more the 
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adhesion properties of the micelles above the LCST. Hence the high proportions of 
the DEGMA were probably undermining the colloidal stability of the polymer when 
incubating at 37°C9,30. It is also possible to speculate that this effect might have been 
reduced if the distribution of the OEGMA chains could have been controlled during 
the synthesis of the block copolymer. However, the statistical method used to 
synthesise these polymers does not allow this control. Another phenomenon that 
promoted aggregation and interfered with the stability of polymer 8 was the tendency 
for aggregation upon storage. This may have been due to too high concentration of 
the stock suspension of polymer in storage (7.5 mg/ml) and possible phase 
segregation in the buffer (HEPES 20 mM) leading to polymer-rich regions in 
suspension, chain entanglement and kinetic trapping of aggregates.  
As a recent publication from Albanese et al showed that cells secretions can alter the 
properties of nanoparticles in relation to their tendency to aggregate, the polymer 
formulation 8 was tested both in the presence and in absence of HCT116 cells31. To 
further investigate the nature of the aggregation, the nanoparticles were incubated at 
room temperature and below the TTT of nanoparticle formulation 8 (29°C). Results 
showed that the filamentous network of aggregated particles in these settings did not 
occur, either in the presence or in the absence of cells. From these data it is not 
entirely possible to rule out the involvement of HCT116 cells surface proteins and 
secretions in the formation of polymer nanoparticle-complex filaments aggregates 
obtained at 37°C as it might be possible that cells at room temperature can expose 
different proteins on their surface, since the endocytosis is still active but the trans-
Golgi network cargo sorting on the plasma membrane and exocytosis are inhibited 
and potentially changing the protein expression at the plasma membrane and 
secreted in the media32. However, the aggregation in fact happened in both cell and 
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cell-free conditions suggesting that cellular secretions alone were not responsible for 
the formation of the layers of aggregates of micelles in these settings. It is probable 
that the poly-DEGMA corona might be already sticky and prone to aggregation at 
room temperature and the pre-treatment at 20°C after thawing the micelles was 
stabilising the aggregation. This pretreatment was giving time to the micelles to 
rearrange to a more complex and a reduced entropy sheet conformation. This 
conformation might have been occurring less at higher temperatures because of 
thermal agitation of the solution in which the micelles reside, or the presence of cells 
at 37°C might have stabilised the formation of the worm-like aggregates instead. The 
evidence of aggregation below the TTT of the polymer suggests that the chemistry of 
these polymers was not optimised against the aggregation of the micelles upon 
storage. After rinsing, the majority of large aggregates were removed. However, small 
sheet-like structures were still present to the bottom of the plate after rinsing. This 
show that the nanoparticles had some moderate affinity for the cellBIND treated 
surface of the flask.  
The last set of experiments was with polymer formulation 9 with a TTT of 27°C and a 
monomer composition closely resembling formulation 8. As it was evident from 
previous experiments that the nanoparticles were not stable upon storage, they were 
synthesized and micelles produced immediately before confocal live experiments. In 
this way the freeze-thawing step was avoided and fresh nanoparticles, with a DLS 
reported size (at 20°C) of about 45 nm applied on cells. The temperature was not 
altered and experiments with HCT116 at room temperature and uptake studies run 
after incubation of the polymer with cells for 1 h. Despite the numerous efforts to 
reduce the aggregation, the nanoparticles showed some extent of self association, 
although the aggregation state did not interfere with the internalization of the 
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nanoparticles. However, in these experiments the nanoparticles were internalising 
below the TTT in HCT116 cells. Experiments with polymer formulation 9 carried out 
overnight, with and without preincubation step of 1 h at room temperature showed 
internalization as well. As the concentration of polymer in the experiments at room 
temperature and the ones with the overnight incubation were different, it is not 
possible to verify if the extent of internalization differed with the two settings. One 
explanation can be attempted for the internalization of the micelle-like aggregates 9 
irrespective of the TTT and consistent with the earlier data on polymer self-
association below the TTT. It is known from the literature that PEG chains can 
interact to some level with proteins33. Their antifouling characteristics are given by the 
length of the PEG chain and its ability to produce a thick layer of flexible brushes that 
reduces the interactions of the PEG chain with the proteins34. PEG chains around 
400 Da of Mw are believed to be the less protein-interacting33. However, the OEGMA, 
with Mw of 375Da, is represented for only 5% in the PLA-b-(DEGMA-co-OEGMA) 
SRO\PHUV 7KLV PLJKW PHDQ WKDW WKH µ3(* FRPSRQHQW¶ ZDV WRR VPDOO WR HIIHFWively 
produce a brush to reduce the interaction with proteins. As a result, given that in the 
chosen experimental settings the media was formed by HBSS that contains only a 
few aminoacids, the bulk of the proteins exposed to the polymer were derived from 
the membranes of cells. This might explain why, although below the TTT, the polymer 
was sufficiently interacting with cell proteins to allow a rather fast internalization of the 
polymer that was observed within 1 h from the application of the polymer on cells. 
The signal obtained by the internalised micelles was weak both above and below the 
TTT. Upon overnight incubation, the presence of the aggregates in the media was 
less evident. However, also the concentration used for the overnight experiments was 
halved with respect to the experiments with cells run at room temperature which 
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might reduce aggregation. Consequently, it is not possible to determine the reasons 
for the loss of aggregates in the media of cells upon overnight incubation. 
Furthermore, as pointed out in the results section for polymer formulation 9, the 
fluorescence of the internalised nanoparticles was different with respect to 
formulation 6 and C-PB. The latter nanoparticles appeared as discrete dots of 
different sizes in the cytoplasm and perinuclear accumulation that were also evident 
in immunofluorescence staining of clathrin heavy chain Į and caveolin-1. To some 
extent, for the overnight incubation of the micelles, some increase of polymer 
fluorescence in the perinuclear region was observed. However, it is important to point 
out that there is evidence that Hela cells lysosomes change their distribution towards 
a conformation resembling the diffused fluorescence observed in HCT116 and 3T3 
cells when incubated with toxic drugs that induce apoptosis such as the anticancer 
etoposide35. However, even though this specific polymer was not tested for toxicity, 
other polymers with similar characteristics did not interfere with cell activity according 
to an MTT assay. It is nevertheless true that one test alone does not give the full 
picture of the toxicity of novel materials. If toxicity was occurring, the cells might result 
fluorescent as a consequence of the toxicity instead of the uptake of the material if 
they produce ROS. ROS oxidise proteins making them fluorescent and emitting in the 
green and red channels (the same mechanism underlying the phototoxicity events in 
microscopy that cause auto-fluorescence as a consequence of a too long exposure to 
the high power laser beam). In this experiment, the Green channel did not show 
fluorescence. However, in is known that an oxidised form of riboflavin (vitamin B2) 
produces autofluorescence, emitting around 550 nm which was the region of 
detection of the Rodamine B dye in the confocal settings for these experiments36,37. If 
toxicity and consequent autofluorescence was occurring that might be the reason for 
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fluorescence detection both above and below the TTT. Literature reports that ROS 
production is increased as the surface area of the material increases38. Although the 
morphology of the cells did not suggest toxicity, the CellMask dye also stained some 
extracellular membrane features. These features might be apoptotic bodies as there 
are no macrophages to scavenge for these products and remove from the 
environment (although also non-specialised cells can clear from apoptotic bodies), or 
necrotic remains of cells. The toxicity overnight might also have been triggered by the 
prolonged incubation of cells in HBSS/HEPES media, where the absence of FBS 
might cause the cells to undergo stress and death. The last result for this set of 
experiments suggest that the micelles were undergoing photo-bleaching as the 
fluorescence obtained in the equatorial region of 3D images present a lower 
fluorescence with respect to the single plane images. This effect is reported in the 
literature for Fluorescein but Rhodamine B is considered a rather resistant dye, and 
the reasons underlying this effect are not clear. The next steps are to design the 
synthesis of improved materials and consequent experiments to rule out as much as 
possible any misinterpretation of the experimental results. 
5.1 Conclusions 
These experiments have revealed an unexpected difficulty for these synthetic 
polymers to produce micelles with reproducible characteristics. Polymer presented a 
high tendency to aggregation and inherent instability and little tendency to access 
cells. Although some progress has been made in regards to the manufacture of 
micelles with an automated system that can produce micelles from the same polymer 
that have similar characteristics of size, some improvements must still be addressed. 
One of the main problems for these polymers was their strong tendency to produce 
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bulky aggregates. The aggregation tendency was variable in different polymers. 
Polymer 6 with a PLGA-b-(PEGMA-co-PPGMA) chemistry was the most resistant to 
aggregation and produced stable micelles sizes for a period of two weeks. However, 
upon longer periods of storage the polymer presented extensive aggregation that was 
not compatible with the intended in vitro studies. This tendency became even more 
evident in the last two PLA-b-(DEGMA-co-OEGMA) polymers. Another issue that 
makes the control of aggregation more challenging is the statistical method used to 
synthesise these polymers. This way of producing polymers does not allow for a 
control of the distribution of the OEGMA in the hydrophilic chain of the polymer 
rendering the polymer tendency to agglomerate difficult to manage especially for 
polymers at low percentages of OEGMA. If this problem is not resolved by an 
optimization of the OEGMA ratio that is also compatible with a physiologically 
relevant TTT, other methods that allow for a more controlled synthesis of polymers 
for physiological applications might be worth some consideration39-43. 
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Polymer-therapeutics are a stimulating field for the pharmaceutical industry. They 
have been intensely investigated for their new approach to treatments and for their 
clinical potential. Many polymer-drug conjugates have now reached the market and 
have succeeded in their promise to improve the array of choices for medicinal 
UHPHGLHV UHGXFLQJ WR[LFLW\ LQFUHDVLQJVSHFLILFLW\DQGFRQVHTXHQWO\SDWLHQWV¶RYHUDOO
quality of life1. However, recent progress in polymer chemistry has fuelled the 
SRO\PHUVWKHUDSHXWLFVILHOGZLWKQHZDQGLQVSLULQJµVPDUW¶PDWHULDOVWKDWFDQUHVSRQG
to environmental changes providing potentially elegant and sophisticated ways to 
deliver drugs2-5. Evidence in the literature indicates that responsive materials can 
increase selectivity of drug targeting and reduce toxicity and in vivo studies are 
gradually changing the perception of the field6,7. One of the most important 
possibilities for these (nano)materials is that they can enhance delivery of drugs at 
the cellular and subcellular level. However, the understanding of endocytic processes 
underlying the uptake of many nanomaterials is limited at the moment and 
approaches to direct the nanocarriers of drugs towards one specific endocytic 
pathway have not yet led to improved results in clinical trials. This has created a 
renewed interest in the understanding of the mechanisms that lead to endocytosis of 
nanocarriers. Deciphering these mechanisms would allow controlled intracellular 
delivery and could open new and unexplored perspectives for the pharmaceutical 
industry in areas such as gene delivery and, more importantly, provide a therapeutic 
approach for many untreatable diseases.  
The aim of this thesis was to investigate the uptake of synthetic nanoparticles in vitro 
using inhibitors of endocytosis and to recognize any similarities in the uptake of 
carboxylated polystyrene bead nanoparticles (C-PB) and thermoresponsive block co-
polymer core-shell nanoparticles. As the polymers used for the study presented a 
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PEGMA brush that reduced their interactions with proteins and hence with a surface 
chemistry that was only marginally affected by the presence of FBS, C-PB studies 
were carried out in a buffer in the absence of FBS to better mimic the surface 
chemistry of the thermoresponsive polymers. Although thermoresponsive core-shell 
micelle-like nanoparticles with a similar chemistry had already been synthesized in 
our group in the past and showed good internalization rates in a specific cancer cell 
line, the newly synthesized thermoresponsive nanoparticles demonstrated a high 
tendency to aggregate above their thermal transition temperature (TTT) and an 
overall colloidal instability that hampered further endocytosis studies8,9. The colloidal 
instability of PLGA-b-(PEGMA-co-PPGMA) and PLA-b-(DEGMA-co-OEGMA) 
nanoparticles, while not unexpected over prolonged time periods above the TTT, had 
not been reported before upon storage well below the TTT of the nanoparticles. 
Some ways to address this issue have been suggested in chapter 5; however, if not 
resolved, the colloidal instability might undermine any possibility of clinical 
applications of these nanocarriers. For this reason the aim of the experiments 
reported here remains unmet overall. Nevertheless, the study gave some information 
on aspects of endocytosis and C-PB uptake.  
The first finding regarding the choice of cell viability tests for materials that interfere 
with endocytosis and/or are endocytosed confirms results shown in the literature. The 
choice of cell activity tests should be tailored to the material used, as nanomaterials 
can interfere with the test adopted and alter the concentration of the dye used as 
indicator of the viability of cells making difficult the interpretation of the results10. 
Many assays for cell viability rely on the endocytosis and exocytosis of viability 
markers11-13. Results in this thesis show that this sort of activity test might 
overestimate the toxicity of some materials and should be used in conjunction with 
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other tests that do not rely on endocytosis/exocytosis. Also, viability tests that rely on 
enzymes to report cell activity interference should be used with caution when testing 
nanoparticles as some of these materials may interact with proteins and hence the 
enzymes of the assay compromising their activity14-16.  
Some ground rules were also established on the inhibition of endocytosis of Htf (a 
CME marker) with CPZ. CPZ inhibition of Htf endocytosis was revealed to be time-
dependent and its internalization was only transiently inhibited by CPZ. Furthermore, 
the inhibition reached a maximum that was cell- and time-dependent and after that 
timepoint the uptake of Htf recovered despite the presence of CPZ suggesting that 
Htf can internalize through an alternative way that is not CPZ sensitive. Also, the 
study revealed that the CPZ inhibition was dependent upon the passage number and 
ageing of cells. Many laboratories that work on endocytosis consider CPZ inhibition 
µWHPSHUDPHQWDO¶DQGPDQ\FHOO OLQHV µUHVLVWDQW¶ WR LWV LQKLELWLRQ7KHUHVXOWVVKRZQLQ
this thesis attempt an interpretation of the reasons for the unpredictable ability of CPZ 
to inhibit internalization of Htf. This study reveals that two factors can affect the 
VXSSRVHG µUHVLVWDQFH¶ WR LQKLELWLRQ RI +WI XSWDNH ZLWK &3= WKH WLPH RI LQFXEDWLRQ
which should be tailored for the specific cell line, and the cell lines used for the study, 
which should be at low passage number in order to observe the inhibitory effect of 
CPZ. Previous literature has reported that dynamin expression is reduced in ageing 
cells and this could explain the reduced inhibitory action of CPZ in the same cell 
lines17.  
Further steps on this first set of results would be to complement the flow cytometry 
experiments presented in this thesis with confocal microscopy studies to confirm the 
reduction in the internalization of the Htf and to add on any relevant information such 
as redistribution of the Htf-labeled endosomes in the presence of CPZ. Furthermore, 
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exploring the hypothesis of the involvement of TR2 in the recovery of the endocytosis 
of Htf in the presence of CPZ would aid the scientific relevance of these studies. 
Experiments should be done to evaluate the level of expression of TR2 in the cell 
lines used in this thesis to confirm the expression of the receptor as indirectly 
suggested by the current results and the literature. Easy methods to quantify the level 
of expression of the TR2 would be through Western blot and real time RT-PCR as 
these two methods allow for quantification of expression both at the protein and at the 
transcription level. These techniques could be complemented with 
immunofluorescence followed by flow cytometry and confocal microscopy for 
quantitative and qualitative evaluation of the expression of the two receptors18. To 
confirm that the recovery of inhibition of Htf is not an artifact produced by a non-
specific inhibitor of endocytosis such as CPZ, the inhibition of Htf uptake should be 
explored by other means and a good starting point would be by siRNA silencing of 
the AP2 gene19,20. These investigations would confirm that the inhibition observed 
with CPZ is mediated by the AP2 protein as reported in the literature. If this is the 
case, as expected, the uptake of Htf should recover after a temporary inhibition while 
the AP2 protein expression is knocked-down by the siRNA. As siRNA is a temporary 
way of silencing the expression of proteins, a good way to avoid misinterpretation in 
these experiments would involve a timepoint quantification of the levels of AP-2 
protein and mRNA during the knockdown in relation to the levels of TR1 and 2. 
Moreover, it would be interesting to investigate the involvement of the caveolin or 
other lipid raft pathways that might be involved in the internalization of TR2. A first 
screening could easily be done with siRNAs against caveolin-1 and dynamin and with 
pharmacological inhibition of dynamin by Dynasore or the recent and more powerful 
version: Dingo-4a20,21. As flotillins have been suggested to provide an alternative 
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endocytosis machinery when clathrin-mediated endocytosis is inhibited and they also 
localize in lipid rafts (as shown by Calzolari and coworkers which detected the TR2 in 
lipid rafts22), they could constitute an alternative candidate for the endocytosis of Htf 
when cells are treated with CPZ22,23. Flotillin involvement could be investigated with a 
flotillin-1 and 2 dominant negative mutants, such as Y160F and Y163F that perturbs 
the endocytosis through this pathway24. Less immediate but fascinating experiments 
would involve the expression of a fluorescent or luminescent reporter for transferrin 
receptor 1 and 2 to further study the dynamics of expression upon inhibition of the 
CME pathway.  
Data in this thesis and the literature suggest that dynamin might have a role in the 
loss of inhibition of CME in ageing cells. Hence, the quantification of dynamin levels 
in cells at low and high passage numbers would give interesting data to compare to 
the results with CPZ inhibition studies25. Finally, to attempt an explanation of the 
reasons underlying different sensitivity to CPZ in different cell lines, the level of 
expression of calmodulin and MARCKS might be quantified26,27. 
Results on C-PB studies revealed that 50 nm C-PB access epithelial colon HCT116 
and gastric MGLVA-1 cancer cells through a CPZ sensitive pathway which suggests 
the involvement of a CME or a macrophagic/macropinocytic uptake. The inhibition of 
endocytosis with CPZ did not appear to recover over time for these nanoparticles at 
the time points investigated suggesting a specific interaction of 50 nm C-PB with 
some membrane components (i.e. receptors) that are internalized by a CME or 
macropinocytic/phagocytic pathway. This suggests that some non-functionalized 
nanoparticles with properties similar to the carboxylated polystyrene nanoparticles, 
can also be internalized by a specific pathway implying that it might be possible to 
direct endocytosis towards one specific pathway without the use of targeting ligands. 
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To add information on this observed effect, 50 nm negatively charged nanoparticles 
other than C-PB might be a useful comparison. In addition, expanding the panel of 
cells for the studies, introducing other colon and gastric cancer cells as well as other 
fibroblasts, would add information confirming and defining the specificity of 
endocytosis of 50 nm C-PB which are negatively-charged, but still slightly 
hydrophobic. Finally, comparing the susceptibility to CPZ of 50 nm C-PB in the 
presence and in the absence of FBS could give useful information on the translation 
of these results in a more in vivo relevant environment. 
Results on 100 nm C-PB showed that they are internalized by a CPZ sensitive 
pathway in 3T3 cells and by a MBCD sensitive pathway in MGLVA-1 cells. However, 
the internalization of 100 nm C-PB was only transiently inhibited by these endocytosis 
inhibitors and the uptake recovered over time suggesting a non specific mechanism 
of internalization for 100 nm C-PB. Consistent with this hypothesis, it was observed 
that, when the inhibitor of endocytosis was not effective in inhibiting the internalization 
of C-PB, it often caused an increase in the endocytosis of the nanoparticles. This 
finding mirrored the effects of CPZ in LacCer (a CIE marker) inhibition studies. When 
CPZ was used to verify that the drug was not interfering with CIE, a strong increment 
of CIE was observed that was increasing the internalization of LacCer up to 3 times 
more than the positive control. All together, these findings suggest a more dynamic 
and interconnected way of looking at endocytosis with activity of certain pathways 
being intensified and providing alternative machinery for endocytosis in response to 
the failure of other endocytosis mechanisms. This result suggests an additional 
complexity relating to the endocytosis of nanoparticles for drug delivery. However, it 
is possible to speculate that not all the possible pathways for the endocytosis of 
nanomaterials are interchangeable and a thorough investigation aimed to dissect all 
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the possible molecular mechanisms involved in the internalization of these 
nanoparticles when other pathways of uptake are inhibited could give more definitive 
answers to that hypothesis.  
Microscopy studies with 50 and 100 nm C-PB showed that the nanoparticles 
triggered a rapid and efficient endocytosis. Also, for 100 nm C-PB in 3T3 and 
MGLVA-1 cells, an exocytic process was suggested which might explain how the 
cells reached a plateau in their fluorescence as a result of a maximal internalization 
of fluorescent C-PB. Although the data described in this thesis such as the size of the 
vesicles and the directionality of the movement point in the direction of exocytosis, 
further experiments should be run to confirm that the compartment that is observed 
trafficking to the membrane of cells with confocal microscopy is an exocytic vesicle. 
Labeling of the extracellular compartment with an exocytic marker (e.g. desmoyokin-
Ahnak, d/A) as well as the use of exocytic inhibitors such as Exo I and II could 
confirm the nature of the compartment28. Furthermore, literature reports that 3T3 cells 
can trigger exocytosis by a Ca2+-mediated mechanism29. Intercellular free Ca2+ is a 
known signalling pathway used by cells and it would be interesting to find out if the 
exocytic process triggered by 100 nm C-PB might be mediated by this way. 
Fluorescent indicators of free intracellular Ca2+ are available and a starting point 
might be monitoring their levels by flow cytometry or confocal microscopy29. However, 
TEM studies, with a better resolution, would add information on the 
compartmentalization of the C-PB upon internalization as well as giving more details 
on the membrane trafficking observed in confocal microscopy.  
Some considerations on the possibility for an in vivo translation of the results in this 
thesis are due at this point given that the aim of these studies was for a 
pharmaceutical application. The studies carried out in this thesis were intended as an 
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in vitro preliminary screening of the endocytosis of thermoresponsive nanomaterials. 
As such they were limited by the absence of FBS in the experimental settings, a 3D 
organization that is displayed in tissues, the cellular heterogeneity that is present in a 
whole organ, the absence of immune cells and blood stream. Furthermore, cells in an 
in vivo environment are 100% confluent and hence the expression of receptors and 
proteins on the plasma membrane may be very different to those in culture30. Finally, 
the cells generally employed in in vitro studies are immortalized which means that 
they have undergone a spontaneous or induced process of genetic modification to 
survive in an artificial environment and that often makes them to behave in a less in 
vivo relevant way.  
A first step to improve on these limitations could involve the investigation of 
endocytosis in primary cells. Furthermore, 3D studies might help to translate the 
present results towards an experimental setting more relevant to in vivo studies. 
Indeed, 3D culture might give some more information on how the tridimensional 
organization of cells affects endocytosis when cells are simultaneously involved in 
signalling processes, that share the same machinery of endocytic pathways, and if 
the signalling activity can cause switching of the internalization pathways of 
nanomaterials. Signalling in fact is believed to be reduced to a minimum in 2D 
monocultures where the architectural complexity of in vivo studies is less 
represented. A further advancement towards more in vivo relevant experiments might 
be through the use of co-cultures of epithelial and fibroblastic cells that in vivo cohabit 
and interact in the same tissue. Given that fibroblasts have already been investigated 
in the present studies, co-cultures of 3T3 and HCT116 or 3T3 and MGLVA-1 would 
represent an easy choice. However, it is important to stress that much of the research 
field of endocytosis in mammalian cells at the moment is limited to more or less 
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sophisticated 2D in vitro studies. The reason for such limitations is that 3D culture 
approaches are challenged by the level of perfusion of the more internal 
compartments of the 3D scaffolds. Another important limitation is provided by the 
level of detection of optical fluorescence techniques currently available and the level 
of penetration in thick specimens for the detection of fluorophores. Two-photon or 
multi-photon microscopy is one of the most promising approaches for in vivo 
endocytosis research available at the moment. However, studies of endocytosis in 
functioning organs with a spatial resolution at the cellular and subcellular level in 
mammalians, is limited by the level of perfusion of the organs intended for the study 
of endocytosis and kidney and liver, with a high perfusion rate and, hence, more 
exposed than other organs to blood loaded markers of endocytosis, are the target of 
choice of these investigation31,32. The limit of detection and tissue penetration with 
fluorophores and microscopic techniques could be solved in the near future by the 
optimization of research materials tagged with detection labels other than organic 
fluorophores. Gold nanorods, for example, with a plasmon band resonance in the so 
FDOOHG µZDWHUZLQGRZ¶ -1200 nm) are being evaluated for biological purposes33. 
Their absorption wavelength is useful as water and many other body components do 
not absorb at those wavelengths enhancing the potential of penetration of light. 
Imaging by these means is claimed to give a spatial resolution of 100 nm in two 
photon luminescence microscopy and might well constitute a first step forward to the 
identification of subcellular endocytic processes in a tridimensional organization of 
cells34. However, their irradiation also produces heat and this might potentially alter 
the tissue physiology and a careful evaluation of the level of interference that this 
phenomenon might cause is also a key question to answer. 
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A last challenge can be recognized in the study of the internalization of nanomaterials 
and translation to an in vivo situation. Many pathologies are associated with an 
altered expression of endocytic proteins. Pathologic environments can produce 
hypoxic niches and oxidative stress that can trigger autophagy and alter transiently 
the expression of membrane receptors and endocytic proteins, changing the way 
cells respond to endocytosis of nanoparticles35. Furthermore, these alterations have 
been detected as a permanent hallmark in many pathological conditions. It is known 
in the literature that caveolin-1 overexpression or knockdown is associated with 
different form of cancers and many drug-resistant pathologies rely on a compromised 
endocytosis. It was shown that EGF-mediated gefitinib resistance in cancer is 
mediated by a compromised CME of the EGF receptor upon internalization that fails 
to be directed to degradation in a lysosome compartment36. Other examples of known 
pathologies with an altered expression of endocytic proteins and an altered 
HQGRF\WRVLV DUH GLDEHWHV $O]KHLPHU¶V GLVHDVH DQG 'RZQ¶V V\QGURPH37. These 
aspects of endocytosis make the translation from in vitro studies to the clinic probably 
more challenging but also open to new perspectives and applications. It seems 
possible from results in this thesis and the literature that when one pathway is 
compromised other pathways can be activated and the exploitation of this effect in 
pathologic situations for drug delivery purposes could be worth some investigation.  
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7-Appendix I 
ICOS 3D prediction software results for human cav-1. The first table shows the 2D 
and 3D rearrangements of adjacent aa and their exposure to the solvent. The second 
table shows the analysis for their exposure to the solvent only. The regions 
highlighted in yellow refer to the epitope of the mAb clone 2297. The µAll.con¶ bottom 
row gives a final score for all the parameter taken into account by the analysis. 
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0 - 69 0         1         2         3         4         5         6         
seq MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLNDDVVKIDFED 
cCN.Q2 0000000000011100000000000000000100000000000000001010000000100010011111 
cCN.Q3 0000000000011111010000001000000100000000100010001010011100110111121212 
cCN.Q5 0000000000032212010000000000000300000000200010003020031000300131243434 
cCN.con 0000000000032201000000000000000300000000100000003020010000300030143434 
dCN.Q2 0000000000010000000000000000000100000000000000000000000000100010011111 
dCN.Q3 0000000000011101010000001000000100000000100010001010011000110121121212 
dCN.Q5 0000111010122211121010011111111210010001210111112121111111210131143433 
dCN.con 0000000000021100010000000000000200000000100000001010000000200030043433 
DT.Q2 1000000000000000000000000000000000000000000000000000000000000000010100 
DT.Q3 1100011011011111111100011001011101110010101111111011111111111111111111 
DT.Q5 4000000000000000000000000000000000000000000000000000000000000000030300 
DT.con 3000000000000000000000000000000000000000000000000000000000000000030300 
GG.Q2 0000000000011000000000000000000100000000000000001000000000100010011101 
GG.Q3 0000000000011100000000000000000000000000000000000000000000100020021210 
GG.Q5 0000001100022211111000000000100110000000110011101111111111111121142321 
GG.con 0000000000022100000000000000000100000000000000001000000000200030042311 
MST.Q2 0111111111111111111111111111101111111111111111111111111011111111111111 
MST.Q3 0111111111111111111111111111101111111101111111111111111011111111111111 
MST.Q5 0112111111111111111111111111101111111111111111111111111011111111111111 
MST.con 0222222222222222222222222222202222222212222222222222222022222222222222 
RCH.Q2 0000000000000000000000000000000000000000000000000000000000000000010100 
RCH.Q3 0000000000010000000000000000000100000000000000001000010000100010011111 
RCH.Q5 0000001100022110000000001000000200000000100010002010011000210121132313 
RCH.con 0000000000010000000000000000000100000000000000001000000000100010031301 
RNG.Q2 0000000000011000000000000000000100000000000000001000000000100010011111 
RNG.Q3 0000000000011000000000000000000100000000000000001000000000100010021211 
RNG.Q5 0000011100122111011010011010000200000000100111102121111010211121132322 
RNG.con 0000000000022000000000000000000200000000000000002000000000200020032322 
SA.Q2 1111111111100111111111111111111011111111111111110111111111011101100010 
SA.Q3 2222222222211121222222221222222122222222122222221212211222122101201011 
SA.Q5 4444444444423333444444444444444244444444444444442434433444234413312031 
SA.con 4444444444411333444444443444444144444444344444441434433444134303301030 
All.con 0000000000021100000000000000000200000000000000001010010000200020032312 
70 - 139 0         1         2         3         4         5         6         
seq VIAEPEGTHSFDGIWKASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAILSFLHIWAVVPCIKSFLIE 
cCN.Q2 1110100000101111111111111011110111111111111111101111111111111111111010 
cCN.Q3 2211100111101221222122122112221222222222222222222222221222222222122121 
cCN.Q5 4432300313313343433344334234442333444444444444333433333444444443333232 
cCN.con 4431300101303343433344334134441333444444444444323433333444444443333131 
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dCN.Q2 1110100000100111111111111011110111111111111111101111111111111111011010 
dCN.Q3 2211100111101221222122122112221222222222222222212222222222222222122121 
dCN.Q5 4311111211212342433344334133431333444444343333313433233444444443133131 
dCN.con 4320200100201342433344334033430333444444343333303433333444444443033030 
DT.Q2 0100000000000010100011000001110110111011101110101011010011110111011010 
DT.Q3 1111110110111111111111111111111111111111111111111111111111111111111111 
DT.Q5 0300000000000030300033000003330330333033303330303033030033330333003030 
DT.con 0300000000000030300033000003330330333033303330303033030033330333023030 
GG.Q2 1100100000100111111111111011111111111111111111111111111111111111111111 
GG.Q3 2200000000000121211122122122222222222222222222222222221222222222222222 
GG.Q5 3311101111101232332244233224442443444344434443424444242343443344334343 
GG.con 3300100000100232332244233134443443444344434443434444342343443344334343 
MST.Q2 1111111111111111111111111111111111111111111111111111111111111111111111 
MST.Q3 1111111111111111111111111111211111112211121122211211111111111121111111 
MST.Q5 1121111111111111111111111111211111112211121123101211111111111121111111 
MST.con 2222222222222222222222222222322222223322232233322322222222222232222222 
RCH.Q2 1100000000000010110011011001110111111111111111101111010111111111011010 
RCH.Q3 1100100101100111111111111111111111122222211112111111111122222221111111 
RCH.Q5 3311200212201332333233333233333333333333333333333333333333333333333233 
RCH.con 3300100101100131331133133113331333333333333333313333131333333333133131 
RNG.Q2 1100100000100111111111111011111111111111111111111111111111111111111111 
RNG.Q3 2100100101100121211122122012221221222222122222111221121122221121122121 
RNG.Q5 3211201112201232332233233123332332333333233232322332232233332233233232 
RNG.con 3200200001200232332233233023332332333333233333322332232233332233233232 
SA.Q2 0010011010010001000100100100001000000000000000000000000000000000100000 
SA.Q3 0012122112121001001100110110001000000000000000010000101100000000100101 
SA.Q5 0033344434243013002200300210003000000000000000020000102101000000300202 
SA.con 0032144132141003001200300200003000000000000000010000001000000000300101 
All.con 3311200101201232322233233123331332333333333333323333232233333333233132 
140 - 178 0         1         2         3        
seq IQCISRVYSIYVHTVCDPLFEAVGKIFSNVRINLQKEI 
cCN.Q2 11110011011101110111011101100111110000 
cCN.Q3 21221122022212221222122112211212121100 
cCN.Q5 32331233133313332443133313332434332111 
cCN.con 32330133033303331443033303311434331000 
dCN.Q2 10110011011101110111011101100111110000 
dCN.Q3 21220122022212220222122212211212121100 
dCN.Q5 32331133133313331343133323311434331112 
dCN.con 31330033033303330343033313300434330000 
DT.Q2 10110011001100100011001001100101010001 
DT.Q3 11111111111111111111111111111111111111 
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DT.Q5 30330033033300300333003003300303030004 
DT.con 30330033013300300133003003300303030003 
GG.Q2 11111111111101110111111111110111110000 
GG.Q3 22221122122202220222122212200212120000 
GG.Q5 43442244244413432243244324311324231000 
GG.con 43442244244403430343244324310324230000 
MST.Q2 11111111111111111111111111111111111111 
MST.Q3 11111111111111111111122211111111111111 
MST.Q5 11110111111111111111122311111111111111 
MST.con 22222222222222222222233322222222222222 
RCH.Q2 10110011011101100111011101100101000000 
RCH.Q3 11111111011101110111111101110111110000 
RCH.Q5 33332233133313331333233313311323331100 
RCH.con 31331133033303310333133303300313110000 
RNG.Q2 11111111111101110111111111100111110000 
RNG.Q3 21221122122201210122122112110212110000 
RNG.Q5 32332233233312321233233323221323221100 
RNG.con 32332233233302320233233323210323220000 
SA.Q2 00001100100010000000100010001010101111 
SA.Q3 01001100100010001000100010012010112222 
SA.Q5 01003301300030013000300020033030313444 
SA.con 00003300300030001000300020013030303444 
All.con 32331133133302321333133313310323220000 
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0 - 69 0         1         2         3         4         5         6         
seq MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLNDDVVKIDFED 
SA.Q2 1111111111100111111111111111111011111111111111110111111111011101100010 
SA.Q3 2222222222211121222222221222222122222222122222221212211222122101201011 
SA.Q5 4444444444423333444444444444444244444444444444442434433444234413312031 
SA.con 4444444444411333444444443444444144444444344444441434433444134303301030 
All.con 0000000000022101000000000000000200000000000000002010011000200031032413 
70 - 139 0         1         2         3         4         5         6         
seq VIAEPEGTHSFDGIWKASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAILSFLHIWAVVPCIKSFLIE 
SA.Q2 0010011010010001000100100100001000000000000000000000000000000000100000 
SA.Q3 0012122112121001001100110110001000000000000000010000101100000000100101 
SA.Q5 0033344434243013002200300210003000000000000000020000102101000000300202 
SA.con 0032144132141003001200300200003000000000000000010000001000000000300101 
All.con 4411200211202431442144134134441444444444444444424444342343444444144242 
140 - 178 0         1         2         3        
seq IQCISRVYSIYVHTVCDPLFEAVGKIFSNVRINLQKEI 
SA.Q2 00001100100010000000100010001010101111 
SA.Q3 01001100100010001000100010012010112222 
SA.Q5 01003301300030013000300020033030313444 
SA.con 00003300300030001000300020013030303444 
All.con 43441143144414432444144414420414130000 
 
 
 
  
 
8-Appendix II 
ICOS 3D prediction software results for murine cav-1. The first table shows the 
analysis for the 2D and 3D rearrangements of adjacent aa and their exposure to the 
solvent. The second table takes into consideration their exposure to the solvent only. 
The regions highlighted in yellow refer to the epitope of the mAb clone 2297. The 
µAll.con¶ bottom row gives a final score for all the parameters taken into account by 
the analysis. 
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0 - 69 0         1         2         3         4         5         6         
seq MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADEVTEKQVYDAHTKEIDLVNRDPKHLNDDVVKIDFED 
cCN.Q2 0000010000011111000000010000000000000000100000000010000000100010010100 
cCN.Q3 0000011000112221110001111010000000000000110110001010011100100011111111 
cCN.Q5 0000032000134443330000032030000000000000300010002020000300300132131301 
cCN.con 0000031000034443110000031010000000000000300000001020000100300031030300 
dCN.Q2 0000010000011111000000000000000000000000000000000000000000100010010100 
dCN.Q3 0000011000122221110001111010000000000000100010001010010100100011010201 
dCN.Q5 0001122111134441121111121111111110011011211111112121111111210131121311 
dCN.con 0000021000034442010000010000000000000000100000001010000000200030020300 
DT.Q2 1000000000001100000000000000000000000000000000000000000000000000000000 
DT.Q3 1100111101011111110110111111011101100011110111111111111110101011110111 
DT.Q5 4000000000003300000000000000000000000000000000000000000000000000000000 
DT.con 3000000000003300000000000000000000000000000000000000000000000000000000 
GG.Q2 0000001000011110000000010000000000000000100000001010000000100010010100 
GG.Q3 0000000000012210000000000000000000000000000000000010000000000010010100 
GG.Q5 0001111010123321111011111110101110000010111110101111111111110121111211 
GG.con 0000001000023320000000010000000000000000100000001020000000100020020200 
MST.Q2 0111011110111111111111111111111111111111111111111111111111111111111111 
MST.Q3 0111011110121111111111111111111111111111111111111111111111111111111111 
MST.Q5 0111011110221111111111111111111111111111111111111111111111111111111111 
MST.con 0222022220232222222222222222222222222222222222222222222222222222222222 
RCH.Q2 0000000000001100000000000000000000000000000000000000000000000000000000 
RCH.Q3 0000010000011111010000010000000000000000100000000010000000100010010100 
RCH.Q5 0001022000033331121011121020000100010000210010101010011100210021130200 
RCH.con 0000010000013310010000010000000000000000100000000000000000100010010100 
RNG.Q2 0000011000011111010001010010000000000000100000000010000000100010010100 
RNG.Q3 0000011000012211010001010010000000000000100000000010000000100011010100 
RNG.Q5 0001122010123322121011121120101110010010210111101121111101210021121211 
RNG.con 0000022000023322020002020020000000000000200000000020000000200020020200 
SA.Q2 1111100111100000101110101101111111111111011111110101111111011101101011 
SA.Q3 2222211222210011112222211212222222222222122212221212211122122211212122 
SA.Q5 4444433434410133444444443444444444444444444444444424433444234413413144 
SA.con 4444411434400011314442413414444444444444144434441414433344134403403044 
All.con 0000011000023321010001010010000000000000100000001010000000200021020200 
70 - 139 0         1         2         3         4         5         6         
seq VIAEPEGTHSFDGIWKASFTTFTVTKYWFYRLLSTIFGIPMALIWGIYFAILSFLHIWAVVPCIKSFLIE 
cCN.Q2 1100000000101111111111111111111111111111111111111111011111111111111111 
cCN.Q3 2100100111101221222122122222221222222222222222222222122222222222222221 
cCN.Q5 3301310223313443433344344344443444444444444444434443344444444444344342 
cCN.con 3300100111303443433344344344443444444444444444434443144444444444344342 
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dCN.Q2 1100000000101111111111111111111111111111111111111111011111111111111110 
dCN.Q3 1100100111101221222122122222222222222222222222222222122222222222222221 
dCN.Q5 3311111211213343433334334344443434344433334433333333133444444444344342 
dCN.con 3300000100203343433334334344443434344433334433333333033444444444344341 
DT.Q2 0000000000000110100011000001110110011001101110101011010011110001001010 
DT.Q3 1111110111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 0000000000000330300033000033330330033003003330303033030033330003003330 
DT.con 0000000000000330300033000013330330033003203330303033030033330003003130 
GG.Q2 1100000000100111111111111111111111111111111111111111111111111111111111 
GG.Q3 2200000000001221211122022122221222222222222222222222122222221012122221 
GG.Q5 3311101111202332422234233233432443444344434443444344243343432124234342 
GG.con 3300000000201332422234233233432443444344434443444344243343432124234342 
MST.Q2 1111111111111111111111111111111111111111111111111111111111111111111111 
MST.Q3 1121111111112111111111111111111111111211121122111111111111111111111111 
MST.Q5 1121111111112111111111111111111111111211121122111111111111111111111111 
MST.con 2232222222223222222222222222222222222322232233222222222222222222222222 
RCH.Q2 0000000000000110110011011011110111111111111111111111010111111011011010 
RCH.Q3 1100100101101111111111111112221121121112112111111111111122221111111121 
RCH.Q5 3301200111202332333333233333333333333333333333333333333333333333333333 
RCH.con 1100100000101331331133133133331333333333333333333333131333333133133131 
RNG.Q2 1100100101101111111111111111111111111111111111111111111111111111111111 
RNG.Q3 1100100101101221211122122122221221222121212211211221121222221122122121 
RNG.Q5 2211201211212332322233233233332332233232333332322332232333332233233232 
RNG.con 2200200202202332322233233233332332333232333332322332232333332233233232 
SA.Q2 0011011010011001000100100100001000000000000000000000000000000000100001 
SA.Q3 1022122122121001001100100100001000000000000000000000101000000100100101 
SA.Q5 0143344444142013002300300310003000000000000000000000300100000000300202 
SA.con 0043144142042003001300300300003000000000000000000000100000000000300102 
All.con 2200100101202332322233233233332333333333333333333333132333332233233231 
140 - 178 0         1         2         3        
seq IQCISRVYSIYVHTFCDPLFEAIGKIFSNIRISTQKEI 
cCN.Q2 10110011011101110111011101101111110000 
cCN.Q3 21221122012202221221022212211212121101 
cCN.Q5 42331233133313332333133313332434332211 
cCN.con 41330133033303331333033303312434331100 
dCN.Q2 10110011011101110111011101100111110000 
dCN.Q3 21220122012201221221012212211212121101 
dCN.Q5 31331133133313331333133323311434331112 
dCN.con 30330033033303330333033313300434330001 
DT.Q2 10110011001100110011001001100101010001 
DT.Q3 11111111111111111111111111111111111111 
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DT.Q5 30330033003303330033003003300303030004 
DT.con 30330033003301330033003003300303030003 
GG.Q2 11111111111111111111111111100111110000 
GG.Q3 21221122122212221222122212200212120000 
GG.Q5 42442244244423442343234324311424231100 
GG.con 42442244244423442343234324300424230000 
MST.Q2 11111111111111111111111111111111111111 
MST.Q3 11111111111111111111112211111111111111 
MST.Q5 11110111111101111111022311111111111111 
MST.con 22222222222222222222223322222222222222 
RCH.Q2 10110011001101110111011101100101010000 
RCH.Q3 11111111011111211111011101100111110000 
RCH.Q5 31332233233323333333133333300333331100 
RCH.con 30331133013313331333033303300313130000 
RNG.Q2 11111111111111111111111111110111111000 
RNG.Q3 21221122122212221222122112110212111000 
RNG.Q5 32332233233323332333233223221323222110 
RNG.con 32332233233323332333233223220323222000 
SA.Q2 01001100100010000000100010011010101111 
SA.Q3 01001100100010001000200010021010101222 
SA.Q5 03003200300030003000300020133030203344 
SA.con 03003200300030001000300020033030203344 
All.con 31331133123313331333133313311323231001 
  
 
0 - 69 0         1         2         3         4         5         6         
seq MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADEVTEKQVYDAHTKEIDLVNRDPKHLNDDVVKIDFED 
SA.Q2 1111100111100000101110101101111111111111011111110101111111011101101011 
SA.Q3 2222211222210011112222211212222222222222122212221212211122122211212122 
SA.Q5 4444433434410133444444443444444444444444444444444424433444234413413144 
SA.con 4444411434400011314442413414444444444444144434441414433344134403403044 
All.con 0000022000034322020001021020000000000000200000002020011000200031030300 
70 - 139 0         1         2         3         4         5         6         
seq VIAEPEGTHSFDGIWKASFTTFTVTKYWFYRLLSTIFGIPMALIWGIYFAILSFLHIWAVVPCIKSFLIE 
SA.Q2 0011011010011001000100100100001000000000000000000000000000000000100001 
SA.Q3 1022122122121001001100100100001000000000000000000000101000000100100101 
SA.Q5 0143344444142013002300300310003000000000000000000000300100000000300202 
SA.con 0043144142042003001300300300003000000000000000000000100000000000300102 
All.con 3300200201301431442144144134441444444444444444444444243344444344144241 
140 - 178 0         1         2         3        
seq IQCISRVYSIYVHTFCDPLFEAIGKIFSNIRISTQKEI 
SA.Q2 01001100100010000000100010011010101111 
SA.Q3 01001100100010001000200010021010101222 
SA.Q5 03003200300030003000300020133030203344 
SA.con 03003200300030001000300020033030203344 
All.con 41441144144414442444044414301414141000 
 
 
  
 
9-Appendix III 
ICOS 3D prediction software results for human &+&Į 7KH UHJLRQ KLJKOLJKWHG LQ
yellow refers to the epitope of the mAb clone X22. The µAll.con¶ bottom row gives a 
final score for all the parameters taken into account by the analysis. The first table 
gives the results for the rearrangements of the aa in 2D and 3D, their point of contact 
and their exposure to the solvent. The second table gives the score for their exposure 
to the solvent only. 
 290 
 
 
0 - 69 0         1         2         3         4         5         6         
seq AQILPIRFQEHLQLQNLGINPANIGFSTLTMESDKFICIREKVGEQAQVVIIDMNDPSNPIRRPISADSA 
cCN.Q2 0001111111110100101000110101111110111111100000111111110000011110101111 
cCN.Q3 0012221212221211112000121211222121122222211001112222221011121111212222 
cCN.Q5 1133443434342311313111341433444343344443412001334444441113133333314444 
cCN.con 0013443434341300303000340413444341344443401000334444440001033331304444 
dCN.Q2 0011111111110100101000110100111110111111100000111111110000010110101111 
dCN.Q3 0012221212221211212010121211212121122222211001112222221011121121212222 
dCN.Q5 1113443434441311313111131311434111344444311111334444441111132131314444 
dCN.con 0023443434440300303000230300434230344444300000334444440000031230304444 
DT.Q2 1111111111111111010111111111111101111111100010001111111111111111110111 
DT.Q3 1111111111111111111111111111111111111111111121111111111111111111111111 
DT.Q5 4333333333333333030434333343333334333333300040033333333033333333340433 
DT.con 3333333333333333030333333333333313333333300040013333333233333333330333 
GG.Q2 0001110111110100101000110101111110011111100000011111110000010000101011 
GG.Q3 0002221210220200102000020100212000122222000000012222220000000010201012 
GG.Q5 0013342421331311203110131211324111234343211001124444341101111121313123 
GG.con 0003341421330300203000130201324110134343200000024444340000010010303023 
MST.Q2 0111111111111111111011111111111111111111111111111111111111111111111111 
MST.Q3 0111111111111111111011111111111111111211111111111111111111111111112112 
MST.Q5 0111111111111111112011111111111111111211111111111111111111111111112112 
MST.con 0222222222222222222022222222222222222322222222222222222222222222223223 
RCH.Q2 0001111101110100101000110101111100111111000000011111110000011110101111 
RCH.Q3 0002222212221222101010121222222222222222101000112222220011122212202222 
RCH.Q5 0014444434444344343000331444444444444444313000333444430033333333404444 
RCH.con 0004444414441322313000330424444422444444101000133444430011133332404444 
RNG.Q2 0001111111110100101000010100111110011111100000011111110000010000101011 
RNG.Q3 0001221211110100101000110100212110022222100000012222110000010000101012 
RNG.Q5 0012332322221211202010221212323221133333211001223333221111121111212123 
RNG.con 0002332322220200202000120200323220033333200000023333220000020000202023 
SA.Q2 1110001010001011010111001010000101100000011111110000001111101111010000 
SA.Q3 2220001011002022120222102021010122100001121222110000002112211111020110 
SA.Q5 4441013031113034141344313143030344310001233444230000103344333323131300 
SA.con 4440003030003034040344103041010324300000133444230000003334313323030100 
All.con 0013332323331311212010231312333221233333201000123333331011121221313233 
70 - 139 0         1         2         3         4         5         6         
seq IMNPASKVIALKAGKTLQIFNIEMKSKMKAHTMTDDVTFWKWISLNTVALVTDNAVYHWSMEGESQPVKM 
cCN.Q2 1111001111111011111111000011111010011111111000111111111111111000001111 
cCN.Q3 2222111222221111222212011012112121112222222111222222112222212100112122 
cCN.Q5 4444213444433132434433111123334231324444444322344444334444434100013334 
cCN.con 4444103444433032434433000023334130124444444111344444334444434000003334 
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dCN.Q2 1111001111110001111111000011111010001111111000111111011111111000001111 
dCN.Q3 2222112222221111222212011012112121112222222111222222112222212100012122 
dCN.Q5 4443113444431122434413111113334131114444343111344444114443423111113334 
dCN.con 4443003444430012434423000023334030004444343000344444024443423000003334 
DT.Q2 1111111111111111111111111111111111111111111111111111100111111111011111 
DT.Q3 1111111111111111111111111111111111111111111121111111211111111112111111 
DT.Q5 3333333333333333333333333333333334443333333043333333400333333444033333 
DT.con 3333333333333333333333333333333333333333333243333333400333333334033333 
GG.Q2 1111000111110000111111010001001010001111111000111111011111101000001111 
GG.Q3 2211001222210001212202010002012020002222122000122222001222212000002112 
GG.Q5 4332112443421112424314121113213131114343234101243443112443423100012224 
GG.con 4332001443420001424314020003003030004343234000243443012443413000003224 
MST.Q2 1111111111111111111111111111111111111111111111111111111111111111111111 
MST.Q3 1111111112111111111111111111111111111111111101112111111111111111111111 
MST.Q5 1111111112111111111111111111111111111111111111112111111111111111111111 
MST.con 2222222223222222222222222222222222222222222212223222222222222222222222 
RCH.Q2 1111001111100001111111000011011010001111111000111111001111101000001111 
RCH.Q3 2222222222221011222222011012212222122222222101222222222222222000102122 
RCH.Q5 4444444444433033344443033133343444344444444404344444444444443300313334 
RCH.con 4444224444421013344443011033233242124444444101344444224444423000103334 
RNG.Q2 1111000111110001111101010001011010001111111000111111011111111000001111 
RNG.Q3 2211000222211001212201010001012010002122121000122222012221211000002112 
RNG.Q5 3322111333321112323312121112123220113233232101233333123332322110113223 
RNG.con 3322000333320002323302020002023020003233232000233333023332322000003223 
SA.Q2 0000111000011111000000111110110101110000100111000000110000010111110110 
SA.Q3 0000221000011211010010211210110202210000100122100000210001010222221110 
SA.Q5 0011433000033433030131333421331314330100210343200000430002131444431320 
SA.con 0000433000033433010010333420330304330000200343100000430001030444430320 
All.con 3333112333321112333323011013123131113333233111333333123333323100013223 
140 - 209 0         1         2         3         4         5         6         
seq FDRHSSLAGCQIINYRTDAKQKWLLLTGISAQQNRVVGAMQLYSVDRKVSQPIEGHAASFAQFKMEGNAE 
cCN.Q2 1010001011111111110001111111111000011111111110001101101111111110100000 
cCN.Q3 2121112122222222211011222222211001121222222211111212212222222121201000 
cCN.Q5 4332033334344443431133444444433001243434344431112434444444444342310101 
cCN.con 4131013134344443430013444444433000143434344430002414414444444341300000 
dCN.Q2 1010001011111111100001111111110000011111111110001111101111111110100000 
dCN.Q3 2121112112222222210011222222211001121222222220001212212222222121200000 
dCN.Q5 4131114114344443311113444444431111143434344331113314414444444341311111 
dCN.con 4030004024344443300003444444430000043434344330003324404444444340300000 
DT.Q2 1111111011111111111110111111101110111011111111111111111111111111110010 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111121111 
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DT.Q5 3333333330333333334430333333303440333033333334333333343333333333340040 
DT.con 3333333132333333333330333333303330333033333333333333333333333333340030 
GG.Q2 1010001001011111100000111111110000010111111110001101101111111010100000 
GG.Q3 2010002002122221210000222222200000021212122110000001201121022021200000 
GG.Q5 3121113113244332320011344433411001132324243221111112312222133142300101 
GG.con 3020003003144332310000344433410000031324243220001102302232133041300000 
MST.Q2 1111111111111111111111111111111111111111111111111111111111111111111111 
MST.Q3 1111111111111111111111111112111111111211111111111111112122112111111111 
MST.Q5 1111111111111111111111111112111111111211111111111111112122112111111111 
MST.con 2222222222222222222222222223222222222322222222222222223233223222222222 
RCH.Q2 1011101001111111100000111111110000011111111110000101101111111010100000 
RCH.Q3 2222222122222222210011222222211000022222222210001222222222222222200000 
RCH.Q5 4333343444444444330033444444433000133444444330103334444444444434300101 
RCH.con 4233323124444444310011444444431000033444444330001324424444444232300000 
RNG.Q2 1010001001111111110000111111110000011111111110000101101111111111100000 
RNG.Q3 2010001002122221210000222222210000021212122110001101101111122121100000 
RNG.Q5 3121112112233232220011333333321001132323233220111212212222223232201101 
RNG.con 3020002003233332320000333333320000032323233220000202202222233232200000 
SA.Q2 0101110110100000001111000000001111101000000001110010010000000101011111 
SA.Q3 0211120210100001012211000000012222201010100112221021020100100101122222 
SA.Q5 1333441341300002124433100000034444303020201124443131130101000303144443 
SA.con 0313340330300001014433000000014444303010100014441030030000000303044443 
All.con 3131113113233333320011333333321000132333333320002313313333333231300000 
210 - 279 0         1         2         3         4         5         6         
seq ESTLFCFAVRGQAGGKLHIIEVGTPPTGNQPFPKKAVDVFFPPEAQNDFPVAMQISEKHDVVFLITKYGY 
cCN.Q2 0111111111000111111111100000010110111111110010011111111101111111111111 
cCN.Q3 1222222222111221222222100000111211122222211111122222222101222222222222 
cCN.Q5 1444444443333343444444110000133333344444433033344444444312444444444444 
cCN.con 0444444443111343444444200000031331344444431031144444444302444444444444 
dCN.Q2 0111111111000111111111000000010100111111110010011111111000111111111111 
dCN.Q3 1222222222111221222222100000011211222222211011122222222101222222222222 
dCN.Q5 1334444433111342444414111111111321334443431111144444434111444444444444 
dCN.con 0334444433000342444434000000020310334443430020044444434000444444444444 
DT.Q2 1011111111011001111111111110011111111111111101111111111011111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111121111111111111 
DT.Q5 4033333333033003333333044340433333033433334403333333333343333333333333 
DT.con 3033333333033003333333233330133333233333333303333333333143333333333333 
GG.Q2 0111111111000010111101000000000100001011100010011111111000101111111111 
GG.Q3 0212222211000001222202000000010200002221100010002222212000112222221212 
GG.Q5 1324444322100122434413000100011311123232210011113343424101224444432233 
GG.con 0324444322000021434403000000000300003132200020013343424000214444432333 
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MST.Q2 1111111111111111111111111111111111111111111111111111111111111111111111 
MST.Q3 1111111211111121111111211111111111111111111111111112111101121111111121 
MST.Q5 1111111211111121111111111111111111111111111111111112111111121111111121 
MST.con 2222222322222232222222322222222222222222222222222223222212232222222232 
RCH.Q2 0111111111000111111101000000011111111111111010111111111000111111111111 
RCH.Q3 0122222221211222222222100000011221222222222122122222222201222222222222 
RCH.Q5 1334444444333444444443300000033333344444444033344444443303344444444444 
RCH.con 0334444443211444444423100000033333344444444032344444443201344444444444 
RNG.Q2 0111111111000011111101000000000100011011100010001111111100101111110111 
RNG.Q3 0112222211000011212201000000000100012011100010001122212100112222221112 
RNG.Q5 0223333322111122323322110001111211123121210021112233323201223333322223 
RNG.con 0223333322000022323302000000000200023022200020002233323200213333331223 
SA.Q2 1010000001111001000000111111111011100100011101100000000011000000001000 
SA.Q3 2010000011122101010010121222212012110101111212110000010121110000001100 
SA.Q5 4120000022344103010031343444433133311111124433331000020343130000003101 
SA.con 4020000012344003000010343444433033300200023413310000010143010000003000 
All.con 1223333332111232333323100000021311223233321021123333333101323333332333 
280 - 349 0         1         2         3         4         5         6         
seq IHLYDLETGTCIYMNRISGETIFVTAPHEATAGIIGVNRKGQVLSVCVEEENIIPYITNVLQNPDLALRM 
cCN.Q2 1111111111111111110011111100001111111100111111110000110110011000011001 
cCN.Q3 2222222222222221221122222211001122222211212222221001221221011001022112 
cCN.Q5 4444444444444443431344444411003444444411334444442101331331023011033113 
cCN.con 4444444444444443430144444400003344444400334444441000330330023000033003 
dCN.Q2 1111111111111111110011111100000111111100111111110000110110001000011001 
dCN.Q3 2222222222222222221222222210001122222211212222221100220121011000012111 
dCN.Q5 4444444444444333431144444411111144444311324444331111331331113111033113 
dCN.con 4444444444444333430144444400000244444300324444330000330330003000033003 
DT.Q2 1111111111111111101111111111110011111111111111111110111111111101111111 
DT.Q3 1111111111111111111111111121111111111111111111111211111111111111111111 
DT.Q5 3333333303333333304433333344443033333334333333333440333333333303433333 
DT.con 3333333323333333303333333343331033333333333333333430333333333303333333 
GG.Q2 1111111111111111110011111100000001111100001111110000110111011000011111 
GG.Q3 2222120021222101210012222200000002222100102222120000220221011000022212 
GG.Q5 4344231132343212321124443311001124434211214434231011431342122111143324 
GG.con 4344231132343212320024443300000004434200104434230000430342022000043324 
MST.Q2 1111111111111111111111111101111111111111111111111111111111111111111111 
MST.Q3 1111111121111111111111111201111121121111211111111111111111111110112111 
MST.Q5 1111111121111111111111111201111121121111211111111111111111111111112111 
MST.con 2222222232222222222222222302222232232222322222222222222222222221223222 
RCH.Q2 1111111111111111110011111100000111111100111111110000111111000000011001 
RCH.Q3 2222222222222222222222222200001222222200222222210001222221121000022112 
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RCH.Q5 4444444444444444444444444303003344444400344444431000344343333010034333 
RCH.con 4444444444444444442244444300001344444400344444430000344343121000034113 
RNG.Q2 1111111111111111110011111100000011111100111111110000110111111000011111 
RNG.Q3 2222111111111111110012221100000012222100112212110000110121111000012111 
RNG.Q5 3333221222232222221123332201001123333211223323221101221222222110133222 
RNG.con 3333222222232222220023332200000023333200223323220000220232222000033222 
SA.Q2 0000000000000000001100000011110000000011000000001111001000110111100110 
SA.Q3 0000001101000111002110000021222110000122110010112222002101211211200110 
SA.Q5 0000103301100113114310000133443320000133130020213443013103431433300230 
SA.con 0000001100000001004300000033442110000033010010103443003001430433300230 
All.con 3333332333333332321133333301001133333311323333331100331332122000033213 
350 - 419 0         1         2         3         4         5         6         
seq AVRNNLAGAEELFARKFNALFAQGNYSEAAKVAANAPKGILRTPDTIRRFQSVPAQPGQTSPLLQYFGIL 
cCN.Q2 0000010010011100100110000100110111010001110001100100100001011111111011 
cCN.Q3 0111020121012111210220110100221222120001211102201210100111112222122112 
cCN.Q5 1222030231033312311331111311341343131103311213312310211313133444333333 
cCN.con 0111030130033301300330000300340343030003320103301300200103033444333133 
dCN.Q2 0000010010001100100110000100110111010001110001100100100001000111111011 
dCN.Q3 0011020120012111210220110100221222110101211102101110100112111222122112 
dCN.Q5 1111131131123211311330111311331343131112311103311310211111121444233133 
dCN.con 0000030030013200300330000300330343030002320003300300200003010444233033 
DT.Q2 1111111111111111111111101110111111101111111111111111111010011111111101 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3333333333333333333333330333333333303333333343333333033330033333333303 
DT.con 3333333333333333333333312331333333303333333333333333233130033333333303 
GG.Q2 1100010111111111111110000100111111010001100001101110100000000111111111 
GG.Q3 1010021122122211211220000201221222010001200002212210100000000222222122 
GG.Q5 2121032242234323422441111312442443121112321113423421201110111344344234 
GG.con 2110031243234323422440000301442443020002300003413420200000000344344234 
MST.Q2 1111111111111111111111111101110111111111111011101111111111111111111111 
MST.Q3 1111110121111111111111111101221121111111111011111111111112111111111011 
MST.Q5 1111111111111111111111111101220121111111111111111111111112211111111011 
MST.con 2222221232222222222222222202330232222222222022202222222223222222222122 
RCH.Q2 0000010111011111100110000100110111010001100001101100000000011111111011 
RCH.Q3 0121020222222222211221110101221222120102211002211201100111122222222222 
RCH.Q5 1333031343434433433334330301343444430303333303333330301333344444444434 
RCH.con 0121030343234433411331110300341444130103311003313300100111144444444234 
RNG.Q2 1101010111111111111110000101111111010001100001111100100000000111111111 
RNG.Q3 1110010121112111211220000101221221010001100002211100100001000122122112 
RNG.Q5 2221121232223222322331111212332332120112211112322211201111111233233223 
RNG.con 2211020232223222322330000202332332020002200003322200200000000233233223 
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SA.Q2 1110101000100010001001111011001000101110001110011011011110111000000000 
SA.Q3 2111101101110111012002111021001000202121011120021012122121211000100110 
SA.Q5 3433313303310233033003333143003000414343123340033034244344433000210310 
SA.con 3331303101300131013003333043003000404341013340033034144341433000100100 
All.con 1111031232123322321331110301331333120102311103312310200111011333333223 
420 - 489 0         1         2         3         4         5         6         
seq LDQGQLNKYESLELCRPVLQQGRKQLLEKWLKEDKLECSEELGDLVKSVDPTLALSVYLRANVPNKVIQC 
cCN.Q2 1000010011111110111000000110011000010110011011001110111111001011001101 
cCN.Q3 1000120012221221222100110220121000110220121022001221222122112011012212 
cCN.Q5 3010131133343443443201120331233001131331133033103441443334213133134334 
cCN.con 3000030033343441443100010330133000030330033033003440443334103033014314 
dCN.Q2 1000010011110110111000000110011000010110011011001010111011001011001101 
dCN.Q3 1000020011221221222100010220121000120221021022001120222122102012012212 
dCN.Q5 3011131122331441333111121331133001131331132133112131444133113121114314 
dCN.con 3000030022330440333000010330033000030330032033002030444033003023004304 
DT.Q2 1110000111111111111111111111111111111111110111110111111111110111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3330033333333333333333033333033344334333330333330333333333330303333333 
DT.con 3330011333333333333333233333233333333333330333330333333333330323333333 
GG.Q2 1000010011111111111000010111111000010100011011000010111111101010011111 
GG.Q3 2000010012222222222000010221122000020110022022001020222222202000012212 
GG.Q5 3111131123343443334111121442244111131321143143112131444344313012124424 
GG.con 3000030023343443334000020442244000030310043043001030444344303010024424 
MST.Q2 1111111111111111111111111110111111111110111011011111111111111111011111 
MST.Q3 1111111111111111111111111110111111111110112111111111121111112111011111 
MST.Q5 1111111111111110111111111110111111111110112011011111121111112111111111 
MST.con 2222222222222222222222222220222222222220223022022222232222223222022222 
RCH.Q2 1000010011111111111000000110111000011110011011001111111111101001011111 
RCH.Q3 2000111122222222222110110221121001110220021022002222222222212012122222 
RCH.Q5 3013130134444444443330330343333001333333333033103434444444443333134444 
RCH.con 3000030034444444443110110341333000132330033033003434444444413013034444 
RNG.Q2 1000010001111111111100000111111000010100011111000010111111101010011111 
RNG.Q3 1000010001121221121100000221122000010110022121000010222122101010012212 
RNG.Q5 2111121122232332232210111332233111121211132232111121333233213121123323 
RNG.con 2000020002232332232200000332233000020200033232000020333233203020023323 
SA.Q2 0110101110000001000011111001100111101001100100110001000000010100110010 
SA.Q3 0222201211001001100122112001100222211011200200121101000100120211210010 
SA.Q5 1433313321003002000344223003310444313113301310342313000200231422330030 
SA.con 0432303320001002000144223003300444303003300300341103000100130411330030 
All.con 3000020123332332333110110331233001131320132033002231333233213022023323 
490 - 559 0         1         2         3         4         5         6         
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seq FAETGQVQKIVLYAKKVGYTPDWIFLLRNVMRISPDQGQQFAQMLVQDEEPLADITQIVDVFMEYNLIQQ 
cCN.Q2 1101001001101100001001110110011011100110110111000011101101101110100101 
cCN.Q3 2211102002102200102122221221122112201210221221000021212212202210101101 
cCN.Q5 4312013013313301113244432332233131301331342233000033414113313330201212 
cCN.con 4302003003303300003124431331133033300330341333000033404303303330200202 
dCN.Q2 1100001001101100001001110110011011100110110111000010101101101110000101 
dCN.Q3 2201101002102101102122221221122112201210221121000021212012202210101101 
dCN.Q5 4311113113213311113111331331133133311321341133000132413313313321211211 
dCN.con 4300003003203300003013330330033033300320340233000031403203303320100202 
DT.Q2 1110001101111111111111111111111111111001111111111111111111111111011111 
DT.Q3 1111111111111111111111111111111111111111111111112111111111111111111111 
DT.Q5 3333303333333333330343333333333333340333333333344433333333333333033333 
DT.con 3331103313333333332333333333333333332113333333334333333333333333033333 
GG.Q2 1100001001111100001001111111111010101111111111000000101011101110101101 
GG.Q3 2211012012212200001000221221122121201221222222000000202012212220201201 
GG.Q5 4412124124324411112111332442244122312432443343100011314124424431212312 
GG.con 4401014014324400002001332442244031302432443343000000304024414430302302 
MST.Q2 1101111011101101111111111111111111101111111111111111111111111111111111 
MST.Q3 1101111111101101111111111110111111101210121111111111111111111111111111 
MST.Q5 1111111111101101111111111110111111101211121111111111111111111111111111 
MST.con 2202222022202202222222222221222222202321232222222222222222222222222222 
RCH.Q2 1101001001101100001001111111111111100110111111000011101101101110100101 
RCH.Q3 2221112002102101101222222222222222201210222221000011222222222222201212 
RCH.Q5 4444313013313313303344444443444434303331444433000033444444444434303334 
RCH.con 4423103003303301103224444443444434301330444433000033424424424432301314 
RNG.Q2 1111001011111110001000111111111010101111111111000010101011111110101101 
RNG.Q3 2201001012112210001000111221121010101211221121000010101012212210100101 
RNG.Q5 3312112123223321102111222332232122212322332232100021212123322321202212 
RNG.con 3312002023223320002000222332232020202322332232000020202023323320202202 
SA.Q2 0011110110010011110110000001000100011001001100111100010010010001010010 
SA.Q3 0021110210120021121121011001100111021012001101222211010110010012121111 
SA.Q5 0033331430131043341343113003300311143013002101444443130330031014242233 
SA.con 0033330430030043340341001003100300043003002200444411030130030004141131 
All.con 3312103013213301102112332332233132301321332232000021313223313331202212 
560 - 629 0         1         2         3         4         5         6         
seq CTAFLLDALKNNRPSEGPLQTRLLEMNLMHAPQVADAILGNQMFTHYDRAHIAQLCEKAGLLQRALEHFT 
cCN.Q2 1101110110000000001110110111000001101110001111101001100100001100100110 
cCN.Q3 2202210120000000012221221221010002101220101222101102201200102101210110 
cCN.Q5 3313331331111001013333333333111013313431113443313113312310203302320330 
cCN.con 3303330330000000003331331333000003303430003443303003301300103301310330 
dCN.Q2 1101110110000000001110110111000001101110001101101001100100001100100110 
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dCN.Q3 2102210110000000002221221221010002201220101221101102201200101101210110 
dCN.Q5 3313331331111001113331331333111113312331112412213113311311103201310330 
dCN.con 3303330330000000003330330333000003302330002412203003300300003200300330 
DT.Q2 1111111111110111011111111111100101111111111111111111011111001111111011 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3333333333340444033333333333330433330333333333333303133333003333333034 
DT.con 3333333333330333033333333333310313332333333333333323033333003333333033 
GG.Q2 1111111110000000001111111111000001111110001111001001101110001101110110 
GG.Q3 2212221220000000002221221222000002212220001201002012212210202202220210 
GG.Q5 4324432441101000124333442433111114323441112311213224423421224323321320 
GG.con 4324432440000000004333442433000004323440002312003014413420104303330320 
MST.Q2 1101111111111111111111111111111111111111111111111111101111111111111111 
MST.Q3 2111111111111011211111111111111111111111111111111011201111122111211111 
MST.Q5 2111111111111011211111111111111111111111111111111111201110121111211111 
MST.con 3202222222222122322222222222222222222222222222222122302222233222322222 
RCH.Q2 1101110110000000001111111111000001101110001111101001100100001101100110 
RCH.Q3 2212222220000001012222222222010002222222112222202101201110102101210110 
RCH.Q5 4444444331000000133444444443131003444444343444313313303330303333330330 
RCH.con 4414442330000000013444444443010003424442113444303103301310103303310330 
RNG.Q2 1111111110000000001111111111000001111110001111001011111110001111110110 
RNG.Q3 2212211120000000001111221211000002112210001111001012211210101111210110 
RNG.Q5 3223322331101001112222332332111113222321102212112123322321212222321220 
RNG.con 3323322330000000002222332332000003223320002222002023322320102222320220 
SA.Q2 0010001001111111110001000000111110010001110000010110011011110011011001 
SA.Q3 0020002002212222210001001001111120021002121011111120021022120121012002 
SA.Q5 0030013104433444330003003101333430131013342133231330032034331132034114 
SA.con 0030003004433444330003001000333330030003341011130330032034330032034004 
All.con 3313331330000000013332332333110003313331112322213113312310103212320220 
630 - 699 0         1         2         3         4         5         6         
seq DLYDIKRAVVHTHLLNPEWLVNYFGSLSVEDSLECLRAMLSANIRQNLQICVQVASKYHEQLSTQSLIEL 
cCN.Q2 0100111111010010001100110010000110110011000000110111011001100111001101 
cCN.Q3 0201211222121120102210120010101110221012011111221222022112101212002101 
cCN.Q5 1311323343231231113320331130201231331033123212331343133213201333113303 
cCN.con 0300323343130130003310330030100230330033011101330343033103200333003303 
dCN.Q2 0100101111010010001110110010000110110011000000110111011001100101001101 
dCN.Q3 0101212222121120102210120010101110221012011101220122122111101212012101 
dCN.Q5 1311311443131131113321331130101231331023111111331343133113301313113303 
dCN.con 0300303443030030003320330030000230330023000000330343033003300303003303 
DT.Q2 1111111111111111111111111111111111011111101100111111111111111101111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 4333333333333334333333330330340333333333303330333333333333340303303333 
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DT.con 3333333333333333333333332332332333133333303310333333333333332303323333 
GG.Q2 0100111111010010001110110010001110111011011111111111111111100101001101 
GG.Q3 0100222222010020002220220010001221221122111211221222122222200202012212 
GG.Q5 1211433442121131113431341131212332342234212322442444243334311313124424 
GG.con 0200433443020030003430340030002331342134122322442444243334300303014414 
MST.Q2 1111111111111111101110111111101110111111111111111111111111101111011101 
MST.Q3 1111111111111111101110111111101110111111111111111111112111111121011101 
MST.Q5 1111111111111111101110111111101111111111111111111111112111101121011101 
MST.con 2222222222222222202220222222202220222222222222222222223222202232022202 
RCH.Q2 0100111111111010001110110010000110110011000101110111011001100111001101 
RCH.Q3 0101212222222220002221221010101210221222111211221222122112200222012101 
RCH.Q5 0303344444444331304434433030303331343343133333443443344333300333033303 
RCH.con 0301334444444230004431431030101330341243011313441443144113300333013303 
RNG.Q2 0101111111010010001111110010001111111111111111111111111111100111011111 
RNG.Q3 0100211211010010001211110010001111221112111111221121122112100101012212 
RNG.Q5 1211322322121120113322221121112222332223222222322233233223211222123323 
RNG.con 0201322322020020003322220020002222332223222222332233233223200222023323 
SA.Q2 1011010000101101110001001101111001001100100010001000100010011000110010 
SA.Q3 2111011000101102120012001212121102001110211111001100200110022010110020 
SA.Q5 4133032001314313340013103413343213103300333233103000300231143121330131 
SA.con 4033031000303303340003003403343103003300311131003000300130043010330030 
All.con 0201323333131130103321331020101231331133112212331333133223300323013303 
700 - 769 0         1         2         3         4         5         6         
seq FESFKSFEGLFYFLGSIVNFSQDPDVHFKYIQAACKTGQIKEVERICRESNCYDPERVKNFLKEAKLTDQ 
cCN.Q2 1001011001111100110110000111011011101001001001100001101001001100001001 
cCN.Q3 2001021012212210210100110122122122101001012102210002101002101210011001 
cCN.Q5 3103133133323331331301110333244234312013023313310013313013212310113113 
cCN.con 3003033013323310330310000333144134302003013103300003303003102300003003 
dCN.Q2 1001011001111100110110000111011011100001001001100001100001001100001001 
dCN.Q3 2001021012211210210100010121122122201001012102200002101001001210001001 
dCN.Q5 3113133113322311331231111333143134311112113113311113311013113310113111 
dCN.con 3003033003322300330220000333043034300002003003300003300003003300003002 
DT.Q2 1110111111111111101011011111111101111010111111111110111101111111110111 
DT.Q3 1111111211111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3330333433333333303034033333333333333003333333334440333303333334003443 
DT.con 3330333433333333303033033333333313333021333333333330333303333333221333 
GG.Q2 1101011011111110110000000111111111101001001111100001101001101110001000 
GG.Q3 2001011012222210210100000222122122201002012112210002101012112220001000 
GG.Q5 4112122023333421321210121343244234312113124224321113212114223431112011 
GG.con 4102022023333420320100000343244234302003014224310003202004213430002000 
MST.Q2 1111111111111111111111111111111011111111111111111111111011111111111011 
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MST.Q3 1111111021111111111111111211111022111111111111111111111111111111111011 
MST.Q5 1111111021111111111111111111111022101111111111111111111011111111111011 
MST.con 2222222132222222222222222322222033222222222222222222222022222222222022 
RCH.Q2 1001011111111110110100000111111111100001001001100001100001001110000001 
RCH.Q3 2101022222222222221110000222222222201101112212221102101011111210001002 
RCH.Q5 3303044444444444430330133344444444303013033333330003303013333330103004 
RCH.con 3103044444444442430310000344444444301003013213320003301003113330001004 
RNG.Q2 1101011011111110110000000111111111101001011111100001100011111110001000 
RNG.Q3 2101010011111210110000000111122122101001012112100001100012112210001000 
RNG.Q5 3212122022222221221110111222233233312112123223211112211123223321102011 
RNG.con 3202022022222320220000000222233233302002023223200002200023223320002000 
SA.Q2 0110100100000011001101111000100000011110110010011110010110110011110110 
SA.Q3 0221211110111012112112112010100100021211210110012220111210120012221211 
SA.Q5 0341412300121033124344333101300300042431330330034441231430331034341333 
SA.con 0340401300010033014314333000300100042430330130034440130430330034340331 
All.con 3102032123323321320110010333233233302002013213310003202013113320002012 
770 - 839 0         1         2         3         4         5         6         
seq LPLIIVCDRFDFVHDLVLYLYRNNLQKYIEIYVQKVNPSRLPVVIGGLLDVDCSEDVIKNLILVVRGQFS 
cCN.Q2 0111111101011001101110001101101110010110110111111010100011001111100110 
cCN.Q3 1222222211022012212220002112211221111211221222222120200022112211210121 
cCN.Q5 3444434313133113323431113213333331133433443444444141310133213333310231 
cCN.con 1444434303033003313430003203313330031431441444444040300033103333300230 
dCN.Q2 0111111001011001101110001101101110010100110111111010100011001101100010 
dCN.Q3 1222222111022002212220002112212220012211221222222020200012112211200110 
dCN.Q5 2344344113133113313331113213313331131311431444444131311133113412311131 
dCN.con 1344344003033003303330003203303330031300430444444030300033003402300030 
DT.Q2 1111111110111111111111111111110111101111011111111111011111011111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3333333333433333333333333333330333333333333333333334343333033333333333 
DT.con 3333333331333333333333333333330333313333133333333333133333033333333333 
GG.Q2 0111111101011001111110001101111110011000110111011010100011111111110010 
GG.Q3 1222222001022012222220002212212221020000110222022010100022112222210020 
GG.Q5 2344343112134124423441113324423442131111221343233121211134224433421131 
GG.con 1344343102034014433440003314423441031000220343033020200034224433420030 
MST.Q2 1111111111111011111111111111111111111111111111111111111111111111111111 
MST.Q3 1111112111111011111110111111111111111111111112111111211111111111111111 
MST.Q5 1111112111111011111110111111111111111111111112111111211111111111111111 
MST.con 2222223222222022222221222222222222222222222223222222322222222222222222 
RCH.Q2 0111111111011001111110001111111111011111110111111010100011101111100110 
RCH.Q3 2222222222022022222222102222222222222222222222222222211022122222212220 
RCH.Q5 4444444444033034434434304344444443144444444444444443300033334444433330 
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RCH.con 2444444444033024434432104344444443144444442444444242300033324444412330 
RNG.Q2 0111111101011011111110001111111110010100110111111010100011111111110010 
RNG.Q3 1122122101011012212210001112211220011100110121111010100012112211210010 
RNG.Q5 1233233212022123323321102223322332122211221232122120211123223322321221 
RNG.con 0233233202022023323320002223322330021200220232222020200023223322320020 
SA.Q2 1000000010100110000001110010000001100001001000100101011100110010011101 
SA.Q3 1000100121200110010002110110010001211112101000100211012210110011012101 
SA.Q5 2000100231410330021014330231031003312143113001201433134310230032034313 
SA.con 2000000130400330010004330130010003301013003000200413034300230031034303 
All.con 1333333212033013323331103223322331122221331333233131310033123323311131 
840 - 909 0         1         2         3         4         5         6         
seq TDELVAEVEKRNRLKLLLPWLEARIHEGCEEPATHNALAKIYIDSNNNPERFLRENPYYDSRVVGKYCEK 
cCN.Q2 1001100100001101111110001001000101100110111000001001100101100011101100 
cCN.Q3 2002101200101212210221011000101111211221222010002001200102211112112200 
cCN.Q5 3113302310212313331331022001101333332343333110113113311313313233213311 
cCN.con 3003301300102303331330012001000313311341333000003003300303301133203300 
dCN.Q2 1001100100000101110110001000000101100110111000001001100101100011001100 
dCN.Q3 2002101200101212210220011000100112211221222010002001200102221112102201 
dCN.Q5 3113301310111313321331112001111113311431333111113113311313311223113311 
dCN.con 3003300300000303320330002000000203300430333000003003300303310123003300 
DT.Q2 1111110111111111111111111110011111111111111110101101111111111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3333330333333333333333033340033333333333333330303303333343333333333333 
DT.con 3333330333333333333333233330033333333333333330303303333333333333333333 
GG.Q2 1001101110001111111111111000000011111111111000001011100101100011101100 
GG.Q3 2002211210102212221221112000000102221221222000002012210201201022202200 
GG.Q5 4114422421212424432342233112111213332442434110113124421202311124313311 
GG.con 4004412420103424432342233000000113332442434000003024410302300034303300 
MST.Q2 1011101111111111110111111111101111111111111111111011111101111111111111 
MST.Q3 1011101111111111110111111111101111111121111111111111111101111111211211 
MST.Q5 1011101111111111110111111111101111111121111111111011101101111111211211 
MST.con 2022202222222222220222222222202222222232222222222022222202222222322322 
RCH.Q2 1001100100001101111110001000000111110111111000001001100101110011101100 
RCH.Q3 2001101210111212222221111000101222222222222111002012200102222122112211 
RCH.Q5 3013303330333344444434333000303334444444443413113033310303443334333333 
RCH.con 3003301310113314444431113000101334442444443101003013300303442134313311 
RNG.Q2 1011111110001111111111111000000001111111111000001011100101100011001100 
RNG.Q3 1012211210101211211221111000000002211221211000001011210101100011001100 
RNG.Q5 2123322321112322322332222111111112322332322110112123321202211122112211 
RNG.con 2023322320002322322332222000000003322332322000002023310202200022002200 
SA.Q2 0110011011110010001000100111111100011001000111110110011010011100110011 
 301 
 
 
SA.Q3 0220021012121010011002210221121110011001000211220210022121011110120022 
SA.Q5 1330133033332030023103321444343330023003010334431331034142133310131143 
SA.con 0330033033331030013002310443343310023003000333430330034041033300230043 
All.con 3013301310112313331331122000101223322332333110003013310203311123213311 
910 - 979 0         1         2         3         4         5         6         
seq RDPHLACVAYERGQCDLELINVCNENSLFKSLSRYLVRRKDPELWGSVLLESNPYRRPLIDQVVQTALSE 
cCN.Q2 0111111111001010001101110111100110111000000110011000001100110111011100 
cCN.Q3 1122222222011010111202221212211221121011010220122000101101220122122200 
cCN.Q5 2344444443113131113313333443321331233011131331233000013311331343233301 
cCN.con 1344444443003030003303331433310330233000010330133000003300330343133300 
dCN.Q2 1111111111000010001101010111100110111000000110011000001100110111011100 
dCN.Q3 1122222222001010001202121222211221121011010220122000001101220122122200 
dCN.Q5 1111444443121131113313131313311331333011121331133001113211331343133311 
dCN.con 2233444443000030003303030333300330333000010330033000003200330343033300 
DT.Q2 1011111111110111111111111111111111111110011111111111111111111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111121111111111111111111 
DT.Q5 3333333333330433333333333333333333333333033333333344043330333333333334 
DT.con 3133333333330333333333333333333333333331033333333343233332333333333333 
GG.Q2 0100111111100010001101010111111111111000010111111000001100111111111100 
GG.Q3 0000222222010010002200010222211222222000010221122000001100221222122200 
GG.Q5 1111433443121121113412121334422443344111121442344100102211442344233311 
GG.con 0100433443110020003402020334422443344000020442344000002200442344233300 
MST.Q2 1111111111011111111111111111111111111011111110111111111111111111111111 
MST.Q3 1111111121111111011111111121111121111011110110111111111101110111112111 
MST.Q5 1111111121011111101111111121111121111011111110111111111111110111112111 
MST.con 2222222232022222122222222232222232222022221220222222222212221222223222 
RCH.Q2 1111111111000010001101110111110111111000000110011000001100110111011100 
RCH.Q3 2222222222221012112202222222222222222011010221122000101201221222222220 
RCH.Q5 3444444444433031133314444444443443443033130333333000303303444444444430 
RCH.con 3444444444221031013304442444442443443011010331133000103301441444244420 
RNG.Q2 0000111111100010001101010111111111111000000111111000000101111111111100 
RNG.Q3 0000111221100010001101010111211121121000000221121000000000221122112100 
RNG.Q5 1111222233211121112212121222322232232111111332232100101111332233223211 
RNG.con 0000222333200020002202020222322232232000000332232000000101332233223200 
SA.Q2 1000000000111101110010101000011000000111101001100111010011001000100011 
SA.Q3 1111000000211211121021111010011001000211112001100222121121002100100022 
SA.Q5 3343001001333413331031313100133102101433323003201344332243003100310134 
SA.con 3111000000333403330030303000033001000433313003200344131143003000300034 
All.con 1222333333111021113303131333322332333011010331233000102201331333233310 
980 - 1049 0         1         2         3         4         5         6         
seq TQDPEEVSVTVKAFMTADLPNELIELLEKIVLDNSVFSEHRNLQNLLILTAIKADRTRVMEYINRLDNYD 
 302 
 
 
cCN.Q2 1000001101101110101100110110011000001001111011111111000000100110110010 
cCN.Q3 1000002112211210102101220220021101012001112112222222111101210220120020 
cCN.Q5 3010013313332331213212331331133201013103333333444343111202321331231131 
cCN.con 3000003303312330203201330330033100003003333133444343000101310330230030 
dCN.Q2 1000001011101110001000110110011000001000001001111111000000100110010010 
dCN.Q3 1000002112211210101101220220021101002001112112222221111101210220120010 
dCN.Q5 1111013113312321113111331331133201113111113113343333111201311331231131 
dCN.con 2000003023302320003000330330033100003000003003343333000100300330130030 
DT.Q2 0101111111110111110111111111111111111110111111111111101110111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 0304433333330333343333333333333343333340333333333333303333333333334330 
DT.con 0303333333330333331333333333333333333330333333333333303331333333333332 
GG.Q2 0000001111111110101001110111111100001001011111111111010001110110010010 
GG.Q3 0000002222212220001000221221122000001000112112222222110201221220120020 
GG.Q5 2111114334423431203111442442243210112111224224444434211312432441231131 
GG.con 0000004334423430203001441442243200002001124224444434120202431440130030 
MST.Q2 1111111111111111111101110110111111111111111111111111111111111110111111 
MST.Q3 1111011111111111111111110110111111111111111111111121111011111110111111 
MST.Q5 1111011111101111111101110110111111111111111111111121111111111110111111 
MST.con 2222122222222222222202220220222222222222222222222232222122222220222222 
RCH.Q2 0000001101101110101001110110011000001001101011111111000101110110110010 
RCH.Q3 1000002222222220102202220221122100001001112222222222111101210220120111 
RCH.Q5 3010003344443344303303441343133303013003334444444443333333431331330330 
RCH.con 1000003324423341303203440341033100003003314244444443111303430330330130 
RNG.Q2 1000001111111110101001111111111100001001011111111111110001111110010010 
RNG.Q3 1000002112212210101001221221121100001001011112212122110001211220010010 
RNG.Q5 2111113223323321202112332332232211112111122223322233121112322331120121 
RNG.con 2000003223323320202002332332232200002002022223323233220002322330020020 
SA.Q2 0111110000010001010110001001100011110110100000000000111111001001101101 
SA.Q3 1221210110011012120121002002101121221221110110000000111121012002102201 
SA.Q5 3433430030031014341333013003301344431443230320000001333242023103214413 
SA.con 1433430010030004140331003003300143430441210110000000333242013003204403 
All.con 1000003223322331202102331331133201013002123223333333111102321330130130 
1050 - 1119 0         1         2         3         4         5         6         
seq APDIANIAISNELFEEAFAIFRKFDVNTSAVQVLIEHIGNLDRAYEFAERCNEPAVWSQLAKAQLQKGMV 
cCN.Q2 1001101100001100110110010000011011100100100100110010000110011011100001 
cCN.Q3 1002201210101201221220010111022022201110101210120010000221122111100012 
cCN.Q5 3013303320103313332331130121133133312311301320331131111343233133301013 
cCN.con 3003303310003301331330030010033033301300300310330030000341133033300003 
dCN.Q2 1001101100001100110110010000011011100100100100110010000110011011100001 
dCN.Q3 1002201210101101221220010111022012201110101210120010000221122111100001 
 303 
 
 
dCN.Q5 3113313310102311331331130111133133311211301311330131111341133133311013 
dCN.con 3003303300002300330330030000033033300200300300330030000340033033300003 
DT.Q2 0101011111011111111111101011111111111100111101111111011111111111110001 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 0303133334040333333333304033333313333300333333333334033333333333330433 
DT.con 0303033333032333333333303033333323333300333313333333033333333333330113 
GG.Q2 1001101110001101111110010000011111100100101110110010000111111111100001 
GG.Q3 1012212220001201221220010000022122211211201221221020000221122122200002 
GG.Q5 2124324431112312432441120111134244422322412432441130111443243233311113 
GG.con 2014314430002302432440020000034244411311402431440030000443243233300003 
MST.Q2 1011101111111111111110111111111011101111101111110111111111111111111111 
MST.Q3 2011201211111101211110111111121011111111101211120111111111112111111111 
MST.Q5 1011201211111101211110111111121011111111101211120111111111112121111111 
MST.con 3022302322222212322220222222232022202222202322230222222222223222222222 
RCH.Q2 1001101100001101111110010000011011100100100110110010000111111011100001 
RCH.Q3 1002201210101222222220010111022122211210101210220010000222222122200001 
RCH.Q5 3013303330103344443431130333033334333310303331330130000444344443300013 
RCH.con 3003303310003324443430030111033134311300301330330030000444344143300003 
RNG.Q2 1011111110001101111111010000011111110100101111111010000111111111100001 
RNG.Q3 1012212210001101211221010000022122211100101211221010000221122121100001 
RNG.Q5 2123323321102212332332120111133233322211212322332120101332233222211012 
RNG.con 2023323320002202332332020000033233321200202322332020000332233232200002 
SA.Q2 0110010001110010001001101111100100011011011001001101111000100100011110 
SA.Q3 1210021012121021001002212111200200021111021012002202212001100100022210 
SA.Q5 1430031024341143013113314333300310033133143023103314333012200311144431 
SA.con 0430030014340041003003304333300300033033043013003304333001200300044430 
All.con 2013303320002312332330020111033133311310301321330030000332233133300003 
1120 - 1189 0         1         2         3         4         5         6         
seq KEAIDSYIKADDPSSYMEVVQAANTSGNWEELVKYLQMARKKARESYVETELIFALAKTNRLAELEEFIN 
cCN.Q2 0011011101001001001101100000100110110010000001011101111110100100100110 
cCN.Q3 0022022212011012102201200100100210220110001001122212222221200100210220 
cCN.Q5 1143134313113013213302310201311331331231011013133334444442301311311331 
cCN.con 0043034303003003103302300100300330330130000003033314444441300300300330 
dCN.Q2 0011011101001001001101100000100110110010000000011101111110100100100110 
dCN.Q3 0022022212001002102101200100100210220110001001022212222221100100200220 
dCN.Q5 1143134313113113113302310101311331331131011011133314444441301301311331 
dCN.con 0043034303003003003302300000300330330030000000033304444440300300300330 
DT.Q2 1111101110101111111110111010110111111011101101111111111111110110111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3313313333403303333330334040330333333333303343333333333333343330333333 
DT.con 3323303331303323333330333030330333333133303313333333333333331330333333 
 304 
 
 
GG.Q2 0011111101001001001101100000100111111111000001011111111111100100110110 
GG.Q3 0122122201001002112212200000201221221221010000021212222221200201211220 
GG.Q5 1244234422012113214423411101312442442342121111142324434432311312422441 
GG.con 0144234402002003104413400000301442442342010001042324434432300301421440 
MST.Q2 0111011111111111111101101111101110110111111111111111111111111101110111 
MST.Q3 0121011112111111111101201111101110111111111111111111112121111101111111 
MST.Q5 0121011112111111111101201111101110110111111111111111112121111101111111 
MST.con 0232022223222222222202302222202220220222222222222222223232222202220222 
RCH.Q2 0011011101001001001101100000100110110010000001111111111111100100100110 
RCH.Q3 0122122222002002102101100100101210221111011002122222222222200100110110 
RCH.Q5 0333444433033013313313310301303331333333033013344444444444301301331330 
RCH.con 0133144423003003103303300100301330331131011003344444444444300300310330 
RNG.Q2 0111111101001001111111110000101111111111111000011111111110100101111110 
RNG.Q3 0122112101001001012212210000001221221121111000011112212220100101211210 
RNG.Q5 1233233212012112123323321201112332332232222111122223323331201212322321 
RNG.con 0233233202002002123323320000102332332232222000022223323330200202322320 
SA.Q2 1100100010110110010010011111011001001001111110100000000001011011001001 
SA.Q3 2100200020211210120021022121121002002101211221101010000002021021022002 
SA.Q5 3300311031431431330032034343133013103303433433301030000103143133033014 
SA.con 3300300030430430130031034343033003003103433431300010000003043033023004 
All.con 0133133313002003113302300100201331331231111002133323333331300301311330 
1190 - 1259 0         1         2         3         4         5         6         
seq GPNNAHIQQVGDRCYDEKMYDAAKLLYNNVSNFGRLASTLVHLGEYQAAVDGARKANSTRTWKEVCFACV 
cCN.Q2 0011101001100110000101111110010010111011101001001101100100101100110111 
cCN.Q3 1122201002101210001102212221120021122122212002002102211101102211221121 
cCN.Q5 1343313113201320001314423431230131144344323013114314311301313321332233 
cCN.con 0143303003200320000304423430130030244144313003004304300300303310331233 
dCN.Q2 0111101001000100000101111110010010011011101001001101100100101100110111 
dCN.Q3 0121201002101210001202211221110021122122212002002102201101202210221121 
dCN.Q5 1113313113202320111313332331131131144144313113113313311311313311331232 
dCN.con 0233303003101310000303332330030030044044303003003303300300303300330232 
DT.Q2 0111111101011111100111111111111111111111111111101111111110111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 0333303303033334403333333333333433333333333333303330333340333333333333 
DT.con 0333323303033333301333333333333333333333333333303332333330333333333333 
GG.Q2 0010101001101110000101111110010010111111111111111101110100101111111111 
GG.Q3 0000102012212220000202222220120020122122212112112212210200102211221222 
GG.Q5 1111213124323421011313334442231131244244424224224423421311213422432333 
GG.con 0010203014313430000303334440130030244244424224224413420300203422432333 
MST.Q2 1111111011110111111111111111111111111111111111111111111111101111111111 
MST.Q3 1111211012210111111111211111111111111111111111112111211111101111111221 
 305 
 
 
MST.Q5 1111211012210111111111211111111111112111111111112111211111101111111221 
MST.con 2222322023320222222222322222222222222222222222223222322222202222222332 
RCH.Q2 0001101001000100000101111110110010111111111001001101100100101100111111 
RCH.Q3 1211202001101210001102222222120022222222222101102222211101201211221221 
RCH.Q5 3443333013303330003314444443330044344444433313314414433303303333444333 
RCH.con 1213303003101310001304444442330042344444433103104414411301303311443333 
RNG.Q2 0010101011111110000101111111010010111111111111111111111100101111111111 
RNG.Q3 0010101012111210000101211221010010122122212112112211211100102211221221 
RNG.Q5 1122212123222321111212322332121121233233322223223323322211213322332332 
RNG.con 0020202023222320000202322332020020233233323223223323322200203322332332 
SA.Q2 1100010110011001111010010001101101100000010110110010011011010011000000 
SA.Q3 1111110220021012221020011002102201100100010210120020011021120011001100 
SA.Q5 3343131330033024443131021003314313200300030330330130033143131133003101 
SA.con 3311030330033014443030020003304303200100030330330030033043030033001000 
All.con 0122303013211320001303323331130031233233323113113313311301303311332333 
1260 - 1329 0         1         2         3         4         5         6         
seq DGKEFRLAQMCGLHIVVHADELEELINYYQDRGYFEELITMLEAALGLERAHMGMFTELAILYSKFKPQK 
cCN.Q2 0000101101111011001001001101100001100110110011010000111111111111010000 
cCN.Q3 0100201211221122112012002201100101201220220122010001112222222222110101 
cCN.Q5 0101313333343133214113113312201213312331331233030001334444444443131201 
cCN.con 0000303313343033104003003302200103301330330133030000334444444443030100 
dCN.Q2 0000101100111011001001001101100001100110110011010000101110111111010000 
dCN.Q3 0000211211221122112002002201100101201210221121010001112222222222110101 
dCN.Q5 0111312312332133113013113312211113311331331133031111213331444431131101 
dCN.con 0000302301332033003003003302200003300330330033030000203331444433030000 
DT.Q2 1011111111111111111111111111111111111111111111101111111111111111111111 
DT.Q3 1111111111111111111111111111111111111111111111112111111111111111111111 
DT.Q5 4033333333333333333333333333333333333333333303304443333333333333333333 
DT.con 3033333333333333333333333333333333333333333323304333333333333333333333 
GG.Q2 0000111111111011001011101111100001101111111111010000101111111111010001 
GG.Q3 0000212212221011002012112212200002201221221122010000012221222220010001 
GG.Q5 1111324423432123113124224423311213312442442233120011114332433442121112 
GG.con 0000324423432023003024214423300003302442442233020000104332433442020002 
MST.Q2 1111111101111111111011011111111111101110110111110111111111111111111101 
MST.Q3 1111111201221111112011011111111111101110110121010111121111121111111111 
MST.Q5 1111111211221011112011111111111111101110110122010111121111121111111111 
MST.con 2222222302332222223022022222222222202220220232120222232222232222222202 
RCH.Q2 0000101111111111001111001101100001101110110111010000111111111111010000 
RCH.Q3 0001212222222222112012002212100102202221221122010002222222222222110101 
RCH.Q5 0103333444444444334033113333313303403431433333030003344444444444331303 
RCH.con 0001313444444444114133003313300103403430431333030002344444444444130101 
 306 
 
 
RNG.Q2 0000111111111011001011111111110001101111111111010000101111111111010001 
RNG.Q3 0000111211111011002012112211110001101221221121010000101111121221010001 
RNG.Q5 1111322322222122113123223322221112212332332232120111212222322322121112 
RNG.con 0000322322222022003023223322220002202332332232020000202222332332020002 
SA.Q2 1111010000000100110110110010011110010001001000101111010000000000101111 
SA.Q3 2121010011001201110110120011122121021002001100212221110001000001212121 
SA.Q5 4333131032002411331330330031233341133003003301414444230003000010313343 
SA.con 4333030011001400330330330030133340031003003100404443130001000000303343 
All.con 0001313322332133113023113312211103302331331233020001223332333333120101 
1330 - 1399 0         1         2         3         4         5         6         
seq MREHLELFWSRVNIPKVLRAAEQAHLWAELVFLYDKYEEYDNAIITMMNHPTDAWKEGQFKDIITKVANV 
cCN.Q2 1101101110110100110010000110111111101001001101110010011000011011101001 
cCN.Q3 2101201210120211110120011221222222111001012212220110021000121022212111 
cCN.Q5 3203312320231311330231122332344443212013114413430230133010232134313133 
cCN.con 3203302320230300330130011331344443202003004403430130033000132034303013 
dCN.Q2 1000100100010100110010000110011111001001001101110000011000010011101001 
dCN.Q3 2101101210120211210110011220122222111001002212220110021000121022202111 
dCN.Q5 3201312320131311330131111331143443213013114413331111133110232134313112 
dCN.con 3100301310030300330030000330043443103003004403330000033000131034303002 
DT.Q2 1111111111111111111011111111111111111111101111111111101111011111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3333333333333333333033333333333333333443303333334333403333333333333303 
DT.con 3333333333333333333033333333333333333333303333333333303333133333333323 
GG.Q2 1101111110010100110111111111111111101001011111110000001000111011101011 
GG.Q3 2212212220120201221221111221222222201002012222220000001000122122211001 
GG.Q5 4323423431231412442242222442243444212113124423431110112111243244322112 
GG.con 4313423430130401441342222442343444302003024433430000002000243144312012 
MST.Q2 1111111111111101110111111110111111111111111111111111111110111011111111 
MST.Q3 1111111111111101110121111110111111111111112111111111121110111111111111 
MST.Q5 1111101111111101110121111110111111111111112111111111121110111111111111 
MST.con 2222222222222202220232222220222222222222223222222222232220222022222222 
RCH.Q2 1101101110110100110010011111111111001001001111110010011000011011111111 
RCH.Q3 2102212211222222210111111222222222221001012222220120011010122222222222 
RCH.Q5 3344343430434443330333333444444444433003334444433333033110334444444444 
RCH.con 3314313430432422330131133444444444223003014444430130033000134244444444 
RNG.Q2 1111111110010101111111111111111111100001011111110000011000111111101000 
RNG.Q3 2111211110010101221121111221121121100001012211210000011000121122101001 
RNG.Q5 3222322221121212332232222332232333211012123322321111122111232233212112 
RNG.con 3222322220020202332232222332232333200002023322320000022000232233202001 
SA.Q2 0010010001101011001001100001000000010110110000001001100101000100010000 
SA.Q3 0121021012101011002102111001100000111220210010002112211212101200010111 
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SA.Q5 0231032014313033003303323013300101232431430020014334411334202300131332 
SA.con 0130031004303033003103311003100000131430430010004114400314101300030111 
All.con 3212312320131311330131122331233333212003013323330120022010232133313112 
1400 - 1469 0         1         2         3         4         5         6         
seq ELYYRAIQFYLEFKPLLLNDLLMVLSPRLDHTRAVNYFSKVKQLPLVKPYLRSVQNHNNKSVNESLNNLF 
cCN.Q2 0111011011100010111011011000101111101100000111100110011001000100111011 
cCN.Q3 0122022122201120122122122101212222201200101222210220121012101210221022 
cCN.Q5 0233133224302131333243133211314334302310202444421331132013202331343134 
cCN.con 0233033134301030333143033100304334302300101444410330032003101310343034 
dCN.Q2 0111011011100000011011011000101111101100000111100110011001000100111011 
dCN.Q3 0121022112201110121122022101212222201200101222210220121012101210221022 
dCN.Q5 1233133134311111233143133111313333313310211414311331133113211311343133 
dCN.con 0233033034300000133043033000303333303300100434300330033003100300343033 
DT.Q2 1111111111111111111111111111111111111111011111111111111101110111011111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3333333333333333333333333343333333333333043333333333333303330333033333 
DT.con 3333333333333333333333333333333333333333033333333333333303330333033333 
GG.Q2 0111111111100000111111111000101011101100000101100111111011101110111111 
GG.Q3 0222122122200000122122122000202122212200000202210222122112211221222122 
GG.Q5 1343234234411111243244244111313134423411111313321342243224322432344244 
GG.con 0343234234400000243244244000303034413400000303310343243124312431344244 
MST.Q2 1111011111101110111111011111111111111111111111110110111011101111111011 
MST.Q3 0111021111101111111111011111111111111111111111110110111111101110211011 
MST.Q5 1111021111111111111111111111111111101111111111110110111011101111211011 
MST.con 1222032222202220222222022222222222222222222222220220222022202221322022 
RCH.Q2 1111011111100110111011011000101111101100000111100110011001100110111011 
RCH.Q3 2222022222201220222222222102222222211200101222212221121012101222222222 
RCH.Q5 4443444444303330343444433303444444433310303344440333333033303443444444 
RCH.con 4443144444301330343244233102424444413300101344411331133013301442444244 
RNG.Q2 0111111111100000111111111000101011111100000101100111111111111111111111 
RNG.Q3 0122122112200000111122121000101012111100000101100221121111111211221122 
RNG.Q5 1232233223311121222233232211212123322211201212211332233223222322332233 
RNG.con 0233233223300000222233232000202023322200000202200332233223222322332233 
SA.Q2 1000100000011101000100100111010000010011011010011001100100010001000100 
SA.Q3 1100200110021112100100100122010110021022122010012001100210121012000200 
SA.Q5 4201300311043333201300300343131120031034343131033102300320133013000300 
SA.con 3100300100043313100300300343030010030034143030033002300310031003000300 
All.con 1233133233301120233233133101313233312300101323310331133113201321333133 
1470 - 1539 0         1         2         3         4         5         6         
seq ITEEDYQALRTSIDAYDNFDNISLAQRLEKHELIEFRRIAAYLFKGNNRWKQSVELCKKDSLYKDAMQYA 
cCN.Q2 1000010010011001001011011001000011010011111100000100110110000110011011 
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cCN.Q3 1111110121012012112112022012001022121122222211100201220221000110122022 
cCN.Q5 3212230231033013213333133113101033132234434411201311331331021331243134 
cCN.con 3101130130033003103133033003000033031134434400100300330330000330143034 
dCN.Q2 1000010010011001001011011001000011010011111100000100110110000110011011 
dCN.Q3 1011110121012002112111022011001022121122212211100201220221000110122022 
dCN.Q5 3111130131133013113113133113101133131134434311111311331331011331143134 
dCN.con 3000030030033003003023033003000033030034434300000300330330000330043034 
DT.Q2 1111111011101111111111111111110111111111111111100111111111111111111111 
DT.Q3 1111111111111111111111111111111211111111111111111111111111111111111111 
DT.Q5 3333313033303333333333333333340433333333333333303333333333343333333333 
DT.con 3333323033303333333333333333330433333333333333301333333333333333333333 
GG.Q2 1111110111011001001011011011000011011111111110000100111111000110111111 
GG.Q3 2111121121122002001012022112000022122122222211000201221221000120122122 
GG.Q5 4221232242234113113123144224111133243243334422111311442432111231244234 
GG.con 4222231242134003003023044124000033143243334421000300442432000230244234 
MST.Q2 1111110111011111111111111011011011111111111111111101110111111110111011 
MST.Q3 1111110111011111111111112011111011111112211111111101210111111110121012 
MST.Q5 1111110111111111111111112011111011111112211111111101210111111110121012 
MST.con 2222220222022222222222223022022022222223322222222202320222222220232023 
RCH.Q2 1000010010011001111111011001000011011011111111000100110110000110011011 
RCH.Q3 2211110121022002222222112111001022222222222211100201220221021120122122 
RCH.Q5 3333330333033003344443333133003033333444444433301303331333033330344344 
RCH.con 3211130131033003344443133013001033233244444433100301330331021330144144 
RNG.Q2 1111111111111001001001111111000011111111111110100101111111000110111111 
RNG.Q3 2111121121122001001001122112000011121122212110100101221221000110122122 
RNG.Q5 2222232232233112112112233223111022232233323321211212332332111221233233 
RNG.con 3222232232233002002002233223000022232233323320200202332332000220233233 
SA.Q2 0101001101100110110100100110110100100100000011011011001001101001100100 
SA.Q3 0112102101200220120110200210221201101100010011121021002001212102100200 
SA.Q5 0333313303300431431321300330443301302300020133343133003103443113300310 
SA.con 0313103303300430330310300330441300301300010033143033003003413003300300 
All.con 3121230131133003113123133113001033132233333321100301331331011230133133 
1540 - 1609 0         1         2         3         4         5         6         
seq SESKDTELAEELLQWFLQEEKRECFGACLFTCYDLLRPDVVLETAWRHNIMDFAMPYFIQVMKEYLTKVD 
cCN.Q2 1010000110011011100000011111111110110101110111110100111111111110110010 
cCN.Q3 1110010121122012101001122222222221221211211122110211222222211210210120 
cCN.Q5 2131020332133134301012444444444442432433323333331334444443323320330230 
cCN.con 2030010331033034300001144444444441431413321333330311444443323320330130 
dCN.Q2 0000000110011011100000011111111110110101110111010100111111101110110010 
dCN.Q3 1110010121122012100001122222222221221212221122110211222222211210210110 
dCN.Q5 1111111331133133301111144444444441431413331233231311444443313221331131 
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dCN.con 0000000330033033300000044444444440430403330233130300444443303320330030 
DT.Q2 1100011111111111111111111111111111111111111111111111111111111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3303033333333333333443303333333333333333333333333333333333333333333033 
DT.con 3301033333333333333333323333333333333333333333333333333333333333333233 
GG.Q2 1010000111111111100000011111111110110101111111110100111111111110110110 
GG.Q3 2010000221122122200000022222221220220202221222110200212222222221221121 
GG.Q5 3111111442244234311011133434432321331313442433221311332333433432432242 
GG.con 3020000442244234300000033434432330330303442433220300333333433431431241 
MST.Q2 1111110111111011101111111111111111110111111111111111111111111111111110 
MST.Q3 2121110221111011101111121121111211110111111121111111111111111111111110 
MST.Q5 2111110121111011101111121121111211110111111111111111111111111111111111 
MST.con 3232220332222022202222232232222322220222222232222222222222222222222220 
RCH.Q2 1000000110011011100000111111111110110111110111110110111111111111110010 
RCH.Q3 1110010121122122100001222222222222222222222222222222222222222222220110 
RCH.Q5 3330130333333333301013344444444444444444444444440444444444444444431331 
RCH.con 3110010331133133300001344444444442442444442444441442444444444444430130 
RNG.Q2 1010000111111111100000011111111110110101111111110100111111111111111111 
RNG.Q3 2010000121122122100000011222211110110101211122110100111111212111211121 
RNG.Q5 2121111232233233211011122333322221221212322233220211222222323222322232 
RNG.con 3020000232233233200000022333322220220202322233220200222222323222322232 
SA.Q2 0101111000100100011111000000000001001000000000001001000000010001001101 
SA.Q3 1212112001100210021221200000001002001010001100112012001001010112002102 
SA.Q5 1324334103300310143433400000011013113130013000214133101002031023113303 
SA.con 0314334001300300043433200000000003003010001000104013000001030013003303 
All.con 2120010332133133301001133333333331331313332333220311333333323321331131 
1610 - 1674 0         1         2         3         4         5         6    
seq KLDASESLRKEEEQATETQPIVYGQPQLMLTAGPSVAVPPQAPFGYGYTAPPYGQPQPGFGYSM 
cCN.Q2 0100000000000000000011000111111111111111111111111111111111111111 
cCN.Q3 0100000000000000000022111222222222222222222222222222222222222202 
cCN.Q5 1310010000000000000033331344444444444444444444444444444444444411 
cCN.con 0300000000000000000033110344444444444444444444444444444444444413 
dCN.Q2 0100000000000000000011000011111111111111111111111111111111111111 
dCN.Q3 0100000000000000000012111222222222222222222222222222222222222202 
dCN.Q5 1310010001000000001023111144444444444444444444444444444444444444 
dCN.con 0300000000000000000023000144444444444444444444444444444444444434 
DT.Q2 0101000100001001111111111111111111111111111111111111111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 0303000330003034444333334333333333333333333333333333333333333334 
DT.con 0303000310003013333333333333333333333333333333333333333333333333 
GG.Q2 1100010001000000000011000001111111111111011111111111111100110000 
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GG.Q3 1211111111000000000001000002222011011101011111011111111100120100 
GG.Q5 2422222222211111101012101113332122121211112212121212222211221200 
GG.con 2411121112000000000012000003333122122212022222122222222200230100 
MST.Q2 1111111111111111111111111111111111111111111111111111111111111111 
MST.Q3 1111111111111111111111111111111122111111111121211111121111222211 
MST.Q5 1111111111111111111111111111111121111111111121211111121111222121 
MST.con 2222222222222222222222222222222233222222222232322222232222333322 
RCH.Q2 0100000000000000000011111111111111111111111111111111111111111111 
RCH.Q3 0110000000000000000022222222222222222222222222222222222222222000 
RCH.Q5 1311110111110000000333444444444444444444444444444444444444444400 
RCH.con 0300000000000000000033444444444444444444444444444444444444444311 
RNG.Q2 1111111111111100000001000001111010110101011111111111111100111000 
RNG.Q3 1211111111111100000001000001111110111101011111111111111100111000 
RNG.Q5 2322222222222211100012111112222222222212122222222222222211222110 
RNG.con 2322222222222200000002000002222120221202022222222222222200222000 
SA.Q2 1011111111111111111110111100000000000000000000000000000000000011 
SA.Q3 2022212222222222222211122110000100001010110000001000001011000022 
SA.Q5 3033333343444444444433343431001100111111311101011110111131011144 
SA.con 3033333343444444444431343310000000000000100000000000000010000044 
All.con 1311010111001000000023111223333233333323233333333333333322333211 
  
 
0 - 69 0         1         2         3         4         5         6         
seq MAQILPIRFQEHLQLQNLGINPANIGFSTLTMESDKFICIREKVGEQAQVVIIDMNDPSNPIRRPISADS 
SA.Q2 1111000101000101101011100101000010110000001111111000000111110111101000 
SA.Q3 2121100101100202212022210202101012210000112122211000000211221111102011 
SA.Q5 4344201303111303414134431314303034431000123344422000010334433332313131 
SA.con 4343100303000303404034410304101032430000013344422000000333431332303010 
All.con 0100243141333040030300023030242411013444320100011444434010002111130323 
70 - 139 0         1         2         3         4         5         6         
seq AIMNPASKVIALKAGKTLQIFNIEMKSKMKAHTMTDDVTFWKWISLNTVALVTDNAVYHWSMEGESQPVK 
SA.Q2 0000011100001111100000011111011010111000010011100000011000001011111011 
SA.Q3 0000022100001121101001021121011020221000010012210000021000101022222111 
SA.Q5 0001143300003343303013133342133131433010021034320000043000213144443132 
SA.con 0000043300003343301001033342033030433000020034310000043000103044443032 
All.con 4443300144441101142432301101311303001434413410024444401444231300000311 
140 - 209 0         1         2         3         4         5         6         
seq MFDRHSSLAGCQIINYRTDAKQKWLLLTGISAQQNRVVGAMQLYSVDRKVSQPIEGHAASFAQFKMEGNA 
SA.Q2 0010111011010000000111100000000111110100000000111001001000000010101111 
SA.Q3 0021112021010000101221100000001222220101010011222102102010010010112222 
SA.Q5 0133344134130000212443310000003444430302020112444313113010100030314444 
SA.con 0031334033030000101443300000001444430301010001444103003000000030304444 
All.con 4302100300314444232001134444442000004142424332000230330434334414130000 
210 - 279 0         1         2         3         4         5         6         
seq EESTLFCFAVRGQAGGKLHIIEVGTPPTGNQPFPKKAVDVFFPPEAQNDFPVAMQISEKHDVVFLITKYG 
SA.Q2 1101000000111100100000011111111101110010001110110000000001100000000100 
SA.Q3 2201000001112210101001012122221201211010111121111000001012111000000110 
SA.Q5 3412000002234410301003134344443313331121113443331100002034313000000310 
SA.con 3402000001234400300001034344443303330020003341330000001014301000000300 
All.con 0031444442110034143442310100001031013313331002113344442420132444444134 
280 - 349 0         1         2         3         4         5         6         
seq YIHLYDLETGTCIYMNRISGETIFVTAPHEATAGIIGVNRKGQVLSVCVEEENIIPYITNVLQNPDLALR 
SA.Q2 0000000000000000000110000001111000000001100000000111100100111011110011 
SA.Q3 0000000110100011100211000002122211000012211001011222200210121121120012 
SA.Q5 1000010330110011311431000013344332000013313002021344301310343143341023 
SA.con 0000000110000000100430000003344211000003301001010344300300343043340023 
All.con 3444434224334433233013444430100122444430032442423000043034101301103410 
350 - 419 0         1         2         3         4         5         6         
seq MAVRNNLAGAEELFARKFNALFAQGNYSEAAKVAANAPKGILRTPDTIRRFQSVPAQPGQTSPLLQYFGI 
SA.Q2 0111010100010001000100111101100100010111000111001101101111011100000000 
SA.Q3 0211110110111011101200211102100100020212101112002101212212121100010011 
SA.Q5 0343331330331023303301333314300300041434312334003303424434443300021031 
SA.con 0333130310130013101300333304300300040434101334003303414434143300010010 
All.con 4001213124213421242043011130144144403010232110440141020010201144423423 
420 - 489 0         1         2         3         4         5         6         
 312 
 
 
seq LLDQGQLNKYESLELCRPVLQQGRKQLLEKWLKEDKLECSEELGDLVKSVDPTLALSVYLRANVPNKVIQ 
SA.Q2 0011010111000000100001111100110011110100110010011000100000001010011001 
SA.Q3 0022220121100100110012211200110022221101120020012110100010012021121001 
SA.Q5 0143331332100300200034422300331044431411330131034231300020023142233003 
SA.con 0043230332000100200014422300330044430300330030034110300010013041133003 
All.con 4300103101344244134420011044113400003033104303410223144424420302201441 
490 - 559 0         1         2         3         4         5         6         
seq CFAETGQVQKIVLYAKKVGYTPDWIFLLRNVMRISPDQGQQFAQMLVQDEEPLADITQIVDVFMEYNLIQ 
SA.Q2 0001111011001001111011000000100010001100100110011110101001001000101001 
SA.Q3 0002111021012002112112101100110011102101200110122221101011001001212111 
SA.Q5 0003333133013104334134311300330032114301300211144444313033003101424223 
SA.con 0003333033003004334034100100310031004300300220044441303013003000414113 
All.con 4440111301430340110310233244124412330143044113300002131421441343020221 
560 - 629 0         1         2         3         4         5         6         
seq QCTAFLLDALKNNRPSEGPLQTRLLEMNLMHAPQVADAILGNQMFTHYDRAHIAQLCEKAGLLQRALEHF 
SA.Q2 0001000100111111111000100000011111001000111000001011001101111001101100 
SA.Q3 1002000200221222221000100100111112002100212101111112002102212012101200 
SA.Q5 3003001310433344433001300300133343013101334213323133003203433113203411 
SA.con 1003000300433344433000300100033333003000334101113033003203433003203400 
All.con 2440443034001000001443144244311100430343010232221310440140010330141033 
630 - 699 0         1         2         3         4         5         6         
seq TDLYDIKRAVVHTHLLNPEWLVNYFGSLSVEDSLECLRAMLSANIRQNLQICVQVASKYHEQLSTQSLIE 
SA.Q2 1101101000010110111000100110111100100110010000100100010001001100011001 
SA.Q3 2211101100010110212001200121212110200111021111100110020011002201011002 
SA.Q5 4413303200031431334001310341334321310330033313300300030023114313133003 
SA.con 4403303100030330334000300340334310300330031101300300030013004301033003 
All.con 0031141244413013010443034103010123034113402232144134404421330032311440 
700 - 769 0         1         2         3         4         5         6         
seq LFESFKSFEGLFYFLGSIVNFSQDPDVHFKYIQAACKTGQIKEVERICRESNCYDPERVKNFLKEAKLTD 
SA.Q2 0011010010000001100101111100010010001111011001001111001011011001111011 
SA.Q3 1022121120001001101211211201010010002121121011001222011121012001222121 
SA.Q5 1034141230012103312424433300130030004243133033003444123143033103434133 
SA.con 0034040130001003301413433300030030004243033013003444013043033003434033 
All.con 3400303204432341132020011043314414440101301421441000321301410341000301 
770 - 839 0         1         2         3         4         5         6         
seq QLPLIIVCDRFDFVHDLVLYLYRNNLQKYIEIYVQKVNPSRLPVVIGGLLDVDCSEDVIKNLILVVRGQF 
SA.Q2 0100000001010011000000111001000000110000100100010010101110011001001110 
SA.Q3 1100010012120011001000211011001000121111210100010021101221011001101210 
SA.Q5 3200010023141033002101433023103100331214311300020143313431023003203431 
SA.con 1200000013040033001000433013001000330101300300020041303430023003103430 
All.con 2144434420303411442343011421342344103232033144414302131003411441241013 
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840 - 909 0         1         2         3         4         5         6         
seq STDELVAEVEKRNRLKLLLPWLEARIHEGCEEPATHNALAKIYIDSNNNPERFLRENPYYDSRVVGKYCE 
SA.Q2 1011001101111001000100010011111110001100100011111011001101001110011001 
SA.Q3 1022002101212101001100221022112111001100100021122021002212101111012002 
SA.Q5 3133013303333203002310332144434333002300301033443133103414213331013114 
SA.con 3033003303333103001300231044334331002300300033343033003404103330023004 
All.con 1300430141010241442134102300010112441144143401000301340030231113410330 
910 - 979 0         1         2         3         4         5         6         
seq KRDPHLACVAYERGQCDLELINVCNENSLFKSLSRYLVRRKDPELWGSVLLESNPYRRPLIDQVVQTALS 
SA.Q2 1100000000011110111001010100001100000011110100110011101001100100010001 
SA.Q3 2111100000021121122102111111001100100021111200110022212112100200010002 
SA.Q5 3334300100133341333203131310113310210143332300330134433123300310031003 
SA.con 3311100000033340333103030300003300100043331300330034413013300300030003 
All.con 0122244344301103100240313133331134234301112044114300020320144034413440 
980 - 1049 0         1         2         3         4         5         6         
seq ETQDPEEVSVTVKAFMTADLPNELIELLEKIVLDNSVFSEHRNLQNLLILTAIKADRTRVMEYINRLDNY 
SA.Q2 1111111001001000101011000100110001111011011000000000011111100100110110 
SA.Q3 2121121011001101212012100200210112122122111011000001021112101200210220 
SA.Q5 4343243013003101434133301300330134343144223033000000133324302310331441 
SA.con 4343243003003000414033100300330014343044123011000000033324301300330440 
All.con 0101101431441343020310243044014320100300211422444443301110142034013003 
1050 - 1119 0         1         2         3         4         5         6         
seq DAPDIANIAISNELFEEAFAIFRKFDVNTSAVQVLIEHIGNLDRAYEFAERCNEPAVWSQLAKAQLQKGM 
SA.Q2 1011001000111001000100110111110010001101101000100110111100010010001111 
SA.Q3 1121002001212102100100221211120020002111102101200210211200110010102221 
SA.Q5 3143003101434114301301331433330031013313314202310331433300320031114443 
SA.con 3043003000434004100300330433330030003303304101300330433300120030004443 
All.con 1301440343010330243143003011104403430131130242034013011044214413330001 
1120 - 1189 0         1         2         3         4         5         6         
seq VKEAIDSYIKADDPSSYMEVVQAANTSGNWEELVKYLQMARKKARESYVETELIFALAKTNRLAELEEFI 
SA.Q2 0110010001011011011001001111101100100100111111010001000000101101100100 
SA.Q3 0210020002121121012002102212112100200110221222110101000000102102102200 
SA.Q5 0330031003143243133013203434313300300330343343130103000000314313303301 
SA.con 0330030003043143033003103434303300300310343343030003000000304303302300 
All.con 4014403440301201310430240010130144044124001000314341444444130130141043 
1190 - 1259 0         1         2         3         4         5         6         
seq NGPNNAHIQQVGDRCYDEKMYDAAKLLYNNVSNFGRLASTLVHLGEYQAAVDGARKANSTRTWKEVCFAC 
SA.Q2 1110001011001100111101001000110110110000000011011001001101101001100000 
SA.Q3 2111111022002101222102001100210220110010001021012002001112102001100110 
SA.Q5 4334313133003302444313102100331441330030003033033013003314313003300310 
SA.con 4331103033003301444303002000330440330010001033033003003304303003300100 
 314 
 
 
All.con 0112231300440142000130341344013003114424442401410430441130130441144234 
1260 - 1329 0         1         2         3         4         5         6         
seq VDGKEFRLAQMCGLHIVVHADELEELINYYQDRGYFEELITMLEAALGLERAHMGMFTELAILYSKFKPQ 
SA.Q2 0111101000000010011011011001001111001000100100010111100000000000010111 
SA.Q3 0212101001100020011011012001112211102100200110021222111000100000021212 
SA.Q5 1433313103200141133133033003123334113300300330142444423000300001031324 
SA.con 0433303001100040033033033003013333003100300310041444311000100000030324 
All.con 3010131342244303311311410441320010330244044124302000022444244443403010 
1330 - 1399 0         1         2         3         4         5         6         
seq KMREHLELFWSRVNIPKVLRAAEQAHLWAELVFLYDKYEEYDNAIITMMNHPTDAWKEGQFKDIITKVAN 
SA.Q2 1001001100110101100100110000100000011011011001000100110010100010001000 
SA.Q3 1012102100210102100210111100210000011122021001000211221121210120002011 
SA.Q5 3023103201431313300320332301330010133243143002101433441243420230013133 
SA.con 3013003200430303300310331100310000033143043002000411440141410130003011 
All.con 1420340143013130144024112243024434311200301441343022003202024204430322 
1400 - 1469 0         1         2         3         4         5         6         
seq VELYYRAIQFYLEFKPLLLNDLLMVLSPRLDHTRAVNYFSKVKQLPLVKPYLRSVQNHNNKSVNESLNNL 
SA.Q2 0100010000001110100010010011101000001001101101001100110010001000100010 
SA.Q3 1110020010002111210010010012201111002102212201001200110021012101200020 
SA.Q5 2320130031104331310130030034313112003203434313103310230032013301300030 
SA.con 1310030010004330300030030034303001003103414303003300230031003100300030 
All.con 2124304423340113034314414410031332440240020031341034114402430243044404 
1470 - 1539 0         1         2         3         4         5         6         
seq FITEEDYQALRTSIDAYDNFDNISLAQRLEKHELIEFRRIAAYLFKGNNRWKQSVELCKKDSLYKDAMQY 
SA.Q2 0010100110110011011010010011011010010010000001101101100100110100110010 
SA.Q3 0011210210120022012011020021022120110110001001112102100200121210210020 
SA.Q5 0033331330330043143132130033044330130230002013334313300310344311330031 
SA.con 0031310330330043033031030033044130030130001003314303300300341300330030 
All.con 4412023014104400300312304401400204314214442431120130144034102033014403 
1540 - 1609 0         1         2         3         4         5         6         
seq ASESKDTELAEELLQWFLQEEKRECFGACLFTCYDLLRPDVVLETAWRHNIMDFAMPYFIQVMKEYLTKV 
SA.Q2 0010111100010010001111100000000000100100000000000100100000001000100110 
SA.Q3 0121211200110021002122120000000100200101000110011201200100101011200210 
SA.Q5 0132433410330031014343341000001101311313001300021413310100203102311330 
SA.con 0031433400130030004343320000000000300301000100010401300000103001300330 
All.con 4302011034214403430100113444443343033132443234423032034344241332033014 
1610 - 1675 0         1         2         3         4         5         6     
seq DKLDASESLRKEEEQATETQPIVYGQPQLMLTAGPSVAVPPQAPFGYGYTAPPYGQPQPGFGYSM 
SA.Q2 11011111111111111111110111100000000000000000000000000000000000011 
SA.Q3 22022212122222222222211122110000100001010110000001000101011000022 
SA.Q5 33033333343444444444433343431001100111111311101011111111131011144 
 315 
 
 
SA.con 33033333343444444444431343310000000000000100000000000000010000044 
All.con 00400010100000000000012100023443344333333233343433333333323433300 
 
 
  
 
10-Appendix IV 
ICOS 3D prediction software results for murine &+&Į The first table shows the 
analysis of the 2D and 3D rearrangements, point of contact of adjacent aa and their 
exposure to the solvent. In the second analysis, only the exposure to the solvent is 
taken into account. The region highlighted in yellow refers to the epitope of the mAb 
clone X22. The µAll.con¶ bottom row gives a final score for all the parameters taken 
into account by the analysis.  
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0 - 69 0         1         2         3         4         5         6         
seq AQILPIRFQEHLQLQNLGINPANIGFSTLTMESDKFICIREKVGEQAQVVIIDMNDPSNPIRRPISADSA 
cCN.Q2 0001111111110100101000110101111110111111100000111111110000011110101111 
cCN.Q3 0012221212221211112000121211222121122222211001122222221011121111212122 
cCN.Q5 1133443434342311313111341433444343344443412001334444441113133333314444 
cCN.con 0013443434341300303000340413444341344443401000334444440001033331304344 
dCN.Q2 0011111111110100101000110100111110111111100000111111110000010110101011 
dCN.Q3 0012221212221211212010121211212121122222211001112222221011121121212222 
dCN.Q5 1113443434441311313111131311434111344444311111334444441111132131314144 
dCN.con 0023443434440300303000230300434230344444300000334444440000031230304144 
DT.Q2 1111111111111111010111111111111101111111100010011111111111111111110111 
DT.Q3 1111111111111111111111111111111111111111111121111111111111111111111111 
DT.Q5 4333333333333333030434333343333334333333300040033333333033333333340433 
DT.con 3333333333333333030333333333333313333333300040033333333233333333330333 
GG.Q2 0001110111110100101000110101111110011111100000011111110000010000101011 
GG.Q3 0002221210220200102000020100212000122222000000012222220000000010201012 
GG.Q5 0013342421331311203110131211324111234343211001124444341101111121313123 
GG.con 0003341421330300203000130201324110134343200000024444340000010010303023 
MST.Q2 0111111111111111111011111111111111111111111111111111111111111111111111 
MST.Q3 0111111111111111111011111111111111111211111111111111111111111111112112 
MST.Q5 0111111111111111112011111111111111111211111111111111111111111111112112 
MST.con 0222222222222222222022222222222222222322222222222222222222222222223223 
RCH.Q2 0001111101110100101000110101111100111111000000011111110000011110101111 
RCH.Q3 0002222212221222101010121222222222222222101000112222220011122212202222 
RCH.Q5 0014444434444344343000331444444444444444313000333444430033333333404444 
RCH.con 0004444414441322313000330424444422444444101000133444430011133332404444 
RNG.Q2 0001111111110100101000010100111110011111100000011111110000010000101011 
RNG.Q3 0001221211110100101000110100212110022222100000012222110000010000101012 
RNG.Q5 0012332322221211202010221212323221133333211001223333221111121111212123 
RNG.con 0002332322220200202000120200323220033333200000023333220000020000202023 
SA.Q2 1110001010001011010111001010000101100000011111110000001111101111010000 
SA.Q3 2220001011002022120222102021010122100001121222110000002112211111020110 
SA.Q5 4441013031113034141344313143030344310001233444220000103344333323131310 
SA.con 4440003030003034040344103041010324300000133444220000003334313323030100 
All.con 0013332323331311212010231312333221233333201000123333331011121221313233 
70 - 139 0         1         2         3         4         5         6         
seq IMNPASKVIALKAGKTLQIFNIEMKSKMKAHTMTDDVTFWKWISLNTVALVTDNAVYHWSMEGESQPVKM 
cCN.Q2 1111001111111011111111000011111010011111111000111111111111111000001111 
cCN.Q3 2222111222221111222212011012112121112222222111222222112222212100112122 
cCN.Q5 4444213444433132434433111123334231324444444322344444334444434100013334 
cCN.con 4444103444433032434433000023334130124444444111344444334444434000003334 
 318 
 
 
dCN.Q2 1111001111110001111111000011111010001111111000111111011111111000001111 
dCN.Q3 2222112222221111222212011012112121112222222111222222112222212100012122 
dCN.Q5 4443113444431122434413111113334131114444343111344444114443423111113334 
dCN.con 4443003444430012434423000023334030004444343000344444024443423000003334 
DT.Q2 1111111111111111111111111111111111111111111111111111100111111101011111 
DT.Q3 1111111111111111111111111111111111111111111121111111211111111112111111 
DT.Q5 3333333333333333333333333333333334443333333043333333400333333444033333 
DT.con 3333333333333333333333333333333333333333333243333333400333333314033333 
GG.Q2 1111000111110000111111010001001010001111111000111111011111101000001111 
GG.Q3 2211001222210001212202010002012020002222122000122222001222212000002112 
GG.Q5 4332112443421112424314121113213131114343234101243443112443423100012224 
GG.con 4332001443420001424314020003003030004343234000243443012443413000003224 
MST.Q2 1111111111111111111111111111111111111111111111111111111111111111111111 
MST.Q3 1111111112111111111111111111111111111111111101112111111111111111111111 
MST.Q5 1111111112111111111111111111111111111111111111112111111111111111111111 
MST.con 2222222223222222222222222222222222222222222212223222222222222222222222 
RCH.Q2 1111001111100001111111000011011010001111111000111111001111101000001111 
RCH.Q3 2222222222221011222222011012212222122222222101222222222222222000102122 
RCH.Q5 4444444444433033344443033133343444344444444404344444444444443300313334 
RCH.con 4444224444421013344443011033233242124444444101344444224444423000103334 
RNG.Q2 1111000111110001111101010001011010001111111000111111011111111000001111 
RNG.Q3 2211000222211001212201010001012010002122121000122222012221211000002112 
RNG.Q5 3322111333321112323312121112123220113233232101233333123332322110113223 
RNG.con 3322000333320002323302020002023020003233232000233333023332322000003223 
SA.Q2 0000111000011111000000111110110101110000100111000000110000010111110110 
SA.Q3 0000221000011211010010211210110202210000100122100000210001010222221110 
SA.Q5 0011433000033433030131333421331314330100210343200000430002131444431320 
SA.con 0000433000033433010010333420330304330000200343100000430001030444430320 
All.con 3333112333321112333323011013123131113333233111333333123333323100013223 
140 - 209 0         1         2         3         4         5         6         
seq FDRHSSLAGCQIINYRTDAKQKWLLLTGISAQQNRVVGAMQLYSVDRKVSQPIEGHAASFAQFKMEGNAE 
cCN.Q2 1010001011111111110001111111111000011111111110001101101111111110100000 
cCN.Q3 2121112122222222211011222222211001121222222211111212212222222121201000 
cCN.Q5 4332033334344443431133444444433001243434344431112434444444444342310101 
cCN.con 4131013134344443430013444444433000143434344430002414414444444341300000 
dCN.Q2 1010001011111111100001111111110000011111111110001111101111111110100000 
dCN.Q3 2121112112222222210011222222211001121222222220001212212222222121200000 
dCN.Q5 4131114114344443311113444444431111143434344331113314414444444341311111 
dCN.con 4030004024344443300003444444430000043434344330003324404444444340300000 
DT.Q2 1111111111111111111110111111101110111011111111111111111111111111110010 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111121111 
 319 
 
 
DT.Q5 3333333330333333334430333333303440333033333334333333343333333333340040 
DT.con 3333333332333333333330333333303330333033333333333333333333333333340030 
GG.Q2 1010001001011111100000111111110000010111111110001101101111111010100000 
GG.Q3 2010002002122221210000222222200000021212122110000001201121022021200000 
GG.Q5 3121113113244332320011344433411001132324243221111112312222133142300101 
GG.con 3020003003144332310000344433410000031324243220001102302232133041300000 
MST.Q2 1111111111111111111111111111111111111111111111111111111111111111111111 
MST.Q3 1111111111111111111111111112111111111211111111111111112122112111111111 
MST.Q5 1111111111111111111111111112111111111211111111111111112122112111111111 
MST.con 2222222222222222222222222223222222222322222222222222223233223222222222 
RCH.Q2 1011101001111111100000111111110000011111111110000101101111111010100000 
RCH.Q3 2222222122222222210011222222211000022222222210001222222222222222200000 
RCH.Q5 4333343444444444330033444444433000133444444330103334444444444434300101 
RCH.con 4233323124444444310011444444431000033444444330001324424444444232300000 
RNG.Q2 1010001001111111110000111111110000011111111110000101101111111111100000 
RNG.Q3 2010001002122221210000222222210000021212122110001101101111122121100000 
RNG.Q5 3121112112233232220011333333321001132323233220111212212222223232201101 
RNG.con 3020002003233332320000333333320000032323233220000202202222233232200000 
SA.Q2 0101110110100000001111000000001111101000000001110010010000000101011111 
SA.Q3 0211120210100001012211000000012222201010100112221021020100100101122222 
SA.Q5 1333441341300002124433100000034444303020201124443131130101000303144443 
SA.con 0313340330300001014433000000014444303010100014441030030000000303044443 
All.con 3131113113233333320011333333321000132333333320002313313333333231300000 
210 - 279 0         1         2         3         4         5         6         
seq ESTLFCFAVRGQAGGKLHIIEVGTPPTGNQPFPKKAVDVFFPPEAQNDFPVAMQISEKHDVVFLITKYGY 
cCN.Q2 0111111111000111111111100000010110111111110010011111111101111111111111 
cCN.Q3 1222222222111221222222100000111211122222212111122222222101222222222222 
cCN.Q5 1444444443333343444444110000133333344444433133344444444312444444444444 
cCN.con 0444444443111343444444200000031331344444432031144444444302444444444444 
dCN.Q2 0111111111000111111111000000010100111111100010011111111000111111111111 
dCN.Q3 1222222222111221222222100000011221222222211011122222222101222222222222 
dCN.Q5 1334444433111342444414111111111321334443411111144444434111444444444444 
dCN.con 0334444433000342444434000000020310334443400020044444434000444444444444 
DT.Q2 1011111111011001111111111110011111111111111101111111111011111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111121111111111111 
DT.Q5 4033333333033003333333044340433333033433334433333333333343333333333333 
DT.con 3033333333033003333333233330133333233333333313333333333143333333333333 
GG.Q2 0111111111000010111101000000000100001011100010011111111000101111111111 
GG.Q3 0212222211000001222202000000010200102221100000002222212000112222221212 
GG.Q5 1324444322100122434413000100011311123232210011113343424101224444432233 
GG.con 0324444322000021434403000000000300003132200010013343424000214444432333 
 320 
 
 
MST.Q2 1111111111111111111111111111111111111111111111111111111111111111111111 
MST.Q3 1111111211111121111111211111111111111111111111111112111101121111111121 
MST.Q5 1111111211111121111111111111111111111111111111111112111111121111111121 
MST.con 2222222322222232222222322222222222222222222222222223222212232222222232 
RCH.Q2 0111111111000111111101000000010111111111111010111111111000111111111111 
RCH.Q3 0122222221211222222222100000010221222222222212122222222201222222222222 
RCH.Q5 1334444444333444444443300000033333444444444044444444443303344444444444 
RCH.con 0334444443211444444423100000030333444444444132344444443201344444444444 
RNG.Q2 0111111111000011111101000000000100011010100010011111111100101111110111 
RNG.Q3 0112222211000011212201000000000100012011100010001122212100112222221112 
RNG.Q5 0223333322111122323322110001111211123121210021112233323201223333322223 
RNG.con 0223333322000022323302000000000200023020200020012233323200213333331223 
SA.Q2 1010000001111001000000111111111011100100011101100000000011000000001000 
SA.Q3 2010000011122101010010121222212012110101111211110000010121110000001100 
SA.Q5 4120000022344113010031343444433133311211134433311000020343130000003101 
SA.con 4020000012344003000010343444433033300200033413300000010143010000003000 
All.con 1223333332111232333323100000021311223232311121123333333101323333332333 
280 - 349 0         1         2         3         4         5         6         
seq IHLYDLETGTCIYMNRISGETIFVTAPHEATAGIIGVNRKGQVLSVCVEEENIIPYITNVLQNPDLALRM 
cCN.Q2 1111111111111111110011111100000111111100111111110000110110011000011001 
cCN.Q3 2222222222222221221122222211001122222211212222221001221221011000022111 
cCN.Q5 4444444444444443431344444411003444444411334444442101331331023011033113 
cCN.con 4444444444444443430144444400001344444400334444441000330330023000033003 
dCN.Q2 1111111111111111110011111100000111111100111111110000110110001000011001 
dCN.Q3 2222222222222222221222222210001122222211212222221100220121011000012111 
dCN.Q5 4444444444444333431144444411111144444311324444331111331331112011033213 
dCN.con 4444444444444333430144444400000244444300324444330000330330002000033103 
DT.Q2 1111111111111111101111111111110011111111111111111110111111111101111111 
DT.Q3 1111111111111111111111111121111111111111111111111211111111111111111111 
DT.Q5 3333333303333333304433333344443033333334333333333440333333333303433333 
DT.con 3333333323333333303333333343331033333333333333333430333333333303333333 
GG.Q2 1111111111111111110011111100000001111100001111110000110111011000011111 
GG.Q3 2222120021222101210012222200000002222100102222120000220221011000022212 
GG.Q5 4344231132343212321124443311001124434211214434231011431342122111143323 
GG.con 4344231132343212320024443300000004434200104434230000430342022000043323 
MST.Q2 1111111111111111111111111101111111111111111111111111111111111111111111 
MST.Q3 1111111121111111111111111201111121121111211111111111111111111110112111 
MST.Q5 1111111121111111111111111201111121121111211111111111111111111111112111 
MST.con 2222222232222222222222222302222232232222322222222222222222222221223222 
RCH.Q2 1111111111111111110011111100000111111100111111110000111110001000011001 
RCH.Q3 2222222222222222222222222200001222222200222222210001222221111000022112 
 321 
 
 
RCH.Q5 4444444444444444444444444303003344444400344444431000344343333010034333 
RCH.con 4444444444444444442244444300001344444400344444430000344341113000034113 
RNG.Q2 1111111111111111110011111100000011111100111111110000110111111000011111 
RNG.Q3 2222111111111111110012221100000012222100112212110000110121111000012111 
RNG.Q5 3333221222232222221123332201001123333211223323221101221222222110133222 
RNG.con 3333222222232222220023332200000023333200223323220000220232222000033222 
SA.Q2 0000000000000000001100000011110000000011000000001111001001110111100110 
SA.Q3 0000001101000111002110000021222110000122110010112222002101211211200120 
SA.Q5 0000103301100113114310000133443320000133130020213443013103431433410230 
SA.con 0000001100000001004300000033442110000033010010103443003003430433400230 
All.con 3333332333333332321133333301001133333311323333331100331331122000033213 
350 - 419 0         1         2         3         4         5         6         
seq AVRNNLAGAEELFARKFNALFAQGNYSEAAKVAANAPKGILRTPDTIRRFQSVPAQPGQTSPLLQYFGIL 
cCN.Q2 0000010010011100100110000100110111010001110001100100100001011111111011 
cCN.Q3 0111020121012111210220110100221222120001211102201210100111112222122112 
cCN.Q5 1121030231033312311331111311341343131103311213312310211313133444333333 
cCN.con 0010030130033301300330000300340343030003320103301300200103033444333133 
dCN.Q2 0000010010001100100110000100110111010001110001100100100001000111111011 
dCN.Q3 0011020120012111210220110100221222110101211102101110100112111222122112 
dCN.Q5 1111131131123211311330111311331343131112311103311310211111121444233133 
dCN.con 0000030030013200300330000300330343030002320003300300200003010444233033 
DT.Q2 1111111111111111111111101110111111101111111111111111111010011111111101 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3333333333333333333333330333333333303333333343333333033330033333333303 
DT.con 3333333333333333333333312331333333303333333333333333233130033333333303 
GG.Q2 0110010111111111111110000100111111010001100001101110100000000111111111 
GG.Q3 1010021122122211211220000201221222010001200002212210100000000222222122 
GG.Q5 2122032242234323422441111312442443121112321113423421201110111344344234 
GG.con 1120031243234323422440000301442443020002300003413420200000000344344234 
MST.Q2 1111111111111111111111111101110111111111111011101111111111111111111111 
MST.Q3 1111110121111111111111111101221121111111111011111111111112111111111011 
MST.Q5 1111111111111111111111111101220121111111111111111111111112211111111011 
MST.con 2222221232222222222222222202330232222222222022202222222223222222222122 
RCH.Q2 0000010111011111100110000100110111010001100001101100000000011111111011 
RCH.Q3 0111020222222222211221110101221222120102211002211201100111122222222222 
RCH.Q5 1333031343434433433334330301343444430303333303333330301333344444444434 
RCH.con 0111030343234433411331110300341444130103311003313300100111144444444234 
RNG.Q2 1110010111111111111110000101111111010001100001111100100000000111111111 
RNG.Q3 1110010121112111211220000101221221010001100002211100100001000122122112 
RNG.Q5 2221121232223222322331111212332332120112211112322211201111111233233223 
RNG.con 2220020232223222322330000202332332020002200003322200200000000233233223 
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SA.Q2 1111101000100010001001111011001000101110001110011011011110111000000000 
SA.Q3 2111101101110111012002111021001000202121011120021012122121211000100110 
SA.Q5 3333313303310233033013333143003000414343123340033034244344433000210310 
SA.con 3333303101300131013003333043003000404341013340033034144341433000100100 
All.con 1111031232123322321331110301331333120102311103312310200111011333333223 
420 - 489 0         1         2         3         4         5         6         
seq LDQGQLNKYESLELCRPVLQQGRKQLLEKWLKEDKLECSEELGDLVKSVDPTLALSVYLRANVPNKVIQC 
cCN.Q2 1000010011111110111000000110011000010110011011001110111111001011001101 
cCN.Q3 1000120012221221222100110220121000110220121022001221222122112011012212 
cCN.Q5 3010131133343443443201120331233001131331133033103441443334213133134334 
cCN.con 3000030033343441443100010330133000030330033033003440443334103033014314 
dCN.Q2 1000010011110110111000000110011000010110011011001010111011001011001101 
dCN.Q3 1000020011221221222100010220121000120221021022001120222122102012012212 
dCN.Q5 3011131122331441333111121331133001131331132133112131444133113121114314 
dCN.con 3000030022330440333000010330033000030330032033002030444033003023004304 
DT.Q2 1110011111111111111111111111011111111111110111110111111111110111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3330033333333333333333033333033344334333330333330333333333330303333333 
DT.con 3330033333333333333333233333033333333333330333330333333333330323333333 
GG.Q2 1000010011111111111000010111111000010100011011000010111111101010011111 
GG.Q3 2000010012221222222000010221122000020110022022001020222222202000012212 
GG.Q5 3111131123343443334111121442244111131321143143112131444344313012124424 
GG.con 3000030023343443334000020442244000030310043043001030444344303010024424 
MST.Q2 1111111111111111111111111110111111111110111011011111111111111111011111 
MST.Q3 1111111111111111111111111110111111111110112111111111121111112111011111 
MST.Q5 1111111111111110111111111110111111111110112011011111121111112111111111 
MST.con 2222222222222222222222222220222222222220223022022222232222223222022222 
RCH.Q2 1000010011111111111000000110111000011110011011001111111111101001011111 
RCH.Q3 2000111122222222222110110221121001110220021022002222222222212012122222 
RCH.Q5 3013130134444444443330330343333001333333333033103434444444443333134444 
RCH.con 3000030034444444443110110341333000132330033033003434444444413013034444 
RNG.Q2 1000010001111111111100000111111000010100011111000010111111101010011111 
RNG.Q3 1000010001121221121100000221122000010110022121000010222122101010012212 
RNG.Q5 2111121112232332232210111332233111121211132232111121333233213121123323 
RNG.con 2000020002232332232200000332233000020200033232000020333233203020023323 
SA.Q2 0110101110000001000011111001100111101001100100110001000000010100110010 
SA.Q3 0222201211001001100122112001100222211011200200121101000100120211210010 
SA.Q5 1433313321003002000344223003310444313113301310342313000200231422330030 
SA.con 0432303320001002000144223003300444303003300300341103000100130411330030 
All.con 3000031123332332333110110331133001131320132033002231333233213022023323 
490 - 559 0         1         2         3         4         5         6         
 323 
 
 
seq FAETGQVQKIVLYAKKVGYTPDWIFLLRNVMRISPDQGQQFAQMLVQDEEPLADITQIVDVFMEYNLIQQ 
cCN.Q2 1100001001101100001001110110011011100110110111000011101101101110100101 
cCN.Q3 2211102002102200102122221221122112201210221221000021212212202210101101 
cCN.Q5 4312013013313301113244432332233131301331342233000033414113313330201212 
cCN.con 4301003003303300003124431331133033300330341333000033404303303330200202 
dCN.Q2 1100001001101100001001110110011011100110110111000010101101101110000101 
dCN.Q3 2201101002102101102122221221122112201210221121000021212012201210101101 
dCN.Q5 4311113113213311113111331331133133311321341133000132413313313321211211 
dCN.con 4300003003203300003013330330033033300320340233000031403203303320100202 
DT.Q2 1110001101111111111111111111111111111001111111111111111111111111010111 
DT.Q3 1111111111111111111111111111111111111111111111112111111111111111111111 
DT.Q5 3333303333333333330343333333333333340333333333344433333333333333033333 
DT.con 3331103313333333332333333333333333332113333333334333333333333333031333 
GG.Q2 1100001001111100001001111111111010101111111111000000101011101110101101 
GG.Q3 2211012012212200001000221221122121201221222222000000202012212220201201 
GG.Q5 4412124124324411112111332442244122312432443343100011314124424431212312 
GG.con 4401014014324400002001332442244031302432443343000000304024414430302302 
MST.Q2 1101111011101101111111111111111111101111111111111111111111111111111111 
MST.Q3 1101111111101101111111111110111111101210121111111111111111111111111111 
MST.Q5 1111111111101101111111111110111111101211121111111111111111111111111111 
MST.con 2202222022202202222222222221222222202321232222222222222222222222222222 
RCH.Q2 1101001001101100001001111111111111100110111111000011101101101110000101 
RCH.Q3 2221112002102101101222222222222222201210222221000011222222222222201212 
RCH.Q5 4444313013313313303344444443444434303331444433000033444444444434303334 
RCH.con 4423103003303301103224444443444434301330444433000033424424424432201314 
RNG.Q2 1111001011111110001000111111111010101111111111000010101011111110101101 
RNG.Q3 2201001012112210001000111221121010101211221111000010101012212210100101 
RNG.Q5 3312112123223321102111222332232122212322332222100021212123322321202212 
RNG.con 3312002023223320002000222332232020202322332222000020202023323320202202 
SA.Q2 0011110110010011110110000001000100011001001100111101010010010001010010 
SA.Q3 0021110210120021121121011001100111021012001101222211010110010012121111 
SA.Q5 0033331430131043341343113003300311143013002101444433130330031014242233 
SA.con 0033330430030043340341001003100300043003002200444413030130030004141131 
All.con 3311103013213301102112332332233132301321332232000021313223313331201212 
560 - 629 0         1         2         3         4         5         6         
seq CTAFLLDALKNNRPSEGPLQTRLLEMNLMHAPQVADAILGNQMFTHYDRAHIAQLCEKAGLLQRALEHFT 
cCN.Q2 1101110110000000001110110111000001101110001111101001100100001100100110 
cCN.Q3 2202210120000000012221221221010002101220101222101102201200102101210110 
cCN.Q5 3313331331111001013333333333111013313431113443313113312310203302320330 
cCN.con 3303330330000000003331331333000003303430003443303003301300103301310330 
dCN.Q2 1101110110000000001110110111000001101110001101101001100100001100100110 
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dCN.Q3 2202210110000000002221221221010002201220101221101102201200101101210110 
dCN.Q5 3313331331111001113331331333111113312331112412213113311311103201310330 
dCN.con 3303330330000000003330330333000003302330002412203003300300003200300330 
DT.Q2 1111111111110111011111111111100101111111111111111111011111001111111011 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3333333333340444033333333333330433330333333333333303133333003333333034 
DT.con 3333333333330333033333333333310313332333333333333323033333003333333033 
GG.Q2 1111111110000000001111111111000001111110001111001001101110001101110110 
GG.Q3 2212221220000000002221221222000002212220001201002012212210102202220210 
GG.Q5 4324432441101000124333442433111114323441112311213224423421224323321320 
GG.con 4324432440000000004333442433000004323440002312003014413420104303330320 
MST.Q2 1101111111111111111111111111111111111111111111111111101111111111111111 
MST.Q3 2111111111111011211111111111111111111111111111111011201111122111211111 
MST.Q5 2111111111111011211111111111111111111111111111111111201110121111211111 
MST.con 3202222222222122322222222222222222222222222222222122302222233222322222 
RCH.Q2 1101110110000000001111111111000001101110001111101001100100001101100110 
RCH.Q3 2212222220000001012222222222010002222222112222202101201110102101210110 
RCH.Q5 4444444331000000133444444443131003444444343444313313303330303333330330 
RCH.con 4414442330000000013444444443010003424442113444303103301310103303310330 
RNG.Q2 1111111110000000001111111111000001111110001111001011111110001111110110 
RNG.Q3 2212211120000000001111221211000002112210001111001012211210101111210110 
RNG.Q5 3223322331101001112222332332111113222321102212112123322321212222321220 
RNG.con 3323322330000000002222332332000003223320002222002023322320102222320220 
SA.Q2 0010001001111111110001000000111110010001110000010110011011110011011001 
SA.Q3 0020002002212222210001001001111120021002121011111120021022120121012002 
SA.Q5 0030013104433444330003003101333430131013342133231330032034331132034114 
SA.con 0030003004433444330003001000333330030003341011130330032034330032034004 
All.con 3313331330000000013332332333110003313331112322213113312310103212320220 
630 - 699 0         1         2         3         4         5         6         
seq DLYDIKRAVVHTHLLNPEWLVNYFGSLSVEDSLECLRAMLSANIRQNLQICVQVASKYHEQLSTQSLIEL 
cCN.Q2 0100111111010010001100110010000110110011000000110111011001100111001101 
cCN.Q3 0201211222121120102210120010101110221012011111221222022112101212002101 
cCN.Q5 1311323343231231113320331130201321331033112212331343133213201333113303 
cCN.con 0300323343130130003310330030100320330033001101330343033103200333003303 
dCN.Q2 0100101111010010001110110010000110110011000000110111011001100101001101 
dCN.Q3 0101212222121120102210120010101110221012011111220122122111101212012101 
dCN.Q5 1311311443131131113321331131101220331023111111331343133113301313113303 
dCN.con 0300303443030030003320330030000220330023000000330343033003300303003303 
DT.Q2 1111111111111111111111111111111111011111101100111111111111111101101111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 4333333333333334333333330330343333333333000330333333333333340303303333 
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DT.con 3333333333333333333333332332333333133333202310333333333333332303303333 
GG.Q2 0100111111010010001110110010001110111011011111111111111111100101001101 
GG.Q3 0100222222010020002220220010001221221122111211221222122222200202012212 
GG.Q5 1211433442121131113431341131212332342234212322442444243334311313124424 
GG.con 0200433443020030003430340030002331342134122322442444243334300303014414 
MST.Q2 1111111111111111101110111111101110111111111111111111111111101111011101 
MST.Q3 1111111111111111101110111111101110211111111111111111112111111121011101 
MST.Q5 1111111111111111101110111111101110211111111111111111112111101121011101 
MST.con 2222222222222222202220222222202220322222222222222222223222202232022202 
RCH.Q2 0100111111111010001110110010000110110011000100110111011001100111001101 
RCH.Q3 0101212222222220002221221010102210221222111211221222122112200222012101 
RCH.Q5 0303344444444331304434443030303331343333133333443443344333300333033303 
RCH.con 0301334444444230004431441030102330341233011311441443144113300333013303 
RNG.Q2 0101111111010010001111110010001111111111111111111111111111100111011111 
RNG.Q3 0100211211010010001211110010001111221112111111221121122112100101012212 
RNG.Q5 1211322322121120113322221121112222332223222222322233233223211222123323 
RNG.con 0201322322020020003322220020002222332223222222332233233223200222023323 
SA.Q2 1011010000101101110001001101111001001100110000001000100010011000110010 
SA.Q3 2111011000101102120012001212121102001110211111001100200110022010110020 
SA.Q5 4133032001314313340013103413343213103300333233103000300231143121330131 
SA.con 4033031000303303340003003403343103003300331111003000300130043010330030 
All.con 0201323333131130103321331020102221331133112211331333133223300323013303 
700 - 769 0         1         2         3         4         5         6         
seq FESFKSFEGLFYFLGSIVNFSQDPDVHFKYIQAACKTGQIKEVERICRESNCYDPERVKNFLKEAKLTDQ 
cCN.Q2 1001011001111100110110000111011011101001001001100001101001001100001001 
cCN.Q3 2001021012212210210100110122122122101001012102210002101002101210011001 
cCN.Q5 3103133133323331331301110333244234312013023313310013313013212310113113 
cCN.con 3003033013323310330310000333144134302003013103300003303003102300003003 
dCN.Q2 1001011001111100110110000111011011100001001001100001100001001100001001 
dCN.Q3 2001021012211210210100010121122122201001012102200002101001001210001001 
dCN.Q5 3113133113322311331231111333143134311112113113311113311013113310113111 
dCN.con 3003033003322300330220000333043034300002003003300003300003003300003002 
DT.Q2 1110111111111111101011011111111101111010111111111110111111111111110111 
DT.Q3 1111111211111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3330333433333333303034033333333333333003333333334440333303333334003443 
DT.con 3330333433333333303033033333333313333021333333333330333323333333221333 
GG.Q2 1101011011111110110000000111111111101001001111100001101001101110001000 
GG.Q3 2001011012222210210100000222122122201002012112210002101012112220001000 
GG.Q5 4112122023333421321210121343244234312113124224321113212114223431112011 
GG.con 4102022023333420320100000343244234302003014224310003202004213430002000 
MST.Q2 1111111111111111111111111111111011111111111111111111111011111111111011 
 326 
 
 
MST.Q3 1111111021111111111111111211111022111111111111111111111111111111111011 
MST.Q5 1111111021111111111111111111111022101111111111111111111011111111111011 
MST.con 2222222132222222222222222322222033222222222222222222222022222222222022 
RCH.Q2 1001011011111110110100000111111111100001001001100001100001001110000001 
RCH.Q3 2101022222222222221110000222222222201101112212221102101011111210001002 
RCH.Q5 3303044444444444430330133344444444303013033333330003303013333330103004 
RCH.con 3103044244444442430310000344444444301003013213320003301003113330001004 
RNG.Q2 1101011011111110110000000111111111101001011111100001100011111110001000 
RNG.Q3 2101010011111210110000000111122122101001012112100001100012112210001000 
RNG.Q5 3212022022222221221110111222233233312112123223211112211123223321102011 
RNG.con 3202022022222320220000000222233233302002023223200002200023223320002000 
SA.Q2 0110100100000011001101111000100000011110110010011110010110110011110110 
SA.Q3 0221211110111012112112112010100100021211210110012220111210120012221211 
SA.Q5 0341412300121033124344333101300300042431330330034441231430331034341333 
SA.con 0340401300010033014314333000300100042430330130034440130430330034340331 
All.con 3102032123323321320110010333233233302002013213310003202013113320002012 
770 - 839 0         1         2         3         4         5         6         
seq LPLIIVCDRFDFVHDLVLYLYRNNLQKYIEIYVQKVNPSRLPVVIGGLLDVDCSEDVIKNLILVVRGQFS 
cCN.Q2 0111111101011001101110001101101110010110110111111010100011001101100010 
cCN.Q3 1222222211022012212220002112211221111211221222222120200022112211210121 
cCN.Q5 3444434313133113323431113213333331133433443444444141310133213333310231 
cCN.con 1444434303033003313430003203313330031431441444444040300033103313300130 
dCN.Q2 0111111001011001101110001101101110010100110111111010100011001101100010 
dCN.Q3 1222222111022002212220002112212220012211221222222020200012112211200110 
dCN.Q5 2344344113133113313331113213313331131311431444444131311133113412311131 
dCN.con 1344344003033003303330003203303330031300430444444030300033003402300030 
DT.Q2 1111111110111111111111111111111111100111111111111111011111011111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3333333333433333333333333333330333333333333333333334343333033333333333 
DT.con 3333333331333333333333333333332333311333333333333333133333033333333333 
GG.Q2 0111111101011001111110001101111110011000110111011010100011111111110010 
GG.Q3 1222222001022012222220002212212221020000110222022010100022112222210020 
GG.Q5 2344343112134124423441113324423442131111221343233121211134224433421131 
GG.con 1344343102034014433440003314423441031000220343033020200034224433420030 
MST.Q2 1111111111111011111111111111111111111111111111111111111111111111111111 
MST.Q3 1111112111111011111110111111111111111111111112111111211111111111111111 
MST.Q5 1111112111111011111110111111111111111111111112111111211111111111111111 
MST.con 2222223222222022222221222222222222222222222223222222322222222222222222 
RCH.Q2 0111111111011001111110001111111111011111110111111010100011101111100110 
RCH.Q3 2222222222022022222222102222222222222222222222222222211022122222212220 
RCH.Q5 4444444444033034434434304344444443144444444444444443300033334444433330 
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RCH.con 2444444444033024434432104344444443144444442444444242300033324444412330 
RNG.Q2 0111111101011011111110001111111110010100100111111010100011111111110010 
RNG.Q3 1122122101011012212210001112211221011100100121111010100012112211210010 
RNG.Q5 1233233212022123323321102223322332122211221232122120211123223322321221 
RNG.con 0233233202022023323320002223322331021200200232222020200023223322320020 
SA.Q2 1000000010100110000001110010000001100001001000100101011100110010011101 
SA.Q3 1000100121200110010002110110010001211112101000100211012210110011012101 
SA.Q5 2000100231410330021014330231031003312143113000201433134310230032034313 
SA.con 2000000130400330010004330130010003301013003000200413034300230031034303 
All.con 1333333212033013323331103223323331122221331333233131310033123323311131 
840 - 909 0         1         2         3         4         5         6         
seq TDELVAEVEKRNRLKLLLPWLEARIHEGCEEPATHNALAKIYIDSNNNPERFLRENPYYDSRVVGKYCEK 
cCN.Q2 1001100100001101111110001001000111100110111000001001100101100011101100 
cCN.Q3 2002101200101212210221011000101122211221222010002001200102211112112200 
cCN.Q5 3113302310212313331331023011101333302343333110113113311313313233213311 
cCN.con 3003301300102303331330013001000333301341333000003003300303301133203300 
dCN.Q2 1001100100000101110110001001000101100110111000001001100101100011001100 
dCN.Q3 2002101200101212210220011000100122211221222010002001200102221112102201 
dCN.Q5 3113301310111313321331113003111113311341333111113113311313311223113311 
dCN.con 3003300300000303320330003002000213300340333000003003300303310123003300 
DT.Q2 1111110111111111111111111110011111111111111110101101111111111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3333330333333333333333033340033333333333333330303303333343333333333333 
DT.con 3333330333333333333333233330033333333333333330303303333333333333333333 
GG.Q2 1001101110001111111111111000000011111111111000001011100101100011101100 
GG.Q3 2002211210102212221221112000000102221221222000002012210201201022202200 
GG.Q5 4114422421212424432342233112111213332442434110113124421202311124313311 
GG.con 4004412420103424432342233000000113332442434000003024410302300034303300 
MST.Q2 1011101111111111110111111111101111111111111111111011111101111111111111 
MST.Q3 1011101111111111110111111111101111111111111111111011111101111111211211 
MST.Q5 1011101111111111110111111111101111111121111111111011101101111111211211 
MST.con 2022202222222222220222222222202222222222222222222022222202222222322322 
RCH.Q2 1001100100001101111110001000000111110111111000001001100101110011101100 
RCH.Q3 2001101210111212222222111000101222222222222111002112200102222122112210 
RCH.Q5 3013303330333344444434333000303344444443444310013333310303343334333333 
RCH.con 3003301310113314444432113000101344442443444100003113300303342134313310 
RNG.Q2 1011111110001111111111111000000011111111111000001011100101100011001100 
RNG.Q3 1012211210101211211221111000000012211221212000001011210101100011001100 
RNG.Q5 2123322321112322322332222111111122322332323110112123321202211122112211 
RNG.con 2023322320002322322332222000000023322332323000002023310202200022002200 
SA.Q2 0110011011110010001000100111111100011001000111110110011010011100110011 
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SA.Q3 0220021012121010011002210221121110011001000211220210022121011110120022 
SA.Q5 1330133033332030023103321443343310123003010334431331034142133310131143 
SA.con 0330033033331030013002310443343300023003000333430330034041033300230043 
All.con 3013301310112313331332123001101223322332333110003013310203311123213311 
910 - 979 0         1         2         3         4         5         6         
seq RDPHLACVAYERGQCDLELINVCNENSLFKSLSRYLVRRKDPELWGSVLLESNPYRRPLIDQVVQTALSE 
cCN.Q2 0111111111001010001101110111100110111000000110011000001100110111011100 
cCN.Q3 1122222222011010111202221212211221121011010220122000101101220122122200 
cCN.Q5 2343444443113131113313333443321331233011131331233000013311331343233301 
cCN.con 1343444443003030003303331433310330233000010330133000003300330343133300 
dCN.Q2 1111111111000010001101010111100110111000000110011000001100110111011100 
dCN.Q3 1122222222001010001202121222211221121011010220122000001101220122122200 
dCN.Q5 1111444443122131113313131313311331333011121331133001113211331343133311 
dCN.con 2233444443001030003303030333300330333000010330033000003200330343033300 
DT.Q2 1011111111110111111111111111111111111110011111111111011111111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111121111111111111111111 
DT.Q5 3033333333330433333333333333333333333333033333333344043330333333333334 
DT.con 3033333333330333333333333333333333333331033333333343033332333333333333 
GG.Q2 0100111111100010001101010111111111111000010111111000001100111111111100 
GG.Q3 0000222222010010002200010222211222222000010221122000001100221222122200 
GG.Q5 1111433443121121113412121334422443344111121442344100102211442344233311 
GG.con 0100433443110020003402020334422443344000020442344000002200442344233300 
MST.Q2 1111111111011111111111111111111111111011111110111111111111111111111111 
MST.Q3 1111111121111111011111111121111121111011110110111111111101110111112111 
MST.Q5 1111111121011111101111111121111121111011111110111111111111110111112111 
MST.con 2222222232022222122222222232222232222022221220222222222212221222223222 
RCH.Q2 1111111111000010001101110111110111111000000110011000001100110111011100 
RCH.Q3 2222222222221012112202222222222222222011010221122000101201221222222220 
RCH.Q5 3344444444433031133314444444443443443033130333333000303303444444444430 
RCH.con 3344444444221031013304442444442443443011010331133000103301441444244420 
RNG.Q2 0000111111100010001101010111111111111000000111111000000101111111111100 
RNG.Q3 0000111221100010001101010111211121121000000221121000000000221122112100 
RNG.Q5 1111222233211121112212121222322232232111111332232100101111332233223211 
RNG.con 0000222333200020002202020222322232232000000332232000000101332233223200 
SA.Q2 1000000000111101110010101000011000000111101001100111010011001000100011 
SA.Q3 1111000000211211121021111010011001000211112001100222121121002100100022 
SA.Q5 3333001001333413331031313100133102100433323003201344332243003100310134 
SA.con 3111000000333403330030303000033001000433313003200344131143003000300034 
All.con 1222333333111021113303131333322332333011010331233000102201331333233310 
980 - 1049 0         1         2         3         4         5         6         
seq TQDPEEVSVTVKAFMTADLPNELIELLEKIVLDNSVFSEHRNLQNLLILTAIKADRTRVMEYINRLDNYD 
 329 
 
 
cCN.Q2 1000001101101110101100110110011000001000111011111111000000100110110010 
cCN.Q3 1000002112211210102101220220021101012001112112222222111101210220120010 
cCN.Q5 3010013313332331213312331331133201013003333334444343121202321331231131 
cCN.con 3000003303312330203301330330033100003001333134444343010101310330230030 
dCN.Q2 1000001011101110001000110110011000001000001011111111000000100110010010 
dCN.Q3 1000002112211210101101210220021101002001112112222221111101210220120010 
dCN.Q5 1111013113312321113111330331133201113111113113443333111201311331231131 
dCN.con 2000003023302320003000330330033100003000003023443333000100300330130030 
DT.Q2 0101111111110111110111111111111111111110111111111111101111111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 0304433333330333343333333333333343333340333333333333303333333333334330 
DT.con 0303333333330333331333333333333333333330333333333333303333333333333332 
GG.Q2 0000001111111110001000110111011100001001011111111111010001110110010010 
GG.Q3 0000002222212220002000221221122000001000112122222222110201221220120010 
GG.Q5 2111114334423431103111442442243211112111224234444434211312432441231121 
GG.con 0000004334423430003000441442143200002001124234444434120202431440130020 
MST.Q2 1111111111111111111111110110111111111111111111111111111111111110111111 
MST.Q3 1111011111111111111111110110111111111111111111111121111011111110111111 
MST.Q5 1111011111101111111111110110111111111111111111111121111111111110111111 
MST.con 2222122222222222222222220220222222222222222222222232222122222220222222 
RCH.Q2 0000001101101110101000110110011000001001111011111111000101110110110010 
RCH.Q3 1000002222222222102202220221122101001001122222222222111101210220120110 
RCH.Q5 3010003344443344303303441343133303013003334444444443333333431331330330 
RCH.con 1000003324423342303202440341033101003003334244444443111303430330330130 
RNG.Q2 1000001111111110101001111111111100001001011111111111110001111110010010 
RNG.Q3 1000002112212210101001211221121100001001011112212122110001211220010010 
RNG.Q5 2111113223323321202112332332232211112111122223322233121112322331120121 
RNG.con 2000003223323320202002332332232200002002022223323233220002322330020020 
SA.Q2 0111110000010001010110001001100011110110100000000000101111001001101101 
SA.Q3 1221210110011012120121002002101122221221110110000000111121012002102201 
SA.Q5 3433430030031014341233013003301344431443230310000001333242023103214413 
SA.con 1433430010030004140231003003300144430441210100000000313242013003204403 
All.con 1000003223322331203101331331133201013001123233333333111102321330130120 
1050 - 1119 0         1         2         3         4         5         6         
seq APDIANIAISNELFEEAFAIFRKFDVNTSAVQVLIEHIGNLDRAYEFAERCNEPAVWSQLAKAQLQKGMV 
cCN.Q2 1001101100001100110110010000011011100100100100110010000110011011100001 
cCN.Q3 1002201210101101221220010111022122101110101210120020000221122112100001 
cCN.Q5 3013313320103313332331130122133134302311301320331130111342233123301013 
cCN.con 3003303310003301331330030011033034301300300310330030000341133023300003 
dCN.Q2 1001101100001100110110010000011011100100100100110010000110011011100001 
dCN.Q3 1002201210101101211220010111022012201110101210120010000221122011100002 
 330 
 
 
dCN.Q5 3113313320103311331331130111133133301211301310331131111341133133301013 
dCN.con 3003303310003300330330030000033033300200300300330030000340033033300003 
DT.Q2 0101011111011111111111101111111111111100111101111101111111111111110101 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 0403133334040333333333304033333333333300333333333313443333333333330033 
DT.con 0303033333032333333333303233333333333300333313333303333333333333330213 
GG.Q2 1001101110001101111110010000011111100100101110110010000111111111100001 
GG.Q3 1012212220001201221220010000022122201211201221221020000221122122200002 
GG.Q5 2124324431112312432441120111134244422322412432441131111342243233311114 
GG.con 2014314430002302432440020000034244401311402431440030000342243233300004 
MST.Q2 1011101111111101111110111111111011101111101111110111111111111111111111 
MST.Q3 2011201211111101211110111111121011101111101210120111111111112011111111 
MST.Q5 1011201211111101211110111111121011101111101210120111111111112121111111 
MST.con 3022302322222202322220222222232022202222202321230222222222223122222222 
RCH.Q2 1001101100001100111110010000011011100100100110110010000110011011100001 
RCH.Q3 1002201210101202221220010111022122211210101210220010000221122122100001 
RCH.Q5 3013303330103304443331130333033334333310303331330030000333344333300013 
RCH.con 3003303310003302443330030111033134311300301330330030000331144133300003 
RNG.Q2 1011111110001101111111010000011111111100101111111010000111111111100001 
RNG.Q3 1012212210001101211221010000022122211100101211221010000111122121100001 
RNG.Q5 2123323321102212332332120111133233322211212322332121101232233222211012 
RNG.con 2023323320002202332332020000033233322200202322332020000232233232200002 
SA.Q2 0110010001110010001001101111100100011011011001001101111001100100011110 
SA.Q3 1210021012121021001002212111200100021111021012002202222001100100022210 
SA.Q5 1430031014341143013113314333300310033133143023103314343003300311144430 
SA.con 0430030004340041003003304333300300033033043013003304343003300300044430 
All.con 2013313320002302332330020111033133311310301321330020000331133133300003 
1120 - 1189 0         1         2         3         4         5         6         
seq KEAIDSYIKADDPSSYMEVVQAANASGNWEELVKYLQMARKKARESYVETELIFALAKTNRLAELEEFIN 
cCN.Q2 0011011101001001001101100000100110110010000001011101111110100100100110 
cCN.Q3 0022022201001012102201200100100210220110001001122212222221200100200220 
cCN.Q5 0133134313113013213302310201311331331231011013133334444442301311311331 
cCN.con 0033034303003003103302300100300330330130000003033314444441300300300330 
dCN.Q2 0011011101001001001101100000100110110010000000011101111110100100100110 
dCN.Q3 0021012201001002102101200100100210220110001001022212222221100100200220 
dCN.Q5 1133113313112113113302310101311331331131011011133314444441301301311331 
dCN.con 0033023303002003003302300000300330330030000000033304444440300300300330 
DT.Q2 1101101110101101111110111010110111111011111101111111111111110110111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3303303330403303333330334040330333333333303343333333333333343333333333 
DT.con 3303303330303303333330333030330333333133323313333333333333331331333333 
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GG.Q2 0011111101000001101101100000100111111111000001011111111111100100110110 
GG.Q3 0022122201001002112212200000201221221221010000021212222221200201211220 
GG.Q5 1134234312012113224423411101312442442342121111242424434432311312422441 
GG.con 0034234302001003214413400000301442442342010001042424434432300301421440 
MST.Q2 0111011111111111111101101111101110110111111111111111111111111101110111 
MST.Q3 0121011112111111111101201111101110111111111111111111112121111101101111 
MST.Q5 0121011112111111111101201111101110110111111111111111112121111101111111 
MST.con 0232022223222222222202302222202220220222222222222222223232222202210222 
RCH.Q2 0011011101001001001101100000100110110010000001111111111111100100100110 
RCH.Q3 0122022222001002102101100100101210221111011002122222222222200100110110 
RCH.Q5 0133144403033013313313310301303331333333033013144444444444301301330330 
RCH.con 0033044413003003103303300100301330331131011003244444444444300300310330 
RNG.Q2 0111111101001001111111110000101111111111110000011111111110100101111110 
RNG.Q3 0122112101001001012212210000001221221121110000011112212220100101211210 
RNG.Q5 1233223212012012123323321201112332332232221111122223323331201212322321 
RNG.con 0233223202002002123323320000102332332232220000022223323330200202322320 
SA.Q2 1100100010110110010010011111011001001001111110100000000001011011001001 
SA.Q3 2200200021211210120021022121121002002101212221101010000002021021012002 
SA.Q5 3300311141431431330032034343133013103303433432301030000103143133033014 
SA.con 3300300040430430130031034343033003003103433431300010000003043033013004 
All.con 0133123312002003213302300100201331331231111002133323333331300301311330 
1190 - 1259 0         1         2         3         4         5         6         
seq GPNNAHIQQVGDRCYDEKMYDAAKLLYNNVSNFGRLASTLVHLGEYQAAVDGARKANSTRTWKEVCFACV 
cCN.Q2 0011101001100110000101111110010010111011101001001101100100101100110011 
cCN.Q3 1121201002101210001102212221120021122122212002002102211101102211221121 
cCN.Q5 1343313113201320001314423431230131144344323013114314311301313321332233 
cCN.con 0143303003200320000304423430130030244144313003004304300300303310331133 
dCN.Q2 0110101001000100000101111110010010011011101001001101100100101100110011 
dCN.Q3 0121201002101210001202211221120021122122212002002102201101202210221121 
dCN.Q5 1111313113202320111313332331131131144144313113113313311111313311331232 
dCN.con 0230303003101310000303332330030030044044303003003303300200303300330132 
DT.Q2 0111111101111111100111111111111111111111111111101111111010111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 0330303303033334403333333333333433333333333333303330333040333333333333 
DT.con 0332323303233333301333333333333333333333333333303332333030333333333333 
GG.Q2 0010101001101110000101111110010010111111111101111101110100101111111111 
GG.Q3 0000102012212220000202222220120020122122212112112212210000102211221222 
GG.Q5 1111213124323321011313334442231131244244424224224423321101213422432333 
GG.con 0010203014313330000303334440130030244244424214224413320100203422432333 
MST.Q2 1111111011110111111111111111111111111111111111111111111111101111111111 
MST.Q3 1111211012210111111111211111111111111111111111112111211111101111111221 
 332 
 
 
MST.Q5 1111211012210111111111211111111111112111111111112111211111101111111121 
MST.con 2222322023320222222222322222222222222222222222223222322222202222222332 
RCH.Q2 0100101001000100000101111110110010111111111001001101100000101100111111 
RCH.Q3 1221201001101110001102222222120022222222222101112222211101201211221121 
RCH.Q5 3434333013303330003314444444330044344444433313304414431303303333444333 
RCH.con 1421303003101310001304444442330042344444433103104414410101303311443333 
RNG.Q2 0010101011111110000101111111010010111111111111111111110100101111111111 
RNG.Q3 0000101012111210000101211221010010122122212112112212210100102211221221 
RNG.Q5 1121212123222321111212322332121121233233322223223323321201213322332332 
RNG.con 0020202023222320000202322332020020233233323223223323320200203322332332 
SA.Q2 1100010110011001111010010001101101100000010110110010011011010011000000 
SA.Q3 1111110220021012221020011002102201100100010210120020012121120011001100 
SA.Q5 3343131330032024443131021003313313200300030330330131033343130133003201 
SA.con 3311030330032014443030020003303303200100030330330030033143030033001100 
All.con 0121303013211320001303323331130031233233323113113313311201303311332233 
1260 - 1329 0         1         2         3         4         5         6         
seq DGKEFRLAQMCGLHIVVHADELEELINYYQDRGYFEELITMLEAALGLERAHMGMFTELAILYSKFKPQK 
cCN.Q2 0000101101111011001001001101100001100110110011010000111111111111010000 
cCN.Q3 0100201211221122112012002201100101201220220122010011222222222222110101 
cCN.Q5 0101313333343133214113113312201213312331331233030134444444444443131201 
cCN.con 0000303313343033104003003302200103301330330133030011444444444443030100 
dCN.Q2 0000101100111011001001001101100001100110110011010000111111111111010000 
dCN.Q3 0000211211221122112002002201100101201210221121010011222222222222110101 
dCN.Q5 0111312312332133113013113312211113311331331133031111314444444431131101 
dCN.con 0000302301332033003003003302200003300330330033030000334444444433030000 
DT.Q2 1011111111111111111111111111111111111111111111101101111111111111111111 
DT.Q3 1111111111111111111111111111111111111111111111112111111111111111111111 
DT.Q5 4033333333333333333333333333333333333333333303304333333333333333333333 
DT.con 3033333333333333333333333333333333333333333323304313333333333333333333 
GG.Q2 0000111111111011001011101111100001101111111111010001101111111111010001 
GG.Q3 0000212212221011002012112212200002201221221122010000112222222220010001 
GG.Q5 1111324423432123113124224423311213312442442233121111214333433442121112 
GG.con 0000324423432023003024214423300003302442442233020001204333433442020002 
MST.Q2 1111111101111111111011011111111111101110110111111111111111111111111111 
MST.Q3 1111111201221111112011011111111111101110110121011111121111121111111111 
MST.Q5 1111111211221011112011111111111111101110110122011111121111121111111111 
MST.con 2222222302332222223022022222222222202220220232122222232222232222222222 
RCH.Q2 0000101111111111001111001101100001101110110111000000111111111111010000 
RCH.Q3 0001212222222222112012002212100102202221221122010012222222222222110201 
RCH.Q5 0103333444444444334033113333313303403431433333030033444444444444333303 
RCH.con 0001313444444444114133003313300103403430431333010012444444444444130201 
 333 
 
 
RNG.Q2 0000111111111011001011111111110001101111111111010000111111111111010001 
RNG.Q3 0000111211111011002012112211110001101221221121010000111111211221010001 
RNG.Q5 1111322322222122113123223322221112212332332232121112222222322322121112 
RNG.con 0000322322222022003023223322220002202332332232020000222222322332020002 
SA.Q2 1111010000000100110110110010011110010001001000101110000000000000101111 
SA.Q3 2121010011001201110110120011122121021002001100212221110000000001212121 
SA.Q5 4333131032002411331330330031233341133003003301424443110001000010313343 
SA.con 4333030011001400330330330030133340031003003100414441000000000000303343 
All.con 0001313322332133113023113312211103302331331233020011333333333333121101 
1330 - 1399 0         1         2         3         4         5         6         
seq MREHLELFWSRVNIPKVLRAAEQAHLWAELVFLYDKYEEYDNAIITMMNHPTDAWKEGQFKDIITKVANV 
cCN.Q2 1101101110110100110010000110111111101001001101110010011000011011101001 
cCN.Q3 2101201210121211110120011221222222111002012212220110021010121022112111 
cCN.Q5 3203312331231311330131121333344444212013114414430230133010332134313113 
cCN.con 3203302330230300330030010331344444202003004404430130033000132034303003 
dCN.Q2 1000100100010100110010000110011111001001001101110000011000011011101001 
dCN.Q3 2101201210120210110110011220122222111002002212220110021000121022202001 
dCN.Q5 3201312320131311330131111331143443212013114413331111133111232133113112 
dCN.con 3100301310030300330030000330043443102003004403330000033000132033303002 
DT.Q2 1111111111111111111011111111111111111111101111111111101111011111111101 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3333333333333333333033333333333333333443303333334333403433333333333303 
DT.con 3333333333333333333033333333333333333333303333333333303333133333333303 
GG.Q2 1101111110010100110111111111111111101001011111110000001000111011101001 
GG.Q3 2212212220020201221121111221122222201002012222220000001000122122202001 
GG.Q5 4323423431131412442242232442243444212113124423431111112111243244313112 
GG.con 4313423430030401441242232442243444302003024433430000002000243144303002 
MST.Q2 1111111111111101110111111110111111111111111111111111111111111011111111 
MST.Q3 1111111111111101110121111110111111111111112111111111121110111011111111 
MST.Q5 1111111111111101110121111110111111111111112111111111121110111111111111 
MST.con 2222222222222202220232222220222222222222223222222222232221222022222222 
RCH.Q2 1101101110110100110010011111111111001001001111110110011000111011111001 
RCH.Q3 2102212210222222210111111222222222221002012222221110011010122222222222 
RCH.Q5 3344343330444443330331333444444444433003333444444333033130334444404444 
RCH.con 3314313330442422330130133444444444223003013444441330033010334244424224 
RNG.Q2 1111111110010101111111111111111111100001011111110000011000111111101000 
RNG.Q3 2111211110010101221121111221121122100001012211210000011000121122101001 
RNG.Q5 3222322221121212332232222332232333211012123322321111122111232233212112 
RNG.con 3222322220020202332232222332232333200002023322320000022000232233202001 
SA.Q2 0010010001100011001101101001000000010110110000001001100111000100010100 
SA.Q3 0121021012101011002102111001100000111220210010002112211212101200120211 
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SA.Q5 0131032014313033003303323113300101232431430020004334411434202300131332 
SA.con 0030031004301033003303313003100000131430430010004114400434101300030311 
All.con 3212312320131311330131122331233333212003013323331110022010232133313112 
1400 - 1469 0         1         2         3         4         5         6         
seq ELYYKAIQFYLEFKPLLLNDLLMVLSPRLDHTRAVNYFSKVKQLPLVKPYLRSVQNHNNKSVNESLNNLF 
cCN.Q2 0111011011100000111011011000101111101100100111100110011001000100111011 
cCN.Q3 0121022112101110122122022101212122201200101222210221121012101210221022 
cCN.Q5 0232133124302131333243133212344444413311303444421331133013203331343133 
cCN.con 0232033024301010333143033101314344403300301444410330033003101310343033 
dCN.Q2 0011011011100000011011011000101111101100000111100110011001000100111011 
dCN.Q3 0121022012101110121122022101212222201200101222210220021012101210221022 
dCN.Q5 0243133133301111233143133111413134413311111414311331132113211311343133 
dCN.con 0143033033300000133043033000403334403300000434300330032003100300343033 
DT.Q2 1111111111111111111111111111111111111111011111111111111101110111011111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3333333333333333333333333333333333333333343333334333333303300333033333 
DT.con 3333333333333333333333333333333333333333133333333333333303320333033333 
GG.Q2 0111111111100000111111111000101011101100000101100111111011101110111111 
GG.Q3 0222122122200000122122122000200012201200000202210222122112211221222122 
GG.Q5 1343244234411111242244244111311123412311111313321342243224322432343244 
GG.con 0343244234400000243244244000301023402300000303310343243124312431343244 
MST.Q2 1111111011101111111111111111111111111111111111110110111011101111111011 
MST.Q3 0111121011101111111111111111111111111111111111110110111011101110211011 
MST.Q5 0111021111111111111111111111111111111111111111110110111011101111211011 
MST.con 1222232022202222222222222222222222222222222222220220222022202221322022 
RCH.Q2 1111011011100110111011011000101111101100000111100110011001100110111011 
RCH.Q3 2221122122201220222222222101222222222200102222210221121012101222222222 
RCH.Q5 4443344434303330343444433303344444433300303444440333333033303443444444 
RCH.con 4443144134301330343244233101324444423300102444410331133013301442444244 
RNG.Q2 0111111111100000111111111000101011101100000101100111111111111111111111 
RNG.Q3 0122122112100000111122121000100012101100000101100121121112111211221122 
RNG.Q5 1232233223211111222233232211212112312211101212211332233223222322332233 
RNG.con 0233233223200000222233232000202023302200000202200332233223222322332233 
SA.Q2 1000100100011101000100100111010100010011111010011001100110010001000100 
SA.Q3 1100200100021122101100100121011110021022121010012001100210121012000200 
SA.Q5 3201300311043343201300300343133320031134343131033102300320133013000300 
SA.con 3100300300043323100300300343031310030034343030033002300320031003000300 
All.con 1233133133301110233233133101312233312300101323310331133013201321333133 
1470 - 1539 0         1         2         3         4         5         6         
seq ITEEDYQALRTSIDAYDNFDNISLAQRLEKHELIEFRRIAAYLFKGNNRWKQSVELCKKDSLYKDAMQYA 
cCN.Q2 1000010010011001001011011001000011011011111100000100110110000110011011 
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cCN.Q3 1001110121012012112112022012001022121122222211100201220221000110122022 
cCN.Q5 3002230231033113233333133113101033132234434411201311331331021331243134 
cCN.con 3001130130033003113133033003000033032134434400100300330330000330143034 
dCN.Q2 1000010010011001001011011001000011010011111100000100110110000110011011 
dCN.Q3 1001110121012002112111022011001022121122212211100201220221000110122022 
dCN.Q5 3111130131133013113113133113101133131134434311111311331331011331143134 
dCN.con 3000030030033003003023033003000033030034434300000300330330000330043034 
DT.Q2 1111101011101111111111111111110111111111111111100111111111111111111111 
DT.Q3 1111111111111111111111111111111211111111111111111111111111111111111111 
DT.Q5 3333313033303333333333333333340433333333333333303333333333343333333333 
DT.con 3333303033303333333333333333330433333333333333301333333333333333333333 
GG.Q2 1111110111011001001011011011000011011111111110000100111111000110111111 
GG.Q3 2111121122122002001012022112000022122122222211000201221221000120122122 
GG.Q5 4222232242234113113123144224111133243243334422111311442432111231244234 
GG.con 4222231243134003003023044124000033143243334421000300442432000230244234 
MST.Q2 1111110111011111111111111011011011111111111111111101110111111110111011 
MST.Q3 1111110111011111111111112011111011111112211111111101210111111110121012 
MST.Q5 1111110111111111111111112011111011111112211111111101210111111110121012 
MST.con 2222220222022222222222223022022022222223322222222202320222222220232023 
RCH.Q2 1000010010011001111111011001000011011011111111000100110110000110011011 
RCH.Q3 2211110121022102222222112111001022222222222211100201220221021120122122 
RCH.Q5 3333330333033003444443333133003033333444444433301303331333033330344344 
RCH.con 3211130131033003444443133013001033233244444433100301330331021330144144 
RNG.Q2 1111111111111001001001111111000011111111111110100101111111000110111111 
RNG.Q3 1111121121112001001001122112000011121122212110100101221221000110122122 
RNG.Q5 3222222232233112112112233223111022232233323321211212332332111221233233 
RNG.con 3222232232233002002002233223000022232233323320200202332332000220233233 
SA.Q2 0111101101100110110100100110110100100100000011011011001001101001100100 
SA.Q3 0221102101200220120110200210221201101100010011121021002001212102100200 
SA.Q5 1333313303310331431321300330443301302300020133343133003103443113300310 
SA.con 0333303303300330330310300330441300301300010033143033003003413003300300 
All.con 3111120132123003113123133113001033132233333321100301331331011230133133 
1540 - 1609 0         1         2         3         4         5         6         
seq SESKDTELAEELLQWFLQEEKRECFGACLFTCYDLLRPDVVLETAWRHNIMDFAMPYFIQVMKEYLTKVD 
cCN.Q2 1010000110011011100000011111111110110101110111110100111111111110110010 
cCN.Q3 1110010121122012101001122222222221221211211122110211222222211210210120 
cCN.Q5 2131020332133134301012444444444442432433323333331334444443323320330230 
cCN.con 2030010331033034300001144444444441431413321333330311444443323320330130 
dCN.Q2 0000000110011011100000011111111110110101110111010100111111101110110010 
dCN.Q3 1110010121122012100001122222222221221212221122110211222222211210210110 
dCN.Q5 1111111331133133301111144444444441431413331233231311444443313221331131 
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dCN.con 0000000330033033300000044444444440430403330233130300444443303320330030 
DT.Q2 1101011111111111111111111111111111111111111111111111111111111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 3303033333333333333443303333333333333333333333333333333333333333333033 
DT.con 3303033333333333333333323333333333333333333333333333333333333333333233 
GG.Q2 1010000111111111100000011111111110110101111111110100111111111110110110 
GG.Q3 2010000221122122200000022222221220220202221222110200212222222221221121 
GG.Q5 3111111442244234311011133434432321331313442433221311332333433432432242 
GG.con 3020000442244234300000033434432330330303442433220300333333433431431241 
MST.Q2 1111110111111011101111111111111111110111111111111111111111111111111110 
MST.Q3 2121110221111011101111121121111211110111111121111111111111111111111110 
MST.Q5 2111110121111011101111121121111211110111111111111111111111111111111111 
MST.con 3232220332222022202222232232222322220222222232222222222222222222222220 
RCH.Q2 1000000110011011100000111111111110110111110111110110111111111111110010 
RCH.Q3 1110010121122122100001222222222222222222222222222222222222222222220110 
RCH.Q5 3330130333333333301013344444444444444444444444440444444444444444431331 
RCH.con 3110010331133133300001344444444442442444442444441442444444444444430130 
RNG.Q2 1010000111111111100000011111111110110101111111110100111111111111111111 
RNG.Q3 2010000121122122100000011222211110110101211122110100111111212111211121 
RNG.Q5 2121111232233233211011122333322221221212322233220211222222323222322232 
RNG.con 3020000232233233200000022333322220220202322233220200222222323222322232 
SA.Q2 0101111000100100011111000000000001001000000000001001000000010001001101 
SA.Q3 1212112001100210021221200000001002001010001100112012001001010112002102 
SA.Q5 1324334103300310143433400000011013113130013000214133101002031023113303 
SA.con 0314334001300300043433200000000003003010001000104013000001030013003303 
All.con 2120010332133133301001133333333331331313332333220311333333323321331131 
1610 - 1674 0         1         2         3         4         5         6    
seq KLDASESLRKEEEQATETQPIVYGQPQLMLTAGPSVAVPPQAPFGYGYTAPPYGQPQPGFGYSM 
cCN.Q2 0100000000000000000011110111111111111111111111111111111111111111 
cCN.Q3 0100000000000000000021121222222222222222222222222222222222222202 
cCN.Q5 1310010000000000000033333344444444444444444444444444444444444411 
cCN.con 0300000000000000000033331344444444444444444444444444444444444413 
dCN.Q2 0100000000000000000011100011111111111111111111111111111111111111 
dCN.Q3 0100000000000000000011121122222222222222222222222222222222222200 
dCN.Q5 1310010001000000001122111144444444444444444444444444444444444444 
dCN.con 0300000000000000000022210044444444444444444444444444444444444433 
DT.Q2 0100000100001001111111111111111111111111111111111111111111111111 
DT.Q3 1111111111111111111111111111111111111111111111111111111111111111 
DT.Q5 0303000330003034444333334333333333333333333333333333333333333334 
DT.con 0301000310003013333333333333333333333333333333333333333333333333 
GG.Q2 1100110001000000000011000001111001111111011111111111111110110000 
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GG.Q3 1211111111000000000000100002222011111101011111111211111101120101 
GG.Q5 2422222222211111100022200113332122221212112212121212222212221202 
GG.con 2411221112000000000022100003333012222212022222222322222211230101 
MST.Q2 1111111111111111111111111111111111111111111111111111111111111111 
MST.Q3 1111111111111111111111111111111122111111111121211111121111222211 
MST.Q5 1111111111111111111111111111111121111111111121211111121111222121 
MST.con 2222222222222222222222222222222233222222222232322222232222333322 
RCH.Q2 0100000000000000000011111011111111111111111111111111111111111111 
RCH.Q3 0110000000000000000022222222222222222222222222222222222222222000 
RCH.Q5 1311110111110000000334444444444444444444444444444444444444444400 
RCH.con 0300000000000000000034444244444444444444444444444444444444444311 
RNG.Q2 1111111111111100000001000001111010110101011111111111111101110000 
RNG.Q3 1211111111111100000001000001111110110101011111111111111101111000 
RNG.Q5 2322222222222211100012111112222222221212122222222222222211221110 
RNG.con 2322222222222200000002000002222120220202022222222222222202220000 
SA.Q2 1011111111111111111100011100000000000000000000000000000000000011 
SA.Q3 2022212122222222222211112110000100001010110100001000101011000022 
SA.Q5 3033333343444444444433343431001010111111311101011111111131011144 
SA.con 3033333343444444444411133310000000000000100000000000000010000044 
All.con 1311110111001000000022211123333233332323233333333333333323332211 
  
 
0 - 69 0         1         2         3         4         5         6         
seq MAQILPIRFQEHLQLQNLGINPANIGFSTLTMESDKFICIREKVGEQAQVVIIDMNDPSNPIRRPISADS 
SA.Q2 1111000101000101101011100101000000110000011111110000000111110111101010 
SA.Q3 2222100101100202202022210202100011110000112222211000010221221111102021 
SA.Q5 4344111303311303414134431314300033431000233444433000021434431332313141 
SA.con 4344000303100303404034410304100011330000133444431000010433430332303040 
All.con 0000333141233040030300023030244422013444210000012444423000003111130303 
70 - 139 0         1         2         3         4         5         6         
seq AIMNPASKVIALKAGKTLQIFNIEMKSKMKAHTMTDDVTFWKWISLNTVALVTDNAVYHWSMEGESQPVK 
SA.Q2 0000111100001111000000010111011010111000010011100000011000000011111001 
SA.Q3 0011122100001221101001021222012020222010010112210000022100101022222111 
SA.Q5 1113343300003333202003031343133131443100131134320000044301213144443133 
SA.con 0001343300003333101001030343033030443000030034310000044100101044443013 
All.con 3332100144441001242442403000310303000334313310024444400243232300000321 
140 - 209 0         1         2         3         4         5         6         
seq MFDRHSSLAGCQIINYRTDAKQKWLLLTGISAQQNRVVGAMQLYSVDRKVSQPIEGHAASFAQFKMEGNA 
SA.Q2 0010111011010000101111100000000011010100000000111101001000000010101111 
SA.Q3 0011122021110000101221100000001122210101010011222111102100010020212222 
SA.Q5 0133344144130000313443310000002344330302020132444343114010000031314444 
SA.con 0031344043030000303443300000001144230301010011444313004000000030304444 
All.con 4312100300314444131001134444442200114142424322000121330334434403030000 
210 - 279 0         1         2         3         4         5         6         
seq EESTLFCFAVRGQAGGKLHIIEVGTPPTGNQPFPKKAVDVFFPPEAQNDFPVAMQISEKHDVVFLITKYG 
SA.Q2 1101000001111110100000011111111101110000000010110000000001101000000100 
SA.Q3 2211000001112210100001011122222202211110101121111000001012211000000110 
SA.Q5 3412000003234430301003134344443413431131112343343100001034313000000320 
SA.con 3402000003234430300001033344443403430010001141331000000014303000000310 
All.con 0031444441110014143442310100000030013323332202102344443420031444444124 
280 - 349 0         1         2         3         4         5         6         
seq YIHLYDLETGTCIYMNRISGETIFVTAPHEATAGIIGVNRKGQVLSVCVEEENIIPYITNVLQNPDLALR 
SA.Q2 0000000000000000100110000001111110000001101000000111100100011011110011 
SA.Q3 0000010120100011100221000001122121000011201001010222100200021121220012 
SA.Q5 1010010330300031311432000014344442010013313001020334300310143243430023 
SA.con 0000000120100010300431000003344341000003303000010334300300043143430023 
All.con 3434434214244423133002444430100002434431031443424000144034301201004410 
350 - 419 0         1         2         3         4         5         6         
seq MAVRNNLAGAEELFARKFNALFAQGNYSEAAKVAANAPKGILRTPDTIRRFQSVPAQPGQTSPLLQYFGI 
SA.Q2 0011010110110001101100110101100100010111000001001101101111111000000000 
SA.Q3 1022121220111012101200221102100100021221101012002102212212221100010010 
SA.Q5 1043342430321023303311443313300300042433113124003303424434443300020031 
SA.con 0043141430320013303300441303300300041433001014003303414434443100010010 
All.con 3400202004113420141033002130144144402001332320440140020010001244424423 
420 - 489 0         1         2         3         4         5         6         
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seq LLDQGQLNKYESLELCRPVLQQGRKQLLEKWLKEDKLECSEELGDLVKSVDPTLALSVYLRANVPNKVIQ 
SA.Q2 0011110110100000100011111100110011110100110000011000100010001010011000 
SA.Q3 0022220121110200100022211200210022210200210010012110200010012020111001 
SA.Q5 0143431342340300300034432400331144431410330020033211300030123141133002 
SA.con 0043430341310200300034432400330044430400330010033100300030013040033001 
All.con 4300003102124144144400011044013300013034014424410233044414320303311442 
490 - 559 0         1         2         3         4         5         6         
seq CFAETGQVQKIVLYAKKVGYTPDWIFLLRNVMRISPDQGQQFAQMLVQDEEPLADITQIVDVFMEYNLIQ 
SA.Q2 0001101011001001101011100000000010001100100100011110001001001000100001 
SA.Q3 0002111011002002212111100100110011102101200110022211001011001001212102 
SA.Q5 0004213133013103314133311100330021114301300310144444113033003101323213 
SA.con 0004203033003003304033300000110020004300300300044431003013003000312103 
All.con 4440131311430340030311133344224413330143044134300002331421441343021230 
560 - 629 0         1         2         3         4         5         6         
seq QCTAFLLDALKNNRPSEGPLQTRLLEMNLMHAPQVADAILGNQMFTHYDRAHIAQLCEKAGLLQRALEHF 
SA.Q2 0001000100111111111000100000010011001100111001001001001001100001000100 
SA.Q3 1002001200221222222011100101111112002100222101112111002002211001100200 
SA.Q5 3003101300433344443131300303233344003301434313213333003103313013201411 
SA.con 1003000300433344443010300101131134003300434103103113003003301003100400 
All.con 2440343044001000000323144242212200440143000231230221440340032431243033 
630 - 699 0         1         2         3         4         5         6         
seq TDLYDIKRAVVHTHLLNPEWLVNYFGSLSVEDSLECLRAMLSANIRQNLQICVQVASKYHEQLSTQSLIE 
SA.Q2 1101000000010110101000100110111100100110010001000000000001001100011001 
SA.Q3 2201101100120110212001200220112100200110021011100100010012002201021002 
SA.Q5 4313302200031331313001310441334301300330032013300200030023004313133003 
SA.con 4303101100030330303000300440334300300330031003100100010013004301033003 
All.con 0031242244303113030443034003110143044114402431244244424420440032301440 
700 - 769 0         1         2         3         4         5         6         
seq LFESFKSFEGLFYFLGSIVNFSQDPDVHFKYIQAACKTGQIKEVERICRESNCYDPERVKNFLKEAKLTD 
SA.Q2 0011010010000001100101111100010010001111011011001111001011001001101011 
SA.Q3 0022121120001001100211211200010020002121021011002222111021012002212121 
SA.Q5 0133241130001003311314433300130030014343133033003344113143033103434143 
SA.con 0033140030000003300303433300030030004343033033003344003043013003414043 
All.con 4300203304443441133030011044314404430101301411440000331301420340020301 
770 - 839 0         1         2         3         4         5         6         
seq QLPLIIVCDRFDFVHDLVLYLYRNNLQKYIEIYVQKVNPSRLPVVIGGLLDVDCSEDVIKNLILVVRGQF 
SA.Q2 1000000000010011000000101001001000110101100100000000101110011000001110 
SA.Q3 1100000011120021001000212011002000221112201100000010202220011001002110 
SA.Q5 3300000033131133002101333023003010331314311300000131413441033003103431 
SA.con 3100000011030033001000313013003000330304300300000010403440033001003330 
All.con 1244444422303301442343020421440434003130033144444323030003411442340013 
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840 - 909 0         1         2         3         4         5         6         
seq STDELVAEVEKRNRLKLLLPWLEARIHEGCEEPATHNALAKIYIDSNNNPERFLRENPYYDSRVVGKYCE 
SA.Q2 1011001001101001000100010011101111000000000000011011001101000110001001 
SA.Q3 1022002101212102001100221022112111001000100011121022002212111111002002 
SA.Q5 3033003203323213112300332044434333011000201033443133103424213332003103 
SA.con 3033003103313103001300231044314333000000100011143033003414101331003003 
All.con 1400440241020230332144102400020111433444243422201300340020232112440340 
910 - 979 0         1         2         3         4         5         6         
seq KRDPHLACVAYERGQCDLELINVCNENSLFKSLSRYLVRRKDPELWGSVLLESNPYRRPLIDQVVQTALS 
SA.Q2 1100100000011110011001000101001100100011111100110011111001100100000000 
SA.Q3 2111100000022120111002001212101110110022111200110022212112200110010012 
SA.Q5 4334300100143431233003101434113320310033332400330134434223300310031013 
SA.con 4311300000043330133003000414003310300033332400330034434113300300010002 
All.con 0122144344300003211440343020331124134400111044114300010220044134423431 
980 - 1049 0         1         2         3         4         5         6         
seq ETQDPEEVSVTVKAFMTADLPNELIELLEKIVLDNSVFSEHRNLQNLLILTAIKADRTRVMEYINRLDNY 
SA.Q2 1111111000001000111011100100110001111011011000000000010011100100110110 
SA.Q3 2121122011101000222112100200110012222122111011000000021112101200210221 
SA.Q5 4443143011003001444134301300330124433144233033000000031324302310330441 
SA.con 4343243000003000444034300300330014433044133011000000030124301300330440 
All.con 0001100433341443000310143044114320000300211422444444403210142034014003 
1050 - 1119 0         1         2         3         4         5         6         
seq DAPDIANIAISNELFEEAFAIFRKFDVNTSAVQVLIEHIGNLDRAYEFAERCNEPAVWSQLAKAQLQKGM 
SA.Q2 1011001000101001000100110110110010001101101100100110111100010010001111 
SA.Q3 1121002001212002100100221211120020002112102101200220221200110020002211 
SA.Q5 3143013102423113300301331422230031013323314202300331433300320031114342 
SA.con 3043003001413003100300330421230030003313304201300330433300120030004332 
All.con 1301430342020330244143003012104403430120130142044003001044214403330001 
1120 - 1189 0         1         2         3         4         5         6         
seq VKEAIDSYIKADDPSSYMEVVQAANASGNWEELVKYLQMARKKARESYVETELIFALAKTNRLAELEEFI 
SA.Q2 0110010001011011011001101111101100100110011111010000000000101101100100 
SA.Q3 0210020001121121012002102212112100200110121222110101000000212102102200 
SA.Q5 0330031113343343133003203434313301310330243343130303000001313313303301 
SA.con 0330030003143143033003203434303300300330143343030101000000303303302300 
All.con 4014403331201201310440140010130143034114201000314242444443030130141043 
1190 - 1259 0         1         2         3         4         5         6         
seq NGPNNAHIQQVGDRCYDEKMYDAAKLLYNNVSNFGRLASTLVHLGEYQAAVDGARKANSTRTWKEVCFAC 
SA.Q2 1100101011001100111001001000010110010000001011011001001101101001100000 
SA.Q3 2111111012002101222102101000210221110010001021022002001112212101100110 
SA.Q5 4334313133003312444213302100331341030010103033033013003314314012300310 
SA.con 4311303033003301444103102000230340030000003033033003003304304002300100 
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All.con 0122131310440132000230241344113003314434341401400430441130030331144234 
1260 - 1329 0         1         2         3         4         5         6         
seq VDGKEFRLAQMCGLHIVVHADELEELINYYQDRGYFEELITMLEAALGLERAHMGMFTELAILYSKFKPQ 
SA.Q2 0111101000101010001011011001001111101100100110010110000000000000010111 
SA.Q3 0212102101101010001121012002102212102100200210021221101000100000021212 
SA.Q5 1333313003213130013143033013104434213300300330141444310000300001041334 
SA.con 0333303001203030003043033003004434203300300330040441100000100000040334 
All.con 3010130342131314431301410430340010130144044014303002233444244443403010 
1330 - 1399 0         1         2         3         4         5         6         
seq KMREHLELFWSRVNIPKVLRAAEQAHLWAELVFLYDKYEEYDNAIITMMNHPTDAWKEGQFKDIITKVAN 
SA.Q2 1001001100110101100110110000100000011011011001000111110011100110001011 
SA.Q3 1012102101210201200210111100110100011122011001000212221122210120012021 
SA.Q5 3023103201431303310330332201330010123143133002001433441133410230023143 
SA.con 3013003200430303300330331100310000023043033002000433440033400230013043 
All.con 1420340143013041034014112243124334311300311441443010003300034104420301 
1400 - 1469 0         1         2         3         4         5         6         
seq VELYYKAIQFYLEFKPLLLNDLLMVLSPRLDHTRAVNYFSKVKQLPLVKPYLRSVQNHNNKSVNESLNNL 
SA.Q2 0100010010001111100010000011100000001001101101001100110011001100100010 
SA.Q3 1200110010002111110010010011201111002101212102001200110121012100200120 
SA.Q5 1400130031104322310130020033313132003103434313103300330333013301300231 
SA.con 0400030030004322300030010033301011003003414303003300330133003300300130 
All.con 3044314413340111134314424411032322440341020130341044114201430143044203 
1470 - 1539 0         1         2         3         4         5         6         
seq FITEEDYQALRTSIDAYDNFDNISLAQRLEKHELIEFRRIAAYLFKGNNRWKQSVELCKKDSLYKDAMQY 
SA.Q2 0011100100110011011010010011011010010010000001101101100100111100100010 
SA.Q3 0022210210120022022021020011022010110110001001212102100200122210210020 
SA.Q5 1133321330330033143133030033033130130330002013334313300310344311330031 
SA.con 0033310310330033043031030033033030030130001003314303300300344300310030 
All.con 3300023024104400300302404411400314314214442431020130144034100033024403 
1540 - 1609 0         1         2         3         4         5         6         
seq ASESKDTELAEELLQWFLQEEKRECFGACLFTCYDLLRPDVVLETAWRHNIMDFAMPYFIQVMKEYLTKV 
SA.Q2 0010111100110010001111110000000000100101000000000101100000001000100110 
SA.Q3 0121221200210020002122120000000100200102000110011201210100001001200210 
SA.Q5 0134333310330031014343340000001301411314000320123413410100003002311330 
SA.con 0031333300330030004343340000000100400304000110011403400000003001300330 
All.con 4302001034014403430100104444443243033130444224322031034344441442033014 
1610 - 1675 0         1         2         3         4         5         6     
seq DKLDASESLRKEEEQATETQPIVYGQPQLMLTAGPSVAVPPQAPFGYGYTAPPYGQPQPGFGYSM 
SA.Q2 11011111111111111111110011110000000001000000000000000000000000011 
SA.Q3 22012212212222222222111121210101100112011111010001000011011000122 
SA.Q5 33034334334444444444333343431000311114111311101011111143131111144 
 342 
 
 
SA.con 33034334334444444444331143430000100004000100000000000011010000044 
All.con 00410010010000000000112201013343233330333233333433333322323333300 
 
